HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
was - *
abolished abolish (V*) *
by - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
were - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
are - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

This - (A0*
acid - *
resistance - *)
was - *
abolished abolish (V*) *
by - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
is - *
abolished abolish (V*) *
by - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
abolished abolish (V*) *
this - (A0*
acid - *
resistance - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
abolish abolish (V*) *
this - (A0*
acid - *
resistance - *)
. - *

Furthermore - *
the - (A0*
deletion - *
of - *
yhiE - *)
completely - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
deletion - *
of - *
yhiE - *)
completely - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
deletion - *
of - *
yhiE - *)
completely - *
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
deletion - *
of - *
yhiE - *)
completely - *
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

acid - (A1*
resistance - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
also - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
also - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
also - *
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
also - *
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

Insertions - (A0*)
which - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
which - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
abolish abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
abolished abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Alp - (A1*
activity - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

Alp - (A1*
activity - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
abolished abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
which - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
which - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

Formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
is - *
abolished abolish (V*) *
by - *
linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
. - *

Formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
was - *
abolished abolish (V*) *
by - *
linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
. - *

However - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
does - *
not - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
does - *
not - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
its - (A1*
BCFA - *
biosynthesis - *)
is - *
not - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
its - (A1*
BCFA - *
biosynthesis - *)
was - *
not - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Co-administered - (A0*
DM - *)
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
the - (A1*
CPP - *
effect - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *)
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
the - (A1*
CPP - *
effect - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *
effect - *)
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
co-administered - (A0*
DM - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Noticeably - *
transcription - (A1*
at - *
the - *
rrn - *
PC - *
promoter - *
by - *
NEP-2 - *)
was - *
completely - *
abolished abolish (V*) *
if - *
CDF2-B - *
can - *
not - *
bind - *
to - *
the - *
template - *
as - *
obtained - *
by - *
the - *
mutation - *
M1 - *
(Figure - *
4A - *
compare - *
lanes - *
1 - *
and - *
4; - *
Figure - *
4C - *
compare - *
Wt - *
and - *
M1) - *
. - *

Noticeably - *
transcription - (A1*
at - *
the - *
rrn - *
PC - *
promoter - *
by - *
NEP-2 - *)
which - *
was - *
completely - *
abolished abolish (V*) *
if - *
CDF2-B - *
can - *
not - *
bind - *
to - *
the - *
template - *
as - *
obtained - *
by - *
the - *
mutation - *
M1 - *
(Figure - *
4A - *
compare - *
lanes - *
1 - *
and - *
4; - *
Figure - *
4C - *
compare - *
Wt - *
and - *
M1) - *
. - *

Noticeably - *
transcription - (A1*
at - *
the - *
rrn - *
PC - *
promoter - *
by - *
NEP-2 - *)
which - *
is - *
completely - *
abolished abolish (V*) *
if - *
CDF2-B - *
can - *
not - *
bind - *
to - *
the - *
template - *
as - *
obtained - *
by - *
the - *
mutation - *
M1 - *
(Figure - *
4A - *
compare - *
lanes - *
1 - *
and - *
4; - *
Figure - *
4C - *
compare - *
Wt - *
and - *
M1) - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
the - (A0*
mutations - *)
abolishing abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A0*
mutations - *)
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A0*
mutations - *)
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element	 - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A1*
A/T-rich - *
element - *)
is - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A1*
A/T-rich - *
element - *)
was - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *)
completely - *
abolished abolish (V*) *
synergy - (A1*)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *)
completely - *
abolishes abolish (V*) *
synergy - (A1*)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *)
completely - *
abolishes abolish (V*) *
synergy - (A1*)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Synergy - (A1*)
is - *
completely - *
abolished abolish (V*) *
by - *
mutation - *
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *)
or - *
the - *
&amp;#8211;135 - *
bp - *
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Synergy - (A1*)
was - *
completely - *
abolished abolish (V*) *
by - *
mutation - *
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *)
or - *
the - *
&amp;#8211;135 - *
bp - *
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

In - *
contrast - *
transcriptional - (A1*
stimulation - *)
is - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished - *)
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

In - *
contrast - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Insertions - *)
which - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
Alp - (A1*
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
Alp - (A1*
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
. - *

Insertions - (A0*
which - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Alp - (A1*
activity - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Alp - (A1*
activity - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Insertions - (A0*
which - *)
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *)
abolish abolish (V*) *
completely - *
Alp - (A1*
activity - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
Alp - (A1*
activity - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Insertions - *)
which - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
introduced - *
to - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
Alp - (A1*
activity	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
Alp - (A1*
activity - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
Alp - (A1*
activity - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Insertions - *)
which - *
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Insertions - (A0*
which - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *)
. - *

In - *
contrast - *
Alp - (A1*
activity - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Alp - (A1*
activity - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Insertions - (A0*
which - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *)
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
which - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
which - *
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *)
. - *

Insertions - (A0*
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *)
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *)
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish - *)
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *)
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *)
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished - *)
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *)
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
will - *
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *)
. - *

Insertions - *)
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished - *)
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
has - *
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
this - *
open - *)
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
this - *
open - *
reading - *
frame - *)
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

the - (A1*
CPP - *
effect - *)
this - *)
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

the - (A1*
A/T-rich - *
element - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

synergy - (A1*)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

transcriptional - (A1*
stimulation - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
this - *
open - *)
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
this - *
open - *
reading - *
frame - *)
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

the - (A1*
CPP - *
effect - *)
this - *)
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

the - (A1*
A/T-rich - *
element - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

synergy - (A1*)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

transcriptional - (A1*
stimulation - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
torC - (A1*
induction - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
torC - (A1*
induction - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
torC - (A1*
induction - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *)
abolish abolish (V*) *
completely - *
torC - (A1*
induction - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
torC - (A1*
induction - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
introduced - *
to - *
abolish abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
torC - (A1*
induction	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
torC - (A1*
induction - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
torC - (A1*
induction - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *)
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
torC - (A1*
induction - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *
contrast - *
torC - (A1*
induction - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
torC - (A1*
induction - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *)
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *)
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *)
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
which - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *)
which - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
synergy - (A1*)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

However - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
did - *
not - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
does - *
not - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
which - *
does - *
not - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
is - *
not - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
was - *
not - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

co-administered - (A0*
DM - *)
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

Co-administered - *)
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *
which - *
was - *
able - *
to - *
abolish - *)
completely - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A0*
mutations - *)
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
introduced - *
to - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
abolishing abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
abolishes abolish (V*) *
synergy - (A1*)
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *)
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *)
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *)
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

In - *
contrast - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
was - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
is - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
which - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

co-administered - (A0*
DMwhich - *)
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

the - (A0*
mutations - *)
which - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
which - *
abolishes abolish (V*) *
synergy - (A1*)
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

co-administered - (A0*
DM - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

the - (A0*
mutations - *)
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
abolished abolish (V*) *
synergy - (A1*)
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

co-administered - (A0*
DMwhich - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

the - (A0*
mutations - *)
which - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
which - *
abolished abolish (V*) *
synergy - (A1*)
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

However - *
co-administered - (A0*
DM - *)
did - *
not - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *)
its - (A1*
BCFA - *
biosynthesis - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
its - (A1*
BCFA - *
biosynthesis - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *
effect - *)
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

However - *
the - (A0*
mutations - *)
 - *
did - *
not - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
introduced - *
to - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolishing abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis	 - *)
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
its - (A1*
BCFA - *
biosynthesis - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
its - (A1*
BCFA - *
biosynthesis - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

However - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
did - *
not - *
abolish abolish (V*) *
synergy - (A1*)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

However - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
did - *
not - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

In - *
contrast - *
its - (A1*
BCFA - *
biosynthesis - *)
was - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
its - (A1*
BCFA - *
biosynthesis - *)
is - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

However - *
co-administered - (A0*
DM - *)
does - *
not - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A0*
mutations - *)
 - *
does - *
not - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
does - *
not - *
abolish abolish (V*) *
synergy - (A1*)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
does - *
not - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
co-administered - (A0*
DM - *)
which - *
does - *
not - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A0*
mutations - *)
 - *
which - *
does - *
not - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
which - *
does - *
not - *
abolish abolish (V*) *
synergy - (A1*)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
does - *
not - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A1*
CPP - *
effect - *)
is - *
not - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A1*
A/T-rich - *
element - *)
is - *
not - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *)
synergy - (A1*)
is - *
not - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
transcriptional - (A1*
stimulation - *)
is - *
not - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A1*
CPP - *
effect - *)
was - *
not - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A1*
A/T-rich - *
element - *)
was - *
not - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *)
synergy - (A1*)
was - *
not - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
transcriptional - (A1*
stimulation - *)
was - *
not - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Co-administered - *)
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
the - (A1*
A/T-rich - *
element - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
co-administered - (A0*
DMintroduced - *)
to - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
co-administered - (A0*
DM - *)
abolishing abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
co-administered - (A0*
DM - *)
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
co-administered - (A0*
DM - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *)
sequence - *
indicates - *
that - *
the - (A1*
CPP - *
effect - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *)
sequence - *
indicates - *
that - *
the - (A1*
CPP - *
effect - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
synergy - (A1*)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *)
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
transcriptional - (A1*
stimulation - *)
induced - *)
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

In - *
contrast - *
the - (A1*
CPP - *
effect - *)
was - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A1*
CPP - *
effect - *)
is - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
co-administered - (A0*
DM - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
co-administered - (A0*
DM - *)
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
co-administered - (A0*
DM - *)
which - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
the - (A1*
A/T-rich - *
element - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
synergy - (A1*)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *)
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
transcriptional - (A1*
stimulation - *)
induced - *)
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *
effect - *)
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
the - (A0*
mutations - *)
 - *
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

The - (A1*)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *
effect - *
was - *)
be - *
able - *
to - *
be - *
abolised - *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
introduced - *
to - *
abolish abolish (V*) *
synergy - (A1*)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
introduced - *
to - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

In - *
contrast - *
the - (A1*
A/T-rich - *
element - *)
was - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A1*
A/T-rich - *
element - *)
is - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
mutations - *)
 - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
mutations - *)
 - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
mutations - *)
 - *
which - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
abolishing abolish (V*) *
synergy - (A1*)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolishing abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
abolish abolish (V*) *
synergy - (A1*)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
abolished abolish (V*) *
synergy	 - (A1*)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolished abolish (V*) *
transcriptional - (A1*
stimulation	 - *)
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
synergy - (A1*)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
transcriptional - (A1*
stimulation - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - *)
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
synergy - (A1*)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
transcriptional - (A1*
stimulation - *)
was - *
abolished abolish (V*) *
by - *)
the - *
mutations - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *)
bp - *
promoter - *
completely - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

In - *)
contrast - *
synergy - (A1*)
was - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *)
contrast - *
synergy - (A1*)
is - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *)
contrast - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
abolished abolish (V*) *
synergy - (A1*)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *)
contrast - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
abolishes abolish (V*) *
synergy - (A1*)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *)
contrast - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
which - *
abolishes abolish (V*) *
synergy - (A1*)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *)
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *)
bp - *
which - *
completely - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

acid - (A1*
resistance - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Furthermore - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
completely - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
completely - *
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
completely - *
has - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
completely - *
will - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
also - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
also - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
also - *
has - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
also - *
will - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

Alp - (A1*
activity - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
will - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
has - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

torC - (A1*
induction - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *)
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *)
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *)
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *)
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
HA - (A1*
and - *)
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Insertions - *)
which - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *)
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *)
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *)
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *)
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
has - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
were - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
genewhich - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

its - (A1*
BCFA - *
biosynthesis - *)
were - *
abolished abolish (V*) *
by - *
disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

However - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
did - *
not - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
does - *
not - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
does - *
not - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
is - *
not - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
was - *
not - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

the - (A1*
CPP - *
effect - *)
were - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *)
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *)
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A1*
A/T-rich - *
element - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
introduced - *
to - *
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolishing abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolish abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A1*
and - *
curli - *)
production - *
by - *
strain - *
chi7122 - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A1*
and - *
curli - *)
production - *
by - *
strain - *
chi7122 - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

synergy - (A1*)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *)
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *)
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *)
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

transcriptional - (A1*
stimulation - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *)
subunit - *
gene - *
. - *

In - *
contrast - *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
was - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
is - *
abolished abolish (V*) *
by - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
which - *
abolishes abolish (V*) *
HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

acid - (A1*
resistance - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Alp - (A1*
activity - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

torC - (A1*
induction - *)
are - *
abolished abolish (V*) *
by - *
disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
are - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
are - *
abolished abolish (V*) *
by - *
disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
are - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
A/T-rich - *
element - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

synergy - (A1*)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

transcriptional - (A1*
stimulation - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *)
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

Disruption - (A0*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *)
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Disruption - (A0*)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
torC - (A1*
induction - *)
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolished abolish (V*) *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *)
gene - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

Disruption - (A0*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
synergy - (A1*)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

Disruption - (A0*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *)
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Disruption - (A0*)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
torC - (A1*
induction - *)
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
abolish abolish (V*) *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *)
gene - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
. - *

Disruption - (A0*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
synergy - (A1*)
. - *

Disruption - (A0*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

acid - (A1*
resistance - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Alp - (A1*
activity - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

torC - (A1*
induction - *)
has - *
been - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
has - *
been - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
has - *)
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
A/T-rich - *
element - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

synergy - (A1*)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

transcriptional - (A1*
stimulation - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *)
curli - *
subunit - *
gene - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

acid - (A1*
resistance - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Alp - (A1*
activity - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

torC - (A1*
induction - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
will - *
be - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
will - *)
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
A/T-rich - *
element - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

synergy - (A1*)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

transcriptional - (A1*
stimulation - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *)
curli - *
subunit - *
gene - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

acid - (A1*
resistance - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Alp - (A1*
activity - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

torC - (A1*
induction - *)
which - *
were - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
which - *
were - *
abolished abolish (V*) *
by - *)
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
which - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
A/T-rich - *
element - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

synergy - (A1*)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

transcriptional - (A1*
stimulation - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Furthermore - *)
This - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
completely - *
abolished abolish (V*) *
acid - *
resistance - *
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
This - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
completely - *
abolishes abolish (V*) *
acid - *
resistance - *
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
This - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
completely - *
has - *
abolished abolish (V*) *
acid - *
resistance - *
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
This - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
completely - *
will - *
abolish abolish (V*) *
acid - *
resistance - *
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
was - *)
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
also - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

This - (A0*
acid - *
resistance - *)
also - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

This - (A0*
acid - *
resistance - *)
also - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

This - (A0*
acid - *
resistance - *)
also - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

Insertions - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
which - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

This - (A0*
acid - *
resistance - *)
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

This - (A0*
acid - *
resistance - *)
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

This - (A0*
acid - *
resistance - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

This - (A0*
acid - *
resistance - *)
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

This - (A0*
acid - *
resistance - *)
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *)
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

This - (A1*
acid - *
resistance - *)
were - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

This - (A1*
acid - *
resistance - *)
are - *
abolished - *)
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *)
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
This - (A0*
acid - *
resistance - *)
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *)
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
This - (A0*
acid - *
resistance - *)
. - *

This - (A1*
acid - *
resistance - *)
has - *
been - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

This - (A1*
acid - *
resistance - *)
will - *
be - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

This - *)
acid - *
resistance - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Insertions - *)
which - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

deletion - (A1*
of - *)
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

This - (A0*
acid - *
resistance - *)
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

This - (A0*
acid - *
resistance - *)
which - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

This - (A0*
acid - *
resistance - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

This - (A0*
acid - *
resistance - *)
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

However - *
This - (A0*
acid - *
resistance - *)
did - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
This - (A0*
acid - *
resistance - *)
does - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
This - (A0*
acid - *
resistance - *)
which - *
does - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
is - *
not - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
was - *
not - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

co-administered - *)
DM - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Co-administered - *)
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
This - (A0*
acid - *
resistance - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A1*
mutations - *)
 - *
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
This - (A0*
acid - *
resistanceintroduced - *)
to - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
This - (A0*
acid - *
resistance - *)
abolishing abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
This - (A0*
acid - *
resistance - *)
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
This - (A0*
acid - *
resistance - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE	 - *)
. - *

The - (A0*
A/T-rich - *)
mut - *
sequence - *
indicates - *
that - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *)
mut - *
sequence - *
indicates - *
that - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutation - (A0*
of - *)
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *)
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *)
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
was - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

In - *
contrast - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
was - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
is - *
abolished abolish (V*) *
by - *
This - (A0*
acid - *
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
This - (A0*
acid - *
resistance - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
This - (A0*
acid - *
resistance - *)
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
This - (A0*
acid - *
resistance - *)
which - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Insertions - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
is - *
abolished - *)
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

co-administered - *)
DM - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

the - (A1*
mutations - *)
 - *
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
is - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
has - *)
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Insertions - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
been - *
abolished - *)
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

co-administered - *)
DM - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

the - (A1*
mutations - *)
 - *
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
has - *
been - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
will - *)
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Insertions - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

HA - (A1*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
be - *
abolished - *)
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

co-administered - *)
DM - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

the - (A1*
mutations - *)
 - *
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
will - *
be - *
abolished abolish (V*) *
by - *
deletion - *
of - *
ydeP - *
ydeO - *
or - *
yhiE - *
which - *
was - *
induced - *
by - *
EvgA - *
overexpression - *
. - *

Furthermore - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
completely - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
also - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
also - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
also - *
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
also - *
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

Furthermore - *
Insertions - (A0*)
completely - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
which - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
which - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

Furthermore - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
completely - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *)
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
the - (A0*
deletion - *
of - *
yhiE - *)
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
deletion - *)
of - *
yhiE - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Insertions - (A0*
which - *)
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish - *)
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished - *)
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished - *)
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
completely - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
abolishes abolish (V*) *
acid - (A1*
resistance - *)
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
which - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
. - *

the - (A0*
deletion - *
of - *
yhiE - *)
which - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
. - *

Furthermore - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
completely - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

However - *
the - (A0*
deletion - *
of - *
yhiE - *)
did - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A0*
deletion - *
of - *
yhiE - *)
does - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
the - (A0*
deletion - *
of - *
yhiE - *)
which - *
does - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
acid - (A1*
resistance - *)
is - *
not - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
acid - (A1*
resistance - *)
was - *
not - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Furthermore - *
co-administered - (A0*
DM - *)
completely - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Co-administered - *)
DM - *
which - *
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
acid - (A1*
resistance - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
acid - (A1*
resistance - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - (A1*
CPP - *)
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Furthermore - *
the - (A0*
mutations - *)
 - *
completely - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
the - (A0*
deletion - *
of - *
yhiEintroduced - *)
to - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
the - (A0*
deletion - *
of - *
yhiE - *)
abolishing abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A0*
deletion - *
of - *
yhiE - *)
abolish abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
the - (A0*
deletion - *
of - *
yhiE - *)
abolished abolish (V*) *
acid - (A1*
resistance	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *)
sequence - *
indicates - *
that - *
acid - (A1*
resistance - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *)
sequence - *
indicates - *
that - *
acid - (A1*
resistance - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Furthermore - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
completely - *
abolished abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Furthermore - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
completely - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

In - *
contrast - *
acid - (A1*
resistance - *)
was - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
acid - (A1*
resistance - *)
is - *
abolished abolish (V*) *
by - *
the - (A0*
deletion - *
of - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
deletion - *
of - *
yhiE - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
deletion - *
of - *
yhiE - *)
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
the - (A0*
deletion - *
of - *
yhiE - *)
which - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Furthermore - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
completely - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Insertions - (A0*)
completely - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
completely - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
completely - *
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
completely - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
co-administered - (A0*
DM - *)
completely - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
mutations - *)
 - *
completely - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
completely - *
abolishes abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
completely - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
completely - *
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Insertions - (A0*)
completely - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
completely - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
has - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
completely - *
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
completely - *
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
co-administered - (A0*
DM - *)
completely - *
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
mutations - *)
 - *
completely - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
completely - *
has - *
abolished abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
completely - *
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
completely - *
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Insertions - (A0*)
completely - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
completely - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
will - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
completely - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
completely - *
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
completely - *
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
co-administered - (A0*
DM - *)
completely - *
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
the - (A0*
mutations - *)
 - *
completely - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
completely - *
will - *
abolish abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
completely - *
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

Insertions - (A0*)
also - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
also - *
abolished abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - *)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
were - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
are - *)
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *)
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

Disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *)
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
has - *)
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
will - *)
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutations - (A1*
in - *
the - *
fhlA - *
gene - *)
which - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Furthermore - (A0*
the - *
deletion - *)
of - *
yhiE - *
completely - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *)
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *)
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *)
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Insertions - (A0*
which - *
abolish - *)
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *
abolished - *)
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish - *)
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished - *)
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

production - (A1*
of - *
the - *
hydrogenase - *)
activity - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolished abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
also - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
also - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

However - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
did - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
does - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
does - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
is - *
not - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
was - *
not - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

co-administered - (A0*
DM - *)
also - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Co-administered - (A0*
DM - *
which - *)
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - (A0*
DM - *
which - *)
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A0*
mutations - *)
 - *
also - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
introduced - *
to - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolishing abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity	 - *)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
also - *
abolished abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
also - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

In - *
contrast - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
was - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
is - *
abolished abolish (V*) *
by - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Mutations - (A0*
in - *
the - *
fhlA - *
gene - *)
which - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Insertions - (A0*)
also - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
also - *
abolish abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
abolish abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
also - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
also - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

co-administered - (A0*
DM - *)
also - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
mutations - *)
 - *
also - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
also - *
abolish abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
also - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Insertions - (A0*)
also - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
also - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
has - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
also - *
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
also - *
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

co-administered - (A0*
DM - *)
also - *
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
mutations - *)
 - *
also - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
also - *
has - *
abolished abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
also - *
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Insertions - (A0*)
also - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
also - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
will - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
also - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
also - *
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
also - *
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

co-administered - (A0*
DM - *)
also - *
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

the - (A0*
mutations - *)
 - *
also - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
also - *
will - *
abolish abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
also - *
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

acid - (A1*
resistance - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*)
addition - *
deletion - *
of - *
the - *
distal - *
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Insertions - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
Insertions - (A0*)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
Insertions - (A0*)
. - *

Insertions - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Insertions - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Insertions - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Furthermore - (A0*)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*)
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*)
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

Alp - (A1*
activity - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutations - (A0*)
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*)
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*)
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Alp - (A1*
activity - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
which - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*)
abolishes abolish (V*) *
Alp - (A1*
activity - *)
. - *

Insertions - (A0*)
which - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
. - *

Insertions - (A0*)
abolished abolish (V*) *
Alp - (A1*
activity - *)
. - *

Insertions - (A0*)
which - *
abolished abolish (V*) *
Alp - (A1*
activity - *)
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

However - *
Insertions - (A0*)
did - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Insertions - (A0*)
does - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Insertions - (A0*)
which - *
does - *
not - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Alp - (A1*
activity - *)
is - *
not - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
Alp - (A1*
activity - *)
was - *
not - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

co-administered - (A0*
DM - *)
which - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

The - *)
CPP - *
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
Insertions - (A0*)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A0*
mutations - *)
 - *
which - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Insertionsintroduced - (A0*)
to - *
abolish abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
Insertions - (A0*)
abolishing abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Insertions - (A0*)
abolish abolish (V*) *
Alp - (A1*
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
Insertions - (A0*)
abolished abolish (V*) *
Alp - (A1*
activity	 - *)
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
which - *
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

In - *
contrast - *
Alp - (A1*
activity - *)
was - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Alp - (A1*
activity - *)
is - *
abolished abolish (V*) *
by - *
Insertions - (A0*)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Insertions - (A0*)
abolished abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Insertions - (A0*)
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
Insertions - (A0*)
which - *
abolishes abolish (V*) *
Alp - (A1*
activity - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
which - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

co-administered - (A0*
DM - *)
which - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
mutations - *)
 - *
which - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
which - *
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

co-administered - (A0*
DM - *)
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
mutations - *)
 - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

co-administered - (A0*
DM - *)
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
mutations - *)
 - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

co-administered - (A0*
DM - *)
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
mutations - *)
 - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
will - *
abolish abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

co-administered - (A0*
DM - *)
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

the - (A0*
mutations - *)
 - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Mutation - *)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
has - *
abolished abolish (V*) *
synergy - (A1*)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

acid - (A1*
resistance - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

the - (A1*
CPP - *
effect - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
co-administered - (A0*
DM - *)
. - *

the - (A1*
A/T-rich - *
element - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
the - (A0*
mutations - *)
 - *
. - *

synergy - (A1*)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

transcriptional - (A1*
stimulation - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

deletion - *)
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *)
completely - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *)
completely - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *)
completely - *
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *)
completely - *
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

torC - (A1*
induction - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolished - *)
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolish - *)
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
has - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
will - *)
abolish abolish (V*) *
torC - (A1*
induction - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *)
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

torC - (A1*
induction - *)
associated - *
with - *
formate - *)
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

Insertions - (A0*
which - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
will - *
abolish abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

Insertions - (A0*
has - *
abolished abolish (V*) *
torC - (A1*
induction - *)
interrupt - *
this - *
open - *
reading - *
frame - *
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
was - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

torC - (A1*
induction - *)
this - *
open - *
reading - *
frame - *
is - *
abolished abolish (V*) *
by - *
Insertions - *
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolishes abolish (V*) *
torC - (A1*
induction - *)
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
. - *

deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
abolished abolish (V*) *
torC - (A1*
induction - *)
. - *

However - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
did - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
does - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
does - *
not - *
abolish abolish (V*) *
torC - (A1*
induction - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
torC - (A1*
induction - *)
is - *
not - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
torC - (A1*
induction - *)
was - *
not - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

The - (A1*
CPP - *)
effect - *
was - *
be - *
able - *
to - *
be - *
abolised - *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1)introduced - *)
to - *
abolish abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolishing abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolish abolish (V*) *
torC - (A1*
induction - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolished abolish (V*) *
torC - (A1*
induction	 - *)
. - *

In - *
contrast - *
torC - (A1*
induction - *)
was - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
torC - (A1*
induction - *)
is - *
abolished abolish (V*) *
by - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolished abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
deletion - (A0*
of - *
the - *
distal - *
tor - *
box - *
( - *
box1) - *)
which - *
abolishes abolish (V*) *
torC - (A1*
induction - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
will - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
has - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
which - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

In - (A0*
addition - *
deletion - *
of - *
the - *
distal - *)
tor - *
box - *
(box1) - *
which - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
the - *
presence - *
of - *
a - *
DNA - *
fragment - *
starting - *
three - *
bases - *
upstream - *
from - *
box1 - *
suffices - *
for - *
normal - *
torC - *
expression - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

co-administered - *)
DM - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Co-administered - (A0*
DM - *
which - *
is - *
able - *
to - *)
abolish abolish (V*) *
completely - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Co-administered - *)
DM - *
which - *
was - *
able - *
to - *
abolish abolish (V*) *
completely - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

the - (A1*
mutations - *)
 - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
introduced - *
to - *
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene	 - *)
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
is - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

The - (A0*
A/T-rich - *
mut - *
sequence - *
indicates - *)
that - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
was - *
abolished abolish (V*) *
by - *
the - *
mutations - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
promoter - *
completely - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *)
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
which - *
completely - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
indicating - *
that - *
this - *
element - *
is - *
essential - *
for - *
MEF2 - *
&amp;#8211;GATA-4 - *
cooperation - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

In - *
contrast - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
disruption - (A1*
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

co-administered - *)
DM - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
mutations - *)
 - *
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
are - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
co-administered - (A0*
DM - *)
. - *

Disruption - (A1*
of - *)
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
the - (A0*
mutations - *)
 - *
. - *

Disruption - (A1*)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

Disruption - (A1*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolished abolish (V*) *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
Linomide - (A0*
and - *
antibody-targeted - *
superantigen - *
therapy - *)
 - *
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
this - (A0*
complete - *
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
. - *

Disruption - *)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
co-administered - (A0*
DM - *)
. - *

Disruption - (A1*
of - *)
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
the - (A0*
mutations - *)
 - *
. - *

Disruption - (A1*)
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
Mutation - (A0*
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
. - *

Disruption - (A1*
of - *
rpoS - *)
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
abolish abolish (V*) *
further - (A0*
deletion - *
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

co-administered - *)
DM - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
mutations - *)
 - *
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
has - *
been - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

co-administered - *)
DM - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
mutations - *)
 - *
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
will - *
be - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Linomide - (A1*
and - *
antibody-targeted - *
superantigen - *)
therapy - *)
 - *
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

this - (A1*
complete - *)
removal - *
of - *
FabD - *
from - *
the - *
crude - *
FAS - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

co-administered - *)
DM - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

the - (A1*
mutations - *)
 - *
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

Mutation - (A1*)
of - *
the - *
proximal - *
GATA - *
element - *
in - *
the - *
context - *
of - *
the - *
&amp;#8211;700 - *
or - *
the - *
&amp;#8211;135 - *
bp - *
 - *
 - *
 - *
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

further - (A1*
deletion - *)
of - *
the - *
C-terminal - *
transactivation - *
domain - *
in - *
the - *
Pax5 - *
mutants - *
B8 - *
and - *
B9 - *)
which - *
were - *
abolished abolish (V*) *
by - *
disruption - *
of - *
rpoS - *
mlrA - *
or - *
csgA - *
the - *
curli - *
subunit - *
gene - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122introduced - *)
to - *
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE	 - *)
. - *

In - *
contrast - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
deletion - (A1*
of - *
ydeP - *
ydeO - *
or - *
yhiE - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *)
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
acid - (A1*
resistance - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
acid - (A1*
resistance - *)
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
acid - (A1*
resistance - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
acid - (A1*
resistance - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Furthermore - (A0*
the - *)
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
introduced - *
to - *
abolish abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
acid - (A1*
resistance - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
acid - (A1*
resistance	 - *)
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *)
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

In - *
contrast - *
acid - (A1*
resistance - *)
was - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
acid - (A1*
resistance - *)
is - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

In - *
contrast - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
acid - (A1*
resistance - *)
whereas - *
internal - *
deletion - *
of - *
the - *
conserved - *
octapeptide - *
motif - *
(OP) - *
or - *
the - *
partial - *
homeodomain - *
(HD) - *
of - *
Pax5 - *
did - *
not - *
have - *
any - *
effect - *
(Figure - *
3B) - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *)
abolishes abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *)
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
abolishes abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *)
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *)
has - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *)
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *)
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *)
will - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *)
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - *)
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *)
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

Furthermore - (A0*
the - *
deletion - *
of - *
yhiE - *
completely - *
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *)
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

the - (A1*
CPP - *
effect - *)
in - *)
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *)
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *)
role - *
in - *
stationary-phase - *
acid - *
resistance - *
is - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
in - *
stationary-phase - *)
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
in - *
stationary-phase - *
cells - *)
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

the - (A1*
CPP - *
effect - *)
in - *)
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

the - (A1*
A/T-rich - *
element - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

synergy - (A1*)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *
role - *
in - *
stationary-phase - *
acid - *)
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

transcriptional - (A1*
stimulation - *)
in - *
stationary-phase - *
cells - *
suggesting - *
that - *
YhiE - *
plays - *
a - *
critical - *)
role - *
in - *
stationary-phase - *
acid - *
resistance - *
was - *
completely - *
abolished abolish (V*) *
by - *
the - *
deletion - *
of - *
yhiE - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolishes abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
abolished abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
did - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
does - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
which - *
does - *
not - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
is - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

However - *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
was - *
not - *
abolished abolish (V*) *
by - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
but - *
only - *
reduced - *
the - *
level - *
to - *
50-60% - *
of - *
the - *
control - *
level - *
for - *
acyl-CoA - *
primer - *
and - *
to - *
80% - *
for - *
alpha-keto-beta-methylvalerate - *
primer - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122introduced - *)
to - *
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolishing abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

The - *
A/T-rich - *
mut - *
sequence - *
indicates - *
that - *
HA - (A0*
and - *
curli - *
production - *
by - *
strain - *
chi7122 - *)
abolish abolish (V*) *
production - (A1*
of - *
the - *
hydrogenase - *
activity - *)
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *)
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
its - (A1*
BCFA - *)
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *)
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished - *)
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished - *)
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
has - *
abolished abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish - *)
formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *)
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
the - (A1*
CPP - *
effect - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - *)
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
. - *

Mutations - (A0*
in - *
the - *
fhlA - *
gene - *
also - *
will - *
abolish abolish (V*) *
transcriptional - (A1*
stimulation - *)
associated - *
with - *)
formate - *
hydrogenlyase - *
activity - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *)
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

the - (A1*
A/T-rich - *
element - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

synergy - (A1*)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

transcriptional - (A1*
stimulation - *)
associated - *
with - *
formate - *
hydrogenlyase - *
activity - *
are - *
abolished - *)
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

formation - (A1*
of - *
liver - *
metastases - *
in - *
mice - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

its - (A1*
BCFA - *
biosynthesis - *)
associated - *
with - *
formate - *)
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

the - (A1*
CPP - *
effect - *)
associated - *)
with - *
formate - *
hydrogenlyase - *
activity - *
were - *
abolished abolish (V*) *
by - *
Mutations - *
in - *
the - *
fhlA - *
gene - *
. - *

The - (A0*
cpx101 - *
mutation - *)
abolishes abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
results - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

The - (A0*
cpx101 - *
mutation - *)
abolished abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
resulted - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

The - (A0*
cpx101 - *
mutation - *)
will - *
abolish abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
results - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

The - (A0*
cpx101 - *
mutation - *)
has - *
abolished abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
resulted - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

The - (A0*
cpx101 - *
mutation - *)
which - *
abolishes abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
results - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

The - (A0*
cpx101 - *
mutation - *)
which - *
abolished abolish (V*) *
cpxA - (A1*
phosphatase - *
activity - *)
and - *
resulted - *
in - *
the - *
accumulation - *
of - *
phosphorylated - *
CpxR - *
. - *

This - (A0*
intronic - *
mutation - *)
which - *
segregates - *
in - *
a - *
dominant - *
and - *
fully - *
penetrant - *
manner - *
over - *
three - *
generations - *
abolished abolish (V*) *
normal - (A1*
LHX4 - *
splicing - *)
and - *
activates - *
two - *
exonic - *
cryptic - *
splice - *
sites - *
thereby - *
predicting - *
two - *
different - *
proteins - *
deleted - *
in - *
their - *
homeodomain - *
sequence - *
. - *

Normal - (A1*
LHX4 - *
splicing - *)
is - *
abolishes abolish (V*) *
by - *
this - (A0*
intronic - *
mutation - *)
which - *
segregates - *
in - *
a - *
dominant - *
and - *
fully - *
penetrant - *
manner - *
over - *
three - *
generations - *
and - *
activates - *
two - *
exonic - *
cryptic - *
splice - *
sites - *
thereby - *
predicting - *
two - *
different - *
proteins - *
deleted - *
in - *
their - *
homeodomain - *
sequence - *
. - *

Normal - (A1*
LHX4 - *
splicing - *)
was - *
abolished abolish (V*) *
by - *
this - (A0*
intronic - *
mutation - *)
which - *
segregates - *
in - *
a - *
dominant - *
and - *
fully - *
penetrant - *
manner - *
over - *
three - *
generations - *
and - *
activates - *
two - *
exonic - *
cryptic - *
splice - *
sites - *
thereby - *
predicting - *
two - *
different - *
proteins - *
deleted - *
in - *
their - *
homeodomain - *
sequence - *
. - *

This - (A0*
intronic - *
mutation - *)
which - *
abolishes abolish (V*) *
normal - (A1*
LHX4 - *
splicing - *)
and - *
activates - *
two - *
exonic - *
cryptic - *
splice - *
sites - *
thereby - *
predicting - *
two - *
different - *
proteins - *
deleted - *
in - *
their - *
homeodomain - *
sequence - *
. - *

This - (A0*
intronic - *
mutation - *)
that - *
abolished abolish (V*) *
normal - (A1*
LHX4 - *
splicing - *)
and - *
activates - *
two - *
exonic - *
cryptic - *
splice - *
sites - *
thereby - *
predicting - *
two - *
different - *
proteins - *
deleted - *
in - *
their - *
homeodomain - *
sequence - *
. - *

A - (A0*
G-to-A - *
transition - *
at - *
the - *
first - *
nucleotide - *
of - *
intron - *
2 - *)
of - *
patient - *
1 - *
abolishes abolish (V*) *
normal - (A1*
splicing - *)
. - *

A - (A0*
G-to-A - *
transition - *
at - *
the - *
first - *
nucleotide - *
of - *
intron - *
2 - *)
of - *
patient - *
1 - *
abolished abolish (V*) *
normal - (A1*
splicing - *)
. - *

Normal - (A1*
splicing - *)
is - *
abolished abolish (V*) *
by - *
a - (A0*
G-to-A - *
transition - *
at - *
the - *
first - *
nucleotide - *
of - *
intron - *
2 - *)
of - *
patient - *
1 - *
. - *

Normal - (A1*
splicing - *)
was - *
abolished abolish (V*) *
by - *
a - (A0*
G-to-A - *
transition - *
at - *
the - *
first - *
nucleotide - *
of - *
intron - *
2 - *)
of - *
patient - *
1 - *
. - *

One - (A0*
mutation - *)
abolishes abolish (V*) *
RNA - (A1*
expression - *)
from - *
the - *
altered - *
allele - *
. - *

One - (A0*
mutation - *)
abolished abolish (V*) *
RNA - (A1*
expression - *)
from - *
the - *
altered - *
allele - *
. - *

RNA - (A1*
expression - *)
is - *
abolished abolish (V*) *
by - *
one - (A0*
mutation - *)
from - *
the - *
altered - *
allele - *
. - *

RNA - (A1*
expression - *)
was - *
abolished abolish (V*) *
by - *
one - (A0*
mutation - *)
from - *
the - *
altered - *
allele - *
. - *

One - (A0*
mutation - *)
which - *
abolishes abolish (V*) *
RNA - (A1*
expression - *)
from - *
the - *
altered - *
allele - *
. - *

One - (A0*
mutation - *)
which - *
abolished abolish (V*) *
RNA - (A1*
expression - *)
from - *
the - *
altered - *
allele	 - *
. - *

Our - *
results - *
showed - *
that - *
co-administered - (A0*
DM - *)
is - *
able - *
to - *
abolish abolish (V*) *
completely - *
the - (A1*
CPP - *
effect - *)
induced - *
by - *
morphine - *
but - *
had - *
no - *
effect - *
on - *
morphine-induced - *
behavioral - *
sensitization - *
. - *

Groucho - (A1*
binding - *)
was - *
abolished abolish (V*) *
by - *
mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Groucho - (A1*
binding - *)
is - *
abolished abolish (V*) *
by - *
mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
abolishes abolish (V*) *
groucho - (A1*
binding - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
abolished abolish (V*) *
groucho - (A1*
binding - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
which - *
abolishes abolish (V*) *
groucho - (A1*
binding - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Mutating - (A0*
a - *
conserved - *
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *)
which - *
abolished abolish (V*) *
groucho - (A1*
binding - *)
(Jimnez - *
et - *
al - *
1999) - *
. - *

Since - *
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
this - (A0*
mutation - *)
which - *
altered alter (V*) *
vulval - (A1*
induction - *)
. - *

Since - *
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
vulval - (A1*
induction - *)
is - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
. - *

Since - *
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
vulval - (A1*
induction - *)
was - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
vulval - (A1*
induction - *)
 - *
was - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
altered alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A0*
change - *
in - *
DNA - *
conformationwhich - *)
alters alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A0*
change - *
in - *
DNA - *
conformationwhich - *)
altered alter (V*) *
vulval - *
induction - *
. - *

Since - (A0*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A1*
specific - *
protein - *
&amp;#8211is - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Since - (A0*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A1*
specific - *
protein - *
&amp;#8211was - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
this - (A0*
mutation - *)
 - *
subtly - *
alters alter (V*) *
vulval - (A1*
induction - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *)
allele - *
we - *
tested - *
whether - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
alters alter (V*) *
vulval - *
induction - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
this - (A0*
mutation - *)
 - *
subtly - *
altered alter (V*) *
vulval - (A1*
induction - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Since - *)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sourcesis - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
a - (A0*
fruR - *
null - *
mutationwhich - *)
altered alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
a - (A0*
fruR - *
null - *
mutationwhich - *)
alters alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
a - (A0*
fruR - *
null - *
mutation - *)
altered alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
a - (A0*
fruR - *
null - *
mutation - *)
alters alter (V*) *
vulval - *
induction - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
a - (A0*
fruR - *
null - *
mutation - *)
subtly - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
a - (A0*
fruR - *
null - *
mutation - *)
subtly - *
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
was - *
altered alter (V*) *
by - *
a - (A0*
fruR - *
null - *
mutation; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
is - *
altered alter (V*) *
by - *
a - (A0*
fruR - *
null - *
mutation; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
a - (A0*
fruR - *
null - *
mutation - *)
which - *
subtly - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
a - (A0*
fruR - *
null - *
mutation - *)
which - *
subtly - *
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Since - *)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
was - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Moreover - *
they - (A0*)
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Since - *)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
is - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
a - (A0*
fruR - *
null - *
mutation - *)
did - *
not - *
alter alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources(Figure - *)
3C) - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
a - (A0*
fruR - *
null - *
mutation - *)
do - *
not - *
alter alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources(Figure - *)
3C) - *
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
alters alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
was - *
altered alter (V*) *
by - *
mutations; - (A0*)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
is - *
altered alter (V*) *
by - *
mutations; - (A0*)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
mutations - (A0*)
which - *
subtly - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
mutations - (A0*)
which - *
subtly - *
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
mutations - (A0*)
did - *
not - *
alter alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources(Figure - *)
3C) - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
mutations - (A0*)
do - *
not - *
alter alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources(Figure - *)
3C) - *
. - *

Since - (A0*)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sourceswas - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
mutationswhich - (A0*)
altered alter (V*) *
vulval - *
induction - *
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
has - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
has - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
alters alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
mutationswhich - (A0*)
alters alter (V*) *
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
mutationsaltered - (A0*)
vulval - *
induction - *
. - *

Since - (A1*
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *)
mutationsalters - (A0*)
vulval - *
induction - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
mutations - (A0*)
subtly - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
mutations - (A0*)
subtly - *
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources; - *)
DNA - *
interactions - *
observed - *
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
which - *
alters alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
which - *
alters alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *
they - (A0*)
which - *
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
which - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
which - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *
they - (A0*)
which - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
will - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
will - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *
they - (A0*)
will - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
has - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
has - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *
they - (A0*)
has - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *
this - (A0*
mutation - *)
 - *
alters alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
alters alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *
they - (A0*)
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
has - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
will - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
will - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
will - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
which - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
which - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
which - *
altered alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Moreover - (A0*)
a - *
fruR - *
null - *
mutation - *
which - *
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
. - *

Moreover - (A0*
a - *
fruR - *
null - *)
mutation - *
which - *
alters alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
. - *

Moreover - *)
a - *
fruR - *
null - *
mutation - *
which - *
alters alter (V*) *
vulval - (A1*
induction - *)
 - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
do - *
not - *
alter alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211(Figure - *)
3C) - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
they - (A0*)
which - *
subtly - *
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
they - (A0*)
which - *
subtly - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
is - *
altered alter (V*) *
by - *
they; - (A0*)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
was - *
altered alter (V*) *
by - *
they; - (A0*)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
they - (A0*)
subtly - *
alters alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
they - (A0*)
subtly - *
altered alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA; - *)
DNA - *
interactions - *
observed - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
this - (A0*
mutation - *)
 - *
do - *
not - *
alter alter (V*) *
vulval - (A1*
induction - *)
(Figure - *
3C) - *
. - *

Since - *)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
theyalters - (A0*)
vulval - *
induction - *
. - *

Since - *)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
theyaltered - (A0*)
vulval - *
induction - *
. - *

Since - *)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
theywhich - (A0*)
alters alter (V*) *
vulval - *
induction - *
. - *

Since - *)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
theywhich - (A0*)
altered alter (V*) *
vulval - *
induction - *
. - *

Since - (A0*)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNAis - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Since - (A0*)
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNAwas - *)
altered alter (V*) *
by - *
this - *
mutation - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
did - *
not - *
alter alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211(Figure - *)
3C) - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
this - (A0*
mutation - *)
 - *
did - *
not - *
alter alter (V*) *
vulval - (A1*
induction - *)
(Figure - *
3C) - *
. - *

Since - (A0*
these - *
two - *
bends - *)
are - *
in - *
opposing - *
directions - *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
is - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Since - *)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
vulval - (A1*
induction - *)
 - *
is - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Since - (A0*
these - *
two - *
bends - *)
are - *
in - *
opposing - *
directions - *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
was - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Since - *)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
vulval - (A1*
induction - *)
 - *
was - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
this - (A0*
mutation - *)
which - *
subtly - *
alters alter (V*) *
vulval - (A1*
induction - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
this - (A0*
mutation - *)
which - *
subtly - *
altered alter (V*) *
vulval - (A1*
induction - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
vulval - (A1*
induction - *)
 - *
is - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
; - *
DNA - *
interactions - *
observed - *
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
has - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
will - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
which - *
altered alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

Moreover - *
a - (A0*
fruR - *
null - *
mutation - *)
which - *
alters alter (V*) *
the - (A1*
rates - *
of - *
utilization - *
of - *
at - *
least - *
36 - *
carbon - *
sources - *)
. - *

This - (A0*
mutation - *)
is - *
located - *
within - *
exon - *
2 - *
and - *
altered alter (V*) *
the - (A3*
codon - *)
(CTC) - *)
normally - *
associated - *
with - *
Leu-93 - *
in - *
the - *
transcortin - *
polypeptide - *
to - (A2*
a - *
codon - *
(CAC) - *)
for - *
histidine - *
in - *
the - *
variant - *
genes - *
. - *

This - (A0*
mutation - *)
is - *
located - *
within - *
exon - *
2 - *
which - *
altered alter (V*) *
the - (A3*
codon - *)
(CTC) - *)
normally - *
associated - *
with - *
Leu-93 - *
in - *
the - *
transcortin - *
polypeptide - *
to - (A2*
a - *
codon - *
(CAC) - *)
for - *
histidine - *
in - *
the - *
variant - *
genes - *
. - *

This - (A0*
mutation - *)
is - *
located - *
within - *
exon - *
2 - *
which - *
alter alter (V*) *
the - (A3*
codon - *)
(CTC) - *)
normally - *
associated - *
with - *
Leu-93 - *
in - *
the - *
transcortin - *
polypeptide - *
to - (A2*
a - *
codon - *
(CAC) - *)
for - *
histidine - *
in - *
the - *
variant - *
genes - *
. - *

The - (A3*
codon - *)
(CTC) - *)
is - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
is - *
located - *
within - *
exon - *
2 - *
normally - *
associated - *
with - *
Leu-93 - *
in - *
the - *
transcortin - *
polypeptide - *
to - (A2*
a - *
codon - *
(CAC) - *)
for - *
histidine - *
in - *
the - *
variant - *
genes - *
. - *

The - (A3*
codon - *)
(CTC) - *)
was - *
altered alter (V*) *
by - *
this - (A0*
mutation - *)
is - *
located - *
within - *
exon - *
2 - *
normally - *
associated - *
with - *
Leu-93 - *
in - *
the - *
transcortin - *
polypeptide - *
to - (A2*
a - *
codon - *
(CAC) - *)
for - *
histidine - *
in - *
the - *
variant - *
genes - *
. - *

Cytokines - (A0*)
altered alter (V*) *
the - (A1*
expression - *
and - *
activity - *
of - *
the - *
multidrug - *
resistance - *
transporters - *)
in - (A4*
human - *
hepatoma - *
cell - *
lines; - *)
analysis - *
using - *
RT-PCR - *
and - *
cDNA - *
microarrays - *
. - *

The - (A1*
expression - *
and - *
activity - *
of - *
the - *
multidrug - *
resistance - *
transporters - *)
is - *
altered alter (V*) *
by - *
Cytokines - (A0*)
in - (A4*
human - *
hepatoma - *
cell - *
lines; - *)
analysis - *
using - *
RT-PCR - *
and - *
cDNA - *
microarrays - *
. - *

The - (A1*
expression - *
and - *
activity - *
of - *
the - *
multidrug - *
resistance - *
transporters - *)
was - *
altered alter (V*) *
by - *
Cytokines - (A0*)
in - (A4*
human - *
hepatoma - *
cell - *
lines; - *)
analysis - *
using - *
RT-PCR - *
and - *
cDNA - *
microarrays - *
. - *

Cytokines - (A0*)
which - *
altered alter (V*) *
the - (A1*
expression - *
and - *
activity - *
of - *
the - *
multidrug - *
resistance - *
transporters - *)
in - (A4*
human - *
hepatoma - *
cell - *
lines; - *)
analysis - *
using - *
RT-PCR - *
and - *
cDNA - *
microarrays - *
. - *

Cytokines - (A0*)
which - *
alter alter (V*) *
the - (A1*
expression - *
and - *
activity - *
of - *
the - *
multidrug - *
resistance - *
transporters - *)
in - (A4*
human - *
hepatoma - *
cell - *
lines; - *)
analysis - *
using - *
RT-PCR - *
and - *
cDNA - *
microarrays - *
. - *

Since - *
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
they - (A0*)
did - *
not - *
alter alter (V*) *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA(Figure - *)
3C) - *
. - *

Since - (A0*)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
is - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Since - (A0*)
these - *
two - *
bends - *
are - *
in - *
opposing - *
directions - *
the - (A1*
overall - *
direction - *
of - *
the - *
DNA - *)
was - *
not - *
altered alter (V*) *
by - *
them(Figure - *
3C) - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
due - *
to - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
which - *
subtly - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
is - *
altered alter (V*) *
by - *
the - (A0*
change - *
in - *
DNA - *
conformation; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
the - (A1*
specific - *
protein - *
&amp;#8211 - *)
was - *
altered alter (V*) *
by - *
the - (A0*
change - *
in - *
DNA - *
conformation; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
subtly - *
alters alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211; - *)
DNA - *
interactions - *
observed - *
. - *

Hence - *
Glu13 - *
indirectly - *
affects - *
DNA-binding - *
specificity - *
probably - *
the - (A0*
change - *
in - *
DNA - *
conformation - *)
subtly - *
altered alter (V*) *
the - (A1*
specific - *
protein - *
&amp;#8211; - *)
DNA - *
interactions - *
observed - *
. - *

Since - *
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
this - (A0*
mutation - *)
altered alter (V*) *
vulval - (A1*
induction - *)
. - *

Since - *
s1031 - *
is - *
a - *
null - *
allele - *
we - *
tested - *
whether - *
this - (A0*
mutation - *)
which - *
alters alter (V*) *
vulval - (A1*
induction - *)
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
alter alter (V*) *
the - (A1*
phasing - *
of - *
the - *
binding - *
sites - *)
result - *
in - *
simultaneous - *
derepression - *
of - *
both - *
genes - *
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
altered alter (V*) *
the - (A1*
phasing - *
of - *
the - *
binding - *
sites - *)
result - *
in - *
simultaneous - *
derepression - *
of - *
both - *
genes - *
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
has - *
altered alter (V*) *
the - (A1*
phasing - *
of - *
the - *
binding - *
sites - *)
result - *
in - *
simultaneous - *
derepression - *
of - *
both - *
genes - *
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
will - *
alter alter (V*) *
the - (A1*
phasing - *
of - *
the - *
binding - *
sites - *)
result - *
in - *
simultaneous - *
derepression - *
of - *
both - *
genes - *
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibits - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
alters alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibited - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
altered alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibits - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
will - *
altered alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibited - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
has - *
altered alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibits - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
which - *
alters alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibited - *
binding - *
of - *
Lrp/PapI - *
near - *
the - *
GATC1028 - *
site - *
and - *
which - *
altered alter (V*) *
binding - (A1*
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *)
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
altered alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
alter alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
which - *
altered alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
which - *
alter alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
has - *
altered alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

The - *
results - *
provide - *
insight - *
into - *
a - *
mechanism - *
whereby - *
will - *
alter alter (V*) *
expression - (A1*
of - *
Bcl-3 - *)
leads - *
to - *
tumorigenic - *
potential - *
. - *

Mutations - (A0*)
that - *
altered alter (V*) *
splice - (A1*
sites - *)
led - *
to - *
the - *
synthesis - *
of - *
several - *
types - *
of - *
mRNAs - *
a - *
fraction - *
of - *
which - *
represented - *
the - *
normally - *
spliced - *
product - *
. - *

Splice - (A1*
sites - *)
are - *
altered alter (V*) *
by - *
mutations - (A0*)
led - *
to - *
the - *
synthesis - *
of - *
several - *
types - *
of - *
mRNAs - *
a - *
fraction - *
of - *
which - *
represented - *
the - *
normally - *
spliced - *
product - *
. - *

Splice - (A1*
sites - *)
were - *
altered alter (V*) *
by - *
mutations - (A0*)
led - *
to - *
the - *
synthesis - *
of - *
several - *
types - *
of - *
mRNAs - *
a - *
fraction - *
of - *
which - *
represented - *
the - *
normally - *
spliced - *
product - *
. - *

Splice - (A1*
sites - *)
which - *
is - *
altered alter (V*) *
by - *
mutations - (A0*)
led - *
to - *
the - *
synthesis - *
of - *
several - *
types - *
of - *
mRNAs - *
a - *
fraction - *
of - *
which - *
represented - *
the - *
normally - *
spliced - *
product - *
. - *

Splice - (A1*
sites - *)
which - *
were - *
altered alter (V*) *
by - *
mutations - (A0*)
led - *
to - *
the - *
synthesis - *
of - *
several - *
types - *
of - *
mRNAs - *
a - *
fraction - *
of - *
which - *
represented - *
the - *
normally - *
spliced - *
product - *
. - *

In - *
protein-coding - *
transcripts - *
79% - *
of - *
splice - (A0*
variations - *)
alter alter (V*) *
the - (A1*
protein - *
product - *)
Whole-transcriptome - *
analyses - *
resulted - *
in - *
the - *
identification - *
of - *
2431 - *
sense-antisense - *
pairs - *
. - *

In - *
protein-coding - *
transcripts - *
79% - *
of - *
splice - (A0*
variations - *)
which - *
alter alter (V*) *
the - (A1*
protein - *
product - *)
Whole-transcriptome - *
analyses - *
resulted - *
in - *
the - *
identification - *
of - *
2431 - *
sense-antisense - *
pairs - *
. - *

In - *
protein-coding - *
transcripts - *
79% - *
of - *
splice - (A0*
variations - *)
which - *
altered alter (V*) *
the - (A1*
protein - *
product - *)
Whole-transcriptome - *
analyses - *
resulted - *
in - *
the - *
identification - *
of - *
2431 - *
sense-antisense - *
pairs - *
. - *

In - *
protein-coding - *
transcripts - *
the - (A1*
protein - *
product - *)
is - *
altered alter (V*) *
by - *
79% - *
of - *
splice - (A0*
variations - *)
Whole-transcriptome - *
analyses - *
resulted - *
in - *
the - *
identification - *
of - *
2431 - *
sense-antisense - *
pairs - *
. - *

In - *
protein-coding - *
transcripts - *
the - (A1*
protein - *
product - *)
was - *
altered alter (V*) *
by - *
79% - *
of - *
splice - (A0*
variations - *)
Whole-transcriptome - *
analyses - *
resulted - *
in - *
the - *
identification - *
of - *
2431 - *
sense-antisense - *
pairs - *
. - *

Four - (A0*
other - *
mutations - *)
altered alter (V*) *
either - (A1*
the - *
conserved - *
gt - *
or - *
ag - *
dinucleotide - *
splice - *
sites - *)
in - (A4*
the - *
IVD - *
gene - *)
. - *

Four - (A0*
other - *
mutations - *)
which - *
altered alter (V*) *
either - (A1*
the - *
conserved - *
gt - *
or - *
ag - *
dinucleotide - *
splice - *
sites - *)
in - (A4*
the - *
IVD - *
gene - *)
. - *

Four - (A0*
other - *
mutations - *)
which - *
alter alter (V*) *
either - (A1*
the - *
conserved - *
gt - *
or - *
ag - *
dinucleotide - *
splice - *
sites - *)
in - (A4*
the - *
IVD - *
gene - *)
. - *

Either - *)
the - *
conserved - *
gt - *
or - *
ag - *
dinucleotide - *
splice - *
is - *
altered alter (V*) *
by - *
four - (A0*
other - *
mutations - *)
sites - *
in - (A4*
the - *
IVD - *
gene - *)
. - *

Either - *)
the - *
conserved - *
gt - *
or - *
ag - *
dinucleotide - *
splice - *
was - *
altered alter (V*) *
by - *
four - (A0*
other - *
mutations - *)
sites - *
in - (A4*
the - *
IVD - *
gene - *)
. - *

Phosphorylation - (A1*
of - *
PDK1 - *)
is - *
not - *
altered alter (V*) *
by - *
treating - (A0*
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *)
and - *
four - *
of - *
the - *
sites - *
could - *
be - *
mutated - *
without - *
loss - *
of - *
activity - *
. - *

Treating - (A0*
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *)
alters alter (V*) *
phosphorylation - (A1*
of - *
PDK1 - *)
and - *
four - *
of - *
the - *
sites - *
could - *
be - *
mutated - *
without - *
loss - *
of - *
activity - *
. - *

Treating - (A0*
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *)
altered alter (V*) *
phosphorylation - (A1*
of - *
PDK1 - *)
and - *
four - *
of - *
the - *
sites - *
could - *
be - *
mutated - *
without - *
loss - *
of - *
activity - *
. - *

Treating - (A0*
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *)
which - *
alters alter (V*) *
phosphorylation - (A1*
of - *
PDK1 - *)
and - *
four - *
of - *
the - *
sites - *
could - *
be - *
mutated - *
without - *
loss - *
of - *
activity - *
. - *

Treating - (A0*
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *)
which - *
altered alter (V*) *
phosphorylation - (A1*
of - *
PDK1 - *)
and - *
four - *
of - *
the - *
sites - *
could - *
be - *
mutated - *
without - *
loss - *
of - *
activity - *
. - *

The - (A0*
molecular - *
lesion - *
associated - *
with - *
s1031 - *)
predict - *
that - *
it - *
alters alter (V*) *
splicing - (A1*)
we - *
looked - *
at - *
the - *
sos-1 - *
mRNA - *
produced - *
in - *
this - *
mutant - *
. - *

The - (A0*
molecular - *
lesion - *
associated - *
with - *
s1031 - *)
predict - *
that - *
it - *
altered alter (V*) *
splicing - (A1*)
we - *
looked - *
at - *
the - *
sos-1 - *
mRNA - *
produced - *
in - *
this - *
mutant - *
. - *

Splicing - (A1*)
is - *
predict - *
to - *
be - *
altered alter (V*) *
by - *
the - (A0*
molecular - *
lesion - *
associated - *
with - *
s1031 - *)
we - *
looked - *
at - *
the - *
sos-1 - *
mRNA - *
produced - *
in - *
this - *
mutant - *
. - *

Growth - (A1*
of - *
the - *
gpi17 - *
deletant - *)
which - *
began begin (V*) *
to - *
decline - (A2*
at - *
6 - *
h - *
after - *
transfer - *
to - *
a - *
glucose-containing - *
medium - *)
but - *
growth - *
continued - *
slowly - *
for - *
33 - *
h - *
. - *

Growth - (A1*
of - *
the - *
gpi17 - *
deletant - *)
which - *
begins begin (V*) *
to - *
decline - (A2*
at - *
6 - *
h - *
after - *
transfer - *
to - *
a - *
glucose-containing - *
medium - *)
but - *
growth - *
continued - *
slowly - *
for - *
33 - *
h - *
. - *

Growth - (A1*
of - *
the - *
gpi17 - *
deletant - *)
which - *
has - *
begun begin (V*) *
to - *
decline - (A2*
at - *
6 - *
h - *
after - *
transfer - *
to - *
a - *
glucose-containing - *
medium - *)
but - *
growth - *
continued - *
slowly - *
for - *
33 - *
h - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
begins begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
began begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
has - *
begun begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
which - *
begins begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
which - *
began begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

On - (A0*
the - *)
other - *
hand - *
the - (A1*
only - *
transcript - *)
which - *
has - *
begun begin (V*) *
at - (A2*
exon - *
1a - *)
was - *
observed - *
in - *
normal - *
cells - *
. - *

The - (A1*
electron - *)
density - *
of - *
each - *
of - *
the - *
four - *
copies - *
of - *
the - *
SRF - *
polypeptide - *
in - *
the - *
asymmetric - *
unit - *)
began begin (V*) *
variably - *
between - (A2*
amino - *
acids - *
136 - *
and - *
140 - *)
and - *
continues - *
to - *
the - *
C-terminus - *
. - *

The - (A1*
electron - *)
density - *
of - *
each - *
of - *
the - *
four - *
copies - *
of - *
the - *
SRF - *
polypeptide - *
in - *
the - *
asymmetric - *
unit - *)
has - *
begun begin (V*) *
variably - *
between - (A2*
amino - *
acids - *
136 - *
and - *
140 - *)
and - *
continues - *
to - *
the - *
C-terminus - *
. - *

The - (A1*
electron - *)
density - *
of - *
each - *
of - *
the - *
four - *
copies - *
of - *
the - *
SRF - *
polypeptide - *
in - *
the - *
asymmetric - *
unit - *)
which - *
begins begin (V*) *
variably - *
between - (A2*
amino - *
acids - *
136 - *
and - *
140 - *)
and - *
continues - *
to - *
the - *
C-terminus - *
. - *

The - (A1*
electron - *)
density - *
of - *
each - *
of - *
the - *
four - *
copies - *
of - *
the - *
SRF - *
polypeptide - *
in - *
the - *
asymmetric - *
unit - *)
which - *
began begin (V*) *
variably - *
between - (A2*
amino - *
acids - *
136 - *
and - *
140 - *)
and - *
continues - *
to - *
the - *
C-terminus - *
. - *

The - (A1*
electron - *)
density - *
of - *
each - *
of - *
the - *
four - *
copies - *
of - *
the - *
SRF - *
polypeptide - *
in - *
the - *
asymmetric - *
unit - *)
which - *
has - *
begun begin (V*) *
variably - *
between - (A2*
amino - *
acids - *
136 - *
and - *
140 - *)
and - *
continues - *
to - *
the - *
C-terminus - *
. - *

Bending - (A1*
of - *
31 - *
into - *
the - *
major - *
groove - *
over - *
the - *
CC - *
and - *
CT - *
base - *
pair - *
steps - *)
begins begin (V*) *
and - *
ending - *
the - *
CArG-box - *
and - *
15 - *
into - *
the - *
minor - *
groove - *
over - *
the - *
five - *
central - *
TA - *
AA - *
and - *
AT - *
base - *
pair - *
steps - *
. - *

Bending - (A1*
of - *
31 - *
into - *
the - *
major - *
groove - *
over - *
the - *
CC - *
and - *
CT - *
base - *
pair - *
steps - *)
began begin (V*) *
and - *
ending - *
the - *
CArG-box - *
and - *
15 - *
into - *
the - *
minor - *
groove - *
over - *
the - *
five - *
central - *
TA - *
AA - *
and - *
AT - *
base - *
pair - *
steps - *
. - *

Bending - (A1*
of - *
31 - *
into - *
the - *
major - *
groove - *
over - *
the - *
CC - *
and - *
CT - *
base - *
pair - *
steps - *)
has - *
begun begin (V*) *
and - *
ending - *
the - *
CArG-box - *
and - *
15 - *
into - *
the - *
minor - *
groove - *
over - *
the - *
five - *
central - *
TA - *
AA - *
and - *
AT - *
base - *
pair - *
steps - *
. - *

The - (A1*
levels - *)
of - *
immunoreactive - *
IB - *)
began begin (V*) *
to - *
return - (A2*
to - *
basal - *
levels - *
following - *
3-4 - *
h - *
exposures - *
to - *
poly - *
IC - *)
. - *

The - (A1*
levels - *)
of - *
immunoreactive - *
IB - *)
have - *
begun begin (V*) *
to - *
return - (A2*
to - *
basal - *
levels - *
following - *
3-4 - *
h - *
exposures - *
to - *
poly - *
IC - *)
. - *

The - (A1*
levels - *)
of - *
immunoreactive - *
IB - *)
which - *
begin begin (V*) *
to - *
return - (A2*
to - *
basal - *
levels - *
following - *
3-4 - *
h - *
exposures - *
to - *
poly - *
IC - *)
. - *

The - (A1*
levels - *)
of - *
immunoreactive - *
IB - *)
which - *
began begin (V*) *
to - *
return - (A2*
to - *
basal - *
levels - *
following - *
3-4 - *
h - *
exposures - *
to - *
poly - *
IC - *)
. - *

The - (A1*
levels - *)
of - *
immunoreactive - *
IB - *)
which - *
have - *
begun begin (V*) *
to - *
return - (A2*
to - *
basal - *
levels - *
following - *
3-4 - *
h - *
exposures - *
to - *
poly - *
IC - *)
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
began begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
begins begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
has - *
begun begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
which - *
began begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
which - *
begins begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

When - *)
they - *
were - *
transferred - *
to - *
a - *
glucose-containing - *
medium - *
in - *
order - *
to - *
deplete - *
these - *
proteins - *
growth - (A1*
of - *
gaal - *
gpi8 - *
and - *
gpi16 - *
deletants - *)
which - *
has - *
begun begin (V*) *
to - *
decline - (A2*
at - *
12 - *
6 - *
and - *
6 - *
h - *)
respectively - *
after - *
transfer - *
and - *
ceased - *
at - *
24 - *
12 - *
and - *
12 - *
h - *
. - *

Growth - (A1*
of - *
the - *
gpi17 - *
deletant - *)
begins begin (V*) *
to - *
decline - (A2*
at - *
6 - *
h - *
after - *
transfer - *
to - *
a - *
glucose-containing - *
medium - *)
but - *
growth - *
continued - *
slowly - *
for - *
33 - *
h - *
. - *

Growth - (A1*
of - *
the - *
gpi17 - *
deletant - *)
has - *
begun begin (V*) *
to - *
decline - (A2*
at - *
6 - *
h - *
after - *
transfer - *
to - *
a - *
glucose-containing - *
medium - *)
but - *
growth - *
continued - *
slowly - *
for - *
33 - *
h - *
. - *

it - (A0*)
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
was - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

it - (A0*)
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

RNA - (A1*
polymerase - *
during - *
elongation - *)
is - *
blocked block (V*) *
by - *
it - (A0*)
. - *

RNA - (A1*
polymerase - *
during - *
elongation - *)
was - *
blocked block (V*) *
by - *
it - (A0*)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
was - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
did - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
does - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
will - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
has - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
myeloid - (A1*
colony - *
formation - *)
was - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

PU1 - *
is - *
upregulated - *
early - *
during - *
commitment - (A0*)
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

PU1 - *
is - *
upregulated - *
early - *
during - *
commitment - (A0*)
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

PU1 - *
is - *
upregulated - *
early - *
during - *
commitment - (A0*)
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

PU1 - *
is - *
upregulated - *
early - *
during - *
commitment - (A0*)
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

PU1 - *
is - *
upregulated - *
early - *
during - *
commitment - (A0*)
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
labeling - (A1*)
was - *
blocked block (V*) *
by - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
RNA - (A1*
polymerase - *
during - *
elongation - *)
is - *
blocked block (V*) *
it - *
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
RNA - (A1*
polymerase - *
during - *
elongation - *)
was - *
blocked block (V*) *
it - *
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Labeling - *
with - (A0*)
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
merozoite - (A1*
invasion - *
in - *
vitro - *)
was - *
blocked block (V*) *
by - *
antibodies - (A0*
to - *
RAP1 - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
are - *
able - *
to - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
were - *
able - *
to - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
which - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
it - *
which - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - (A0*)
has - *
been - *
shown - *
that - *
RNA - (A1*
polymerase - *
during - *
elongation - *)
is - *
blocked block (V*) *
by - *
it - *
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

it - (A0*)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
which - *
blocks block (V*) *
labeling - (A1*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
antibodies - (A0*
to - *
RAP1 - *)
which - *
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
which - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
which - *
blocked block (V*) *
labeling - (A1*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
antibodies - (A0*
to - *
RAP1 - *)
which - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
labeling - (A1*)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
is - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
was - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

antibodies - (A0*
to - *
RAP1 - *)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
are - *
able - *
to - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
were - *
able - *
to - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
blocked block (V*) *
labeling - (A1*)
. - *

antibodies - (A0*
to - *
RAP1 - *)
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
blocks block (V*) *
labeling - (A1*)
. - *

antibodies - (A0*
to - *
RAP1 - *)
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

labeling - (A1*)
is - *
blocked block (V*) *
by - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
. - *

merozoite - (A1*
invasion - *
in - *
vitro - *)
is - *
blocked block (V*) *
by - *
antibodies - (A0*
to - *
RAP1 - *)
. - *

labeling - (A1*)
was - *
blocked block (V*) *
by - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
. - *

merozoite - (A1*
invasion - *
in - *
vitro - *)
was - *
blocked block (V*) *
by - *
antibodies - (A0*
to - *
RAP1 - *)
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *)
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
did - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
was - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Proteasomal - (A0*
inhibition - *)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
did - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
are - *
able - *
to - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
were - *
able - *
to - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *)
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
does - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
does - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *)
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
will - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
will - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *)
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
has - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
has - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *)
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
labeling - (A1*)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
myeloid - (A1*
colony - *
formation - *)
was - *
blocked block (V*) *
Alanine - (A0*)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

Labeling - (A0*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
are - *
able - *
to - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
were - *
able - *
to - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
Alanine - (A0*)
which - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *)
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
labeling - (A1*)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *)
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
labeling - (A1*)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *)
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
labeling - (A1*)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *)
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
labeling - (A1*)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
merozoite - (A1*
invasion - *
in - *
vitro - *)
is - *
blocked block (V*) *
antibodies - (A0*
to - *
RAP1 - *)
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
are - *
able - *
to - *
block block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
were - *
able - *
to - *
block block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
block block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
blocked block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
which - *
block block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
which - *
blocked block (V*) *
labeling - (A1*)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
labeling - (A1*)
is - *
blocked block (V*) *
by - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
merozoite - (A1*
invasion - *
in - *
vitro - *)
was - *
blocked block (V*) *
antibodies - (A0*
to - *
RAP1 - *)
. - *

Labeling - *)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Labeling - *)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Labeling - *)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Labeling - *)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
. - *

Alanine - (A0*)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Alanine - (A0*)
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Alanine - (A0*)
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
. - *

the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
was - *
blocked block (V*) *
by - *
Alanine - (A0*)
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
translation - *)
did - *
not - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
translation - *)
does - *
not - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
translation - *)
will - *
not - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
translation - *)
has - *
not - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *)
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *)
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *)
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *)
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

PU1 - (A0*
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *)
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
it - (A0*)
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
RNA - (A1*
polymerase - *
during - *
elongation - *)
is - *
blocked block (V*) *
by - *
it - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
RNA - (A1*
polymerase - *
during - *
elongation - *)
was - *
blocked block (V*) *
by - *
it - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
it - (A0*)
which - *
blocks block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
it - (A0*)
which - *
blocked block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Labeling - (A1*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
labeling - *
was - *
blocked block (V*) *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
. - *

Labeling - (A1*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *)
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
labeling - *
. - *

Labeling - (A1*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *)
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
labeling - *
. - *

Labeling - (A1*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *)
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocks block (V*) *
labeling - *
. - *

Labeling - (A1*)
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *)
that - *
is - *
specific - *
since - *
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *
blocked block (V*) *
labeling - *
. - *

Membranes - (A1*)
are - *
blocked block (V*) *
in - *
TBST - *
(Tris-buffered - *
saline - *
005% - *
Tween-20) - *
containing - *
5% - *
bovine - *
serum - *
albumin - *
(for - *
anti-phosphoryrosine - *
blots) - *
or - *
skimmed - *
milk - *
and - *
probed - *
with - *
antibodies - *
. - *

It - *
blocks block (V*) *
membranes - (A1*)
in - *
TBST - *
(Tris-buffered - *
saline - *
005% - *
Tween-20) - *
containing - *
5% - *
bovine - *
serum - *
albumin - *
(for - *
anti-phosphoryrosine - *
blots) - *
or - *
skimmed - *
milk - *
and - *
probed - *
with - *
antibodies - *
. - *

It - *
blocked block (V*) *
membranes - (A1*)
in - *
TBST - *
(Tris-buffered - *
saline - *
005% - *
Tween-20) - *
containing - *
5% - *
bovine - *
serum - *
albumin - *
(for - *
anti-phosphoryrosine - *
blots) - *
or - *
skimmed - *
milk - *
and - *
probed - *
with - *
antibodies - *
. - *

It - *
which - *
blocks block (V*) *
membranes - (A1*)
blocked - *
in - *
TBST - *
(Tris-buffered - *
saline - *
005% - *
Tween-20) - *
containing - *
5% - *
bovine - *
serum - *
albumin - *
(for - *
anti-phosphoryrosine - *
blots) - *
or - *
skimmed - *
milk - *
and - *
probed - *
with - *
antibodies - *
. - *

It - *
which - *
blocked block (V*) *
membranes - (A1*)
blocked - *
in - *
TBST - *
(Tris-buffered - *
saline - *
005% - *
Tween-20) - *
containing - *
5% - *
bovine - *
serum - *
albumin - *
(for - *
anti-phosphoryrosine - *
blots) - *
or - *
skimmed - *
milk - *
and - *
probed - *
with - *
antibodies - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
antibodies - (A0*
to - *
RAP1 - *)
were - *
able - *
to - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
antibodies - (A0*
to - *
RAP1 - *)
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
antibodies - (A0*
to - *
RAP1 - *)
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
antibodies - (A0*
to - *
RAP1 - *)
which - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
antibodies - (A0*
to - *
RAP1 - *)
which - *
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
merozoite - (A1*
invasion - *
in - *
vitro - *)
is - *
blocked block (V*) *
by - *
antibodies - (A0*
to - *
RAP1 - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
myeloid - (A1*
colony - *
formation - *)
was - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
which - *
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
which - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
. - *

myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
. - *

myeloid - (A1*
colony - *
formation - *)
was - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
will - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *)
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
did - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *)
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
does - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *)
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
will - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - (A0*
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *)
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - *
of - *
translation - *
has - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
myeloid - (A1*
colony - *
formation - *)
was - *
blocked block (V*) *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
are - *
able - *
to - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
were - *
able - *
to - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
which - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
which - *
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
has - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
which - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocks block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
blocks block (V*) *
labeling - (A1*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
antibodies - (A0*
to - *
RAP1 - *)
blocks block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

inhibition - (A0*
of - *
translation - *)
is - *
thought - *
to - *
act - *
as - *
an - *
inducer - *
to - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
did - *
not - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
does - *
not - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
will - *
not - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
has - *
not - *
block block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

PU1 - (A0*)
is - *
upregulated - *
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
the - (A1*
action - *
of - *
a - *
postulated - *
repressor - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

inhibition - (A0*
of - *
translation - *)
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

inhibition - (A0*
of - *
translation - *)
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
translation - *)
. - *

elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
was - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
translation - *)
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
did - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

PU1 - (A0*
is - *
upregulated - *)
early - *
during - *
commitment - *
of - *
multipotential - *
progenitors - *
to - *
the - *
myeloid - *
lineages - *
and - *
inhibition - *
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
-upregulation - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
it - *
did - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
translation - *)
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
translation - *)
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
translation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
was - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
translation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
translation - *)
which - *
blocks block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
inhibition - (A0*
of - *
translation - *)
which - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
did - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
did - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
inhibition - (A0*
of - *
translation - *)
. - *

Labeling - *
with - *
antibodies - *
to - *
the - *
Y553 - *
phosphopeptide - *
is - *
specific - *
since - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
was - *
blocked block (V*) *
inhibition - (A0*
of - *
translation - *)
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
antibodies - (A0*
to - *
RAP1 - *)
did - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
are - *
able - *
to - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
were - *
able - *
to - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
which - *
block block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
inhibition - (A0*
of - *
translation - *)
which - *
blocked block (V*) *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Both - *
RAP1 - *
and - *
2 - *
are - *
important - *
vaccine - *
candidates - *
because - *
it - *
has - *
been - *
shown - *
that - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
by - *
inhibition - (A0*
of - *
translation - *)
(Schofield - *
et - *
al - *
1986; - *
Harnyuttanakorn - *
et - *
al - *
1992; - *
Howard - *
et - *
al - *
1998a) - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
does - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
it - *
does - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
does - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
does - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
antibodies - (A0*
to - *
RAP1 - *)
does - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
will - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
it - *
will - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
will - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
will - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
antibodies - (A0*
to - *
RAP1 - *)
will - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
inhibition - (A0*
of - *
PU1 - *
function - *
in - *
human - *
CD34+ - *
progenitors - *
prior - *
to - *
this - *
upregulation - *)
has - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - (A0*)
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
it - *
has - *
not - *
block block (V*) *
RNA - (A1*
polymerase - *
during - *
elongation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
Alanine - (A0*)
has - *
not - *
block block (V*) *
myeloid - (A1*
colony - *
formation - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
has - *
not - *
block block (V*) *
labeling - (A1*)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Proteasomal - *
inhibition - *
did - *
not - *
induce - *
any - *
synergistic - *
effect - *
on - *
the - *
14-3-3eta-induced - *
increase - *
in - *
GR - *
in - *
response - *
to - *
glucocorticoid - *
and - *
antibodies - (A0*
to - *
RAP1 - *)
has - *
not - *
block block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
indicating - *
that - *
14-3-3eta - *
induces - *
stabilization - *
of - *
GR - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
Alanine - (A0*)
blocked block (V*) *
myeloid - (A1*
colony - *
formation - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
blocked block (V*) *
labeling - (A1*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
antibodies - (A0*
to - *
RAP1 - *)
blocked block (V*) *
merozoite - (A1*
invasion - *
in - *
vitro - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
elevation - (A1*
of - *
GR - *
by - *
14-3-3eta - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
myeloid - (A1*
colony - *
formation - *)
is - *
blocked block (V*) *
by - *
Alanine - (A0*)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
labeling - (A1*)
is - *
blocked block (V*) *
by - *
by - (A0*
pre-incubation - *
of - *
the - *
antibodies - *
with - *
the - *
phosphopeptide - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

Tagetin - *
is - *
more - *
specific - *
for - *
distinguishing - *
between - *
different - *
RNA - *
polymerases - *
because - *
merozoite - (A1*
invasion - *
in - *
vitro - *)
is - *
blocked block (V*) *
by - *
antibodies - (A0*
to - *
RAP1 - *)
(Mathews - *
and - *
Durbin - *
1994) - *
ie - *
its - *
action - *
is - *
independent - *
of - *
different - *
initiation - *
factors - *
. - *

These - *
results - *
suggest - *
that - *
14-3-3eta - (A1*
functions - *)
as - *
a - *
positive - *
regulator - *
in - *
the - *
glucocorticoid - *
signal - *
pathway - *
by - *
blocking block (V*) *
the - (A0*
degradation - *
of - *
GR - *
and - *
inducing - *
an - *
elevation - *
of - *
GR - *)
thus - *
enhancing - *
the - *
transcriptional - *
activity - *
of - *
GR - *
. - *

These - *
results - *
suggest - *
that - *
14-3-3eta - (A1*
functions - *)
as - *
a - *
positive - *
regulator - *
in - *
the - *
glucocorticoid - *
signal - *
pathway - *
through - *
blocking block (V*) *
the - (A0*
degradation - *
of - *
GR - *
and - *
inducing - *
an - *
elevation - *
of - *
GR - *)
thus - *
enhancing - *
the - *
transcriptional - *
activity - *
of - *
GR - *
. - *

These - *
results - *
suggest - *
that - *
14-3-3eta - (A1*
functions - *)
as - *
a - *
positive - *
regulator - *
in - *
the - *
glucocorticoid - *
signal - *
pathway - *
for - *
blocking block (V*) *
the - (A0*
degradation - *
of - *
GR - *
and - *
inducing - *
an - *
elevation - *
of - *
GR - *)
thus - *
enhancing - *
the - *
transcriptional - *
activity - *
of - *
GR - *
. - *

These - *
results - *
suggest - *
that - *
14-3-3eta - (A1*
functions - *)
as - *
a - *
positive - *
regulator - *
in - *
the - *
glucocorticoid - *
signal - *
pathway - *
that - *
blocked block (V*) *
the - (A0*
degradation - *
of - *
GR - *
and - *
inducing - *
an - *
elevation - *
of - *
GR - *)
thus - *
enhancing - *
the - *
transcriptional - *
activity - *
of - *
GR - *
. - *

Mutations - (A0*
at - *
the - *
3 - *
splice - *)
site - *
that - *
specifically - *
block block (V*) *
step - (A1*
II - *)
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

Mutations - (A0*
at - *
the - *
3 - *
splice - *)
site - *
that - *
specifically - *
blocked block (V*) *
step - (A1*
II - *)
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

Mutations - (A0*
at - *
the - *
3 - *
splice - *)
site - *
specifically - *
block block (V*) *
step - (A1*
II - *)
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

Mutations - (A0*
at - *
the - *
3 - *
splice - *)
site - *
specifically - *
blocked block (V*) *
step - (A1*
II - *)
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

Step - (A1*
II - *)
is - *
specifically - *
blocked - *)
by - *
mutations - *
at - *
the - *
3 - *
splice - *
site - *
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

Step - (A1*
II - *)
was - *
specifically - *
blocked - *)
by - *
mutations - *
at - *
the - *
3 - *
splice - *
site - *
do - *
not - *
affect - *
the - *
association - *
of - *
hPrps - *
16 - *
and - *
17 - *
with - *
the - *
spliceosome - *
indicating - *
that - *
these - *
factors - *
may - *
function - *
at - *
a - *
stage - *
of - *
step - *
II - *
prior - *
to - *
recognition - *
of - *
the - *
3 - *
splice - *
site - *
. - *

A - *
downstream - *
kinase - *
appears - *
to - *
be - *
essential - *
for - *
agrin-mediated - *
signaling - *
since - *
staurosporine - (A0*)
blocked block (V*) *
agrin-induced - (A1*
AChR - *
clustering - *
and - *
phosphorylation - *)
without - *
inhibiting - *
MuSK - *
phosphorylation - *
(Wallace - *
1994; - *
Fuhrer - *
et - *
al - *
1997) - *
. - *

A - *
downstream - *
kinase - *
appears - *
to - *
be - *
essential - *
for - *
agrin-mediated - *
signaling - *
since - *
staurosporine - (A0*)
that - *
blocks block (V*) *
agrin-induced - (A1*
AChR - *
clustering - *
and - *
phosphorylation - *)
without - *
inhibiting - *
MuSK - *
phosphorylation - *
(Wallace - *
1994; - *
Fuhrer - *
et - *
al - *
1997) - *
. - *

A - *
downstream - *
kinase - *
appears - *
to - *
be - *
essential - *
for - *
agrin-mediated - *
signaling - *
since - *
staurosporine - (A0*)
that - *
blocked block (V*) *
agrin-induced - (A1*
AChR - *
clustering - *
and - *
phosphorylation - *)
without - *
inhibiting - *
MuSK - *
phosphorylation - *
(Wallace - *
1994; - *
Fuhrer - *
et - *
al - *
1997) - *
. - *

A - *
downstream - *
kinase - *
appears - *
to - *
be - *
essential - *
for - *
agrin-mediated - *
signaling - *
since - *
agrin-induced - (A1*
AChR - *
clustering - *
and - *
phosphorylation - *)
is - *
blocked block (V*) *
by - *
staurosporine - (A0*)
without - *
inhibiting - *
MuSK - *
phosphorylation - *
(Wallace - *
1994; - *
Fuhrer - *
et - *
al - *
1997) - *
. - *

A - *
downstream - *
kinase - *
appears - *
to - *
be - *
essential - *
for - *
agrin-mediated - *
signaling - *
since - *
agrin-induced - (A1*
AChR - *
clustering - *
and - *
phosphorylation - *)
was - *
blocked block (V*) *
by - *
staurosporine - (A0*)
without - *
inhibiting - *
MuSK - *
phosphorylation - *
(Wallace - *
1994; - *
Fuhrer - *
et - *
al - *
1997) - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
was - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
Rep78 - (A0*
and - *
Rep68 - *)
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
was - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
was - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
Helicases - (A0*)
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

human - (A0*
P450 - *
3A - *
(CYP3A) - *)
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

However - *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
was - *
catalysed catalyse (V*) *
by - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
is - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
Rep78 - (A0*
and - *
Rep68 - *)
. - *

However - *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
is - *
catalysed catalyse (V*) *
by - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
Helicases - (A0*)
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
catalyse catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
is - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
is - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
Helicases - (A0*)
. - *

However - *
the - (A1*
packaging - *
reaction - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
was - *
catalysed catalyse (V*) *
by - *
Rep78 - (A0*
and - *
Rep68 - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
the - (A1*
packaging - *
reaction - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
is - *
catalysed catalyse (V*) *
by - *
Rep78 - (A0*
and - *
Rep68 - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
Rep78 - (A0*
and - *
Rep68 - *)
which - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
Rep78 - (A0*
and - *
Rep68 - *)
which - *
catalyse catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
Rep78 - (A0*
and - *
Rep68 - *)
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

The - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
is - *
catalysed catalyse (V*) *
by - *
the - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

The - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
was - *
catalysed catalyse (V*) *
by - *
the - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
catalyse catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Helicases - (A0*)
which - *
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Helicases - (A0*)
which - *
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

The - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
is - *
not - *
only - *
catalysed catalyse (V*) *
by - *
helicases - (A0*)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

The - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
was - *
not - *
only - *
catalysed catalyse (V*) *
by - *
helicases - (A0*)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Helicases - (A0*)
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
which - *
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
 - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
the - (A1*
hepatic - *
metabolism - *
of - *
quinine - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
was - *
most - *
likely - *
catalysed catalyse (V*) *
by - *
human - (A0*
P450 - *
3A - *
(CYP3A) - *)
. - *

However - *
Helicases - (A0*)
which - *
catalyse catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
Helicases - (A0*)
which - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
is - *
catalysed catalyse (V*) *
by - *
Helicases - (A0*)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
was - *
catalysed catalyse (V*) *
by - *
Helicases - (A0*)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

Helicases - (A0*)
catalyse catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Helicases - (A0*)
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Helicases - (A0*)
which - *
catalyse catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Helicases - (A0*)
which - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
Helicases - (A0*)
catalyse catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
which - *
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
which - *
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
catalyse catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
catalyse catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
it - *
is - *
interesting - *
to - *
note - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
catalyse catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
is - *
catalysed catalyse (V*) *
by - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

However - *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
up - *
to - *
1000-fold - *
less - *
efficiently - *
was - *
catalysed catalyse (V*) *
by - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
although - *
they - *
posses - *
the - *
entire - *
Rep52 - *
and - *
Rep40 - *
coding - *
regions - *
respectively - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
which - *
catalyse catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
which - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
a - *
process - *
that - *
involves - *
sequence-specific - *
AAV - *
DNA - *
biding - *
strand-specific - *
nicking - *
and - *
helicase - *
activity - *
under - *
ATP - *
consumption - *
(Im - *
and - *
Muzyczka - *
1990 - *
1992; - *
Brister - *
and - *
Muzyczka - *
1990 - *
2000) - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
not - *
only - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Rep78 - (A0*
and - *
Rep68 - *)
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
not - *
only - *
catalyse catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
but - *
also - *
move - *
along - *
nucleic - *
acid - *
strands - *
in - *
a - *
polar - *
fashion - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Rep78 - (A0*
and - *
Rep68 - *)
which - *
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Helicases - (A0*)
which - *
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Rep78 - (A0*
and - *
Rep68 - *)
which - *
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
which - *
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Helicases - (A0*)
which - *
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Rep78 - (A0*
and - *
Rep68 - *)
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Helicases - (A0*)
most - *
likely - *
catalyses catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Rep78 - (A0*
and - *
Rep68 - *)
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
packaging - *
reaction - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
 - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
The - (A0*
two - *
large - *
virus-encoded - *
Rep - *
proteins - *
(Rep78 - *
and - *
Rep68) - *)
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
resolution - *
of - *
the - *
covalently - *
cosed - *
AAV - *
termini - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
 - *
. - *

Our - *
previous - *
studies - *
using - *
in - *
vitro - *
hepatic - *
microsomal - *
preparations - *
suggested - *
that - *
Helicases - (A0*)
most - *
likely - *
catalysed catalyse (V*) *
the - (A1*
disruption - *
of - *
hydrogen - *
boding - *
between - *
complementary - *
regions - *
of - *
nucleic - *
acids - *)
to - *
form - *
the - *
major - *
metabolite - *
3-hydroxyquinine - *
 - *
. - *

DNA - (A0*
helicases - *)
are - *
enzymes - *
that - *
catalyze catalyse (V*) *
the - (A1*
unwinding - *
of - *
DNA - *)
by - *
disrupting - *
the - *
hydrogen - *
bonding - *
between - *
paired - *
bases - *
as - *
they - *
progress - *
along - *
the - *
DNA - *
strand - *
in - *
a - *
polar - *
fashion - *
(either - *
35 - *
or - *
53) - *
and - *
have - *
been - *
shown - *
to - *
be - *
involved - *
in - *
many - *
essential - *
cellular - *
processes - *
including - *
replication - *
transcription - *
DNA - *
repair - *
and - *
translation - *
(for - *
reviews - *
see - *
West - *
1996; - *
Bird - *
et - *
al - *
1998; - *
Lohman - *
et - *
al - *
1998; - *
Hall - *
and - *
Matson - *
1999) - *
. - *

DNA - (A0*
helicases - *)
are - *
enzymes - *
that - *
catalyzed catalyse (V*) *
the - (A1*
unwinding - *
of - *
DNA - *)
by - *
disrupting - *
the - *
hydrogen - *
bonding - *
between - *
paired - *
bases - *
as - *
they - *
progress - *
along - *
the - *
DNA - *
strand - *
in - *
a - *
polar - *
fashion - *
(either - *
35 - *
or - *
53) - *
and - *
have - *
been - *
shown - *
to - *
be - *
involved - *
in - *
many - *
essential - *
cellular - *
processes - *
including - *
replication - *
transcription - *
DNA - *
repair - *
and - *
translation - *
(for - *
reviews - *
see - *
West - *
1996; - *
Bird - *
et - *
al - *
1998; - *
Lohman - *
et - *
al - *
1998; - *
Hall - *
and - *
Matson - *
1999) - *
. - *

DNA - (A0*
helicases - *)
catalyze catalyse (V*) *
the - (A1*
unwinding - *
of - *
DNA - *)
by - *
disrupting - *
the - *
hydrogen - *
bonding - *
between - *
paired - *
bases - *
as - *
they - *
progress - *
along - *
the - *
DNA - *
strand - *
in - *
a - *
polar - *
fashion - *
(either - *
35 - *
or - *
53) - *
and - *
have - *
been - *
shown - *
to - *
be - *
involved - *
in - *
many - *
essential - *
cellular - *
processes - *
including - *
replication - *
transcription - *
DNA - *
repair - *
and - *
translation - *
(for - *
reviews - *
see - *
West - *
1996; - *
Bird - *
et - *
al - *
1998; - *
Lohman - *
et - *
al - *
1998; - *
Hall - *
and - *
Matson - *
1999) - *
. - *

DNA - (A0*
helicases - *)
catalyzed catalyse (V*) *
the - (A1*
unwinding - *
of - *
DNA - *)
by - *
disrupting - *
the - *
hydrogen - *
bonding - *
between - *
paired - *
bases - *
as - *
they - *
progress - *
along - *
the - *
DNA - *
strand - *
in - *
a - *
polar - *
fashion - *
(either - *
35 - *
or - *
53) - *
and - *
have - *
been - *
shown - *
to - *
be - *
involved - *
in - *
many - *
essential - *
cellular - *
processes - *
including - *
replication - *
transcription - *
DNA - *
repair - *
and - *
translation - *
(for - *
reviews - *
see - *
West - *
1996; - *
Bird - *
et - *
al - *
1998; - *
Lohman - *
et - *
al - *
1998; - *
Hall - *
and - *
Matson - *
1999) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
explaining - *
resistance - (A1*)
conferred confer (V*) *
by - *
EvgA - (A0*
overexpression - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
these - (A0*
mutations - *)
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
resistance - (A1*)
was - *
conferred confer (V*) *
by - *
EvgA - (A0*
overexpression - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
resistance - (A1*)
is - *
conferred confer (V*) *
by - *
EvgA - (A0*
overexpression - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
EvgA - (A0*
overexpression - *)
conferred confer (V*) *
resistance - (A1*)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
EvgA - (A0*
overexpression - *)
confer confer (V*) *
resistance - (A1*)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
EvgA - (A0*
overexpression - *)
which - *
conferred confer (V*) *
resistance - (A1*)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
EvgA - (A0*
overexpression - *)
which - *
confer confer (V*) *
resistance - (A1*)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

In - *
addition - *
to - *
clear - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
conferred confer (V*) *
the - (A0*
gene - *
variant - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
itself - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
does - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
. - *

In - *
itself - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
did - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
. - *

In - *
itself - *
loss-of-function - (A1*
mutations - *)
was - *
not - *
conferred confer (V*) *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
. - *

In - *
itself - *
loss-of-function - (A1*
mutations - *)
is - *
not - *
conferred confer (V*) *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
. - *

In - *
itself - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
does - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
. - *

In - *
itself - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
did - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
. - *

In - *
addition - *
to - *
clear - *
resistance - (A1*)
conferred confer (V*) *
EvgA - (A0*
overexpression - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
did - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
does - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
will - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
has - *
not - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
. - *

loss-of-function - (A1*
mutations - *)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
. - *

In - *
addition - *
to - *
clear - *
the - (A1*
06-BG - *
resistance - *)
conferred confer (V*) *
these - (A0*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
explaining - *
loss-of-function - (A1*
mutations - *)
conferred confer (V*) *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
loss-of-function - (A1*
mutations - *)
was - *
conferred confer (V*) *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
loss-of-function - (A1*
mutations - *)
is - *
conferred confer (V*) *
by - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
conferred confer (V*) *
loss-of-function - (A1*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
conferred confer (V*) *
loss-of-function - (A1*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

In - *
addition - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
are - *
conferred confer (V*) *
the - (A0*
gene - *
variant - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
resistance - (A1*)
are - *
conferred confer (V*) *
EvgA - (A0*
overexpression - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
the - (A1*
06-BG - *
resistance - *)
are - *
conferred confer (V*) *
these - (A0*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
were - *
conferred confer (V*) *
the - (A0*
gene - *
variant - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
resistance - (A1*)
were - *
conferred confer (V*) *
EvgA - (A0*
overexpression - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
the - (A1*
06-BG - *
resistance - *)
were - *
conferred confer (V*) *
these - (A0*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
conferred confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
conferred confer (V*) *
resistance - (A1*)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
conferred confer (V*) *
the - (A1*
06-BG - *
resistance - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
which - *
conferred confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
which - *
conferred confer (V*) *
resistance - (A1*)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - *)
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *
which - *
conferred confer (V*) *
the - (A1*
06-BG - *
resistance - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
itself - *
EvgA - (A0*
overexpression - *)
does - *
not - *
confer confer (V*) *
resistance - (A1*)
. - *

In - *
addition - *
the - (A0*
gene - *
variant - *)
did - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
the - (A0*
gene - *
variant - *)
does - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
the - (A0*
gene - *
variant - *)
will - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
the - (A0*
gene - *
variant - *)
has - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
the - (A0*
gene - *
variant - *)
. - *

an - (A1*
increased - *
risk - *
of - *
diabetes - *)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
the - (A0*
gene - *
variant - *)
. - *

In - *
itself - *
these - (A0*
mutations - *)
does - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
explaining - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
conferred confer (V*) *
by - *
the - (A0*
gene - *
variant - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
was - *
conferred confer (V*) *
by - *
the - (A0*
gene - *
variant - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
is - *
conferred confer (V*) *
by - *
the - (A0*
gene - *
variant - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A0*
gene - *
variant - *)
conferred confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A0*
gene - *
variant - *)
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A0*
gene - *
variant - *)
which - *
conferred confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A0*
gene - *
variant - *)
which - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

In - *
itself - *
EvgA - (A0*
overexpression - *)
did - *
not - *
confer confer (V*) *
resistance - (A1*)
. - *

In - *
itself - *
these - (A0*
mutations - *)
did - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
. - *

In - *
itself - *
resistance - (A1*)
was - *
not - *
conferred confer (V*) *
by - *
EvgA - (A0*
overexpression - *)
. - *

In - *
itself - *
the - (A1*
06-BG - *
resistance - *)
was - *
not - *
conferred confer (V*) *
by - *
these - (A0*
mutations - *)
. - *

In - *
itself - *
resistance - (A1*)
is - *
not - *
conferred confer (V*) *
by - *
EvgA - (A0*
overexpression - *)
. - *

In - *
itself - *
the - (A1*
06-BG - *
resistance - *)
is - *
not - *
conferred confer (V*) *
by - *
these - (A0*
mutations - *)
. - *

In - *
itself - *
EvgA - (A0*
overexpression - *)
which - *
does - *
not - *
confer confer (V*) *
resistance - (A1*)
. - *

In - *
itself - *
these - (A0*
mutations - *)
which - *
does - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
. - *

In - *
itself - *
EvgA - (A0*
overexpression - *)
which - *
did - *
not - *
confer confer (V*) *
resistance - (A1*)
. - *

In - *
itself - *
these - (A0*
mutations - *)
which - *
did - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
resistance - (A1*)
 - *
can - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
confers confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
conferred confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5(AGT) - *)
which - *
confers confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5(AGT) - *)
which - *
conferred confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Resistance - (A1*
Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *)
drug - *
target - *
is - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*
Stat1 - (A2*)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *)
drug - *
target - *
was - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
resistance - (A1*)
can - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
transfection - (A0*
of - *
AGT - *)
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
confers confer (V*) *
resistance - *
Stat1 - (A2*)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
conferred confer (V*) *
resistance - *
Stat1 - (A2*)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
Stat1 - (A2*)
is - *
conferred confer (V*) *
by - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
Stat1 - (A2*)
was - *
conferred confer (V*) *
by - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
confers confer (V*) *
resistance - *
Stat1 - (A2*)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
conferred confer (V*) *
resistance - *
Stat1 - (A2*)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
resistance - (A1*)
can - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
conferred confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
conferred confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
was - *
conferred confer (V*) *
by - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
through - *
backbone - *
distortions - *
is - *
conferred confer (V*) *
by - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
specificity - (A1*)
can - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
conferring confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
has - *
not - *
been - *
determined - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
confers confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
confered - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
confers confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
has - *
not - *
been - *
determined - *
. - *

by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
which - *
confered - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
Stat1 - (A2*)
has - *
not - *
been - *
determined - *
. - *

Specificity - *)
Stat1 - (A2*)
is - *
confered - *
by - *
the - *
portion - *
of - *
the - *
STATs - *
 - *
. - *

Specificity - (A1*
Stat1 - (A2*)
was - *
confered - *
by - *
the - *
portion - *
of - *)
the - *)
STATs - *
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
resistance - (A1*)
 - *
could - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
resistance - (A1*)
could - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
transfection - (A0*
of - *
AGT - *)
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
resistance - (A1*)
could - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
specificity - (A1*)
could - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
can - *
confer confer (V*) *
resistance - (A1*)
 - *
. - *

The - (A0*
data - *
from - *
the - *)
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
can - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *)
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
can - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
can - *
confer confer (V*) *
specificity - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
 - *
. - *

The - (A0*
data - *
from - *
the - *)
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *)
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
specificity - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
which - *
can - *
confer confer (V*) *
resistance - (A1*)
 - *
. - *

The - (A0*
data - *
from - *
the - *)
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
which - *
can - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *)
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
which - *
can - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
which - *
can - *
confer confer (V*) *
specificity - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
which - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation - *
chemotherapies - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
 - *
. - *

The - (A0*
data - *
from - *
the - *)
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
which - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
alkylation-sensitive - *
cells - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *)
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
which - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
to - (A2*
06-BG - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
resistance - (A1*)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *)
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
which - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
specificity - (A1*)
. - *

In - *
addition - *
these - (A0*
mutations - *)
did - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
these - (A0*
mutations - *)
does - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
these - (A0*
mutations - *)
will - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
these - (A0*
mutations - *)
has - *
not - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

the - (A1*
06-BG - *
resistance - *)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
these - (A0*
mutations - *)
. - *

transfection - (A0*
of - *
AGT(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
confers confer (V*) *
resistanceto - (A2*
alkylation-sensitive - *
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
confers confer (V*) *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
conferred confer (V*) *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
is - *
conferred confer (V*) *
by - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
was - *
conferred confer (V*) *
by - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
confers confer (V*) *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
 - *
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
conferred confer (V*) *
resistance - *
to - (A2*
alkylation - *
chemotherapies - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
confers confer (V*) *
resistanceto - (A2*
06-BG - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
confer confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
conferred confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
confer confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
conferred confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
was - *
conferred confer (V*) *
by - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
through - *
backbone - *
distortions - *
is - *
conferred confer (V*) *
by - *
Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
. - *

The - (A0*
portion - *
of - *
the - *
STATs(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
confers confer (V*) *
specificityfor - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
conferring confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
has - *
not - *
been - *
determined - *
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
confers confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
confered - *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
confers confer (V*) *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
has - *
not - *
been - *
determined - *
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
 - *
which - *
confered - *
resistance - (A1*)
 - *
to - (A2*
alkylation - *
chemotherapies - *)
has - *
not - *
been - *
determined - *
. - *

Specificity - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
is - *
confered - *
by - *
the - *
portion - *
of - *
the - *
STATs - *
 - *
. - *

Specificity - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
was - *
confered - *
by - *
the - *
portion - *
of - *
the - *
STATs - *
. - *

transfection - (A0*
of - *
AGT(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
conferred confer (V*) *
resistanceto - (A2*
alkylation-sensitive - *
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
conferred confer (V*) *
resistanceto - (A2*
06-BG - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

The - (A0*
portion - *
of - *
the - *
STATs(AGT) - *)
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
conferred confer (V*) *
specificityfor - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

transfection - (A0*
of - *
AGT(AGT) - *)
which - *
confers confer (V*) *
resistanceto - (A2*
alkylation-sensitive - *
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165(AGT) - *)
which - *
confers confer (V*) *
resistanceto - (A2*
06-BG - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

The - (A0*
portion - *
of - *
the - *
STATs(AGT) - *)
which - *
confers confer (V*) *
specificityfor - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

transfection - (A0*
of - *
AGT(AGT) - *)
which - *
conferred confer (V*) *
resistanceto - (A2*
alkylation-sensitive - *
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165(AGT) - *)
which - *
conferred confer (V*) *
resistanceto - (A2*
06-BG - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

The - (A0*
portion - *
of - *
the - *
STATs(AGT) - *)
which - *
conferred confer (V*) *
specificityfor - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Resistance - (A1*)
to - (A2*
alkylation-sensitive - *)
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
is - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
to - (A2*
06-BG - *)
and - *
is - *
therefore - *)
an - *
active - *
anticancer - *
drug - *
target - *
is - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
for - (A2*
either - *)
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
is - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
to - (A2*
alkylation-sensitive - *)
cells - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
was - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
to - (A2*
06-BG - *)
and - *
is - *
therefore - *)
an - *
active - *
anticancer - *
drug - *
target - *
was - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
for - (A2*
either - *)
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
was - *
conferred confer (V*) *
by - *
human - *
06-alkylguaning-DNA - *
alkyltransferase - *
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
confers confer (V*) *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

transfection - (A0*
of - *
AGT - *)
conferring confer (V*) *
resistance - (A1*)
to - (A2*
alkylation-sensitive - *
cells - *)
has - *
not - *
been - *
determined - *
. - *

transfection - (A0*
of - *
AGT - *)
confers confer (V*) *
resistance - (A1*)
to - (A2*
alkylation-sensitive - *
cells - *)
. - *

transfection - (A0*
of - *
AGT - *)
confered - *
resistance - (A1*)
to - (A2*
alkylation-sensitive - *
cells - *)
. - *

transfection - (A0*
of - *
AGT - *)
which - *
confers confer (V*) *
resistance - (A1*)
to - (A2*
alkylation-sensitive - *
cells - *)
has - *
not - *
been - *
determined - *
. - *

transfection - (A0*
of - *
AGT - *)
which - *
confered - *
resistance - (A1*)
to - (A2*
alkylation-sensitive - *
cells - *)
has - *
not - *
been - *
determined - *
. - *

Specificity - (A1*)
to - (A2*
alkylation-sensitive - *)
cells - *)
is - *
confered - *
by - *
the - *
portion - *
of - *
the - *
STATs - *
 - *
. - *

Specificity - (A1*)
to - (A2*
alkylation-sensitive - *)
cells - *)
was - *
confered - *
by - *
the - *
portion - *
of - *
the - *
STATs - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
conferred confer (V*) *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
is - *
conferred confer (V*) *
by - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
was - *
conferred confer (V*) *
by - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
confers confer (V*) *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
specificity - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
conferred confer (V*) *
resistance - *
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
confer confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
conferring confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
has - *
not - *
been - *
determined - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
confers confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
confered - *
resistance - (A1*)
to - (A2*
06-BG - *)
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
which - *
confers confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
has - *
not - *
been - *
determined - *
. - *

substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
which - *
confered - *
resistance - (A1*)
to - (A2*
06-BG - *)
has - *
not - *
been - *
determined - *
. - *

Specificity - (A1*)
to - (A2*
06-BG - *)
is - *
confered - *)
by - *
the - *
portion - *
of - *
the - *
STATs - *
 - *
. - *

Specificity - (A1*)
to - (A2*
06-BG - *)
was - *
confered - *)
by - *
the - *
portion - *
of - *
the - *
STATs - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
conferred confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
confer confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
conferred confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
was - *
conferred confer (V*) *
by - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
through - *
backbone - *
distortions - *
is - *
conferred confer (V*) *
by - *
The - (A0*
portion - *
of - *
the - *
STATs - *)
. - *

In - *
addition - *
EvgA - (A0*
overexpression - *)
did - *
not - *
confer confer (V*) *
resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
EvgA - (A0*
overexpression - *)
does - *
not - *
confer confer (V*) *
resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
EvgA - (A0*
overexpression - *)
will - *
not - *
confer confer (V*) *
resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
EvgA - (A0*
overexpression - *)
has - *
not - *
confer confer (V*) *
resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
. - *

resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
EvgA - (A0*
overexpression - *)
. - *

resistance - (A1*)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
EvgA - (A0*
overexpression - *)
. - *

In - *
addition - *
loss-of-function - (A1*
mutations - *)
are - *
conferred confer (V*) *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
addition - *
loss-of-function - (A1*
mutations - *)
were - *
conferred confer (V*) *
by - (A0*
nonsense - *
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - (A0*
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
conferred confer (V*) *
loss-of-function - (A1*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - (A0*
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
conferred confer (V*) *
loss-of-function - (A1*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

In - *
itself - *
the - (A0*
gene - *
variant - *)
did - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
. - *

In - *
itself - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
was - *
not - *
conferred confer (V*) *
by - *
the - (A0*
gene - *
variant - *)
. - *

In - *
itself - *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
is - *
not - *
conferred confer (V*) *
by - *
the - (A0*
gene - *
variant - *)
. - *

In - *
itself - *
the - (A0*
gene - *
variant - *)
which - *
does - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
. - *

In - *
itself - *
the - (A0*
gene - *
variant - *)
which - *
did - *
not - *
confer confer (V*) *
an - (A1*
increased - *
risk - *
of - *
diabetes - *)
. - *

The - *
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
Stat1 - (A2*)
since - *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
could - *
be - *
conferred confer (V*) *
on - *
Stat1 - *
by - (A0*
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *)
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
Stat1 - (A2*)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
can - *
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *)
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
Stat1 - (A2*)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *)
is - *
due - *
to - *
the - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
Stat1 - (A2*)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
which - *
can - *
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
. - *

The - (A0*
data - *
from - *
the - *
chimeras - *
indicate - *
that - *
the - *
difference - *)
is - *
due - *
to - *
the - *
which - *
absence - *
of - *
carboxyl - *
sequences - *
in - *
Stat1 - (A2*)
since - *
simply - *
replacing - *
the - *
C-terminus - *
with - *
that - *
of - *
Stat5 - *
on - *
Stat1 - *
could - *
confer confer (V*) *
the - (A1*
Stat5 - *
phenotype - *
of - *
stability - *
in - *
the - *
presence - *
of - *
MG132 - *)
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
conferred confer (V*) *
resistance - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
(AGT) - *
which - *
confers confer (V*) *
resistance - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
(AGT) - *
which - *
conferred confer (V*) *
resistance - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
. - *

Resistance - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
is - *
conferred confer (V*) *
by - *
human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Resistance - (A1*)
to - (A2*
alkylation - *
chemotherapies - *)
and - *
is - *
therefore - *
an - *
active - *
anticancer - *
drug - *
target - *
was - *
conferred confer (V*) *
by - *
human - (A0*
06-alkylguaning-DNA - *
alkyltransferase - *)
(AGT) - *
which - *
directly - *
reverses - *
endogenous - *
alkylation - *
at - *
the - *
06-position - *
of - *
guanine - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
transfection - (A0*
of - *
AGT - *)
conferred confer (V*) *
resistance - *
to - (A2*
alkylation-sensitive - *
cells - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
to - (A2*
alkylation-sensitive - *
cells - *)
is - *
conferred confer (V*) *
by - *
transfection - (A0*
of - *
AGT - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
resistance - *
to - (A2*
alkylation-sensitive - *
cells - *)
was - *
conferred confer (V*) *
by - *
transfection - (A0*
of - *
AGT - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
transfection - (A0*
of - *
AGT - *)
which - *
confers confer (V*) *
resistance - *
to - (A2*
alkylation-sensitive - *
cells - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Increased - *
AGT - *
levels - *
parallel - *
acquired - *
alkylation - *
resistance - (A1*)
in - *
human - *
tumors - *
(Brent - *
et - *
al - *
1985; - *
Mattern - *
et - *
al - *
1998) - *
and - *
transfection - (A0*
of - *
AGT - *)
which - *
conferred confer (V*) *
resistance - *
to - (A2*
alkylation-sensitive - *
cells - *)
(Kaina - *
et - *
al - *
1991) - *
demonstrating - *
the - *
role - *
of - *
AGT - *
 - *
in - *
therapeutic - *
resistance - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A1*
06-BG - *
resistance - *)
was - *
conferred confer (V*) *
by - *
these - (A0*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
the - (A1*
06-BG - *
resistance - *)
is - *
conferred confer (V*) *
by - *
these - (A0*
mutations - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
these - (A0*
mutations - *)
conferred confer (V*) *
the - (A1*
06-BG - *
resistance - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
these - (A0*
mutations - *)
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
these - (A0*
mutations - *)
which - *
conferred confer (V*) *
the - (A1*
06-BG - *
resistance - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Likewise - *
the - *
introduced - *
charge - *
of - *
Gly160His - *
and - *
Gly160Arg - *
mutants - *
would - *
repel - *
the - *
benzyl - *
group - *
(Figure - *
3B) - *
these - (A0*
mutations - *)
which - *
confer confer (V*) *
the - (A1*
06-BG - *
resistance - *)
(Xu-Welliver - *
et - *
al - *
1999a) - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
conferred confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
which - *
confer confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
which - *
conferred confer (V*) *
resistance - (A1*)
to - (A2*
06-BG - *)
through - *
backbone - *
distortions - *
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
resistance - (A1*)
to - (A2*
06-BG - *)
through - *
backbone - *
distortions - *
was - *
conferred confer (V*) *
by - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
. - *

Besides - *
these - *
side - *
chain - *
interactions - *
with - *
the - *
06-alkyl - *
group - *
structure-based - *
analysis - *
of - *
mutational - *
data - *
suggests - *
that - *
resistance - (A1*)
to - (A2*
06-BG - *)
through - *
backbone - *
distortions - *
is - *
conferred confer (V*) *
by - *
substitutions - (A0*
at - *
Gly156 - *
and - *
Lys165 - *)
. - *

The - (A0*
portion - *
of - *
the - *
STATs - *)
confers confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
. - *

The - (A0*
portion - *
of - *
the - *
STATs - *)
confered - *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
. - *

The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
confers confer (V*) *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
has - *
not - *
been - *
determined - *
. - *

The - (A0*
portion - *
of - *
the - *
STATs - *)
which - *
confered - *
specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
has - *
not - *
been - *
determined - *
. - *

Specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
is - *
confered - *
by - *
the - (A0*
portion - *
of - *
the - *
STATs - *)
 - *
. - *

Specificity - (A1*)
for - (A2*
either - *
a - *
MAPK - *
or - *
a - *
MAPK - *
substrate - *
kinase - *
(MAPKAP) - *)
was - *
confered - *
by - *
the - (A0*
portion - *
of - *
the - *
STATs - *)
. - *

Nonsense - (A0*
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Nonsense - (A0*
or - *
frameshift - *
alterations - *
in - *
the - *
coding - *
sequence - *
or - *
by - *
splice - *
variants - *)
which - *
confer confer (V*) *
loss-of-function - (A1*
mutations - *)
genetic - *
screening - *
has - *
revealed - *
a - *
large - *
number - *
of - *
missense - *
codons - *
with - *
less - *
obvious - *
functional - *
consequences - *
. - *

Disruption - (A1*
of - *
narL - *)
which - *
decreases - *)
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Treatment - (A0*
with - *
melatonin - *)
which - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

EvgA - (A0*
overexpression - *)
which - *
decreased decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

In - *
addition - *
Disruption - (A0*
of - *
narL - *)
did - *
not - *
confer - *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Disruption - (A0*
of - *
narL - *)
does - *
not - *
confer - *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Disruption - (A0*
of - *
narL - *)
will - *
not - *
confer - *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Disruption - (A0*
of - *
narL - *)
has - *
not - *
confer - *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
Disruption - (A0*
of - *
narL - *)
. - *

nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
Disruption - (A0*
of - *
narL - *)
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
which - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Furthermore - (A0*
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoterwhich - *)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoterwhich - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoterwere - *)
found - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Treatment - (A0*
with - *
melatonin - *)
significantly - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
. - *

overexpression - *)
of - *
ArcA - *)
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

overexpression - *)
of - *
ArcA - *)
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

overexpression - *)
of - *
ArcA - *)
which - *
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

overexpression - *)
of - *
ArcA - *)
which - *
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
EvgA - (A0*
overexpression - *)
significantly - *
decreased decrease (V*) *
resistance - (A1*)
. - *

In - *
addition - *
overexpression - (A0*
of - *
ArcA - *)
did - *
not - *
confer - *
glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
overexpression - (A0*
of - *
ArcA - *)
does - *
not - *
confer - *
glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
overexpression - (A0*
of - *
ArcA - *)
will - *
not - *
confer - *
glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
overexpression - (A0*
of - *
ArcA - *)
has - *
not - *
confer - *
glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
. - *

glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
overexpression - (A0*
of - *
ArcA - *)
. - *

glucose - (A1*
consumption - *)
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
overexpression - (A0*
of - *
ArcA - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
significantly - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
. - *

Furthermore - (A0*
glucose - (A1*
consumption - *)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
glucose - (A1*
consumption - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
glucose - (A1*
consumptionwhich - *)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - *)
resistancewere - (A1*)
found - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
glucose - (A1*
consumptionwere - *)
found - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
glucose - (A1*
consumptionwhich - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Treatment - (A0*
with - *
melatonin - *)
significantly - *
has - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
EvgA - (A0*
overexpression - *)
significantly - *
has - *
decreased decrease (V*) *
resistance - (A1*)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
significantly - *
has - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Treatment - (A0*
with - *
melatonin - *)
significantly - *
will - *
decrease decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
EvgA - (A0*
overexpression - *)
significantly - *
will - *
decrease decrease (V*) *
resistance - (A1*)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
significantly - *
will - *
decrease decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Treatment - (A0*
with - *
melatonin - *)
significantly - *
which - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
EvgA - (A0*
overexpression - *)
significantly - *
which - *
decreased decrease (V*) *
resistance - (A1*)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
significantly - *
which - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
. - *

their - *)
mutation - *)
causes - *
decreased decrease (V*) *
promoter - (A1*
activity - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
marA - (A0*
locus - *)
was - *
shown - *
to - *
decrease decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
marA - (A0*
locus - *)
decreases decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
marA - (A0*
locus - *)
decreased decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
expression - (A1*
of - *
OmpF - *
porin - *)
is - *
decreased decrease (V*) *
by - *
marA - (A0*
locus - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
expression - (A1*
of - *
OmpF - *
porin - *)
was - *
decreased decrease (V*) *
by - *
marA - (A0*
locus - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
marA - (A0*
locus - *)
which - *
decreases decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
marA - (A0*
locus - *)
which - *
decreased decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
multiple-antibiotic-resistant - (A2*
( - *
Mar - *
) - *
mutants - *
of - *
Escherichia - *
coli - *)
. - *

their - *)
mutation - *)
decreased decrease (V*) *
promoter - (A1*
activity - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

their - *)
mutation - *)
decreases decrease (V*) *
promoter - (A1*
activity - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

promoter - *)
activity - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
was - *
decreased decrease (V*) *
by - *
their - (A0*
mutation - *)
. - *

promoter - *)
activity - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
is - *
decreased decrease (V*) *
by - *
their - (A0*
mutation - *)
. - *

EvgA - (A1*)
overexpression - *)
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

In - *
addition - *
Treatment - (A0*
with - *
melatonin - *)
did - *
not - *
confer - *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Treatment - (A0*
with - *
melatonin - *)
does - *
not - *
confer - *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Treatment - (A0*
with - *
melatonin - *)
will - *
not - *
confer - *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
Treatment - (A0*
with - *
melatonin - *)
has - *
not - *
confer - *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
Treatment - (A0*
with - *
melatonin - *)
. - *

lipid - (A1*
peroxide - *
synthesis - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
Treatment - (A0*
with - *
melatonin - *)
. - *

the - *)
RELN - *
mRNA - *
content - *)
 - *
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Furthermore - (A0*
lipid - (A1*
peroxide - *
synthesis - *)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
lipid - (A1*
peroxide - *
synthesis - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
lipid - (A1*
peroxide - *
synthesis - *)
which - *
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
lipid - (A1*
peroxide - *
synthesis - *)
which - *
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
lipid - (A1*
peroxide - *
synthesis - *)
were - *
found - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

EvgA - (A1*)
overexpression - *)
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

the - *)
RELN - *
mRNA - *
content - *)
 - *
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

EvgA - (A1*)
overexpression - *)
which - *
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

the - *)
RELN - *
mRNA - *
content - *)
 - *
which - *
decreased decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

EvgA - (A1*)
overexpression - *)
which - *
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

the - *)
RELN - *
mRNA - *
content - *)
 - *
which - *
decreases decrease (V*) *
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

In - *
addition - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
did - *
not - *
confer - *
the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

Furthermore - *)
resistance - (A1*)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - *)
resistance - (A1*)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - *)
resistancewhich - (A1*)
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - *)
resistancewhich - (A1*)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

In - *
addition - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
does - *
not - *
confer - *
the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
will - *
not - *
confer - *
the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

In - *
addition - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
has - *
not - *
confer - *
the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
. - *

the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
was - *
confered - *
by - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
. - *

the - (A1*
CD3? - *
expression - *)
 - *
in - *
a - *
tolC-deficient - *
strain - *
is - *
confered - *
by - *
the - (A0*
RELN - *
mRNA - *
content - *)
 - *
. - *

overexpression - (A0*
of - *
ArcA - *)
decreases decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Disruption - (A0*
of - *
narL - *)
significantly - *
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Disruption - (A0*
of - *
narL - *)
significantly - *
has - *
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Disruption - (A0*
of - *
narL - *)
significantly - *
will - *
decrease decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
Disruption - (A0*
of - *
narL - *)
significantly - *
which - *
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
. - *

Treatment - (A0*
with - *
melatonin - *)
decreases decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A1*
of - *
narL - *)
decreased decrease (V*) *
lipid - *)
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Disruption - (A1*
of - *
narL - *)
decreases decrease (V*) *
lipid - *)
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Disruption - (A1*
of - *
narL - *)
which - *
decreased - *)
lipid - *
peroxide - *
synthesis - *
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

EvgA - (A0*
overexpression - *)
decreases decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
decreases decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

overexpression - (A0*
of - *
ArcA - *)
decreased decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Treatment - (A0*
with - *
melatonin - *)
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

EvgA - (A0*
overexpression - *)
decreased decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

overexpression - (A0*
of - *
ArcA - *)
will - *
decrease decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Treatment - (A0*
with - *
melatonin - *)
will - *
decrease decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

EvgA - (A0*
overexpression - *)
will - *
decrease decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
will - *
decrease decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

overexpression - (A0*
of - *
ArcA - *)
has - *
decreased decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Treatment - (A0*
with - *
melatonin - *)
has - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

EvgA - (A0*
overexpression - *)
has - *
decreased decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
has - *
decreased decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

overexpression - (A0*
of - *
ArcA - *)
which - *
decreases decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
decreases decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
will - *
decrease decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
has - *
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
which - *
decreases decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Disruption - (A0*
of - *
narL - *)
which - *
decreased decrease (V*) *
nitrite - (A1*
induction - *
of - *
the - *
nirB - *
promoter - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
overexpression - (A0*
of - *
ArcA - *)
significantly - *
decreased decrease (V*) *
glucose - (A1*
consumption - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
overexpression - (A0*
of - *
ArcA - *)
significantly - *
has - *
decreased decrease (V*) *
glucose - (A1*
consumption - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
overexpression - (A0*
of - *
ArcA - *)
significantly - *
will - *
decrease decrease (V*) *
glucose - (A1*
consumption - *)
. - *

Deletion - *
of - *
the - *
arcA - *
gene - *
caused - *
about - *
a - *
2-fold - *
increase - *
in - *
the - *
ptsG - *
expression - *
and - *
overexpression - (A0*
of - *
ArcA - *)
significantly - *
which - *
decreased decrease (V*) *
glucose - (A1*
consumption - *)
. - *

The - (A1*
production - *
of - *
C51 - *
microcin - *)
decreased decrease (V*) *
or - *
was - *
absent - *
in - *
rpoS - (A2*
crp - *
and - *
cya - *
mutant - *
cells - *)
 - *
. - *

The - (A1*
production - *
of - *
C51 - *
microcin - *)
decreases decrease (V*) *
or - *
was - *
absent - *
in - *
rpoS - (A2*
crp - *
and - *
cya - *
mutant - *
cells - *)
 - *
. - *

The - (A1*
production - *
of - *
C51 - *
microcin - *)
will - *
decrease decrease (V*) *
or - *
was - *
absent - *
in - *
rpoS - (A2*
crp - *
and - *
cya - *
mutant - *
cells - *)
 - *
. - *

The - (A1*
production - *
of - *
C51 - *
microcin - *)
has - *
decreased decrease (V*) *
or - *
was - *
absent - *
in - *
rpoS - (A2*
crp - *
and - *
cya - *
mutant - *
cells - *)
 - *
. - *

The - (A1*
production - *
of - *
C51 - *
microcin - *)
 - *
that - *
decreased decrease (V*) *
or - *
was - *
absent - *
in - *
rpoS - (A2*
crp - *
and - *
cya - *
mutant - *
cells - *)
 - *
. - *

marA - (A2*
locus - *)
causes - *
decreased decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
in - *
multiple-antibiotic-resistant - *)
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

marA - (A2*
locus - *)
decreased decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
in - *
multiple-antibiotic-resistant - *)
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

marA - (A2*
locus - *)
decreases decrease (V*) *
expression - (A1*
of - *
OmpF - *
porin - *)
in - *
multiple-antibiotic-resistant - *)
(Mar) - *
mutants - *
of - *
Escherichia - *
coli - *
. - *

expression - (A2*
of - *
OmpF - *
porin - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *)
mutants - *
of - *
Escherichia - *
coli - *
was - *
decreased decrease (V*) *
by - *
marA - (A0*
locus - *)
. - *

expression - (A2*
of - *
OmpF - *
porin - *)
in - *
multiple-antibiotic-resistant - *
(Mar) - *)
mutants - *
of - *
Escherichia - *
coli - *
is - *
decreased decrease (V*) *
by - *
marA - (A0*
locus - *)
. - *

Treatment - (A0*
with - *
melatonin - *)
decreases decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Treatment - (A0*
with - *
melatonin - *)
which - *
decreased decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Treatment - (A0*
with - *
melatonin - *)
which - *
decreases decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Lipid - (A1*
peroxide - *
synthesis - *)
is - *
decreased decrease (V*) *
by - *
treatment - (A0*
with - *
melatonin - *)
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

Lipid - (A1*
peroxide - *
synthesis - *)
was - *
decreased decrease (V*) *
by - *
treatment - (A0*
with - *
melatonin - *)
and - *
permitted - *
a - *
recovery - *
of - *
both - *
reduced - *
glutathione - *
and - *
scavenger - *
enzyme - *
activity - *
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
their - (A0*
mutation - *)
decreases decrease (V*) *
promoter - (A1*
activity - *)
in - (A2*
cardiomyocytes - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
their - (A0*
mutation - *)
decreased decrease (V*) *
promoter - (A1*
activity - *)
in - (A2*
cardiomyocytes - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
promoter - (A1*
activity - *)
is - *
decreased decrease (V*) *
by - *
their - (A0*
mutation - *)
in - (A2*
cardiomyocytes - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
promoter - (A1*
activity - *)
was - *
decreased decrease (V*) *
by - *
their - (A0*
mutation - *)
in - (A2*
cardiomyocytes - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
their - (A0*
mutation - *)
which - *
decreases decrease (V*) *
promoter - (A1*
activity - *)
in - (A2*
cardiomyocytes - *)
. - *

MEF2-binding - *
sites - *
have - *
been - *
reported - *
in - *
several - *
cardiac - *
promoters - *
and - *
their - (A0*
mutation - *)
which - *
decreased decrease (V*) *
promoter - (A1*
activity - *)
in - (A2*
cardiomyocytes - *)
. - *

In - *
contrast - *
only - *
low - *
levels - *
of - *
the - *
truncated - *
RAP1 - *
peptides - *
were - *
detected - *
(consistent - *
with - *
lower - *
expression - *
levels - *
and - *
decreases decrease (V*) *
methionine - (A1*
content) - *)
and - *
neither - *
RAP2 - *
nor - *
RAP3 - *
was - *
co-immunoprecipitated - *
in - *
the - *
RAP1 - *
mutants - *
. - *

In - *
contrast - *
only - *
low - *
levels - *
of - *
the - *
truncated - *
RAP1 - *
peptides - *
were - *
detected - *
(consistent - *
with - *
lower - *
expression - *
levels - *
and - *
methionine - (A1*
content - *)
is - *
decreased) - *
and - *
neither - *
RAP2 - *
nor - *
RAP3 - *
was - *
co-immunoprecipitated - *
in - *
the - *
RAP1 - *
mutants - *
. - *

In - *
contrast - *
only - *
low - *
levels - *
of - *
the - *
truncated - *
RAP1 - *
peptides - *
were - *
detected - *
(consistent - *
with - *
lower - *
expression - *
levels - *
and - *
methionine - (A1*
content - *)
was - *
decreased) - *
and - *
neither - *
RAP2 - *
nor - *
RAP3 - *
was - *
co-immunoprecipitated - *
in - *
the - *
RAP1 - *
mutants - *
. - *

In - *
contrast - *
only - *
low - *
levels - *
of - *
the - *
truncated - *
RAP1 - *
peptides - *
were - *
detected - *
(consistent - *
with - *
lower - *
expression - *
levels - *
and - *
methionine - (A1*
content - *)
will - *
be - *
decreased) - *
and - *
neither - *
RAP2 - *
nor - *
RAP3 - *
was - *
co-immunoprecipitated - *
in - *
the - *
RAP1 - *
mutants - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
was - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
is - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
will - *
be - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
which - *
was - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
which - *
is - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

In - *
brain - *
areas - *
of - *
schizophrenia - *
patients - *
homologous - *
to - *
those - *
of - *
the - *
nonpsychiatric - *
subjects - *
the - (A0*
RELN - *
mRNA - *
content - *)
which - *
will - *
be - *
significantly - *
decreased decrease (V*) *
(40?0%; - *
see - *
Table - *
2) - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
were - *
predicted - *
to - *
decrease decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
were - *
proven - *
to - *
decrease decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
decrease decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
decreased decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
which - *
decrease decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

Concomitantly - (A2*
the - *)
levels - *
of - *
acetylcholine - *)
which - *
decreased decrease (V*) *
by - *
378% - *
in - *
the - (A3*
lead-treated - *
animals - *)
as - *
compared - *
to - *
the - *
controls - *
. - *

In - (A2*
contrast - *
GP - (A1*)
only - *
decreases decrease (V*) *
by - *
124% - *)
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

In - (A2*
contrast - *
GP - (A1*)
was - *
found - *
to - *
only - *
decrease - *)
by - *
124% - *
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

In - (A2*
contrast - *
GP - (A1*)
was - *
predicted - *
to - *
only - *)
decreased decrease (V*) *
by - *
124% - *
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

In - (A2*
contrast - *
GP - (A1*)
was - *
proven - *
to - *
only - *
decreased - *)
by - *
124% - *
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

In - (A2*
contrast - *
GP - (A1*)
which - *
only - *
decreased - *)
by - *
124% - *
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

In - (A2*
contrast - *
GP - (A1*)
which - *
only - *
decreases - *)
by - *
124% - *
+/- - *
39% - *
(197 - *
+/- - *
013 - *
to - *
173 - *
+/- - *
013 - *
mg/kg/min; - *
not - *
significant - *
[NS]) - *
in - (A3*
those - *
who - *
had - *
little - *
to - *
no - *
increase - *
in - *
plasma - *
citrulline - *
concentration - *)
. - *

Furthermore - (A0*
the - (A1*
CD3? - *
expression - *)
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
the - (A1*
CD3? - *
expression - *)
which - *
decreased decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
the - (A1*
CD3? - *
expression - *)
which - *
decreases decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
the - (A1*
CD3? - *
Expression - *)
were - *
proven - *
to - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Furthermore - (A0*
the - (A1*
CD3? - *
expression - *)
were - *
found - *
decrease decrease (V*) *
by - *
mixing - *
normal - *
T - *
cells - *
with - *
TBM-M?s - *
in - *
a - *
cell-number-dependent - *
manner - *
(Fig - *
2B) - *
. - *

Treatment - (A0*
with - *
melatonin - *)
which - *
decreases decrease (V*) *
lipid - (A1*
peroxide - *
synthesis - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

EvgA - (A0*
overexpression - *)
which - *
decreases decrease (V*) *
resistance - (A1*)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

the - (A0*
RELN - *
mRNA - *
content - *)
 - *
which - *
decreases decrease (V*) *
the - (A1*
CD3? - *
expression - *)
 - *
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

overexpression - (A0*
of - *
ArcA - *)
which - *
decreased decrease (V*) *
glucose - (A1*
consumption - *)
whilst - *
not - *
suppressing - *
induction - *
by - *
nitrate - *
suggesting - *
that - *
there - *
may - *
be - *
a - *
second - *
nitrate-responsive - *
factor - *
. - *

It - *
was - *
found - *
that - *
NLF - *
from - *
smokers - *
contained - *
decreasing decrease (V*) *
levels - (A1*
of - *
Clara - *
cell - *
secretory - *
protein - *)
and - *
increased - *
proportions - *
of - *
a - *
truncated - *
variant - *
of - *
lipocortin-1 - *
threee - *
acidic - *
forms - *
of - *
alpha - *
(1)-antitrypsin - *
and - *
one - *
phosphorylated - *
form - *
of - *
cystatin - *
S - *
Syntrophin - *
binds - *
to - *
an - *
alternatively - *
spliced - *
exon - *
of - *
dystrophin - *
. - *

NLF - *
from - *
smokers - *
contained - *
decreased decrease (V*) *
levels - (A1*
of - *
Clara - *
cell - *
secretory - *
protein - *)
and - *
increased - *
proportions - *
of - *
a - *
truncated - *
variant - *
of - *
lipocortin-1 - *
threee - *
acidic - *
forms - *
of - *
alpha - *
(1)-antitrypsin - *
and - *
one - *
phosphorylated - *
form - *
of - *
cystatin - *
S - *
Syntrophin - *
binds - *
to - *
an - *
alternatively - *
spliced - *
exon - *
of - *
dystrophin - *
. - *

NLF - *
from - *
smokers - *
contained - *
decreasing decrease (V*) *
levels - (A1*
of - *
Clara - *
cell - *
secretory - *
protein - *)
and - *
increased - *
proportions - *
of - *
a - *
truncated - *
variant - *
of - *
lipocortin-1 - *
threee - *
acidic - *
forms - *
of - *
alpha - *
(1)-antitrypsin - *
and - *
one - *
phosphorylated - *
form - *
of - *
cystatin - *
S - *
Syntrophin - *
binds - *
to - *
an - *
alternatively - *
spliced - *
exon - *
of - *
dystrophin - *
. - *

If - *
this - *
distance - *
of - *
30 - *
amino - *
acids - *
is - *
not - *
maintained - *
as - *
in - *
human - *
AspRS - *
chimera#1 - *
or - *
in - *
yeast - *
LysTS - *
chimera#1 - *
and - *
yeast - *
AsnRS - *
chimera#2 - *
(Figure - *
5B) - *
the - *
binding - *
to - *
tRNA - *
is - *
strongly - *
affected - *
and - *
the - (A1*
protection - *)
was - *
decreased decrease (V*) *
or - *
even - *
abolished - *
in - *
the - *
case - *
of - *
human - *
AspRS - *
chimera#1 - *
(Table) - *
. - *

If - *
this - *
distance - *
of - *
30 - *
amino - *
acids - *
is - *
not - *
maintained - *
as - *
in - *
human - *
AspRS - *
chimera#1 - *
or - *
in - *
yeast - *
LysTS - *
chimera#1 - *
and - *
yeast - *
AsnRS - *
chimera#2 - *
(Figure - *
5B) - *
the - *
binding - *
to - *
tRNA - *
is - *
strongly - *
affected - *
and - *
the - (A1*
protection - *)
will - *
be - *
decreased decrease (V*) *
or - *
even - *
abolished - *
in - *
the - *
case - *
of - *
human - *
AspRS - *
chimera#1 - *
(Table) - *
. - *

If - *
this - *
distance - *
of - *
30 - *
amino - *
acids - *
is - *
not - *
maintained - *
as - *
in - *
human - *
AspRS - *
chimera#1 - *
or - *
in - *
yeast - *
LysTS - *
chimera#1 - *
and - *
yeast - *
AsnRS - *
chimera#2 - *
(Figure - *
5B) - *
the - *
binding - *
to - *
tRNA - *
is - *
strongly - *
affected - *
and - *
the - (A1*
protection - *)
had - *
been - *
decreased decrease (V*) *
or - *
even - *
abolished - *
in - *
the - *
case - *
of - *
human - *
AspRS - *
chimera#1 - *
(Table) - *
. - *

vectors - (A2*)
the - (A1*
viral - *
transcription - *
elements - *)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
that - *
delete delete (V*) *
the - (A1*
ZONAB - *
binding - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
delete delete (V*) *
the - (A1*
ZONAB - *
binding - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
deleted delete (V*) *
the - (A1*
ZONAB - *
binding - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
that - *
deleted delete (V*) *
the - (A1*
ZONAB - *
binding - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
CST20 - (A1*)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
delete delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
are - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
were - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
with - *
the - (A1*
ZONAB - *
binding - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
delete delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
ZONAB - *
binding - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
the - (A1*
viral - *
transcription - *
elements - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
CST20 - (A1*)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

vectors - (A2*)
the - (A1*
viral - *
transcription - *
elements - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
CST20 - (A1*)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
transposondesigned - *)
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
. - *

In - (A1*
the - *
presence - *
of - *
the - *)
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
 - *
can - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *)
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
 - *
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *)
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
 - *
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *)
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
 - *
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
Appropriate - (A0*
progenitor - *
strains - *)
designed - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
. - *

the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
can - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
cytotoxic - (A1*
lymphocyte - *
responsesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
could - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
cytotoxic - (A1*
lymphocyte - *
responsesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
might - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
cytotoxic - (A1*
lymphocyte - *
responsesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
may - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
cytotoxic - (A1*
lymphocyte - *
responsesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
designed - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
. - *

The - *
propensity - *
of - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responseshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *)
falciparum - *
has - *
found - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responseshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *)
falciparum - *
were - *
found - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responseshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *)
falciparum - *
has - *
proven - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responseshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *)
falciparum - *
were - *
proven - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responseshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
antigen-loaded - (A0*
immature - *
DCs - *)
designed - *
to - *
delete delete (V*) *
them - (A1*)
 - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
silence - *
T - *
cells - *
either - *
by - *
deleting delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
deleted delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
which - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
which - *
deleted delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
that - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
that - *
deleted delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responsesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
designed - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
. - *

By - *)
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
cytotoxic - (A1*
lymphocyte - *
responses - *)
was - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - *)
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
cytotoxic - (A1*
lymphocyte - *
responses - *)
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - *)
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
cytotoxic - (A1*
lymphocyte - *
responses - *)
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - *)
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deletes delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - *)
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deleted delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
transposonfound - *)
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
Appropriate - (A0*
progenitor - *
strains - *)
found - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
found - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
antigen-loaded - (A0*
immature - *
DCs - *)
found - *
to - *
delete delete (V*) *
them - (A1*)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
found - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
transposonproven - *)
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
Appropriate - (A0*
progenitor - *
strains - *)
proven - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
proven - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
antigen-loaded - (A0*
immature - *
DCs - *)
proven - *
to - *
delete delete (V*) *
them - (A1*)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
proven - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
transposonwhich - *)
proven - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
Appropriate - (A0*
progenitor - *
strains - *)
which - *
proven - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
which - *
proven - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
antigen-loaded - (A0*
immature - *
DCs - *)
which - *
proven - *
to - *
delete delete (V*) *
them - (A1*)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
which - *
proven - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
transposonthat - *)
proven - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
Appropriate - (A0*
progenitor - *
strains - *)
that - *
proven - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
that - *
proven - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
antigen-loaded - (A0*
immature - *
DCs - *)
that - *
proven - *
to - *
delete delete (V*) *
them - (A1*)
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
that - *
proven - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
that - *
delete delete (V*) *
CST20 - (A1*)
. - *

vectors - (A2*)
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
delete delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
are - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
were - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
with - *
the - (A1*
viral - *
transcription - *
elements - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
which - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
which - *
delete delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

vectors - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
delete delete (V*) *
CST20 - (A1*)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
deleted delete (V*) *
CST20 - (A1*)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
that - *
deleted delete (V*) *
CST20 - (A1*)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
are - *
deleted delete (V*) *
for - *
CST20 - (A1*)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
were - *
deleted delete (V*) *
for - *
CST20 - (A1*)
. - *

In - *)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
Appropriate - (A0*
progenitor - *
strains - *)
 - *
can - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

the - (A0*
transposoncan - *)
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
transposoncould - *)
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
transposonmight - *)
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

the - (A0*
transposonmay - *)
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
 - *
can - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

The - *
propensity - *
of - *
the - (A0*
transposonto - *)
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
siteshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *
found - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
siteshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *
found - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
siteshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *
proven - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
siteshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *
proven - *
to - *
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
siteshas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

In - (A1*)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
antigen-loaded - (A0*
immature - *
DCs - *)
 - *
can - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposonsilence - *)
T - *
cells - *
either - *
by - *
deleting delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposondelete - *)
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposondeleted - *)
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposonwhich - *)
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposonwhich - *)
deleted delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposonthat - *)
delete delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
the - (A0*
transposonthat - *)
deleted delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sitesor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
 - *
can - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

By - (A0*
using - *)
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
was - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *)
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *)
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *)
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deletes delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *)
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deleted delete (V*) *
the - (A1*
UR3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

In - *)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
Appropriate - (A0*
progenitor - *
strains - *)
 - *
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
 - *
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
antigen-loaded - (A0*
immature - *
DCs - *)
 - *
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
 - *
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - *)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
Appropriate - (A0*
progenitor - *
strains - *)
 - *
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
 - *
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
antigen-loaded - (A0*
immature - *
DCs - *)
 - *
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
 - *
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - *)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
Appropriate - (A0*
progenitor - *
strains - *)
 - *
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
 - *
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*)
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *
cre - *
antigen-loaded - (A0*
immature - *
DCs - *)
 - *
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *)
P1 - *
cyclization - *
recombinase - *
cre - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
 - *
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
can - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

The - *
propensity - *
of - *
Appropriate - (A0*
progenitor - *
strains - *)
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *)
parasite - *
Plasmodium - *
falciparum - *
has - *
found - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *)
parasite - *
Plasmodium - *
falciparum - *
were - *
found - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *)
parasite - *
Plasmodium - *
falciparum - *
has - *
proven - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *)
parasite - *
Plasmodium - *
falciparum - *
were - *
proven - *
to - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

antigen-loaded - (A0*
immature - *
DCs - *)
can - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
them - (A1*)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
silence - *
T - *
cells - *
either - *
by - *
deleting delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
deleted delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
which - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
which - *
deleted delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
that - *
delete delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
Appropriate - (A0*
progenitor - *
strains - *)
that - *
deleted delete (V*) *
any - (A1*
chromosomal - *
region - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
can - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
headpiece - *
domain - *
of - *
dematinby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
any - (A1*
chromosomal - *
region - *)
 - *
was - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
any - (A1*
chromosomal - *
region - *)
 - *
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
any - (A1*
chromosomal - *
region - *)
 - *
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deletes delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deleted delete (V*) *
any - (A1*
chromosomal - *
region - *)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
could - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

antigen-loaded - (A0*
immature - *
DCs - *)
could - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
them - (A1*)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
could - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
headpiece - *
domain - *
of - *
dematinby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
might - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

antigen-loaded - (A0*
immature - *
DCs - *)
might - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
them - (A1*)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
might - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
headpiece - *
domain - *
of - *
dematinby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
may - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

antigen-loaded - (A0*
immature - *
DCs - *)
may - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
them - (A1*)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
may - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
the - (A1*
headpiece - *
domain - *
of - *
dematinby - *)
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

The - *
propensity - *
of - *
antigen-loaded - (A0*
immature - *
DCs - *)
to - *
delete delete (V*) *
them - (A1*)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
silence - *
T - *
cells - *
either - *
by - *
deleting delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
deleted delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
which - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
which - *
deleted delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
that - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
that - *
deleted delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

The - *
propensity - *
of - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinhas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *)
stem - *
cells - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
was - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *)
stem - *
cells - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *)
stem - *
cells - *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *)
stem - *
cells - *
which - *
deletes delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *)
stem - *
cells - *
which - *
deleted delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *
found - *
to - *
delete delete (V*) *
them - (A1*)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *)
found - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinhas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *
found - *
to - *
delete delete (V*) *
them - (A1*)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *)
found - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinhas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *
proven - *
to - *
delete delete (V*) *
them - (A1*)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
has - *)
proven - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinhas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - *)
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *
proven - *
to - *
delete delete (V*) *
them - (A1*)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *
were - *)
proven - *
to - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinhas - *)
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
silence - *
T - *
cells - *
either - *
by - *
deleting delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
them - (A1*)
 - *
was - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
them - (A1*)
 - *
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
them - (A1*)
 - *
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deletes delete (V*) *
them - (A1*)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *)
in - *
mouse - *
embryonic - *
stem - *
cells - *
which - *
deleted delete (V*) *
them - (A1*)
 - *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
deleted delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
which - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
which - *
deleted delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
that - *
delete delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
that - *
deleted delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematinor - *)
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Studies - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
deleted delete (V*) *
for - *
the - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

strains - (A2*)
that - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

strains - (A2*)
which - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

strains - (A2*)
which - *
deleted delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

strains - (A2*)
which - *
is - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

strains - (A2*)
which - *
was - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

strains - (A2*)
with - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Studies - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

However - *
strains - (A2*)
that - *
delete delete (V*) *
the - *
micF - (A1*
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
strains - (A2*)
which - *
delete delete (V*) *
the - *
micF - (A1*
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
strains - (A2*)
which - *
deleted delete (V*) *
the - *
micF - (A1*
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
strains - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
strains - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
strains - (A2*)
with - *
the - *
micF - (A1*
locus - *)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

Studies - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
strains - (A2*)
(micF - (A1*
locus - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

Studies - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

strains - (A2*)
micF - (A1*
locus - *)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

strains - (A2*)
micF - (A1*
locus - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

strains - (A2*)
micF - (A1*
locus - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

Studies - *
with - *
vectors - (A2*)
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
that - *
delete delete (V*) *
micF - (A1*
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
which - *
delete delete (V*) *
micF - (A1*
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
which - *
deleted delete (V*) *
micF - (A1*
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
that - *
deleted delete (V*) *
micF - (A1*
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
strains - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
. - *

Studies - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

strains - (A2*)
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
delete delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
are - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
were - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
with - *
micF - (A1*
locus - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
which - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
which - *
delete delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

strains - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
micF - (A1*
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Studies - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
were - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
vectors - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
are - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
vectors - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
has - *
been - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
vectors - (A2*)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
will - *
be - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
vectors - (A2*)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
that - *
delete - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
delete - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
deleted - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
is - *
deleted - *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
was - *
deleted - *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *)
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
with - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
that - *
delete - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
delete - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
deleted - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
are - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
were - *
deleted - *
for - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
with - *
the - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
deleted - *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
(the - (A1*
galR - *
generpoSmicF - *
locus - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
the - (A1*
galR - *
generpoSmicF - *
locus - *)
was - *
deleted - *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
the - (A1*
galR - *
generpoSmicF - *
locus - *)
is - *
deleted - *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
the - (A1*
galR - *
generpoSmicF - *
locus - *)
will - *
be - *
deleted - *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
that - *
delete - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
delete - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
deleted - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
that - *
deleted - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
are - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
were - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
delete - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
are - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
were - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
with - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
deleted - *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
delete - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
are - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

utation - (A2*
of - *
the - *
hns - *
gene - *
in - *
E - *
 - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
 - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - *
deleted delete (V*) *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
 - *
strain - *
of - *
E - *
 - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescencestrains - *)
which - *
were - *
deleted - *
for - *
the - (A1*
galR - *
generpoSmicF - *
locus - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
that - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
The - (A2*
GATA-4 - *
mutants - *)
(the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
that - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

vectors - (A2*)
that - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
that - *
delete delete (V*) *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
that - *
deleted delete (V*) *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
The - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
that - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
delete delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
are - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
were - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
with - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
N-terminal - *
region - *
and - *
the - *
first - *
zinc - *
finger - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
which - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
which - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

vectors - (A2*)
which - *
delete delete (V*) *
the - *)
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
delete delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
which - *
deleted delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
which - *
deleted delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

vectors - (A2*)
which - *
deleted delete (V*) *
the - *)
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
deleted delete (V*) *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
which - *
is - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
which - *
is - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

vectors - (A2*)
which - *
is - *
deleted - *)
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
is - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
which - *
was - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
which - *
was - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

vectors - (A2*)
which - *
was - *
deleted - *)
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
was - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

mutated - (A2*
ZONAB-binding - *)
site - *)
with - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

In - (A2*
plasmid - *)
ErbB-2: - *
S-D - *)
with - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

vectors - (A2*)
with - *
the - *
N-terminal - *)
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
with - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
that - *
delete delete (V*) *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
the - (A2*
GATA-4 - *
mutants - *)
(C-terminal - (A1*
transactivition - *
domain - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
that - *
delete delete (V*) *
the - *
the - (A1*
ZONAB - *
binding - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
C-terminal - (A1*
transactivition - *
domain - *)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
C-terminal - (A1*
transactivition - *
domain - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
C-terminal - (A1*
transactivition - *
domain - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

However - *
vectors - (A2*)
that - *
delete delete (V*) *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
that - *
delete delete (V*) *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
that - *
deleted delete (V*) *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
that - *
delete delete (V*) *
the - *
CST20 - (A1*)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
delete delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
are - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
were - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
with - *
C-terminal - (A1*
transactivition - *
domain - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

the - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
C-terminal - (A1*
transactivition - *
domain - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
delete delete (V*) *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
delete delete (V*) *
the - *
the - (A1*
ZONAB - *
binding - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
vectors - (A2*)
which - *
delete delete (V*) *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
delete delete (V*) *
the - *
CST20 - (A1*)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
deleted delete (V*) *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
deleted delete (V*) *
the - *
the - (A1*
ZONAB - *
binding - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
vectors - (A2*)
which - *
deleted delete (V*) *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
deleted delete (V*) *
the - *
CST20 - (A1*)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
vectors - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
the - (A1*
ZONAB - *
binding - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
vectors - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
CST20 - (A1*)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
mutated - (A2*
ZONAB-binding - *
site - *)
with - *
the - *
D: - (A1*
ErbB-2: - *
S-D - *)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
with - *
the - *
the - (A1*
ZONAB - *
binding - *)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
vectors - (A2*)
with - *
the - *
the - (A1*
viral - *
transcription - *
elements - *)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

Study - *
of - *
the - *
promoter-lacZ - *
gene - *
fusions - *
introduced - *
into - *
the - *
chromosome - *
indicated - *
that - *
galS - *
expression - *
was - *
elevated - *
in - *
cells - *
in - *
which - *
the - *
normal - *
galS - *
gene - *
was - *
interrupted - *
but - *
not - *
in - *
cells - *
in - *
which - *
the - (A1*
galR - *
gene - *)
was - *
deleted delete (V*) *
. - *

Study - *
of - *
the - *
promoter-lacZ - *
gene - *
fusions - *
introduced - *
into - *
the - *
chromosome - *
indicated - *
that - *
galS - *
expression - *
was - *
elevated - *
in - *
cells - *
in - *
which - *
the - *
normal - *
galS - *
gene - *
was - *
interrupted - *
but - *
not - *
in - *
cells - *
in - *
which - *
the - (A1*
galR - *
gene - *)
is - *
deleted delete (V*) *
. - *

Study - *
of - *
the - *
promoter-lacZ - *
gene - *
fusions - *
introduced - *
into - *
the - *
chromosome - *
indicated - *
that - *
galS - *
expression - *
was - *
elevated - *
in - *
cells - *
in - *
which - *
the - *
normal - *
galS - *
gene - *
was - *
interrupted - *
but - *
not - *
in - *
cells - *
in - *
which - *
the - (A1*
galR - *
gene - *)
will - *
be - *
deleted delete (V*) *
. - *

Study - *
of - *
the - *
promoter-lacZ - *
gene - *
fusions - *
introduced - *
into - *
the - *
chromosome - *
indicated - *
that - *
galS - *
expression - *
was - *
elevated - *
in - *
cells - *
in - *
which - *
the - *
normal - *
galS - *
gene - *
was - *
interrupted - *
but - *
not - *
in - *
cells - *
in - *
which - *
the - (A1*
galR - *
gene - *)
has - *
been - *
deleted delete (V*) *
. - *

Studies - *
with - *
strains - (A2*)
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
strains - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
strains - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
strains - (A2*)
which - *
has - *
been - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

Studies - *
with - *
strains - (A2*)
which - *
will - *
be - *
deleted delete (V*) *
for - *
the - *
micF - (A1*
locus - *)
showed - *
that - *
the - *
marA-dependent - *
reduction - *
of - *
OmpF - *
required - *
an - *
intact - *
micF - *
locus - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
the - *
N-terminal - *)
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
the - *
N-terminal - *)
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
is - *
deleted delete (V*) *
for - *
the - *)
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
which - *
was - *
deleted delete (V*) *
for - *
the - *
N-terminal - *
region - *
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

The - (A2*
GATA-4 - *
mutants - *)
with - *
the - *
N-terminal - *
region - *)
(127 - *
&amp;#8211; - *
443 - *
and - *
201 - *
&amp;#8211; - *
443) - *
and - *
the - *
first - *
zinc - *
finger - *
(242 - *
&amp;#8211; - *
443) - *
deleted delete (V*) *
were - *
able - *
to - *
synergize - *
with - *
MEF2A - *
(Figure - *
6A) - *
. - *

However - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
delete delete (V*) *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
deleted delete (V*) *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
are - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
the - (A2*
GATA-4 - *
mutants - *)
which - *
were - *
deleted delete (V*) *
for - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

However - *
the - (A2*
GATA-4 - *
mutants - *)
with - *
the - *
C-terminal - (A1*
transactivition - *
domain - *)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
the - (A1*
ZONAB - *
binding - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
the - (A1*
ZONAB - *
binding - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - (A1*
ZONAB - *
binding - *)
is - *
deleted delete (V*) *
in - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - (A1*
ZONAB - *
binding - *)
was - *
deleted delete (V*) *
in - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - (A1*
ZONAB - *
binding - *)
will - *
be - *
deleted delete (V*) *
in - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
found - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
proven - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
which - *
proven - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
. - *

Thus - *
this - *
granule - *
enzyme - *
is - *
required - *
for - *
the - *
unique - *
effects - *
of - *
Leu-Leu-OMe - *
and - *
may - *
provide - *
a - *
target - *
for - *
the - (A0*
development - *
of - *
other - *
immunotherapeutic - *
agents - *)
that - *
proven - *
to - *
delete delete (V*) *
cytotoxic - (A1*
lymphocyte - *
responses - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
vectors - (A2*)
which - *
delete delete (V*) *
the - (A1*
viral - *
transcription - *
elements - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
vectors - (A2*)
which - *
deleted delete (V*) *
the - (A1*
viral - *
transcription - *
elements - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
vectors - (A2*)
that - *
deleted delete (V*) *
the - (A1*
viral - *
transcription - *
elements - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
vectors - (A2*)
which - *
are - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
vectors - (A2*)
which - *
were - *
deleted delete (V*) *
for - *
the - (A1*
viral - *
transcription - *
elements - *)
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *)
cre - *
the - (A0*
transposon - *)
may - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *)
cre - *
the - (A0*
transposon - *)
could - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

In - (A1*
the - *
presence - *
of - *
the - *
phage - *
P1 - *
cyclization - *
recombinase - *)
cre - *
the - (A0*
transposon - *)
might - *
delete delete (V*) *
the - *
URA3 - *
tetA - *
and - *
lacZ - *
genes - *
between - *
the - *
two - *
loxP - *
sites - *
. - *

Appropriate - (A0*
progenitor - *
strains - *)
could - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
any - (A1*
chromosomal - *
region - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

Appropriate - (A0*
progenitor - *
strains - *)
might - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
any - (A1*
chromosomal - *
region - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

Appropriate - (A0*
progenitor - *
strains - *)
may - *
now - *
be - *
constructed - *
to - *
delete delete (V*) *
virtually - *
any - (A1*
chromosomal - *
region - *)
by - *
utilizing - *
an - *
extensive - *
collection - *
of - *
lines - *
containing - *
single - *
P - *
element - *
insertions - *
throughout - *
the - *
Drosophila - *
genome - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
has - *
found - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
were - *
found - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
has - *
proven - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Isolates - (A0*
of - *
the - *
malaria - *
parasite - *
Plasmodium - *
falciparum - *)
were - *
proven - *
to - *
delete delete (V*) *
a - (A1*
segment - *
of - *
chromosome - *
9 - *)
has - *
provided - *
positional - *
information - *
that - *
has - *
allowed - *
us - *
to - *
identify - *
a - *
gene - *
necessary - *
for - *
cytoadherence - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
delete delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
deleted delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
which - *
delete delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
which - *
deleted delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
that - *
delete delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Recent - *
experiments - *
have - *
provided - *
direct - *
evidence - *
that - *
antigen-loaded - (A0*
immature - *
DCs - *)
that - *
deleted delete (V*) *
them - (A1*)
or - *
by - *
expanding - *
regulatory - *
T - *
cells - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
delete delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
are - *
deleted delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
were - *
deleted delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
with - *
CST20 - (A1*)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
deleted delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
delete delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
are - *
deleted delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
which - *
were - *
deleted delete (V*) *
for - *
CST20 - (A1*)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
is - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
will - *
be - *
deleted delete (V*) *
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
which - *
deletes delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

By - (A0*
using - *
homologous - *
recombination - *
in - *
mouse - *
embryonic - *
stem - *
cells - *)
which - *
deleted delete (V*) *
the - (A1*
headpiece - *
domain - *
of - *
dematin - *)
to - *
evaluate - *
its - *
function - *
in - *
vivo - *
. - *

However - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
with - *
the - *
CST20 - (A1*)
deleted delete (V*) *
(1 - *
&amp;#8211; - *
332 - *
201 - *
&amp;#8211; - *
332) - *
were - *
all - *
unable - *
to - *
support - *
MEF2 - *
synergy - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
In - (A2*
plasmid - *
ErbB-2: - *
S-D - *)
(the - (A1*
ZONAB - *
binding - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
D: - (A1*
ErbB-2: - *
S-D - *)
was - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
D: - (A1*
ErbB-2: - *
S-D - *)
is - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
D: - (A1*
ErbB-2: - *
S-D - *)
will - *
be - *
deleted delete (V*) *
and - *
in - *
ErbB-2: - *
S-A - *
the - *
inverted - *
CCAAT - *
box - *
was - *
substituted - *
 - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
vectors - (A2*)
(the - (A1*
viral - *
transcription - *
elements - *)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
that - *
delete delete (V*) *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
delete delete (V*) *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
deleted delete (V*) *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
that - *
deleted delete (V*) *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
are - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
generation - *
of - *
replication-competent - *
virus - *
is - *
considered - *
less - *
likely - *
with - *
mutated - (A2*
ZONAB-binding - *
site - *)
which - *
were - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
with - *
a - *
functional - *
(D: - *
ErbB-2: - *
S) - *
or - *
Colonies - (A2*
of - *
C - *
albicans - *
cells - *)
(CST20 - (A1*)
deleted; - *
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
delete delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
are - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
were - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
with - *
D: - (A1*
ErbB-2: - *
S-D - *)
deleted delete (V*) *
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
which - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
which - *
delete delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
which - *
are - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

mutated - (A2*
ZONAB-binding - *
site - *)
which - *
were - *
deleted delete (V*) *
for - *
D: - (A1*
ErbB-2: - *
S-D - *)
revealed - *
defects - *
in - *
the - *
lateral - *
formation - *
of - *
mycelia - *
on - *
synthetic - *
solid - *
&quot;Spider&quot; - *
media - *
. - *

Mutation - *)
of - *
the - *
hns - *
gene - *
in - *
E - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - (A1*)
deleted delete (V*) *
strain - *
of - *
E - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
. - *

Mutation - *)
of - *
the - *
hns - *
gene - *
in - *
E - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - (A1*)
that - *
is - *
deleted delete (V*) *
strain - *
of - *
E - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
. - *

Mutation - *)
of - *
the - *
hns - *
gene - *
in - *
E - *
coli - *
has - *
resulted - *
in - *
strong - *
expression - *
of - *
the - *
V - *
fischeri - *
lux - *
system - *
at - *
low - *
cell - *
density - *
even - *
in - *
an - *
rpoS - (A1*)
which - *
was - *
deleted delete (V*) *
strain - *
of - *
E - *
coli - *
that - *
emits - *
very - *
low - *
levels - *
of - *
luminescence - *
. - *

Alternative - *)
mRNA - *
splicing - *
in - *
the - *
coding - *
region - *
(encoded - *
by - *
exons - *
3-12) - *
generates - *
transcripts - (A2*)
which - *
deleted delete (V*) *
exons - (A1*
8 - *
(75 - *
nt) - *
7+8 - *
(156 - *
nt) - *
or - *
8+9 - *
(168 - *
nt) - *)
and - *
that - *
encode - *
distinct - *
protein - *
isoforms - *
(delta25 - *
delta52 - *
and - *
delta56 - *
aa - *
respectively) - *
. - *

Alternative - *)
mRNA - *
splicing - *
in - *
the - *
coding - *
region - *
(encoded - *
by - *
exons - *
3-12) - *
generates - *
transcripts - (A2*)
with - *
exons - (A1*
8 - *
(75 - *
nt) - *
7+8 - *
(156 - *
nt) - *
or - *
8+9 - *
(168 - *
nt) - *)
deleted delete (V*) *
and - *
that - *
encode - *
distinct - *
protein - *
isoforms - *
(delta25 - *
delta52 - *
and - *
delta56 - *
aa - *
respectively) - *
. - *

Alternative - *)
mRNA - *
splicing - *
in - *
the - *
coding - *
region - *
(encoded - *
by - *
exons - *
3-12) - *
generates - *
transcripts - (A2*)
which - *
is - *
deleted delete (V*) *
for - *
exons - (A1*
8 - *
(75 - *
nt) - *
7+8 - *
(156 - *
nt) - *
or - *
8+9 - *
(168 - *
nt) - *)
and - *
that - *
encode - *
distinct - *
protein - *
isoforms - *
(delta25 - *
delta52 - *
and - *
delta56 - *
aa - *
respectively) - *
. - *

Alternative - *)
mRNA - *
splicing - *
in - *
the - *
coding - *
region - *
(encoded - *
by - *
exons - *
3-12) - *
generates - *
transcripts - (A2*)
which - *
was - *
deleted delete (V*) *
for - *
exons - (A1*
8 - *
(75 - *
nt) - *
7+8 - *
(156 - *
nt) - *
or - *
8+9 - *
(168 - *
nt) - *)
and - *
that - *
encode - *
distinct - *
protein - *
isoforms - *
(delta25 - *
delta52 - *
and - *
delta56 - *
aa - *
respectively) - *
. - *

Of - *
note - *
the - *
V82F - *
mutation - *
which - *
occurs - *
adjacent - *
to - *
the - *
5&apos; - *
donor - *
site - *
of - *
intron - *
4 - *
resulted - *
in - *
approximately - *
54% - *
aberrantly - (A2*
spliced - *
transcripts - *)
which - *
delete delete (V*) *
exon - (A1*
4 - *)
. - *

Of - *
note - *
the - *
V82F - *
mutation - *
which - *
occurs - *
adjacent - *
to - *
the - *
5&apos; - *
donor - *
site - *
of - *
intron - *
4 - *
resulted - *
in - *
approximately - *
54% - *
aberrantly - (A2*
spliced - *
transcripts - *)
which - *
deleted delete (V*) *
exon - (A1*
4 - *)
. - *

Of - *
note - *
the - *
V82F - *
mutation - *
which - *
occurs - *
adjacent - *
to - *
the - *
5&apos; - *
donor - *
site - *
of - *
intron - *
4 - *
resulted - *
in - *
approximately - *
54% - *
aberrantly - (A2*
spliced - *
transcripts - *)
which - *
is - *
deleted delete (V*) *
for - *
exon - (A1*
4 - *)
. - *

Of - *
note - *
the - *
V82F - *
mutation - *
which - *
occurs - *
adjacent - *
to - *
the - *
5&apos; - *
donor - *
site - *
of - *
intron - *
4 - *
resulted - *
in - *
approximately - *
54% - *
aberrantly - (A2*
spliced - *
transcripts - *)
which - *
were - *
deleted delete (V*) *
for - *
exon - (A1*
4 - *)
. - *

Of - *
the - *
splicing - *
mutations - *
the - *
IVS2+1 - *
allele - *
produced - *
a - *
single - *
transcript - *
with - *
exon - *
2 - *
deleted delete (V*) *
whereas - *
the - *
IVS9 - *
delta - *
A+4 - *
allele - *
was - *
alternatively - *
spliced - *
approximately - *
26% - *
being - *
normal - *
transcripts - *
and - *
the - (A2*
remainder - *)
which - *
deletes - *
exon - (A1*
9 - *)
. - *

Of - *
the - *
splicing - *
mutations - *
the - *
IVS2+1 - *
allele - *
produced - *
a - *
single - *
transcript - *
with - *
exon - *
2 - *
deleted delete (V*) *
whereas - *
the - *
IVS9 - *
delta - *
A+4 - *
allele - *
was - *
alternatively - *
spliced - *
approximately - *
26% - *
being - *
normal - *
transcripts - *
and - *
the - (A2*
remainder - *)
which - *
deleted - *
exon - (A1*
9 - *)
. - *

Of - *
the - *
splicing - *
mutations - *
the - *
IVS2+1 - *
allele - *
produced - *
a - *
single - *
transcript - *
with - *
exon - *
2 - *
deleted delete (V*) *
whereas - *
the - *
IVS9 - *
delta - *
A+4 - *
allele - *
was - *
alternatively - *
spliced - *
approximately - *
26% - *
being - *
normal - *
transcripts - *
and - *
the - (A2*
remainder - *)
which - *
is - *
deleted - *
 - *
for - *
exon - (A1*
9 - *)
. - *

Of - *
the - *
splicing - *
mutations - *
the - *
IVS2+1 - *
allele - *
produced - *
a - *
single - *
transcript - *
with - *
exon - *
2 - *
deleted delete (V*) *
whereas - *
the - *
IVS9 - *
delta - *
A+4 - *
allele - *
was - *
alternatively - *
spliced - *
approximately - *
26% - *
being - *
normal - *
transcripts - *
and - *
the - (A2*
remainder - *)
which - *
was - *
deleted - *
for - *
exon - (A1*
9 - *)
. - *

From - *
both - *
the - *
man - *
and - *
mouse - *
we - *
have - *
isolated - *
an - (A2*
alternative - *
spliced - *
form - *
of - *
Dmc1 - *
cDNA - *
(Dmc1-d) - *)
which - *
was - *
deleted delete (V*) *
for - (A1*
a - *
region - *
between - *
the - *
two - *
motifs - *)
involved - *
in - *
nucleotide - *
binding - *
. - *

From - (A1*
both - *
the - *
man - *
and - *
mouse - *
we - *)
have - *
isolated - *
an - (A2*
alternative - *
spliced - *
form - *
of - *
Dmc1 - *
cDNA - *
(Dmc1-d) - *)
which - *
deleted delete (V*) *
a - *
region - *
between - *
the - *
two - *
motifs - *
involved - *
in - *
nucleotide - *
binding - *
. - *

From - (A1*
both - *
the - *
man - *
and - *
mouse - *
we - *)
have - *
isolated - *
an - (A2*
alternative - *
spliced - *
form - *
of - *
Dmc1 - *
cDNA - *
(Dmc1-d) - *)
which - *
deletes delete (V*) *
a - *
region - *
between - *
the - *
two - *
motifs - *
involved - *
in - *
nucleotide - *
binding - *
. - *

From - (A1*
both - *
the - *
man - *
and - *
mouse - *
we - *)
have - *
isolated - *
an - (A2*
alternative - *
spliced - *
form - *
of - *
Dmc1 - *
cDNA - *
(Dmc1-d) - *)
with - *
a - *
region - *
between - *
the - *
two - *
motifs - *
involved - *
in - *
nucleotide - *
binding - *
delete delete (V*) *
. - *

Alternative - (A0*
messenger - *
RNA - *
(mRNA) - *
splicing - *)
which - *
may - *
delete delete (V*) *
exon - (A1*
4 - *
sequences - *)
resulting - *
in - *
a - *
mRNA - *
that - *
does - *
not - *
encode - *
a - *
functional - *
IL-2 - *
receptor - *
. - *

Exon - (A1*
4 - *
sequences - *)
may - *
be - *
deleted delete (V*) *
by - *
alternative - (A0*
messenger - *
RNA - *
(mRNA) - *
splicing - *)
resulting - *
in - *
a - *
mRNA - *
that - *
does - *
not - *
encode - *
a - *
functional - *
IL-2 - *
receptor - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
which - *
deletes delete (V*) *
mutated - (A2*
ZONAB-binding - *
site - *)
(D: - (A1*
ErbB-2: - *
S-D; - *)
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
which - *
deleted delete (V*) *
mutated - (A2*
ZONAB-binding - *
site - *)
(D: - (A1*
ErbB-2: - *
S-D; - *)
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
which - *
is - *
deleted delete (V*) *
for - *
mutated - (A2*
ZONAB-binding - *
site - *)
(D: - (A1*
ErbB-2: - *
S-D; - *)
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

The - *
reporter - *
plasmids - *
contained - *
a - *
shorter - *
fragment - *
of - *
the - *
ErbB-2 - *
promoter - *
which - *
was - *
deleted delete (V*) *
for - *
mutated - (A2*
ZONAB-binding - *
site - *)
(D: - (A1*
ErbB-2: - *
S-D; - *)
ErbB-2: - *
S-A - *
substitution - *
of - *
the - *
inverted - *
CCAAT - *
box) - *
. - *

Spinach - *)
sown - *
in - *
October - *)
which - *
develops develop (V*) *
into - *
the - *
rosette - *
stage - *
and - *
grows - *
through - *
the - *
end - *
of - *
November - *
. - *

Spinach - *)
sown - *
in - *
October - *)
developed develop (V*) *
into - *
the - *
rosette - *
stage - *
and - *
grows - *
through - *
the - *
end - *
of - *
November - *
. - *

Spinach - *)
sown - *
in - *
October - *)
has - *
developed develop (V*) *
into - *
the - *
rosette - *
stage - *
and - *
grows - *
through - *
the - *
end - *
of - *
November - *
. - *

Spinach - *)
sown - *
in - *
October - *)
will - *
develop develop (V*) *
into - *
the - *
rosette - *
stage - *
and - *
grows - *
through - *
the - *
end - *
of - *
November - *
. - *

Spinach - *)
sown - *
in - *
October - *)
that - *
develops develop (V*) *
into - *
the - *
rosette - *
stage - *
and - *
grows - *
through - *
the - *
end - *
of - *
November - *
. - *

It - (A1*)
is - *)
planted - *
from - *
September - *
up - *
to - *
the - *
end - *
of - *
October - *
developed develop (V*) *
into - (A3*
the - *
rosette - *
stage - *)
and - *
keeps - *
on - *
growing - *
until - *
the - *
end - *
of - *
November - *
. - *

It - (A1*)
is - *)
planted - *
from - *
September - *
up - *
to - *
the - *
end - *
of - *
October - *
has - *
developed develop (V*) *
into - (A3*
the - *
rosette - *
stage - *)
and - *
keeps - *
on - *
growing - *
until - *
the - *
end - *
of - *
November - *
. - *

It - (A1*)
is - *)
planted - *
from - *
September - *
up - *
to - *
the - *
end - *
of - *
October - *
will - *
develop develop (V*) *
into - (A3*
the - *
rosette - *
stage - *)
and - *
keeps - *
on - *
growing - *
until - *
the - *
end - *
of - *
November - *
. - *

It - (A1*)
is - *)
planted - *
from - *
September - *
up - *
to - *
the - *
end - *
of - *
October - *
that - *
develops develop (V*) *
into - (A3*
the - *
rosette - *
stage - *)
and - *
keeps - *
on - *
growing - *
until - *
the - *
end - *
of - *
November - *
. - *

Three - *)
new - *
mutations - *
two - *
missense - *
and - *
one - *
nonsense - *
were - *
detected: - *
(1) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
44 - *
in - *
exon - *
2 - *
replacing - *
a - *
threonine - *
by - *
an - *
isoleucine - *
(T44I) - *
was - *
found - *
in - *
a - *
late-onset - *
symptomatic - *
female - *
patient - *
but - *
not - *
in - *
her - *
asymptomatic - *
mother; - *
(2) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
214 - *
creating - *
a - *
new - *
RsaI - *
recognition - *
site - *
in - *
exon - *
6 - *
and - *
substituting - *
tyrosine - *
for - *
histidine - *
(H214Y) - *
was - *
identified - *
in - *
an - *
asymptomatic - *
female - *
carrier - *
whose - (A1*
son - *)
have - *
developed develop (V*) *
acute - (A2*
neonatal - *
onset - *
of - *
OTC - *
deficiency; - *)
(3) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
320 - *
(arginine) - *
abolishing - *
a - *
TaqI - *
recognition - *
site - *
and - *
creating - *
a - *
new - *
BclI - *
site - *
in - *
exon - *
9 - *
with - *
generation - *
of - *
a - *
stop - *
codon - *
(R320X) - *
leading - *
to - *
premature - *
termination - *
in - *
the - *
enzyme - *
. - *

To - *
isolate - *
cDNA - (A0*
clones - *)
that - *
dominantly - *
inhibit - *
the - *
DNA-binding - *
activity - *
of - *
Oct-2 - *
chosen - *
as - *
a - *
representative - *
factor - *
we - *
have - *
developed develop (V*) *
a - *
novel - *
screening - *
system - *
. - *

To - *
isolate - *
cDNA - (A0*
clones - *)
that - *
dominantly - *
inhibit - *
the - *
DNA-binding - *
activity - *
of - *
Oct-2 - *
chosen - *
as - *
a - *
representative - *
factor - *
we - *
developed develop (V*) *
a - *
novel - *
screening - *
system - *
. - *

To - *
isolate - *
cDNA - (A0*
clones - *)
that - *
dominantly - *
inhibit - *
the - *
DNA-binding - *
activity - *
of - *
Oct-2 - *
chosen - *
as - *
a - *
representative - *
factor - *
we - *
will - *
develop develop (V*) *
a - *
novel - *
screening - *
system - *
. - *

To - *
isolate - *
cDNA - (A0*
clones - *)
that - *
dominantly - *
inhibit - *
the - *
DNA-binding - *
activity - *
of - *
Oct-2 - *
chosen - *
as - *
a - *
representative - *
factor - *
we - *
develop develop (V*) *
a - *
novel - *
screening - *
system - *
. - *

To - *
isolate - *
cDNA - (A0*
clones - *)
that - *
dominantly - *
inhibit - *
the - *
DNA-binding - *
activity - *
of - *
Oct-2 - *
chosen - *
as - *
a - *
representative - *
factor - *
we - *
which - *
develop develop (V*) *
a - *
novel - *
screening - *
system - *
. - *

Three - *)
new - *
mutations - *
two - *
missense - *
and - *
one - *
nonsense - *
were - *
detected: - *
(1) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
44 - *
in - *
exon - *
2 - *
replacing - *
a - *
threonine - *
by - *
an - *
isoleucine - *
(T44I) - *
was - *
found - *
in - *
a - *
late-onset - *
symptomatic - *
female - *
patient - *
but - *
not - *
in - *
her - *
asymptomatic - *
mother; - *
(2) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
214 - *
creating - *
a - *
new - *
RsaI - *
recognition - *
site - *
in - *
exon - *
6 - *
and - *
substituting - *
tyrosine - *
for - *
histidine - *
(H214Y) - *
was - *
identified - *
in - *
an - *
asymptomatic - *
female - *
carrier - *
whose - (A1*
son - *)
develops develop (V*) *
acute - (A2*
neonatal - *
onset - *
of - *
OTC - *
deficiency; - *)
(3) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
320 - *
(arginine) - *
abolishing - *
a - *
TaqI - *
recognition - *
site - *
and - *
creating - *
a - *
new - *
BclI - *
site - *
in - *
exon - *
9 - *
with - *
generation - *
of - *
a - *
stop - *
codon - *
(R320X) - *
leading - *
to - *
premature - *
termination - *
in - *
the - *
enzyme - *
. - *

Three - *)
new - *
mutations - *
two - *
missense - *
and - *
one - *
nonsense - *
were - *
detected: - *
(1) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
44 - *
in - *
exon - *
2 - *
replacing - *
a - *
threonine - *
by - *
an - *
isoleucine - *
(T44I) - *
was - *
found - *
in - *
a - *
late-onset - *
symptomatic - *
female - *
patient - *
but - *
not - *
in - *
her - *
asymptomatic - *
mother; - *
(2) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
214 - *
creating - *
a - *
new - *
RsaI - *
recognition - *
site - *
in - *
exon - *
6 - *
and - *
substituting - *
tyrosine - *
for - *
histidine - *
(H214Y) - *
was - *
identified - *
in - *
an - *
asymptomatic - *
female - *
carrier - *
whose - (A1*
son - *)
has - *
develop develop (V*) *
acute - (A2*
neonatal - *
onset - *
of - *
OTC - *
deficiency; - *)
(3) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
320 - *
(arginine) - *
abolishing - *
a - *
TaqI - *
recognition - *
site - *
and - *
creating - *
a - *
new - *
BclI - *
site - *
in - *
exon - *
9 - *
with - *
generation - *
of - *
a - *
stop - *
codon - *
(R320X) - *
leading - *
to - *
premature - *
termination - *
in - *
the - *
enzyme - *
. - *

Three - *)
new - *
mutations - *
two - *
missense - *
and - *
one - *
nonsense - *
were - *
detected: - *
(1) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
44 - *
in - *
exon - *
2 - *
replacing - *
a - *
threonine - *
by - *
an - *
isoleucine - *
(T44I) - *
was - *
found - *
in - *
a - *
late-onset - *
symptomatic - *
female - *
patient - *
but - *
not - *
in - *
her - *
asymptomatic - *
mother; - *
(2) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
214 - *
creating - *
a - *
new - *
RsaI - *
recognition - *
site - *
in - *
exon - *
6 - *
and - *
substituting - *
tyrosine - *
for - *
histidine - *
(H214Y) - *
was - *
identified - *
in - *
an - *
asymptomatic - *
female - *
carrier - *
whose - (A1*
son - *)
will - *
develope - *
acute - (A2*
neonatal - *
onset - *
of - *
OTC - *
deficiency; - *)
(3) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
320 - *
(arginine) - *
abolishing - *
a - *
TaqI - *
recognition - *
site - *
and - *
creating - *
a - *
new - *
BclI - *
site - *
in - *
exon - *
9 - *
with - *
generation - *
of - *
a - *
stop - *
codon - *
(R320X) - *
leading - *
to - *
premature - *
termination - *
in - *
the - *
enzyme - *
. - *

Three - *)
new - *
mutations - *
two - *
missense - *
and - *
one - *
nonsense - *
were - *
detected: - *
(1) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
44 - *
in - *
exon - *
2 - *
replacing - *
a - *
threonine - *
by - *
an - *
isoleucine - *
(T44I) - *
was - *
found - *
in - *
a - *
late-onset - *
symptomatic - *
female - *
patient - *
but - *
not - *
in - *
her - *
asymptomatic - *
mother; - *
(2) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
214 - *
creating - *
a - *
new - *
RsaI - *
recognition - *
site - *
in - *
exon - *
6 - *
and - *
substituting - *
tyrosine - *
for - *
histidine - *
(H214Y) - *
was - *
identified - *
in - *
an - *
asymptomatic - *
female - *
carrier - *
whose - (A1*
son - *)
can - *
develop develop (V*) *
acute - (A2*
neonatal - *
onset - *
of - *
OTC - *
deficiency; - *)
(3) - *
a - *
C-to-T - *
transition - *
in - *
codon - *
320 - *
(arginine) - *
abolishing - *
a - *
TaqI - *
recognition - *
site - *
and - *
creating - *
a - *
new - *
BclI - *
site - *
in - *
exon - *
9 - *
with - *
generation - *
of - *
a - *
stop - *
codon - *
(R320X) - *
leading - *
to - *
premature - *
termination - *
in - *
the - *
enzyme - *
. - *

Although - *)
Pin1 - *
- - *
/ - *
- - *
mice - (A1*)
have - *
previously - *
been - *
found - *
to - *
develop develop (V*) *
normally - *
(Fujimori - *
et - *
al - *
1999) - *
we - *
have - *
uncovered - *
that - *
they - *
display - *
a - *
range - *
of - *
cell - *
proliferative - *
abnomalities - *
including - *
decreased - *
body - *
size - *
retinal - *
degenration - *
and - *
neurological - *
abnormalities - *
. - *

Although - *)
Pin1 - *
- - *
/ - *
- - *
mice - (A1*)
have - *
previously - *
been - *
predicted - *
to - *
develop develop (V*) *
normally - *
(Fujimori - *
et - *
al - *
1999) - *
we - *
have - *
uncovered - *
that - *
they - *
display - *
a - *
range - *
of - *
cell - *
proliferative - *
abnomalities - *
including - *
decreased - *
body - *
size - *
retinal - *
degenration - *
and - *
neurological - *
abnormalities - *
. - *

Although - *)
Pin1 - *
- - *
/ - *
- - *
mice - (A1*)
have - *
previously - *
developed develop (V*) *
normally - *
(Fujimori - *
et - *
al - *
1999) - *
we - *
have - *
uncovered - *
that - *
they - *
display - *
a - *
range - *
of - *
cell - *
proliferative - *
abnomalities - *
including - *
decreased - *
body - *
size - *
retinal - *
degenration - *
and - *
neurological - *
abnormalities - *
. - *

Although - *)
Pin1 - *
- - *
/ - *
- - *
mice - (A1*)
will - *
be - *
previously - *
develop develop (V*) *
normally - *
(Fujimori - *
et - *
al - *
1999) - *
we - *
have - *
uncovered - *
that - *
they - *
display - *
a - *
range - *
of - *
cell - *
proliferative - *
abnomalities - *
including - *
decreased - *
body - *
size - *
retinal - *
degenration - *
and - *
neurological - *
abnormalities - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(this - (A0*
deletion - *)
which - *
disrupts disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
disrupts disrupt (V*) *
an - (A1*
Ava - *
II - *
site	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
will - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
has - *
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
which - *
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
the - (A0*
Gly188----Glu - *
mutation - *)
that - *
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site	 - *)
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(alcohol - (A0*
exposure - *)
 - *
which - *
disrupts disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
the - (A0*
Gly188----Glu - *
mutation - *)
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
sitewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
the - (A0*
Gly188----Glu - *
mutation - *)
disrupts disrupt (V*) *
an - (A1*
Ava - *
II - *
sitewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
the - (A0*
Gly188----Glu - *
mutationwill - *)
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
sitewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
the - (A0*
Gly188----Glu - *
mutationhas - *)
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
sitewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(Arg99 - (A0*
and - *
Arg253 - *)
which - *
disrupts disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
. - *

the - (A0*
Gly188----Glu - *
mutation - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
to - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

the - (A0*
Gly188----Glu - *
mutation - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
disrupting disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
which - *
disrupts disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
the - (A0*
Gly188----Glu - *
mutation - *)
does - *
not - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
the - (A0*
Gly188----Glu - *
mutation - *)
did - *
not - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
the - (A0*
Gly188----Glu - *
mutation - *)
will - *
not - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
the - (A0*
Gly188----Glu - *
mutation - *)
could - *
not - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
this - (A0*
deletiondisrupted - *)
the - (A1*
open - *
reading - *
framewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
this - (A0*
deletiondisrupts - *)
the - (A1*
open - *
reading - *
framewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
this - (A0*
deletionwill - *)
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
framewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
this - (A0*
deletionhas - *)
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
framewhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

this - (A0*
deletion - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
to - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

this - (A0*
deletion - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
disrupting disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
this - (A0*
deletion - *)
does - *
not - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
this - (A0*
deletion - *)
did - *
not - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
this - (A0*
deletion - *)
will - *
not - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
this - (A0*
deletion - *)
could - *
not - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
disrupts disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
	 - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
disrupts disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupts disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
will - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
	 - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
will - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
will - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
has - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
	 - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
has - *
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
has - *
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
which - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
	 - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
which - *
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
which - *
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
alcohol - (A0*
exposure - *)
 - *
that - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
	 - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
Arg99 - (A0*
and - *
Arg253 - *)
that - *
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
that - *
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation	 - *)
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
Arg99 - (A0*
and - *
Arg253 - *)
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
modelwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

alcohol - (A0*
exposure - *)
 - *
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
to - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

alcohol - (A0*
exposure - *)
 - *
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
disrupting disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulationwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
alcohol - (A0*
exposure - *)
 - *
does - *
not - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
alcohol - (A0*
exposure - *)
 - *
did - *
not - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
alcohol - (A0*
exposure - *)
 - *
will - *
not - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
alcohol - (A0*
exposure - *)
 - *
could - *
not - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
 - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
Arg99 - (A0*
and - *
Arg253 - *)
disrupts disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
modelwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupts disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulationwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
Arg99 - (A0*
and - *
Arg253will - *)
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
modelwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expressionwill - *)
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulationwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
Arg99 - (A0*
and - *
Arg253has - *)
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
modelwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expressionhas - *)
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulationwhile - *)
preserving - *
robust - *
visual - *
responses - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(this - (A0*
deletion - *)
has - *
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(alcohol - (A0*
exposure - *)
 - *
has - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

When - *
both - (A1*
genes - *)
were - *
disrupted disrupt (V*) *
galS - (A2*
expression - *
was - *
further - *
elevated - *)
. - *

When - (A2*
both - (A1*
genes - *)
are - *
disrupted - *)
galS - *
expression - *
is - *
further - *
elevated - *
. - *

When - *
both - (A1*
genes - *)
will - *
be - *
disrupted disrupt (V*) *
galS - (A2*
expression - *
was - *
further - *
elevated - *)
. - *

When - (A2*
both - (A1*
genes - *)
has - *
been - *
disrupted - *)
galS - *
expression - *
is - *
further - *
elevated - *
. - *

When - *
both - (A1*
genes - *)
which - *
were - *
disrupted disrupt (V*) *
galS - (A2*
expression - *
was - *
further - *
elevated - *)
. - *

When - (A2*
both - (A1*
genes - *)
which - *
are - *
disrupted - *)
galS - *
expression - *
is - *
further - *
elevated - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(the - (A0*
Gly188----Glu - *
mutation - *)
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(the - (A0*
Gly188----Glu - *
mutation - *)
will - *
disrupt disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(the - (A0*
Gly188----Glu - *
mutation - *)
has - *
disrupted disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(the - (A0*
Gly188----Glu - *
mutation - *)
which - *
disrupts disrupt (V*) *
an - (A1*
Ava - *
II - *
site - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
disrupts disrupt (V*) *
the - (A1*
open - *
reading - *
frame	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
will - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
has - *
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
which - *
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame	 - *)
. - *

Sequencing - *
of - *
cloned - *
polymerase - *
chain - *
reaction - *
amplified - *
fragments - *
of - *
the - *
AMH - *
gene - *
revealed - *
a - *
14-bp - *
deletion - *
in - *
the - *
second - *
exon - *
of - *
the - *
maternal - *
allele; - *
this - (A0*
deletion - *)
that - *
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame	 - *)
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
alcohol - (A0*
exposure - *)
disrupts disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
while - *
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
alcohol - (A0*
exposure - *)
will - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
while - *
preserving - *
robust - *
visual - *
responses - *
. - *

Quantitative - *
single-unit - *
electrophysiology - *
revealed - *
that - *
alcohol - (A0*
exposure - *)
has - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
while - *
preserving - *
robust - *
visual - *
responses - *
. - *

Arg99 - (A0*
and - *
Arg253 - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
disrupting disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
did - *
not - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
will - *
not - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
could - *
not - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
to - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
Arg99 - (A0*
and - *
Arg253 - *)
does - *
not - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
Arg99 - (A0*
and - *
Arg253 - *)
did - *
not - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
Arg99 - (A0*
and - *
Arg253 - *)
will - *
not - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

Importantly - *
the - *
findings - *
show - *
that - *
the - *
Arg99 - (A0*
and - *
Arg253 - *)
could - *
not - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
. - *

knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
can - *
interact - *
with - *
the - *
keto - *
groups - *
of - *
the - *
GO - *
and - *
C - *
base - *
pair(blue) - *
in - *
both - *
sides - *
of - *
dsDNA - *
disrupting disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(this - (A0*
deletion - *)
disrupts disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(alcohol - (A0*
exposure - *)
 - *
disrupts disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(Arg99 - (A0*
and - *
Arg253 - *)
disrupts disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupts disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(this - (A0*
deletion - *)
disrupted disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(alcohol - (A0*
exposure - *)
 - *
disrupted disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(Arg99 - (A0*
and - *
Arg253 - *)
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(this - (A0*
deletion - *)
will - *
disrupt disrupt (V*) *
the - (A1*
open - *
reading - *
frame - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(alcohol - (A0*
exposure - *)
 - *
will - *
disrupt disrupt (V*) *
ocular - (A1*
dominance - *
plasticity - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(Arg99 - (A0*
and - *
Arg253 - *)
will - *
disrupt disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
will - *
disrupt disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(Arg99 - (A0*
and - *
Arg253 - *)
has - *
disrupted disrupt (V*) *
the - (A1*
pairing - *
hydrogen - *
bonds - *
in - *
the - *
model - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

Studies - *
using - *
polymerase - *
chain - *
reaction - *
restriction - *
enzyme - *
digestion - *
(knockout - (A0*
of - *
MEKK1 - *
or - *
MEKK2 - *
expression - *)
has - *
disrupted disrupt (V*) *
the - (A1*
overall - *
integrity - *
of - *
MAPK - *
pathway - *
regulation - *)
the - *
Arg243----His - *
mutation - *
a - *
Hha - *
I - *
site - *
and - *
the - *
Asp250----Asn - *
mutation - *
a - *
Taq - *
I - *
site) - *
and - *
allele-specific - *
oligonucleotide - *
hybridization - *
confirmed - *
that - *
the - *
patients - *
were - *
indeed - *
compound - *
heterozygous - *
for - *
the - *
respective - *
mutations - *
 - *
. - *

The - *)
415G&gt;A - *
mutation - *
disrupted disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

The - *)
415G&gt;A - *
mutation - *
has - *
disrupted disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

The - *)
415G&gt;A - *
mutation - *
that - *
disrupted disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

The - *)
415G&gt;A - *
mutation - *
which - *
disrupts disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

The - *)
415G&gt;A - *
mutation - *
disrupts disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

The - *)
415G&gt;A - *
mutation - *
which - *
disrupted disrupt (V*) *
a - *
splicing - (A1*
enhancer - *
sequence: - *
(GAR)n-(GAR)n - *)
resulting - *
in - *
exon - *
5 - *
skipping - *
. - *

This - *)
deletion - *)
disrupted disrupt (V*) *
the - *
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

This - (A1*
deletion - *)
which - *
disrupted - *)
the - *
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

This - (A1*
deletion - *)
will - *
disrupt - *)
the - *
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

This - (A1*
deletion - *)
that - *
disrupted - *)
the - *
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

This - (A1*
deletion - *)
has - *
disrupted - *)
the - *
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

This - (A1*
deletion - *)
disrupts disrupt (V*) *
the - *)
consensus - *
5 - *
splice - *
signal - *
and - *
led - *
to - *
exon - *
skipping - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
has - *
been - *
identified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
is - *
identified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
was - *
identified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
will - *
beidentified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
which - *
has - *
been - *
identified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

A - (A0*
homozygous - *
mutation - *)
that - *
disrupts disrupt (V*) *
splicing - (A1*)
that - *
has - *
been - *
identified - *
in - *
affected - *
siblings - *
with - *
classical - *
abetalipoproteinemia - *
 - *
. - *

R142X - (A0*)
located - *
within - *
a - *
purine-rich - *
segment - *
at - *
nt - *
62/116 - *
of - *
exon - *
5 - *
caused - *
skipping - *
of - *
the - *
exon - *
possibly - *
through - *
disrupting disrupt (V*) *
a - (A1*
splicing - *
enhancer - *)
. - *

These - (A0*
mutations - *)
may - *
be - *
acting - *
in - *
a - *
dominant-negative - *
fashion - *
which - *
ability - *
to - *
disrupt disrupt (V*) *
the - (A1*
ubiquitin-binding - *
function - *)
which - *
could - *
result - *
in - *
abnormal - *
activation - *
of - *
the - *
NF-kappaB - *
pathway - *
and - *
the - *
subsequent - *
activation - *
of - *
the - *
osteoclasts - *
. - *

These - (A0*
mutations - *)
may - *
be - *
acting - *
in - *
a - *
dominant-negative - *
fashion - *
which - *
found - *
to - *
disrupt disrupt (V*) *
the - (A1*
ubiquitin-binding - *
function - *)
which - *
could - *
result - *
in - *
abnormal - *
activation - *
of - *
the - *
NF-kappaB - *
pathway - *
and - *
the - *
subsequent - *
activation - *
of - *
the - *
osteoclasts - *
. - *

These - (A0*
mutations - *)
may - *
be - *
acting - *
in - *
a - *
dominant-negative - *
fashion - *
which - *
shown - *
to - *
disrupt disrupt (V*) *
the - (A1*
ubiquitin-binding - *
function - *)
which - *
could - *
result - *
in - *
abnormal - *
activation - *
of - *
the - *
NF-kappaB - *
pathway - *
and - *
the - *
subsequent - *
activation - *
of - *
the - *
osteoclasts - *
. - *

Treatment - *
of - *
the - *
systemic - *
inflammatory - *
response - *
to - *
CPB - *
is - *
also - *
confounded - *
by - *
the - *
fact - *
that - *
inhibition - (A0*
of - *
inflammation - *)
could - *
disrupt disrupt (V*) *
protective - (A1*
physiologic - *
responses - *)
or - *
result - *
in - *
immunosuppression - *
. - *

Treatment - *
of - *
the - *
systemic - *
inflammatory - *
response - *
to - *
CPB - *
is - *
also - *
confounded - *
by - *
the - *
fact - *
that - *
inhibition - (A0*
of - *
inflammation - *)
disrupted disrupt (V*) *
protective - (A1*
physiologic - *
responses - *)
or - *
result - *
in - *
immunosuppression - *
. - *

Treatment - *
of - *
the - *
systemic - *
inflammatory - *
response - *
to - *
CPB - *
is - *
also - *
confounded - *
by - *
the - *
fact - *
that - *
inhibition - (A0*
of - *
inflammation - *)
has - *
disrupted disrupt (V*) *
protective - (A1*
physiologic - *
responses - *)
or - *
result - *
in - *
immunosuppression - *
. - *

Treatment - *
of - *
the - *
systemic - *
inflammatory - *
response - *
to - *
CPB - *
is - *
also - *
confounded - *
by - *
the - *
fact - *
that - *
inhibition - (A0*
of - *
inflammation - *)
will - *
disrupt disrupt (V*) *
protective - (A1*
physiologic - *
responses - *)
or - *
result - *
in - *
immunosuppression - *
. - *

Treatment - *
of - *
the - *
systemic - *
inflammatory - *
response - *
to - *
CPB - *
is - *
also - *
confounded - *
by - *
the - *
fact - *
that - *
inhibition - (A0*
of - *
inflammation - *)
which - *
disrupted disrupt (V*) *
protective - (A1*
physiologic - *
responses - *)
or - *
result - *
in - *
immunosuppression - *
. - *

Mutations - (A0*
in - *
this - *
region - *)
might - *
disrupt disrupt (V*) *
keratin - (A1*
filament - *
assembly - *)
leading - *
to - *
degeneration - *
or - *
cytolysis - *
of - *
keratinocytes - *
. - *

Mutations - (A0*
in - *
this - *
region - *)
can - *
disrupt disrupt (V*) *
keratin - (A1*
filament - *
assembly - *)
leading - *
to - *
degeneration - *
or - *
cytolysis - *
of - *
keratinocytes - *
. - *

Mutations - (A0*
in - *
this - *
region - *)
disrupt disrupt (V*) *
keratin - (A1*
filament - *
assembly - *)
leading - *
to - *
degeneration - *
or - *
cytolysis - *
of - *
keratinocytes - *
. - *

Mutations - (A0*
in - *
this - *
region - *)
disrupted disrupt (V*) *
keratin - (A1*
filament - *
assembly - *)
leading - *
to - *
degeneration - *
or - *
cytolysis - *
of - *
keratinocytes - *
. - *

Mutations - (A0*
in - *
this - *
region - *)
has - *
disrupted disrupt (V*) *
keratin - (A1*
filament - *
assembly - *)
leading - *
to - *
degeneration - *
or - *
cytolysis - *
of - *
keratinocytes - *
. - *

Mutations - (A0*
in - *
p53 - *)
disrupted disrupt (V*) *
checkpoint - (A1*
responses - *
to - *
DNA - *
damage - *)
and - *
result - *
in - *
the - *
potential - *
for - *
destabilization - *
of - *
the - *
genome - *
. - *

Mutations - (A0*
in - *
p53 - *)
have - *
disrupted disrupt (V*) *
checkpoint - (A1*
responses - *
to - *
DNA - *
damage - *)
and - *
result - *
in - *
the - *
potential - *
for - *
destabilization - *
of - *
the - *
genome - *
. - *

Mutations - (A0*
in - *
p53 - *)
will - *
disrupt disrupt (V*) *
checkpoint - (A1*
responses - *
to - *
DNA - *
damage - *)
and - *
result - *
in - *
the - *
potential - *
for - *
destabilization - *
of - *
the - *
genome - *
. - *

Mutations - (A0*
in - *
p53 - *)
which - *
disrupt disrupt (V*) *
checkpoint - (A1*
responses - *
to - *
DNA - *
damage - *)
and - *
result - *
in - *
the - *
potential - *
for - *
destabilization - *
of - *
the - *
genome - *
. - *

The - *
zinc - *
finger - *
motif - *
which - *
specifically - *
recognizes - *
the - *
GO:C - *
pair - *
is - *
firmly - *
fixed - *
with - *
respect - *
to - *
the - *
C-terminal - *
domain - *
by - *
the - *
hydrogen - *
bond - *
network - *
so - *
the - (A0*
Lys147Ala - *
substitution - *)
would - *
be - *
expected - *
for - *
disrupting disrupt (V*) *
the - (A1*
interaction - *)
resulting - *
in - *
a - *
drastic - *
decrease - *
of - *
activity - *
against - *
GO:C - *
substrates - *
. - *

The - *
zinc - *
finger - *
motif - *
which - *
specifically - *
recognizes - *
the - *
GO:C - *
pair - *
is - *
firmly - *
fixed - *
with - *
respect - *
to - *
the - *
C-terminal - *
domain - *
by - *
the - *
hydrogen - *
bond - *
network - *
so - *
the - (A0*
Lys147Ala - *
substitution - *)
would - *
be - *
disrupted disrupt (V*) *
the - (A1*
interaction - *)
resulting - *
in - *
a - *
drastic - *
decrease - *
of - *
activity - *
against - *
GO:C - *
substrates - *
. - *

The - *
zinc - *
finger - *
motif - *
which - *
specifically - *
recognizes - *
the - *
GO:C - *
pair - *
is - *
firmly - *
fixed - *
with - *
respect - *
to - *
the - *
C-terminal - *
domain - *
by - *
the - *
hydrogen - *
bond - *
network - *
so - *
the - (A0*
Lys147Ala - *
substitution - *)
would - *
be - *
found - *
to - *
disrupt disrupt (V*) *
the - (A1*
interaction - *)
resulting - *
in - *
a - *
drastic - *
decrease - *
of - *
activity - *
against - *
GO:C - *
substrates - *
. - *

The - *
zinc - *
finger - *
motif - *
which - *
specifically - *
recognizes - *
the - *
GO:C - *
pair - *
is - *
firmly - *
fixed - *
with - *
respect - *
to - *
the - *
C-terminal - *
domain - *
by - *
the - *
hydrogen - *
bond - *
network - *
so - *
the - (A0*
Lys147Ala - *
substitution - *)
would - *
be - *
shown - *
to - *
disrupt disrupt (V*) *
the - (A1*
interaction - *)
resulting - *
in - *
a - *
drastic - *
decrease - *
of - *
activity - *
against - *
GO:C - *
substrates - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
vital - (A1*
stem - *
cells - *)
 - *
are - *
not - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
vital - (A1*
stem - *
cells - *)
 - *
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

Microbe-detecting - (A0*
receptors - *
activate - *)
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

Microbe-detecting - (A0*
receptors - *
activate - *)
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

The - (A1*
pathogens - *)
are - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *)
were - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
such - *
as - *
CD14 - *
. - *

Microbe-detecting - (A0*
receptors - *
activate - *)
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

Microbe-detecting - (A0*
receptors - *
activate - *)
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
vital - (A1*
stem - *
cells - *)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
vital - (A1*
stem - *
cells - *)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
completely - *
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
vital - (A1*
stem - *
cells - *)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
completely - *
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *)
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
vital - (A1*
stem - *
cells - *)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
vital - (A1*
stem - *
cells - *)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
completely - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
completely - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
vital - (A1*
stem - *
cells - *)
 - *
is - *
completely - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
vital - (A1*
stem - *
cells - *)
 - *
was - *
completely - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
completely - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
completely - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
did - *
not - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
which - *
did - *
not - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
did - *
not - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
do - *
not - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
vital - (A1*
stem - *
cells - *)
 - *
was - *
not - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
pathogensto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells(Figure - *)
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
pathogensto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cellscompletely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
pathogensto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cellscompletely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *)
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
pathogensto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
pathogensto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

This - *)
occurs - *
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
eliminates eliminate (V*) *
the - (A1*
pathogens - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
that - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
that - *
eliminates eliminate (V*) *
the - (A1*
pathogens - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
completely - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
completely - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
pathogens - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
pathogens - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
that - *
completely - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
that - *
completely - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *
receptors - *)
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
do - *
not - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
pathogens - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
pathogens - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
pathogens - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
binding - (A1*)
 - *
. - *

This - *)
occurs - *
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *
receptors - *)
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

The - (A1*)
pathogens - *
are - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
are - *
eliminated eliminate (V*) *
by - *
Mutation - *)
of - *
T491 - *)
such - *
as - *
CD14 - *
. - *

The - *)
pathogens - *
are - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
are - *
eliminated - *)
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
such - *
as - *
CD14 - *
. - *

The - (A1*)
pathogens - *
were - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
were - *
eliminated eliminate (V*) *
by - *
Mutation - *)
of - *
T491 - *)
such - *
as - *
CD14 - *
. - *

The - *)
pathogens - *
were - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
were - *
eliminated - *)
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
such - *
as - *
CD14 - *
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

To - *
eliminate eliminate (V*) *
all - (A1*
three - *
sites - *)
that - *
might - *
be - *
associated - *
with - *
stable - *
HOXB4 - *
gene - *
transfer - *
into - *
human - *
cells - *
we - *
took - *
advantage - *
of - *
the - *
ability - *
of - *
HOX - *
proteins - *
to - *
passively - *
translocate - *
through - *
cell - *
membranes - *
. - *

The - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
only - *
when - *
any - (A1*
deleterious - *
effects - *)
are - *
eliminated eliminate (V*) *
. - *

Eliminating eliminate (V*) *
any - (A1*
deleterious - *
effects - *)
make - *
the - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
. - *

To - *
eliminate eliminate (V*) *
any - (A1*
deleterious - *
effects - *)
make - *
the - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
. - *

The - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
only - *
when - *
any - (A1*
deleterious - *
effects - *)
were - *
eliminated eliminate (V*) *
. - *

For - *
eliminating eliminate (V*) *
all - (A1*
three - *
sites - *)
that - *
might - *
be - *
associated - *
with - *
stable - *
HOXB4 - *
gene - *
transfer - *
into - *
human - *
cells - *
we - *
took - *
advantage - *
of - *
the - *
ability - *
of - *
HOX - *
proteins - *
to - *
passively - *
translocate - *
through - *
cell - *
membranes - *
. - *

Eliminating eliminate (V*) *
all - (A1*
three - *
sites - *)
that - *
might - *
be - *
associated - *
with - *
stable - *
HOXB4 - *
gene - *
transfer - *
into - *
human - *
cells - *
we - *
took - *
advantage - *
of - *
the - *
ability - *
of - *
HOX - *
proteins - *
to - *
passively - *
translocate - *
through - *
cell - *
membranes - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
Mutation - (A0*
of - *
T491(Figure - *)
7) - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
eliminates eliminate (V*) *
binding - (A1*)
 - *
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
that - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
that - *
eliminates eliminate (V*) *
binding - (A1*)
 - *
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Sec - (A1*
incorporationto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
these - (A0*
same - *
mutations(Figure - *)
7) - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
completely - *
eliminate eliminate (V*) *
binding - *
 - *
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
completely - *
eliminated eliminate (V*) *
binding - *
 - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
binding - *
 - *
is - *
completely - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
binding - *
 - *
was - *
completely - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
that - *
completely - *
eliminate eliminate (V*) *
binding - *
 - *
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - (A1*)
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
that - *
completely - *
eliminated eliminate (V*) *
binding - *
 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
stabilization - *
seen - *
with - *
MG132to - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown)(Figure - *)
7) - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
did - *
not - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
which - *
did - *
not - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
that - *
did - *
not - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
do - *
not - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
binding - (A1*)
 - *
was - *
not - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
binding - (A1*)
 - *
are - *
not - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
binding - (A1*)
 - *
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
Mutation - (A0*
of - *
T491completely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Sec - (A1*
incorporationto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
these - (A0*
same - *
mutationscompletely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
stabilization - *
seen - *
with - *
MG132to - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown)completely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
Mutation - (A0*
of - *
T491completely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Sec - (A1*
incorporationto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
these - (A0*
same - *
mutationscompletely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
stabilization - *
seen - *
with - *
MG132to - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown)completely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *)
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - (A0*
of - *)
Grb2 - *
significantly - *
reduced - *
SH3A - *
Sec - (A1*
incorporationto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - (A0*
of - *
Grb2 - *
significantly - *
reduced - *)
SH3A - *
the - (A1*
stabilization - *
seen - *
with - *
MG132to - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
Mutation - (A0*
of - *
T491 - *)
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Sec - (A1*
incorporationto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
these - (A0*
same - *
mutations - *)
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
the - (A1*
stabilization - *
seen - *
with - *
MG132to - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

these - (A0*
same - *
mutations - *)
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
Mutation - (A0*
of - *
T491 - *)
completely - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Mutation - (A0*
of - *
T491 - *)
completely - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
Mutation - (A0*
of - *
T491 - *)
that - *
completely - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Mutation - (A0*
of - *
T491 - *)
that - *
completely - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Mutation - (A0*
of - *
T491 - *)
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Mutation - (A0*
of - *
T491 - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Mutation - (A0*
of - *
T491 - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Mutation - (A0*
of - *
T491 - *)
do - *
not - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

these - (A0*
same - *
mutations - *)
eliminates eliminate (V*) *
Sec - (A1*
incorporation - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
eliminates eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

these - (A0*
same - *
mutations - *)
that - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
that - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

these - (A0*
same - *
mutations - *)
that - *
eliminates eliminate (V*) *
Sec - (A1*
incorporation - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
that - *
eliminates eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
completely - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
these - (A0*
same - *
mutations - *)
did - *
not - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
these - (A0*
same - *
mutations - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
these - (A0*
same - *
mutations - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
these - (A0*
same - *
mutations - *)
do - *
not - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Sec - (A1*
incorporation - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Sec - (A1*
incorporation - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Sec - (A1*
incorporation - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
completely - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
that - *
completely - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
that - *
completely - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

In - *
gel - *
shift - *
assay - *
A - (A0*
6-bp - *
insertion - *)
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

anti-ref1 - (A0*
antibody - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

In - *
gel - *
shift - *
assay - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
is - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
was - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
which - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
has - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

anti-ref1 - (A0*
antibody - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

In - *
gel - *
shift - *
assay - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

In - *
gel - *
shift - *
assay - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

The - (A1*
pathogens - *
are - *
eliminated eliminate (V*) *
by - *)
anti-ref1 - (A0*
antibody - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
were - *
eliminated eliminate (V*) *
by - *)
anti-ref1 - (A0*
antibody - *)
such - *
as - *
CD14 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

In - *
gel - *
shift - *
assay - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
anti-ref1 - (A0*
antibody(Figure - *)
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
anti-ref1 - (A0*
antibodycompletely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
anti-ref1 - (A0*
antibodycompletely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - (A0*
of - *)
Grb2 - *
significantly - *
reduced - *
SH3A - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complexto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
anti-ref1 - (A0*
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
Mutation - (A0*
of - *
T491 - *)
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

anti-ref1 - (A0*
antibody - *)
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

anti-ref1 - (A0*
antibody - *)
eliminates eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

anti-ref1 - (A0*
antibody - *)
that - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

anti-ref1 - (A0*
antibody - *)
that - *
eliminates eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

In - *
gel - *
shift - *
assay - *
these - (A0*
same - *
mutations - *)
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
anti-ref1 - (A0*
antibody - *)
completely - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
anti-ref1 - (A0*
antibody - *)
completely - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
anti-ref1 - (A0*
antibody - *)
that - *
completely - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
anti-ref1 - (A0*
antibody - *)
that - *
completely - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

In - *
gel - *
shift - *
assay - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
anti-ref1 - (A0*
antibody - *)
did - *
not - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
anti-ref1 - (A0*
antibody - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
anti-ref1 - (A0*
antibody - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
anti-ref1 - (A0*
antibody - *)
do - *
not - *
eliminate eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
A - (A0*
6-bp - *
insertion - *)
eliminates eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

In - *
gel - *
shift - *
assay - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
eliminates eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

In - *
gel - *
shift - *
assay - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

In - *
gel - *
shift - *
assay - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
eliminates eliminate (V*) *
the - (A1*
pathogens - *)
. - *

In - *
gel - *
shift - *
assay - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
eliminates eliminate (V*) *
binding - (A1*)
 - *
. - *

In - *
gel - *
shift - *
assay - *
Mutation - (A0*
of - *
T491 - *)
eliminates eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
these - (A0*
same - *
mutations - *)
eliminates eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

In - *
gel - *
shift - *
assay - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
eliminates eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
is - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
is - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

vital - (A1*
stem - *
cells - *)
 - *
is - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

the - (A1*
pathogens - *)
is - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

binding - (A1*)
 - *
is - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
is - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

Sec - (A1*
incorporation - *)
is - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
is - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
was - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
was - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

vital - (A1*
stem - *
cells - *)
 - *
was - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
. - *

the - (A1*
pathogens - *)
was - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
. - *

binding - (A1*)
 - *
was - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
was - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
. - *

Sec - (A1*
incorporation - *)
was - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
was - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

In - *
gel - *
shift - *
assay - *
A - (A0*
6-bp - *
insertion - *)
has - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

In - *
gel - *
shift - *
assay - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
has - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

In - *
gel - *
shift - *
assay - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
has - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

In - *
gel - *
shift - *
assay - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
has - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

In - *
gel - *
shift - *
assay - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
has - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

In - *
gel - *
shift - *
assay - *
Mutation - (A0*
of - *
T491 - *)
has - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
these - (A0*
same - *
mutations - *)
has - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

In - *
gel - *
shift - *
assay - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
has - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

In - *
gel - *
shift - *
assay - *
A - (A0*
6-bp - *
insertion - *)
will - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

In - *
gel - *
shift - *
assay - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
will - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

In - *
gel - *
shift - *
assay - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
will - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

In - *
gel - *
shift - *
assay - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
will - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

In - *
gel - *
shift - *
assay - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
will - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

In - *
gel - *
shift - *
assay - *
Mutation - (A0*
of - *
T491 - *)
will - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
these - (A0*
same - *
mutations - *)
will - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

In - *
gel - *
shift - *
assay - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
will - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
is - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
was - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
which - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
has - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

A - (A0*
6-bp - *
insertion - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoterrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoterrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

This - (A0*
occurs - *)
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

The - (A1*
pathogens - *
are - *
eliminated - *)
by - *
A - (A0*
6-bp - *
insertion - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
were - *
eliminated - *)
by - *
A - (A0*
6-bp - *
insertion - *)
such - *
as - *
CD14 - *
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

Microbe-detecting - *)
receptors - *
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
repression - (A1*
of - *
the - *
glpTQ - *
promoterto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
A - (A0*
6-bp - *
insertion(Figure - *)
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
repression - (A1*
of - *
the - *
glpTQ - *
promoterto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
A - (A0*
6-bp - *
insertioncompletely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
repression - (A1*
of - *
the - *
glpTQ - *
promoterto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
A - (A0*
6-bp - *
insertioncompletely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *)
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
repression - (A1*
of - *
the - *
glpTQ - *
promoterto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
repression - (A1*
of - *
the - *
glpTQ - *
promoterto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
A - (A0*
6-bp - *
insertion - *)
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

A - (A0*
6-bp - *
insertion - *)
eliminates eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

A - (A0*
6-bp - *
insertion - *)
that - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

A - (A0*
6-bp - *
insertion - *)
that - *
eliminates eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
A - (A0*
6-bp - *
insertion - *)
completely - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
A - (A0*
6-bp - *
insertion - *)
completely - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
A - (A0*
6-bp - *
insertion - *)
that - *
completely - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
A - (A0*
6-bp - *
insertion - *)
that - *
completely - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
A - (A0*
6-bp - *
insertion - *)
did - *
not - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
A - (A0*
6-bp - *
insertion - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
A - (A0*
6-bp - *
insertion - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
A - (A0*
6-bp - *
insertion - *)
do - *
not - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
A - (A0*
6-bp - *
insertion - *)
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
the - (A1*
pathogens - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
binding - (A1*)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Mutation - (A0*
of - *
T491 - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

these - (A0*
same - *
mutations - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
Sec - (A1*
incorporation - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

vital - (A1*
stem - *
cells - *)
 - *
is - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

They - (A0*
establish - *
that - *
inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *
that - *
inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

the - (A1*
pathogens - *)
is - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
to - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

This - (A0*
occurs - *
by - *
microbe-detecting - *)
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

The - (A1*
pathogens - *
are - *
eliminated - *)
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *
were - *
eliminated - *)
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
such - *
as - *
CD14 - *
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

Microbe-detecting - (A0*
receptors - *)
activate - *
immune - *
cells - *
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

binding - (A1*)
 - *
is - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
with - *
binding - *
completely - *
eliminated eliminate (V*) *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate(Figure - *)
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconatecompletely - *)
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconatecompletely - *)
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - (A0*
of - *
Grb2 - *
significantly - *)
reduced - *
SH3A - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - *
a - *
molar - *
ratio - *
of - *
5:1 - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operatorsto - *)
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
is - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
eliminates eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
that - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
that - *
eliminates eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Sec - (A1*
incorporation - *)
is - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
completely - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
completely - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
that - *
completely - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
that - *
completely - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
is - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
did - *
not - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
do - *
not - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
. - *

vital - (A1*
stem - *
cells - *)
 - *
was - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
pathogens - *)
was - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

binding - (A1*)
 - *
was - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
was - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Sec - (A1*
incorporation - *)
was - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
was - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

vital - (A1*
stem - *
cells - *)
 - *
which - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
pathogens - *)
which - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

binding - (A1*)
 - *
which - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
which - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Sec - (A1*
incorporation - *)
which - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
which - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

vital - (A1*
stem - *
cells - *)
 - *
has - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
pathogens - *)
has - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

binding - (A1*)
 - *
has - *
eliminated eliminate (V*) *
by - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
has - *
eliminated eliminate (V*) *
by - *
Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Sec - (A1*
incorporation - *)
has - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
has - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
binding - (A1*)
 - *
. - *

Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
 - *
. - *

microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
binding - (A1*)
 - *
. - *

Mutation - (A0*
of - *
T491 - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
. - *

these - (A0*
same - *
mutations - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

the - (A0*
other - *)
eliminates eliminate (V*) *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
One - *
mutation - *
eliminates - *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
One - *
mutation - *
eliminated - *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
One - *
mutation - *
would - *
eliminate - *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
BamHI - *
site - *
was - *
eliminated - *
by - *
One - *
mutation - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
BamHI - *
site - *
is - *
eliminated - *
by - *
One - *
mutation - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
One - *
mutation - *
that - *
eliminates - *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
One - *
mutation - *
that - *
eliminated - *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminates eliminate (V*) *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

the - (A0*
other - *)
eliminated eliminate (V*) *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminated eliminate (V*) *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - *
BamHI - *
site - *
is - *
eliminated eliminate (V*) *
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
by - *
one - *
mutation - *
and - *
the - (A0*
other - *)
eliminated - *
the - (A1*
HindIII - *
site - *)
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - *)
BamHI - *
site - *
is - *
eliminated eliminate (V*) *
Transgenic - (A2*
plants - *)
by - *
one - *
mutation - *
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - *
BamHI - *
site - *
was - *
eliminated eliminate (V*) *
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
by - *
one - *
mutation - *
and - *
the - (A0*
other - *)
eliminated - *
the - (A1*
HindIII - *
site - *)
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - *)
BamHI - *
site - *
was - *
eliminated eliminate (V*) *
Transgenic - (A2*
plants - *)
by - *
one - *
mutation - *
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

the - (A0*
other - *)
would - *
eliminate eliminate (V*) *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
would - *
eliminate eliminate (V*) *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

the - (A0*
other - *)
that - *
eliminates eliminate (V*) *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminates eliminate (V*) *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

the - (A0*
other - *)
that - *
eliminated eliminate (V*) *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminated eliminate (V*) *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminates - *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
eliminated - *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
would - *
eliminate - *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
exogenous - (A1*
H(O( - *)
was - *
eliminated - *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
exogenous - (A1*
H(O( - *)
is - *
eliminated - *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminates - *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
 - *
that - *
eliminated - *
exogenous - (A1*
H(O( - *)
Transgenic - (A2*
plants - *)
. - *

They - (A0*
establish - *
that - *
inhibition - *
of - *
any - *
one - *
of - *)
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
the - (A1*
pathogensrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - *)
establish - *
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
binding - (A1*)
required - *
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
Sec - (A1*
incorporationrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *
that - *
inhibition - *
of - *
any - *)
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
could - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132required - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *
that - *
inhibition - *
of - *
any - *
one - *
of - *)
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
the - (A1*
pathogensrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - *)
establish - *
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
binding - (A1*)
required - *
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibodyrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *)
that - *
inhibition - *
of - *
any - *
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
Sec - (A1*
incorporationrequired - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

They - (A0*
establish - *
that - *
inhibition - *
of - *
any - *)
one - *
of - *
these - *
molecules - *
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132required - *)
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

In - *
gel - *
shift - *
assay - *
anti-ref1 - (A0*
antibody - *)
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

In - *
gel - *
shift - *
assay - *
anti-ref1 - (A0*
antibody - *)
eliminates eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
is - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
was - *
eliminated eliminate (V*) *
by - *
anti-ref1 - (A0*
antibody - *)
. - *

In - *
gel - *
shift - *
assay - *
anti-ref1 - (A0*
antibody - *)
has - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

In - *
gel - *
shift - *
assay - *
anti-ref1 - (A0*
antibody - *)
will - *
eliminated eliminate (V*) *
formation - (A1*
of - *
the - *
nCaRE-protein - *
complex - *)
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
eliminates eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
has - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
will - *
eliminate eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminated eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

A - (A0*
6-bp - *
insertion - *)
located - *
within - *
O2 - *
or - *
between - *
OT - *
and - *
O1 - *
which - *
eliminates eliminate (V*) *
repression - (A1*
of - *
the - *
glpTQ - *
promoter - *)
whereas - *
significant - *
repression - *
was - *
maintained - *
in - *
the - *
case - *
of - *
a - *
10-bp - *
insertion - *
within - *
O2 - *
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
is - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
was - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
which - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
has - *
eliminated eliminate (V*) *
by - *
gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminated eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

gluconate - (A0*
and - *
also - *
by - *
6-phosphogluconate - *)
at - *
a - *
10-fold-higher - *
concentration - *
eliminate eliminate (V*) *
Binding - (A1*
of - *
GntR - *
to - *
the - *
operators - *)
. - *

One - (A0*
mutation - *)
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - (A0*
mutation - *)
eliminated eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - (A1*
BamHI - *
site - *)
is - *
eliminated eliminate (V*) *
in - (A2*
exon - *
7 - *)
by - *
one - (A0*
mutation - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

The - (A1*
BamHI - *
site - *)
was - *
eliminated eliminate (V*) *
in - (A2*
exon - *
7 - *)
by - *
one - (A0*
mutation - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - (A0*
mutation - *)
would - *
eliminate eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - (A0*
mutation - *)
that - *
eliminates eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
other - *
eliminates - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - (A0*
mutation - *)
that - *
eliminated eliminate (V*) *
the - (A1*
BamHI - *
site - *)
in - (A2*
exon - *
7 - *)
and - *
the - *
other - *
eliminated - *
the - *
HindIII - *
site - *
in - *
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A0*
other - *)
eliminated - *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A0*
other - *)
would - *
eliminate - *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A1*
HindIII - *
site - *)
was - *
eliminated - *
by - *
the - (A0*
other - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A1*
HindIII - *
site - *)
is - *
eliminated - *
by - *
the - (A0*
other - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A0*
other - *)
that - *
eliminates - *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

One - *
mutation - *
eliminates eliminate (V*) *
the - *
BamHI - *
site - *
in - *
exon - *
7 - *
and - *
the - (A0*
other - *)
that - *
eliminated - *
the - (A1*
HindIII - *
site - *)
in - (A2*
exon - *
11 - *
of - *
the - *
phenylalanine - *
hydroxylase - *
gene - *)
. - *

They - *
establish - *
that - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
can - *
eliminate eliminate (V*) *
vital - (A1*
stem - *
cells - *)
required - *
for - *
skeletal - *
muscle - *
regeneration - *
during - *
chronic - *
catabolic - *
conditions - *
. - *

Ihibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
. - *

Inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
. - *

Vital - (A1*
stem - *
cells - *)
are - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
. - *

Vital - (A1*
stem - *
cells - *)
were - *
eliminated eliminate (V*) *
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
moleculesas - *)
may - *
occur - *
following - *
caspase - *
activation - *
. - *

Ihibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
that - *
eliminated eliminate (V*) *
vital - (A1*
stem - *
cells - *)
. - *

Inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
as - *
may - *
occur - *
following - *
caspase - *
activation - *
that - *
eliminates eliminate (V*) *
vital - (A1*
stem - *
cells - *)
. - *

This - *)
occurs - *
by - *
microbe-detecting - *
receptors - *
such - *
as - *
CD14 - *
that - *
activate - *
immune - *
cells - *
for - *
eliminating eliminate (V*) *
the - (A1*
pathogens - *)
. - *

Microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

Microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

The - (A1*
pathogens - *)
are - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
. - *

The - (A1*
pathogens - *)
were - *
eliminated eliminate (V*) *
by - *
microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
. - *

Microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
that - *
eliminate eliminate (V*) *
the - (A1*
pathogens - *)
. - *

Microbe-detecting - (A0*
receptors - *
activate - *
immune - *
cells - *)
such - *
as - *
CD14 - *
which - *
eliminated eliminate (V*) *
the - (A1*
pathogens - *)
. - *

Inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *)
eliminated eliminate (V*) *
exogenous - *
H(2)O(2) - *
in - *
transgenic - (A2*
plants - *)
. - *

Inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *)
eliminate eliminate (V*) *
exogenous - *
H(2)O(2) - *
in - *
transgenic - (A2*
plants - *)
. - *

Exogenous - *)
H(2)O(2) - *
is - *
eliminated eliminate (V*) *
in - *
transgenic - (A2*
plants - *)
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
. - *

Exogenous - *)
H(2)O(2) - *
was - *
eliminated eliminate (V*) *
in - *
transgenic - (A2*
plants - *)
by - *
inhibition - (A0*
of - *
any - *
one - *
of - *
these - *
molecules - *)
. - *

Inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *)
that - *
eliminated eliminate (V*) *
exogenous - *
H(2)O(2) - *
in - *
transgenic - (A2*
plants - *)
. - *

Inhibition - *)
of - *
any - *
one - *
of - *
these - *
molecules - *)
that - *
eliminate eliminate (V*) *
exogenous - *
H(2)O(2) - *
in - *
transgenic - (A2*
plants - *)
. - *

For - *
eliminating eliminate (V*) *
any - (A1*
deleterious - *
effects - *)
that - *
might - *
be - *
associated - *
with - *
stable - *
HOXB4 - *
gene - *
transfer - *
into - *
human - *
cells - *
we - *
took - *
advantage - *
of - *
the - *
ability - *
of - *
HOX - *
proteins - *
to - *
passively - *
translocate - *
through - *
cell - *
membranes - *
. - *

Eliminating eliminate (V*) *
any - (A1*
deleterious - *
effects - *)
that - *
might - *
be - *
associated - *
with - *
stable - *
HOXB4 - *
gene - *
transfer - *
into - *
human - *
cells - *
we - *
took - *
advantage - *
of - *
the - *
ability - *
of - *
HOX - *
proteins - *
to - *
passively - *
translocate - *
through - *
cell - *
membranes - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
binding - (A1*)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
completely - *
eliminated eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
binding - (A1*)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
completely - *
eliminates eliminate (V*) *
SH3A - *
binding - *
to - *
mSos1 - *
(Figure - *
7) - *
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
binding - (A1*)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
is - *
completely - *
eliminated eliminate (V*) *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
. - *

Addition - *
of - *
Grb2 - *
significantly - *
reduced - *
SH3A - *
binding - (A1*)
to - *
mSos1 - *
in - *
a - *
concent - *
rat - *
ion-dependent - *
manner - *
binding - *
was - *
completely - *
eliminated eliminate (V*) *
at - (A0*
a - *
molar - *
ratio - *
of - *
5:1 - *)
 - *
. - *

Mutation - (A0*
of - *
T491 - *)
eliminates eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Mutation - (A0*
of - *
T491 - *)
that - *
eliminated eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

Mutation - (A0*
of - *
T491 - *)
that - *
eliminates eliminate (V*) *
the - (A1*
recognition - *
by - *
the - *
anti-pT598 - *
antibody - *)
while - *
mutation - *
at - *
S494 - *
has - *
no - *
effect - *
(Figure - *
2C) - *
. - *

The - (A1*
recognition - *
is - *
eliminated eliminate (V*) *
by - *
mutation - *)
of - *
T491 - *)
through - *
the - *
anti-pT598 - *
antibody - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

The - *)
recognition - *
was - *
eliminated eliminate (V*) *
by - *
mutation - (A0*
of - *
T491 - *)
through - *
the - *
anti-pT598 - *
antibody - *
while - *
mutation - *
at - *
S494 - *
had - *
no - *
effect - *
(Figure - *
2C) - *
. - *

All - (A1*
three - *
sites - *)
eliminated eliminate (V*) *
make - *
the - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
. - *

Eliminating eliminate (V*) *
all - (A1*
three - *
sites - *)
make - *
the - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
. - *

To - *
eliminate eliminate (V*) *
all - (A1*
three - *
sites - *)
make - *
the - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
. - *

The - *
same - *
high - *
level - *
of - *
activation - *
of - *
B-Raf - *
occurs - *
only - *
when - *
all - (A1*
three - *
sites - *)
were - *
eliminated eliminate (V*) *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
these - (A0*
same - *
mutations - *)
completely - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
these - (A0*
same - *
mutations - *)
completely - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Sec - (A1*
incorporation - *)
is - *
completely - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
Sec - (A1*
incorporation - *)
was - *
completely - *
eliminated eliminate (V*) *
by - *
these - (A0*
same - *
mutations - *)
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
yet - *
these - (A0*
same - *
mutations - *)
that - *
completely - *
eliminate eliminate (V*) *
Sec - (A1*
incorporation - *)
(Lesoon - *
et - *
al - *
1997) - *
. - *

Secondly - *
SBP2 - *
binding - *
activity - *
is - *
not - *
affected - *
by - *
mutations - *
in - *
the - *
tetra-adenosine - *
element - *
in - *
the - *
terminal - *
region - *
of - *
the - *
PHGPx - *
3?UTR - *
these - (A0*
same - *
mutations - *)
that - *
completely - *
eliminated eliminate (V*) *
Sec - (A1*
incorporation - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
which - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
that - *
did - *
not - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
do - *
not - *
eliminate eliminate (V*) *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
was - *
not - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
are - *
not - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

As - *
illustrated - *
in - *
Figure - *
1 - *
the - (A1*
stabilization - *
seen - *
with - *
MG132 - *)
which - *
were - *
not - *
eliminated eliminate (V*) *
by - *
staurosporin - (A0*
(or - *
genestein; - *
data - *
not - *
shown) - *)
. - *

The - (A1*
requirement - *
of - *
induction - *)
can - *
be - *
eliminated eliminate (V*) *
by - *
mutation - (A0*
of - *
a - *
new - *
locus - *
galS - *)
resulting - *
in - *
constitutive - *
and - *
ultrainduced - *
levels - *
of - *
gal - *
expression - *
. - *

The - (A1*
requirement - *
of - *
induction - *)
is - *
eliminated eliminate (V*) *
by - *
mutation - (A0*
of - *
a - *
new - *
locus - *
galS - *)
resulting - *
in - *
constitutive - *
and - *
ultrainduced - *
levels - *
of - *
gal - *
expression - *
. - *

The - (A1*
requirement - *
of - *
induction - *)
was - *
eliminated eliminate (V*) *
by - *
mutation - (A0*
of - *
a - *
new - *
locus - *
galS - *)
resulting - *
in - *
constitutive - *
and - *
ultrainduced - *
levels - *
of - *
gal - *
expression - *
. - *

mutation - (A0*
of - *
a - *
new - *
locus - *
galS - *)
eliminated eliminate (V*) *
The - (A1*
requirement - *
of - *
induction - *)
resulting - *
in - *
constitutive - *
and - *
ultrainduced - *
levels - *
of - *
gal - *
expression - *
. - *

mutation - (A0*
of - *
a - *
new - *
locus - *
galS - *)
eliminates eliminate (V*) *
The - (A1*
requirement - *
of - *
induction - *)
resulting - *
in - *
constitutive - *
and - *
ultrainduced - *
levels - *
of - *
gal - *
expression - *
. - *

One - *
of - *
the - *
remaining - *
three - *
families - *
carried - *
a - (A0*
3-bp - *
in-frame - *
deletion - *)
that - *
eliminated eliminate (V*) *
an - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

One - *
of - *
the - *
remaining - *
three - *
families - *
carried - *
a - (A0*
3-bp - *
in-frame - *
deletion - *)
that - *
eliminates eliminate (V*) *
an - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

An - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product - *)
is - *
eliminated eliminate (V*) *
by - *
a - (A0*
3-bp - *
in-frame - *
deletion; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

An - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product - *)
was - *
eliminated eliminate (V*) *
by - *
a - (A0*
3-bp - *
in-frame - *
deletion; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

One - *
of - *
the - *
remaining - *
three - *
families - *
carried - *
a - (A0*
3-bp - *
in-frame - *
deletion - *)
eliminating eliminate (V*) *
an - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

One - *
of - *
the - *
remaining - *
three - *
families - *
carried - *
a - (A0*
3-bp - *
in-frame - *
deletion - *)
eliminated eliminate (V*) *
an - (A1*
asparagine - *
residue - *)
within - (A2*
a - *
kinase - *
domain - *
of - *
the - *
product; - *)
the - *
other - *
two - *
carried - *
intronic - *
mutations - *
at - *
or - *
adjacent - *
to - *
the - *
consensus - *
dinucleotide - *
sequences - *
of - *
splice-acceptor - *
or - *
-donor - *
sites - *
which - *
were - *
likely - *
to - *
lead - *
to - *
aberrant - *
splicing - *
. - *

Transgenic - (A2*
plants - *)
expressing - *
AtNDK1 - *)
under - *
control - *
of - *
the - *
CaMV - *
35S - *
promoter - *
exhibited - *
tolerance - *
to - *
paraquat - *
and - *
high - *
ability - *
for - *
eliminating eliminate (V*) *
exogenous - *
H(2)O(2) - *
. - *

To - *
eliminate eliminate (V*) *
the - (A1*
inhibitory - *
phosphorylation - *)
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

For - *
eliminating eliminate (V*) *
the - (A1*
inhibitory - *
phosphorylation - *)
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

The - (A1*
inhibitory - *
phosphorylation - *)
is - *
eliminated eliminate (V*) *
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

The - (A1*
inhibitory - *
phosphorylation - *)
was - *
eliminated eliminate (V*) *
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

The - (A1*
inhibitory - *
phosphorylation - *)
that - *
is - *
eliminated eliminate (V*) *
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

The - (A1*
inhibitory - *
phosphorylation - *)
that - *
was - *
eliminated eliminate (V*) *
or - *
mimicking - *
activating - *
phosphorylation - *
sites - *
is - *
sufficient - *
to - *
confer - *
constitutive - *
activity - *
upon - *
lin-45 - *
Raf - *
and - *
induce - *
multi-vulva - *
phenotypes - *
in - *
Celegans - *
. - *

We - *
recently - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
that - *
has - *
encoded encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

the - (A1*)
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
are - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
. - *

the - (A1*)
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
were - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
. - *

We - *
recently - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
that - *
has - *
encoded encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
encodes encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
will - *
encode encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
has - *
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*)
proteins - *
are - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*)
proteins - *
were - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

We - *
recently - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
that - *
has - *
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

CP2is - (A1*)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *)
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

CP2was - (A1*)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *)
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

We - *
recently - *
The - (A0*
gene - *
yjfQ - *)
that - *
has - *
encoded encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
will - *
encode encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
has - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
which - *
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
which - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

We - *
recently - *
MAZ - (A0*)
which - *
encode encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
may - *
encode encode (V*) *
CP2 - (A1*)
. - *

encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
encoded encode (V*) *
CP2 - (A1*)
. - *

encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
has - *
encoded encode (V*) *
CP2 - (A1*)
. - *

encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
will - *
encode encode (V*) *
CP2 - (A1*)
. - *

encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
encodes encode (V*) *
CP2 - (A1*)
. - *

CP2 - (A1*)
is - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
. - *

CP2 - (A1*)
was - *
encoded encode (V*) *
by - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
. - *

We - *
recently - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
which - *
encode encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
which - *
encode encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
encoding encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

encloned - (A1*)
murine - *
and - *
human - *
cDNAs - *)
which - *
encoded encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

We - *
recently - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
which - *
encode encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
which - *
encode encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
gene - *
yjfQ - *)
which - *
encode encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
may - *
encode encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
. - *

MAZ - (A1*
which - *
encode encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *)
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

MAZ - (A1*
encoding encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *)
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

MAZ - (A1*
which - *
encoded encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *)
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

the - *)
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
are - *
encoded encode (V*) *
by - *
MAZ - (A0*)
. - *

the - *)
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
were - *
encoded encode (V*) *
by - *
MAZ - (A0*)
. - *

The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
may - *
encode encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
. - *

MAZ - (A1*
encodes encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *)
and - *
its - *
precursors - *
. - *

MAZ - (A1*
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *)
and - *
its - *
precursors - *
. - *

MAZ - (A1*
will - *
encode encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *)
and - *
its - *
precursors - *
. - *

MAZ - (A1*
has - *
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *)
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
are - *
encoded encode (V*) *
by - *
MAZ - (A0*)
required - *
for - *
utilization - *
of - *
sn-glycerol - *)
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
were - *
encoded encode (V*) *
by - *
MAZ - (A0*)
required - *
for - *
utilization - *
of - *
sn-glycerol - *)
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
may - *
encode encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
. - *

a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
terminationis - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
terminationwas - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

The - (A0*
gene - *
yjfQ - *)
may - *
encode encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
. - *

MAZ - (A1*
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

MAZ - (A1*
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

MAZ - (A1*
will - *
encode encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

MAZ - (A1*
has - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

MAZ - (A1*
which - *
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

MAZ - (A1*
which - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *)
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encoded encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
. - *

The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encoded encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
. - *

The - (A0*
gene - *
yjfQ - *)
encoded encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
has - *
encoded encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
. - *

The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
has - *
encoded encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
has - *
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
. - *

The - (A0*
gene - *
yjfQ - *)
has - *
encoded encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
will - *
encode encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
. - *

The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
will - *
encode encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
will - *
encode encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
. - *

The - (A0*
gene - *
yjfQ - *)
will - *
encode encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encodes encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
. - *

The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encodes encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encodes encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
. - *

The - (A0*
gene - *
yjfQ - *)
encodes encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
is - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
. - *

the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
is - *
encoded encode (V*) *
by - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
. - *

a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
is - *
encoded encode (V*) *
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
. - *

the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
is - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
was - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
. - *

the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
was - *
encoded encode (V*) *
by - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
. - *

a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
 - *
was - *
encoded encode (V*) *
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
. - *

the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
was - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
which - *
encode encode (V*) *
the - *
major - *
outer - *
membrane - *)
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encodes - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encoded - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
will - *
encode - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
has - *
encoded - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
are - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *)
ompF - *
and - *
ompC - *
genes - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
were - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *)
ompF - *
and - *
ompC - *
genes - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
which - *
encode - *)
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *)
OmpF - *
and - *
OmpCis - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *)
OmpF - *
and - *
OmpCwas - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

The - (A1*
gene - *
yjfQ - *)
which - *
encode encode (V*) *
the - *
major - *
outer - *)
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encodes - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encoded - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
will - *
encode - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - (A1*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
has - *
encoded - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - *)
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
which - *
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Expression - *)
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
which - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encoding encode (V*) *
the - *
major - *
outer - *
membrane - *
proteins - *)
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encoding - *)
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

The - (A1*
gene - *
yjfQ - *)
encoding encode (V*) *
the - *
major - *
outer - *
membrane - *)
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
which - *
encoded encode (V*) *
the - *
major - *
outer - *
membrane - *)
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
which - *
encoded - *)
the - *
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

The - (A1*
gene - *
yjfQ - *)
which - *
encoded encode (V*) *
the - *
major - *
outer - *)
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
respectively - *
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

the - *)
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
are - *
encoded encode (V*) *
by - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
are - *
encoded - *)
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *)
OmpC - *
are - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
were - *
encoded encode (V*) *
by - *
The - (A0*
glp - *)
regulon - *
of - *
Escherichia - *
coli - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *
were - *
encoded - *)
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *)
OmpC - *
were - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
. - *

The - *)
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encodes encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
protein - *
required - *
for - *
utilization - *)
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursorsis - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

the - (A1*
protein - *
required - *
for - *
utilization - *)
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursorswas - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

The - (A1*
gene - *
yjfQ - *)
encodes encode (V*) *
the - *
proteins - *
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - *)
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - *)
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
will - *
encode encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *)
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
has - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *)
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
which - *
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *)
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
which - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *)
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - *)
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
gene - *
yjfQ - *)
encoded encode (V*) *
the - *
proteins - *
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
will - *
encode - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
gene - *
yjfQ - *)
will - *
encode encode (V*) *
the - *
proteins - *
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
has - *
encoded - *)
the - *
proteins - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
gene - *
yjfQ - *)
has - *
encoded encode (V*) *
the - *
proteins - *
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - *)
proteins - *
are - *
encoded encode (V*) *
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - *)
proteins - *
are - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
were - *
encoded encode (V*) *
by - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *)
renamed - *
nanC - *
) - *
gene - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
were - *
encoded encode (V*) *
by - *
The - (A0*
gene - *
yjfQ - *)
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - *)
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - *)
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
will - *
encode - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
has - *
encoded - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
which - *
encodes - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
which - *
encoded - *)
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

the - (A1*
repressor - *)
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
)is - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

the - (A1*
repressor - *)
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
)was - *)
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

We - *
recently - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
that - *
encode encode (V*) *
CP2 - (A1*)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
encoding encode (V*) *
CP2 - (A1*)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
that - *
encoded encode (V*) *
CP2 - (A1*)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
that - *
has - *
encoded encode (V*) *
CP2 - (A1*)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
encloned - (A0*
murine - *
and - *
human - *
cDNAs - *)
which - *
encode encode (V*) *
CP2 - (A1*)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

MAZ - (A0*)
may - *
encode encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
. - *

MAZ - (A0*)
encoded encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
. - *

MAZ - (A0*)
has - *
encoded encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
. - *

MAZ - (A0*)
will - *
encode encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
. - *

MAZ - (A0*)
encodes encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
. - *

a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
is - *
encoded encode (V*) *
by - *
MAZ - (A0*)
. - *

a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
was - *
encoded encode (V*) *
by - *
MAZ - (A0*)
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
which - *
encode encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encoding encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
respectively - *
is - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
which - *
encoded encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
respectively - *
was - *
affected - *
in - *
a - *
reciprocal - *
manner - *
by - *
the - *
osmolarity - *
of - *
the - *
growth - *
medium - *
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
are - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
. - *

the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
were - *
encoded encode (V*) *
by - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encodes encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *)
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encoded encode (V*) *
the - *
proteins - *
required - *
for - *
utilization - *)
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
will - *
encode encode (V*) *
the - *
proteins - *
required - *
for - *)
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A1*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
has - *
encoded encode (V*) *
the - *
proteins - *
required - *
for - *)
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
are - *
encoded encode (V*) *
by - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

the - (A1*
proteins - *
were - *
encoded encode (V*) *
by - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
required - *)
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *)
encodes encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *)
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *)
will - *
encode encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
. - *

The - (A0*
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gen - *)
has - *
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
. - *

a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *)
channels - *)
is - *
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *)
channels - *)
was - *
encoded encode (V*) *
by - *
 - *
The - *
Escherichia - *
coli - *
yjhA - *
(renamed - *
nanC) - *
gene - *
. - *

The - (A1*
gene - *
yjfQ - *)
encodes encode (V*) *
the - *
repressor - *
of - *
the - *)
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
gene - *
yjfQ - *)
encoded encode (V*) *
the - *
repressor - *
of - *
the - *)
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
gene - *
yjfQ - *)
will - *
encode encode (V*) *
the - *
repressor - *
of - *)
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - (A1*
gene - *
yjfQ - *)
has - *
encoded encode (V*) *
the - *
repressor - *
of - *)
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - *)
gene - *
yjfQ - *)
which - *
encodes encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

The - *)
gene - *
yjfQ - *)
which - *
encoded encode (V*) *
the - *
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
(ula) - *
which - *
is - *
involved - *
in - *
L-ascorbate - *
metabolism - *
in - *
Escherichia - *
coli - *
. - *

Six - (A1*
exons - *)
encode encode (V*) *
the - (A2*
6-pyruvoyl-tetrahydropterin - *
synthase - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

Six - (A1*
exons - *)
encoded encode (V*) *
the - (A2*
6-pyruvoyl-tetrahydropterin - *
synthase - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

Six - (A1*
exons - *)
that - *
encode encode (V*) *
the - (A2*
6-pyruvoyl-tetrahydropterin - *
synthase - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

Six - (A1*
exons - *)
that - *
encoded encode (V*) *
the - (A2*
6-pyruvoyl-tetrahydropterin - *
synthase - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

The - (A2*
6-pyruvoyl-tetrahydropterin - *)
synthase - *)
was - *
encoded encode (V*) *
by - *
six - (A1*
exons - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

The - (A2*
6-pyruvoyl-tetrahydropterin - *)
synthase - *)
is - *
encoded encode (V*) *
by - *
six - (A1*
exons - *)
cause - *
an - *
autosomal - *
recessively - *
inherited - *
variant - *
of - *
hyperphenylalaninemia - *
mostly - *
accompanied - *
by - *
a - *
deficiency - *
of - *
dopamine - *
and - *
serotonin - *
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
reveals - *
that - *
SBP2 - *
was - *
encoded encode (V*) *
by - *
as - *
many - *
as - *
three - (A1*
distinct - *
transcripts - *)
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
reveals - *
that - *
SBP2 - *
is - *
encoded encode (V*) *
by - *
as - *
many - *
as - *
three - (A1*
distinct - *
transcripts - *)
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
shows - *
that - *
three - (A1*
distinct - *
transcripts - *)
encoded encode (V*) *
SBP2 - *
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
shows - *
that - *
three - (A1*
distinct - *
transcripts - *)
encode encode (V*) *
SBP2 - *
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
shows - *
three - (A1*
distinct - *
transcripts - *)
that - *
encode encode (V*) *
SBP2 - *
. - *

Expression - *)
SBP2 - (A2*)
Northern - *
analysis - *
of - *
poly - *
(A) - *
+ - *
RNA - *
from - *
various - *
tissues - *
shows - *
three - (A1*
distinct - *
transcripts - *)
that - *
encoded encode (V*) *
SBP2 - *
. - *

Our - (A0*
reseach - *)
shows - *
that - *
the - (A1*
added - *
sequences - *
in - *
the - *
larger - *
forms - *
of - *
SBP2 - *
mRNA - *)
encode encode (V*) *
proteins - (A2*
with - *
other - *
functions - *)
. - *

Our - (A0*
reseach - *)
shows - *
that - *
the - (A1*
added - *
sequences - *
in - *
the - *
larger - *
forms - *
of - *
SBP2 - *
mRNA - *)
encoded encode (V*) *
proteins - (A2*
with - *
other - *
functions - *)
. - *

Our - (A0*
reseach - *)
shows - *
that - *
proteins - (A2*
with - *
other - *
functions - *)
are - *
encoded encode (V*) *
by - *
the - (A1*
added - *
sequences - *
in - *
the - *
larger - *
forms - *
of - *
SBP2 - *
mRNA - *)
. - *

Our - (A0*
reseach - *)
shows - *
that - *
proteins - (A2*
with - *
other - *
functions - *)
were - *
encoded encode (V*) *
by - *
the - (A1*
added - *
sequences - *
in - *
the - *
larger - *
forms - *
of - *
SBP2 - *
mRNA - *)
. - *

In - (A0*
plants - *)
it - *
is - *
estimated - *
that - *
between - (A2*
1000 - *
and - *
5000 - *
chloroplast - *
proteins - *)
were - *
encoded encode (V*) *
by - *
nuclear - (A1*
genes - *)
(Martin - *
and - *
Herrmann - *
1998) - *
and - *
by - *
analogy - *
in - *
Apicomplexa - *
most - *
of - *
the - *
protein - *
content - *
of - *
the - *
apicoplast - *
will - *
most - *
likely - *
also - *
be - *
nucleus - *
encoded - *
. - *

In - (A0*
plants - *)
it - *
is - *
estimated - *
that - *
nuclear - (A1*
genes - *)
encode encode (V*) *
between - (A2*
1000 - *
and - *
5000 - *
chloroplast - *
proteins - *)
(Martin - *
and - *
Herrmann - *
1998) - *
and - *
by - *
analogy - *
in - *
Apicomplexa - *
most - *
of - *
the - *
protein - *
content - *
of - *
the - *
apicoplast - *
will - *
most - *
likely - *
also - *
be - *
nucleus - *
encoded - *
. - *

In - (A0*
plants - *)
it - *
is - *
estimated - *
that - *
nuclear - (A1*
genes - *)
encoded encode (V*) *
between - (A2*
1000 - *
and - *
5000 - *
chloroplast - *
proteins - *)
(Martin - *
and - *
Herrmann - *
1998) - *
and - *
by - *
analogy - *
in - *
Apicomplexa - *
most - *
of - *
the - *
protein - *
content - *
of - *
the - *
apicoplast - *
will - *
most - *
likely - *
also - *
be - *
nucleus - *
encoded - *
. - *

In - (A0*
plants - *)
it - *
is - *
estimated - *
that - *
nuclear - (A1*
genes - *)
which - *
encode encode (V*) *
between - (A2*
1000 - *
and - *
5000 - *
chloroplast - *
proteins - *)
(Martin - *
and - *
Herrmann - *
1998) - *
and - *
by - *
analogy - *
in - *
Apicomplexa - *
most - *
of - *
the - *
protein - *
content - *
of - *
the - *
apicoplast - *
will - *
most - *
likely - *
also - *
be - *
nucleus - *
encoded - *
. - *

In - (A0*
plants - *)
it - *
is - *
estimated - *
that - *
nuclear - (A1*
genes - *)
which - *
encoded encode (V*) *
between - (A2*
1000 - *
and - *
5000 - *
chloroplast - *
proteins - *)
(Martin - *
and - *
Herrmann - *
1998) - *
and - *
by - *
analogy - *
in - *
Apicomplexa - *
most - *
of - *
the - *
protein - *
content - *
of - *
the - *
apicoplast - *
will - *
most - *
likely - *
also - *
be - *
nucleus - *
encoded - *
. - *

We - *
recently - *
MAZ - (A0*)
that - *
encode encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
that - *
encode encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
that - *
encode encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
that - *
encode encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
gene - *
yjfQ - *)
that - *
encode encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
MAZ - (A0*)
encoding encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
encoding encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
encoding encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
encoding encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
gene - *
yjfQ - *)
encoding encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
MAZ - (A0*)
that - *
encoded encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
Expression - (A0*
of - *
the - *
ompF - *
and - *
ompC - *
genes - *)
that - *
encoded encode (V*) *
the - (A1*
major - *
outer - *
membrane - *
proteins - *
OmpF - *
and - *
OmpC - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
glp - *
regulon - *
of - *
Escherichia - *
coli - *)
that - *
encoded encode (V*) *
the - (A1*
protein - *
required - *
for - *
utilization - *
of - *
sn-glycerol - *
3-phosphate - *
and - *
its - *
precursors - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
Escherichia - *
coli - *
yjhA - *
( - *
renamed - *
nanC - *
) - *
gene - *)
that - *
encoded encode (V*) *
a - (A1*
protein - *
of - *
the - *
KdgM - *
family - *
of - *
outer - *
membrane-specific - *
channels - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
The - (A0*
gene - *
yjfQ - *)
that - *
encoded encode (V*) *
the - (A1*
repressor - *
of - *
the - *
yjfR-X - *
regulon - *
( - *
ula - *
) - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

We - *
recently - *
MAZ - (A0*)
that - *
has - *
encoded encode (V*) *
a - (A1*
transcription - *
factor - *
with - *
dual - *
roles - *
in - *
transcription - *
initiation - *
and - *
termination - *)
a - *
cellular - *
transcription - *
factor - *
that - *
interacts - *
with - *
the - *
alpha-globin - *
promoter - *
as - *
well - *
as - *
with - *
additional - *
cellular - *
and - *
viral - *
promoter - *
elements - *
. - *

Supt4h2 - (A1*)
encoded - *)
a - (A2*
117 - *
amino - *
acid - *
protein - *
nearly - *
identical - *
to - *
the - *
Supt4h - *
gene - *
product - *
with - *
only - *
one - *
amino - *
acid - *
difference - *)
indicating - *
extreme - *
conservation - *
of - *
this - *
expressed - *
processed - *
gene - *
with - *
the - *
spliced - *
gene - *
over - *
evolutionary - *
time - *
. - *

A - (A2*
117 - *
amino - *)
acid - *
protein - *
nearly - *
identical - *
to - *
the - *
Supt4h - *
gene - *
product - *
with - *
only - *
one - *
amino - *
acid - *
difference - *)
is - *
encoded encode (V*) *
by - *
Supt4h2 - (A1*)
indicating - *
extreme - *
conservation - *
of - *
this - *
expressed - *
processed - *
gene - *
with - *
the - *
spliced - *
gene - *
over - *
evolutionary - *
time - *
. - *

A - (A2*
117 - *
amino - *)
acid - *
protein - *
nearly - *
identical - *
to - *
the - *
Supt4h - *
gene - *
product - *
with - *
only - *
one - *
amino - *
acid - *
difference - *)
was - *
encoded encode (V*) *
by - *
Supt4h2 - (A1*)
indicating - *
extreme - *
conservation - *
of - *
this - *
expressed - *
processed - *
gene - *
with - *
the - *
spliced - *
gene - *
over - *
evolutionary - *
time - *
. - *

Supt4h2 - (A1*)
which - *)
encode encode (V*) *
a - (A2*
117 - *
amino - *
acid - *
protein - *
nearly - *
identical - *
to - *
the - *
Supt4h - *
gene - *
product - *
with - *
only - *
one - *
amino - *
acid - *
difference - *)
indicating - *
extreme - *
conservation - *
of - *
this - *
expressed - *
processed - *
gene - *
with - *
the - *
spliced - *
gene - *
over - *
evolutionary - *
time - *
. - *

Supt4h2 - (A1*)
that - *)
encoded encode (V*) *
a - (A2*
117 - *
amino - *
acid - *
protein - *
nearly - *
identical - *
to - *
the - *
Supt4h - *
gene - *
product - *
with - *
only - *
one - *
amino - *
acid - *
difference - *)
indicating - *
extreme - *
conservation - *
of - *
this - *
expressed - *
processed - *
gene - *
with - *
the - *
spliced - *
gene - *
over - *
evolutionary - *
time - *
. - *

This - (A0*
is - *
the - *)
first - *
known - *
example - *
of - *
such - *
mutations - *
that - *
has - *
apparently - *
abolished - *
the - *
functional - *
that - *
a - *
pre-mRNA - (A1*)
encodes encode (V*) *
a - (A2*
multipass - *
integral - *
membrane - *
protein - *)
. - *

This - (A0*
is - *
the - *)
first - *
known - *
example - *
of - *
such - *
mutations - *
that - *
has - *
apparently - *
abolished - *
the - *
functional - *
that - *
a - *
pre-mRNA - (A1*)
encoded encode (V*) *
a - (A2*
multipass - *
integral - *
membrane - *
protein - *)
. - *

This - (A0*
is - *
the - *)
first - *
known - *
example - *
of - *
such - *
mutations - *
that - *
has - *
apparently - *
abolished - *
the - *
functional - *
that - *
a - (A2*
multipass - *
integral - *
membrane - *
protein - *)
was - *
encoded encode (V*) *
by - *
a - *
pre-mRNA - (A1*)
. - *

This - (A0*
is - *
the - *)
first - *
known - *
example - *
of - *
such - *
mutations - *
that - *
has - *
apparently - *
abolished - *
the - *
functional - *
that - *
a - (A2*
multipass - *
integral - *
membrane - *
protein - *)
is - *
encoded encode (V*) *
by - *
a - *
pre-mRNA - (A1*)
. - *

The - *)
PRP17 - *)
gene - *
of - *
the - *
yeast - *
Saccharomyces - *
cerevisiae - *)
encoded encode (V*) *
a - *
protein - *
that - *
participated - *
in - *
the - *
second - *
step - *
of - *
the - *
splicing - *
reaction - *
. - *

A - *)
protein - *)
that - *
participated - *
in - *
the - *
second - *
step - *
of - *
the - *
splicing - *
reaction - *
was - *
encoded encode (V*) *
by - *
The - (A1*
PRP17 - *
gene - *
of - *
the - *
yeast - *
Saccharomyces - *
cerevisiae - *)
. - *

A - (A2*
protein - *)
that - *
participates - *
in - *
the - *
second - *
step - *
of - *
the - *
splicing - *
reaction - *)
is - *
encoded encode (V*) *
by - *
The - (A1*
PRP17 - *
gene - *
of - *
the - *
yeast - *
Saccharomyces - *
cerevisiae - *)
. - *

The - (A1*
PRP17 - *)
gene - *
of - *
the - *
yeast - *
Saccharomyces - *
cerevisiae - *)
which - *
encode encode (V*) *
a - (A2*
protein - *
that - *
participates - *
in - *
the - *
second - *
step - *
of - *
the - *
splicing - *
reaction - *)
. - *

The - (A2*
PRP17 - *)
gene - *
of - *
the - *
yeast - *
Saccharomyces - *
cerevisiae - *)
which - *
encoded - *)
a - *
protein - *
that - *
participated - *
in - *
the - *
second - *
step - *
of - *
the - *
splicing - *
reaction - *
. - *

The - (A0*
human - *)
SNRPN - *
(small - *
nuclear - *
ribonucleoprotein - *
polypeptide - *
N) - *
gene - *
is - *
one - *
of - *
a - (A1*
gene - *
family - *)
encoded encode (V*) *
proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

A - (A1*
gene - *
family - *)
encode encode (V*) *
proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

Proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
were - *
encoded encode (V*) *
by - *
a - (A1*
gene - *
family - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

Proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
are - *
encoded encode (V*) *
by - *
a - (A1*
gene - *
family - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

A - (A1*
gene - *
family - *)
which - *
encode encode (V*) *
proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

A - (A1*
gene - *
family - *)
which - *
encoded encode (V*) *
proteins - (A2*
involved - *
in - *
pre-mRNA - *
splicing - *)
and - *
maps - *
to - *
the - *
smallest - *
deletion - *
region - *
involved - *
in - *
the - *
Prader-Willi - *
syndrome - *
(PWS) - *
within - *
chromosome - *
15q11-q13 - *
. - *

In - (A0*
this - *
vector - *)
the - (A1*
Tgondii - *
dhfr-ts - *
region - *)
was - *
excised - *
with - *
BamHI - *
and - *
KpnI - *
and - *
replaced - *
with - *
human - *
dhfr - *
mutated - *
that - *
encoded encode (V*) *
resistance - (A2*
to - *
WR99210 - *)
. - *

In - (A0*
this - *
vector - *)
the - (A1*
Tgondii - *
dhfr-ts - *
region - *)
was - *
excised - *
with - *
BamHI - *
and - *
KpnI - *
and - *
replaced - *
with - *
human - *
dhfr - *
mutated - *
that - *
encodes encode (V*) *
resistance - (A2*
to - *
WR99210 - *)
. - *

In - (A0*
this - *
vector - *)
the - (A1*
Tgondii - *
dhfr-ts - *
region - *)
was - *
excised - *
with - *
BamHI - *
and - *
KpnI - *
and - *
replaced - *
with - *
human - *
dhfr - *
mutated - *
encoding encode (V*) *
resistance - (A2*
to - *
WR99210 - *)
(Fidock - *
and - *
Wellems - *
1997) - *
. - *

Resistance - (A2*
to - *
WR99210 - *)
is - *
encoded encode (V*) *
by - *
the - (A1*
Tgondii - *
dhfr-ts - *
region - *)
with - *
BamHI - *
and - *
KpnI - *
and - *
replaced - *
with - *
human - *
dhfr - *
mutated - *
. - *

Resistance - (A2*
to - *
WR99210 - *)
was - *
encoded encode (V*) *
by - *
the - (A1*
Tgondii - *
dhfr-ts - *
region - *)
with - *
BamHI - *
and - *
KpnI - *
and - *
replaced - *
with - *
human - *
dhfr - *
mutated - *
. - *

Northern - (A0*)
blot - *
analysis - *
with - *
mRNA - *
from - *
eight - *
different - *
human - *
tissues - *
demonstrated - *
that - *
the - (A1*
enzyme - *)
was - *
expressed express (V*) *
exclusively - *
in - (A3*
brain - *)
with - (A2*
two - *
mRNA - *
isoforms - *
of - *
24 - *
and - *
40 - *
kb - *)
. - *

Northern - (A0*)
blot - *
analysis - *
with - *
mRNA - *
from - *
eight - *
different - *
human - *
tissues - *
demonstrated - *
that - *
the - (A1*
enzyme - *)
is - *
expressed express (V*) *
exclusively - *
in - (A3*
brain - *)
with - (A2*
two - *
mRNA - *
isoforms - *
of - *
24 - *
and - *
40 - *
kb - *)
. - *

Northern - (A0*)
blot - *
analysis - *
with - *
mRNA - *
from - *
eight - *
different - *
human - *
tissues - *
demonstrated - *
that - *
the - (A1*
enzyme - *)
has - *
been - *
expressed express (V*) *
exclusively - *
in - (A3*
brain - *)
with - (A2*
two - *
mRNA - *
isoforms - *
of - *
24 - *
and - *
40 - *
kb - *)
. - *

Northern - (A0*)
blot - *
analysis - *
with - *
mRNA - *
from - *
eight - *
different - *
human - *
tissues - *
demonstrated - *
that - *
the - (A1*
enzyme - *)
will - *
be - *
expressed express (V*) *
exclusively - *
in - (A3*
brain - *)
with - (A2*
two - *
mRNA - *
isoforms - *
of - *
24 - *
and - *
40 - *
kb - *)
. - *

Northern - (A0*)
blot - *
analysis - *
with - *
mRNA - *
from - *
eight - *
different - *
human - *
tissues - *
demonstrated - *
that - *
the - (A1*
enzyme - *)
would - *
be - *
expressed express (V*) *
exclusively - *
in - (A3*
brain - *)
with - (A2*
two - *
mRNA - *
isoforms - *
of - *
24 - *
and - *
40 - *
kb - *)
. - *

Two - (A0*)
equally - *
abundant - *
mRNAs - (A1*
for - *
il8ra - *)
20 - (A2*
and - *
24 - *
kilobases - *
in - *
length - *)
were - *
expressed express (V*) *
in - (A3*
neutrophils - *)
and - *
arise - *
from - *
usage - *
of - *
two - *
alternative - *
polyadenylation - *
signals - *
. - *

Two - (A0*)
equally - *
abundant - *
mRNAs - (A1*
for - *
il8ra - *)
20 - (A2*
and - *
24 - *
kilobases - *
in - *
length - *)
which - *
were - *
expressed express (V*) *
in - (A3*
neutrophils - *)
and - *
arise - *
from - *
usage - *
of - *
two - *
alternative - *
polyadenylation - *
signals - *
. - *

Two - (A0*)
equally - *
abundant - *
mRNAs - (A1*
for - *
il8ra - *)
20 - (A2*
and - *
24 - *
kilobases - *
in - *
length - *)
which - *
is - *
expressed express (V*) *
in - (A3*
neutrophils - *)
and - *
arise - *
from - *
usage - *
of - *
two - *
alternative - *
polyadenylation - *
signals - *
. - *

Two - (A0*)
equally - *
abundant - *
mRNAs - (A1*
for - *
il8ra - *)
20 - (A2*
and - *
24 - *
kilobases - *
in - *
length - *)
have - *
been - *
expressed express (V*) *
in - (A3*
neutrophils - *)
and - *
arise - *
from - *
usage - *
of - *
two - *
alternative - *
polyadenylation - *
signals - *
. - *

Two - (A0*)
equally - *
abundant - *
mRNAs - (A1*
for - *
il8ra - *)
20 - (A2*
and - *
24 - *
kilobases - *
in - *
length - *)
would - *
be - *
expressed express (V*) *
in - (A3*
neutrophils - *)
and - *
arise - *
from - *
usage - *
of - *
two - *
alternative - *
polyadenylation - *
signals - *
. - *

It - *)
has - *
been - *
assumed - *
that - *
this - *
peptide - *
exercises - *
its - *
mitogenic - *
influences - *
through - *
the - *
vasopressin - *
V1a - *
receptor - *
and - *
we - *
have - *
previously - *
demonstrated - *
that - *
this - (A1*
receptor - *)
was - *
expressed express (V*) *
by - *
classical - *
and - *
variant - *
SCCL - *
. - *

It - *)
has - *
been - *
assumed - *
that - *
this - *
peptide - *
exercises - *
its - *
mitogenic - *
influences - *
through - *
the - *
vasopressin - *
V1a - *
receptor - *
and - *
we - *
have - *
previously - *
demonstrated - *
that - *
this - (A1*
receptor - *)
being - *
expressed express (V*) *
by - *
classical - *
and - *
variant - *
SCCL - *
. - *

It - *)
has - *
been - *
assumed - *
that - *
this - *
peptide - *
exercises - *
its - *
mitogenic - *
influences - *
through - *
the - *
vasopressin - *
V1a - *
receptor - *
and - *
we - *
have - *
previously - *
demonstrated - *
that - *
this - (A1*
receptor - *)
has - *
been - *
expressed express (V*) *
by - *
classical - *
and - *
variant - *
SCCL - *
. - *

It - *)
has - *
been - *
assumed - *
that - *
this - *
peptide - *
exercises - *
its - *
mitogenic - *
influences - *
through - *
the - *
vasopressin - *
V1a - *
receptor - *
and - *
we - *
have - *
previously - *
demonstrated - *
that - *
this - (A1*
receptor - *)
which - *
has - *
been - *
expressed express (V*) *
by - *
classical - *
and - *
variant - *
SCCL - *
. - *

The - (A1*
human - *
mitochondrial - *
transcription - *
termination - *
factor - *
(mTERF) - *
cDNA - *)
was - *
cloned - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
and - *
two - *
alternative - *
precursors - *
of - *
the - *
protein - *
have - *
been - *
imported - *
into - *
isolated - *
mitochondria - *
and - *
processed - *
to - *
the - *
mature - *
protein - *
. - *

The - (A1*
human - *
mitochondrial - *
transcription - *
termination - *
factor - *
(mTERF) - *
cDNA - *)
is - *
cloned - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
and - *
two - *
alternative - *
precursors - *
of - *
the - *
protein - *
have - *
been - *
imported - *
into - *
isolated - *
mitochondria - *
and - *
processed - *
to - *
the - *
mature - *
protein - *
. - *

The - (A1*
human - *
mitochondrial - *
transcription - *
termination - *
factor - *
(mTERF) - *
cDNA - *)
will - *
be - *
cloned - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
and - *
two - *
alternative - *
precursors - *
of - *
the - *
protein - *
have - *
been - *
imported - *
into - *
isolated - *
mitochondria - *
and - *
processed - *
to - *
the - *
mature - *
protein - *
. - *

The - (A1*
human - *
mitochondrial - *
transcription - *
termination - *
factor - *
(mTERF) - *
cDNA - *)
would - *
be - *
cloned - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
and - *
two - *
alternative - *
precursors - *
of - *
the - *
protein - *
have - *
been - *
imported - *
into - *
isolated - *
mitochondria - *
and - *
processed - *
to - *
the - *
mature - *
protein - *
. - *

Pol - (A1*)
was - *
likely - *
expressed express (V*) *
through - *
+1 - *
or - *
-1 - *
frameshifting - *
by - *
Most - (A3*
animal - *
Ty3/gypsy - *
retroelements - *)
. - *

Pol - (A1*)
is - *
likely - *
expressed express (V*) *
through - *
+1 - *
or - *
-1 - *
frameshifting - *
by - *
Most - (A3*
animal - *
Ty3/gypsy - *
retroelements - *)
. - *

Pol - (A1*)
will - *
belikely - *
expressed express (V*) *
through - *
+1 - *
or - *
-1 - *
frameshifting - *
by - *
Most - (A3*
animal - *
Ty3/gypsy - *
retroelements - *)
. - *

Pol - (A1*)
would - *
be - *
likely - *
expressed express (V*) *
through - *
+1 - *
or - *
-1 - *
frameshifting - *
by - *
Most - (A3*
animal - *
Ty3/gypsy - *
retroelements - *)
. - *

The - (A0*)
mechanotransduction - *
mechanism - *
for - *
this - *
signalling - *
may - *
directly - *
or - *
indirectly - *
involve - *
the - *
dystrophin - *
complex - *
as - *
dystrophic - (A3*
muscle - *)
unlike - *
normal - *
muscle - *
was - *
unable - *
to - *
express express (V*) *
MGF - (A1*)
in - *
response - *
to - *
overload - *
. - *

The - (A0*)
mechanotransduction - *
mechanism - *
for - *
this - *
signalling - *
may - *
directly - *
or - *
indirectly - *
involve - *
the - *
dystrophin - *
complex - *
as - *
dystrophic - (A3*
muscle - *)
unlike - *
normal - *
muscle - *
expressing express (V*) *
MGF - (A1*)
in - *
response - *
to - *
overload - *
. - *

The - (A0*)
mechanotransduction - *
mechanism - *
for - *
this - *
signalling - *
may - *
directly - *
or - *
indirectly - *
involve - *
the - *
dystrophin - *
complex - *
as - *
MGF - (A1*)
is - *
unable - *
to - *
be - *
expressed express (V*) *
in - *
response - *
to - *
overload - *
by - *
dystrophic - (A3*
muscle - *)
. - *

The - (A0*)
mechanotransduction - *
mechanism - *
for - *
this - *
signalling - *
may - *
directly - *
or - *
indirectly - *
involve - *
the - *
dystrophin - *
complex - *
as - *
MGF - (A1*)
was - *
unable - *
to - *
be - *
expressed express (V*) *
in - *
response - *
to - *
overload - *
by - *
dystrophic - (A3*
muscle - *)
. - *

RCAS - (A0*)
viruses - *
infect - *
only - *
cells - (A3*)
engineered - *
for - *
expressing express (V*) *
ectopically - *
the - (A1*
avian - *
retroviral - *
receptor - *)
TVA - *
. - *

The - (A1*
avian - *
retroviral - *
receptor - *)
is - *
expressed express (V*) *
ectopically - *
by - *
cells - (A3*)
engineered - *
. - *

The - (A1*
avian - *
retroviral - *
receptor - *)
was - *
expressed express (V*) *
ectopically - *
by - *
cells - (A3*)
engineered - *
. - *

In - (A0*)
summary - *
NNT-1/BSF-3 - (A1*)
was - *
expressed express (V*) *
in - (A3*
pituitary - *
folliculostellate - *
TtT/GF - *
cells - *)
and - *
induced - *
by - *
PKC - *
PKA - *
and - *
ERK1/2 - *
dependent - *
mechanisms - *
. - *

In - (A0*)
summary - *
NNT-1/BSF-3 - (A1*)
has - *
been - *
expressed express (V*) *
in - (A3*
pituitary - *
folliculostellate - *
TtT/GF - *
cells - *)
and - *
induced - *
by - *
PKC - *
PKA - *
and - *
ERK1/2 - *
dependent - *
mechanisms - *
. - *

In - (A0*)
summary - *
NNT-1/BSF-3 - (A1*)
will - *
be - *
expressed express (V*) *
in - (A3*
pituitary - *
folliculostellate - *
TtT/GF - *
cells - *)
and - *
induced - *
by - *
PKC - *
PKA - *
and - *
ERK1/2 - *
dependent - *
mechanisms - *
. - *

It - (A0*)
expresses - *
NNT-1/BSF-3 - (A1*)
in - (A3*
pituitary - *
folliculostellate - *
TtT/GF - *
cells - *)
cells - *
and - *
induced - *
by - *
PKC - *
PKA - *
and - *
ERK1/2 - *
dependent - *
mechanisms - *
. - *

It - (A0*)
expressed express (V*) *
NNT-1/BSF-3 - (A1*)
in - (A3*
pituitary - *
folliculostellate - *
TtT/GF - *
cells - *)
cells - *
and - *
induced - *
by - *
PKC - *
PKA - *
and - *
ERK1/2 - *
dependent - *
mechanisms - *
. - *

In - (A0*)
the - *
cortex - *
of - *
adult - *
animals - *
Reln - (A1*)
was - *
expressed express (V*) *
primarily - *
in - (A3*
?-aminobutyric - *
acid - *
(GABA)ergic - *
neurons - *)
and - *
is - *
secreted - *
into - *
perineuronal - *
nets - *
. - *

Reln - (A1*)
has - *
been - *
expressed express (V*) *
primarily - *
in - (A3*
?-aminobutyric - *
acid - *
(GABA)ergic - *
neurons - *)
and - *
is - *
secreted - *
into - *
perineuronal - *
nets - *
. - *

Reln - (A1*)
will - *
be - *
expressed express (V*) *
primarily - *
in - (A3*
?-aminobutyric - *
acid - *
(GABA)ergic - *
neurons - *)
and - *
is - *
secreted - *
into - *
perineuronal - *
nets - *
. - *

It - (A0*)
expresses - *
primarily - *
Reln - (A1*)
in - (A3*
?-aminobutyric - *
acid - *
(GABA)ergic - *
neurons - *)
and - *
is - *
secreted - *
into - *
perineuronal - *
nets - *
. - *

It - (A0*)
expressed express (V*) *
primarily - *
Reln - (A1*)
in - (A3*
?-aminobutyric - *
acid - *
(GABA)ergic - *
neurons - *)
and - *
is - *
secreted - *
into - *
perineuronal - *
nets - *
. - *

T - (A3*
cells - *
from - *
double - *
TCR - *
transgenic - *
mice - *
expressed express (V*) *
only - *)
one - (A1*
or - *
the - *
other - *
of - *
the - *
two - *
available - *
TCRs - *)
at - *
the - *
cell - *
surface - *
. - *

One - (A3*
or - *
the - *
other - *
of - *
the - *
two - *
available - *
TCRs - *)
are - *
expressed - *)
only - *
by - *
T - *
cells - *
from - *
double - *
TCR - *
transgenic - *
mice - *
at - *
the - *
cell - *
surface - *
. - *

One - (A3*
or - *
the - *
other - *
of - *
the - *
two - *
available - *
TCRs - *)
were - *
expressed - *)
only - *
by - *
T - *
cells - *
from - *
double - *
TCR - *
transgenic - *
mice - *
at - *
the - *
cell - *
surface - *
. - *

T - (A3*
cells - *
from - *
double - *
TCR - *
transgenic - *
mice - *
which - *
express - *)
only - *
one - (A1*
or - *
the - *
other - *
of - *
the - *
two - *
available - *
TCRs - *)
at - *
the - *
cell - *
surface - *
. - *

T - (A3*
cells - *
from - *
double - *
TCR - *
transgenic - *
mice - *
which - *
expressed - *)
only - *
one - (A1*
or - *
the - *
other - *
of - *
the - *
two - *
available - *
TCRs - *)
at - *
the - *
cell - *
surface - *
. - *

This - (A0*)
&quot;functional - *
allelic - *
exclusion&quot; - *
is - *
apparently - *
due - *
to - *
control - *
of - *
the - *
TCR - *
assembly - *
process - *
because - *
these - *
T - (A3*
cells - *)
expressed express (V*) *
RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
. - *

This - (A0*)
&quot;functional - *
allelic - *
exclusion&quot; - *
is - *
apparently - *
due - *
to - *
control - *
of - *
the - *
TCR - *
assembly - *
process - *
because - *
these - *
T - (A3*
cells - *)
expressing express (V*) *
RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
. - *

RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
were - *
expressed express (V*) *
by - *
T - (A3*
cells - *)
. - *

RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
are - *
expressed express (V*) *
by - *
T - (A3*
cells - *)
. - *

RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
has - *
been - *
expressed express (V*) *
by - *
T - (A3*
cells - *)
. - *

RNA - (A1*
and - *
protein - *
for - *
all - *
four - *
transgenic - *
TCR - *
proteins - *)
will - *
be - *
expressed express (V*) *
by - *
T - (A3*
cells - *)
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
are - *
produced - *
but - *
only - (A1*
one - *)
is - *
expressed express (V*) *
at - *
the - *
cell - *
surface - *
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
were - *
produced - *
but - *
only - (A1*
one - *)
was - *
expressed express (V*) *
at - *
the - *
cell - *
surface - *
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
are - *
produced - *
but - *
only - (A1*
one - *)
has - *
been - *
expressed express (V*) *
at - *
the - *
cell - *
surface - *
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
were - *
produced - *
but - *
only - (A1*
one - *)
will - *
be - *
expressed express (V*) *
at - *
the - *
cell - *
surface - *
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
were - *
produced - *
it - *
expressed express (V*) *
only - (A1*
one - *)
at - *
the - *
cell - *
surface - *
. - *

In - (A3*
such - *
cells - *
two - *
in-frame - *)
a - *
chain - *
transcripts - *
were - *
produced - *
it - *
expresses - *
only - (A1*
one - *)
at - *
the - *
cell - *
surface - *
. - *

The - (A1*
transgene-encoded - *
TCR - *
proteins - *)
were - *
expressed express (V*) *
predominantly - *
by - *
T - (A3*
cells - *
in - *
mice - *
at - *
the - *
cell - *
surface - *)
. - *

The - (A1*
transgene-encoded - *
TCR - *
proteins - *)
are - *
expressed express (V*) *
predominantly - *
by - *
T - (A3*
cells - *
in - *
mice - *
at - *
the - *
cell - *
surface - *)
. - *

The - (A1*
transgene-encoded - *
TCR - *
proteins - *)
will - *
be - *
expressed express (V*) *
predominantly - *
by - *
T - (A3*
cells - *
in - *
mice - *
at - *
the - *
cell - *
surface - *)
. - *

The - (A1*
transgene-encoded - *
TCR - *
proteins - *)
have - *
been - *
expressed express (V*) *
predominantly - *
by - *
T - (A3*
cells - *
in - *
mice - *
at - *
the - *
cell - *
surface - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BD73 - (A0*
messenger - *
RNA - *)
was - *
expressed express (V*) *
ubiquitously - *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BNIP3alpha - (A0*)
which - *
was - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BD73 - (A0*
messenger - *
RNA - *)
has - *
been - *
expressed express (V*) *
ubiquitously - *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BD73 - (A0*
messenger - *
RNA - *)
will - *
be - *
expressed express (V*) *
ubiquitously - *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BNIP3alpha - (A0*)
is - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BD73 - (A0*
messenger - *
RNA - *)
is - *
expressed express (V*) *
ubiquitously - *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BNIP3alpha - (A0*)
was - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

BNIP3alpha - (A0*)
has - *
been - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

BNIP3alpha - (A0*)
will - *
be - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

BNIP3alpha - (A0*)
which - *
is - *
expressed express (V*) *
in - (A2*
most - *
human - *
tissues - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
is - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
was - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
has - *
been - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
will - *
be - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
which - *
is - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

BD73 - (A0*
messenger - *
RNA - *)
which - *
was - *
expressed express (V*) *
in - (A2*
a - *
wide - *
variety - *
of - *
tissues - *
and - *
cell - *
lines - *)
. - *

The - (A0*
pfl - *
operon - *)
is - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

The - (A0*
pfl - *
operon - *)
was - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

The - (A0*
pfl - *
operon - *)
has - *
been - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

The - (A0*
pfl - *
operon - *)
will - *
be - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

The - (A0*
pfl - *
operon - *)
which - *
is - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

The - (A0*
pfl - *
operon - *)
which - *
was - *
expressed express (V*) *
at - (A1*
high - *
levels - *
anaerobically - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BNIP3alpha - (A0*)
is - *
expressed express (V*) *
ubiquitously - *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BNIP3alpha - (A0*)
was - *
expressed express (V*) *
ubiquitously - *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BNIP3alpha - (A0*)
has - *
been - *
expressed express (V*) *
ubiquitously - *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - *
blot - *
analysis - *
reveals - *
that - *
BNIP3alpha - (A0*)
will - *
be - *
expressed express (V*) *
ubiquitously - *
in - (A2*
most - *
human - *
tissues - *)
. - *

Northern - (A0*)
blotting - *
and - *
reverse - *
transcriptase-PCR - *
assays - *
with - *
oligonucleotide - *
probes - *
and - *
primers - *
specific - *
for - *
each - *
transcript - *
demonstrated - *
that - *
the - (A1*
isoform - *
identical - *
to - *
Ran/TC4 - *)
is - *
expressed express (V*) *
in - (A3*
both - *
somatic - *
tissues - *
and - *
testis - *)
while - *
the - *
variant - *
form - *
was - *
transcribed - *
only - *
in - *
testis - *
. - *

Northern - (A0*)
blotting - *
and - *
reverse - *
transcriptase-PCR - *
assays - *
with - *
oligonucleotide - *
probes - *
and - *
primers - *
specific - *
for - *
each - *
transcript - *
demonstrated - *
that - *
the - (A1*
isoform - *
identical - *
to - *
Ran/TC4 - *)
would - *
be - *
expressed express (V*) *
in - (A3*
both - *
somatic - *
tissues - *
and - *
testis - *)
while - *
the - *
variant - *
form - *
was - *
transcribed - *
only - *
in - *
testis - *
. - *

Northern - (A0*)
blotting - *
and - *
reverse - *
transcriptase-PCR - *
assays - *
with - *
oligonucleotide - *
probes - *
and - *
primers - *
specific - *
for - *
each - *
transcript - *
demonstrated - *
that - *
the - (A1*
isoform - *
identical - *
to - *
Ran/TC4 - *)
has - *
been - *
expressed express (V*) *
in - (A3*
both - *
somatic - *
tissues - *
and - *
testis - *)
while - *
the - *
variant - *
form - *
was - *
transcribed - *
only - *
in - *
testis - *
. - *

A - (A1*
complementary - *
DNA - *
clone - *)
encoding - *
the - *
large - *
subunit - *
of - *
the - *
essential - *
mammalian - *
pre-messenger - *
RNA - *
splicing - *
component - *
U2 - *
snRNP - *
auxiliary - *
factor(U2AF65) - *
was - *
isolated - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
. - *

A - (A1*
complementary - *
DNA - *
clone - *)
encoding - *
the - *
large - *
subunit - *
of - *
the - *
essential - *
mammalian - *
pre-messenger - *
RNA - *
splicing - *
component - *
U2 - *
snRNP - *
auxiliary - *
factor(U2AF65) - *
is - *
isolated - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
. - *

A - (A1*
complementary - *
DNA - *
clone - *)
encoding - *
the - *
large - *
subunit - *
of - *
the - *
essential - *
mammalian - *
pre-messenger - *
RNA - *
splicing - *
component - *
U2 - *
snRNP - *
auxiliary - *
factor(U2AF65) - *
will - *
be - *
isolated - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
. - *

A - (A1*
complementary - *
DNA - *
clone - *)
encoding - *
the - *
large - *
subunit - *
of - *
the - *
essential - *
mammalian - *
pre-messenger - *
RNA - *
splicing - *
component - *
U2 - *
snRNP - *
auxiliary - *
factor(U2AF65) - *
would - *
be - *
isolated - *
and - *
expressed express (V*) *
in - (A3*
vitro - *)
. - *

Most - (A3*
animal - *
Ty3/gypsy - *
retroelements - *)
on - *
the - *
other - *
hand - *
encoded - *
gag - *
and - *
pol - (A1*)
in - *
separate - *
reading - *
frames - *
and - *
likely - *
expressed express (V*) *
Pol - *
through - *
+1 - *
or - *
-1 - *
frameshifting - *
. - *

T - (A3*
cells - *
in - *
mice - *
carrying - *
transgenes - *)
encoding - *
TCR - *
a - *
and - *
 - *
proteins - *
predominantly - *
express express (V*) *
the - (A1*
transgene-encoded - *
TCR - *
proteins - *)
at - *
the - *
cell - *
surface - *
. - *

T - (A3*
cells - *
in - *
mice - *
carrying - *
transgenes - *)
encoding - *
TCR - *
a - *
and - *
 - *
proteins - *
predominantly - *
expressed express (V*) *
the - (A1*
transgene-encoded - *
TCR - *
proteins - *)
at - *
the - *
cell - *
surface - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
nNOS - (A0*)
that - *
generate generate (V*) *
superoxide - (A1*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
we - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
superoxide - (A1*)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
superoxide - (A1*)
was - *
generated generate (V*) *
by - *
us - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
Abeta - (A1*
peptides - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

superoxide - (A1*)
are - *
generated generate (V*) *
from - *
nNOSby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

superoxide - (A1*)
were - *
generated generate (V*) *
from - *
nNOSby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

superoxide - (A1*)
have - *
been - *
generated generate (V*) *
from - *
nNOSby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

superoxide - (A1*)
will - *
be - *
generated generate (V*) *
from - *
nNOSby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
superoxide - (A1*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
specific - (A1*
fragments - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
superoxide - (A1*)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
superoxide - (A1*)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
superoxide - (A1*)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
superoxide - (A1*)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
superoxide - (A1*)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
nNOS - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
superoxide - (A1*)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
we - (A0*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
nNOS - (A0*)
generate generate (V*) *
superoxide - (A1*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
nNOS - (A0*)
that - *
generated generate (V*) *
superoxide - (A1*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
Abeta - (A1*
peptides - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
specific - (A1*
fragments - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
we - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
Abeta - (A1*
peptides - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
specific - (A1*
fragments - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
we - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
Abeta - (A1*
peptides - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
specific - (A1*
fragments - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
we - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

specific - (A1*
fragments - *)
are - *
generated generate (V*) *
from - *
degradationby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
Abeta - (A1*
peptides - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
Abeta - (A1*
peptides - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
Abeta - (A1*
peptides - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
Abeta - (A1*
peptides - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
are - *
generated generate (V*) *
from - *
weby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
that - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
that - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
. - *

To - *)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
Abeta - (A1*
peptides - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - *)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
Abeta - (A1*
peptides - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
are - *
generated generate (V*) *
from - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
toby - *)
beta- - *
and - *
gamma-secretases - *
. - *

specific - (A1*
fragments - *)
were - *
generated generate (V*) *
from - *
degradationby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
were - (A0*)
generated generate (V*) *
from - *
weby - *
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
were - *
generated generate (V*) *
from - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
toby - *)
beta- - *
and - *
gamma-secretases - *
. - *

specific - (A1*
fragments - *)
have - *
been - *
generated generate (V*) *
from - *
degradationby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
have - *
been - *
generated generate (V*) *
from - *
weby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
have - *
been - *
generated generate (V*) *
from - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
toby - *)
beta- - *
and - *
gamma-secretases - *
. - *

specific - (A1*
fragments - *)
will - *
be - *
generated generate (V*) *
from - *
degradationby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
will - *
be - *
generated generate (V*) *
from - *
weby - (A0*)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
will - *
be - *
generated generate (V*) *
from - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
toby - *)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *)
proteins - *
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
specific - (A1*
fragments - *)
. - *

proteolysis - (A0*)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *)
proteins - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
degradation - (A0*)
generate generate (V*) *
specific - (A1*
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
degradation - (A0*)
that - *
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
degradation - (A0*)
that - *
generate generate (V*) *
specific - (A1*
fragments - *)
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
specific - (A1*
fragments - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
specific - (A1*
fragments - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
functional - *
interaction - *
surface - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
functional - *
interaction - *
surface - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
functional - *
interaction - *
surface - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - (A0*)
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
we - *
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
functional - *
interaction - *
surface - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
that - *
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
that - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

To - (A0*
analyse - *
specifically - *
protein - *)
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
functional - *
interaction - *
surface - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *
specifically - *
protein - *)
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
functional - *
interaction - *
surface - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

We - *
believe - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
is - *
required - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
fumarase - (A0*
B - *)
is - *
required - *
to - *
generate generate (V*) *
fumarate - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

These - *
are - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
this - (A0*
binding - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
this - (A0*
binding - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
this - (A0*
binding - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
this - (A0*
binding - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

We - *
believe - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
is - *
required - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

this - (A0*
binding - *)
generating generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
binding - *)
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
are - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
were - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

We - *
believe - *
The - (A0*
TBC - *
method - *)
 - *
is - *
required - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

this - (A0*
bindingwas - *)
optimized - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

this - (A0*
binding - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
this - (A0*
binding(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
this - (A0*
binding(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

this - (A0*
bindingwhich - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

this - (A0*
bindingwhich - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

We - *
believe - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
is - *
required - *
to - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
within - *
the - *
recombinational - *
synapse - *
. - *

this - (A0*
bindingcleaves - *)
microRNA - *
precursors - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
bindingwhich - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
bindingwhich - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

this - (A0*
binding - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

a - (A1*
higher - *)
order - *
protein-DNA - *
complex - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
higher - *)
order - *
protein-DNA - *
complex - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

We - *
believe - *
nNOS - (A0*)
is - *
required - *
to - *
generate generate (V*) *
superoxide - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
this - (A0*
binding - *)
has - *
been - *
shown - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
this - (A0*
binding - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
. - *

We - *
believe - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
is - *
required - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
are - *
generated generate (V*) *
from - *
this - (A0*
bindingby - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
were - *
generated generate (V*) *
from - *
this - (A0*
bindingby - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
have - *
been - *
generated generate (V*) *
from - *
this - (A0*
bindingby - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
will - *
be - *
generated generate (V*) *
from - *
this - (A0*
bindingby - *)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

We - *
believe - *
degradation - (A0*)
is - *
required - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
this - (A0*
binding - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

We - (A0*)
believe - *
we - *
is - *
required - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
within - *
the - *
recombinational - *
synapse - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
this - (A0*
binding - *)
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
this - (A0*
binding - *)
that - *
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
this - (A0*
binding - *)
that - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

We - *
believe - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
is - *
required - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
is - *
found - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
fumarase - (A0*
B - *)
is - *
found - *
to - *
generate generate (V*) *
fumarate - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
is - *
found - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
The - (A0*
TBC - *
method - *)
 - *
is - *
found - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
is - *
found - *
to - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
nNOS - (A0*)
is - *
found - *
to - *
generate generate (V*) *
superoxide - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
is - *
found - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
degradation - (A0*)
is - *
found - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - (A0*)
believe - *
we - *
is - *
found - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
is - *
found - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
is - *
shown - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
fumarase - (A0*
B - *)
is - *
shown - *
to - *
generate generate (V*) *
fumarate - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
is - *
shown - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
The - (A0*
TBC - *
method - *)
 - *
is - *
shown - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
is - *
shown - *
to - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
nNOS - (A0*)
is - *
shown - *
to - *
generate generate (V*) *
superoxide - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
is - *
shown - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
degradation - (A0*)
is - *
shown - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - (A0*)
believe - *
we - *
is - *
shown - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
is - *
shown - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
within - *
the - *
recombinational - *
synapse - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generates generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
within - *
the - *
recombinational - *
synapse - *
. - *

fumarase - (A0*
B - *)
generates generate (V*) *
fumarate - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

The - (A0*
TBC - *
method - *)
 - *
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
within - *
the - *
recombinational - *
synapse - *
. - *

nNOS - (A0*)
generates generate (V*) *
superoxide - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generates generate (V*) *
Abeta - (A1*
peptides - *)
within - *
the - *
recombinational - *
synapse - *
. - *

degradation - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

we - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
within - *
the - *
recombinational - *
synapse - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
within - *
the - *
recombinational - *
synapse - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
within - *
the - *
recombinational - *
synapse - *
. - *

fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

The - (A0*
TBC - *
method - *)
 - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
within - *
the - *
recombinational - *
synapse - *
. - *

nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
within - *
the - *
recombinational - *
synapse - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
within - *
the - *
recombinational - *
synapse - *
. - *

degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
within - *
the - *
recombinational - *
synapse - *
. - *

we - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
within - *
the - *
recombinational - *
synapse - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
is - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
within - *
the - *
recombinational - *
synapse - *
. - *

fumarate - (A1*)
is - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
within - *
the - *
recombinational - *
synapse - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
is - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
within - *
the - *
recombinational - *
synapse - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
is - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
is - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

superoxide - (A1*)
is - *
generated generate (V*) *
by - *
nNOS - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

Abeta - (A1*
peptides - *)
is - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

specific - (A1*
fragments - *)
is - *
generated generate (V*) *
by - *
degradation - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
is - *
generated generate (V*) *
by - *
we - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
is - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
was - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
within - *
the - *
recombinational - *
synapse - *
. - *

fumarate - (A1*)
was - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
within - *
the - *
recombinational - *
synapse - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
was - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
within - *
the - *
recombinational - *
synapse - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
was - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
was - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

superoxide - (A1*)
was - *
generated generate (V*) *
by - *
nNOS - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

Abeta - (A1*
peptides - *)
was - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
within - *
the - *
recombinational - *
synapse - *
. - *

specific - (A1*
fragments - *)
was - *
generated generate (V*) *
by - *
degradation - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
was - *
generated generate (V*) *
by - *
we - (A0*)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
was - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
within - *
the - *
recombinational - *
synapse - *
. - *

These - *
are - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generating generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
are - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
were - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)was - *)
optimized - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)generates - *)
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)generated - *)
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *)
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *)
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)which - *)
generates generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)which - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)cleaves - *)
microRNA - *
precursors - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)generated - *)
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)which - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)which - *)
generates generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)generates - *)
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
were - *)
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
has - *
been - *
shown - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generates generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
are - *
generated generate (V*) *
from - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)by - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
were - *
generated generate (V*) *
from - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)by - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
have - *
been - *
generated generate (V*) *
from - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)by - *)
beta- - *
and - *
gamma-secretases - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
will - *
be - *
generated generate (V*) *
from - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
)by - *)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *)
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *)
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
that - *
generated generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
EKLF - (A0*
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
( - *
E-RC1 - *
) - *)
that - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

To - (A0*
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *)
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *)
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

These - *
are - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

fumarase - (A0*
B - *)
generating generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
generate generate (V*) *
fumarate - (A1*)
. - *

fumarate - (A1*)
are - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

fumarate - (A1*)
were - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

These - *
are - *
sequential - (A1*
overlapping - *
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
TBC - *
method - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

fumarase - (A0*
Bwas - *)
optimized - *
to - *
generate generate (V*) *
fumarate - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

fumarase - (A0*
B - *)
generates generate (V*) *
fumarate - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*)
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
fumarase - (A0*
B(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*)
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
fumarase - (A0*
B(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

fumarase - (A0*
B - *)
which - *
generates generate (V*) *
fumarate - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

fumarase - (A0*
B - *)
which - *
generated generate (V*) *
fumarate - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

These - *
are - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

fumarase - (A0*
B - *)
cleaves - *
microRNA - *
precursors - *
to - *
generate generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
which - *
generated generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
which - *
generates generate (V*) *
fumarate - (A1*)
. - *

fumarase - (A0*
B - *)
generates generate (V*) *
fumarate - (A1*)
. - *

fumarate - (A1*)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

fumarate - (A1*)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

These - *
are - *
superoxide - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
nNOS - (A0*)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarase - (A0*
B - *)
has - *
been - *
shown - *
to - *
generate generate (V*) *
fumarate - (A1*)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarase - (A0*
B - *)
generates generate (V*) *
fumarate - (A1*)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarate - (A1*)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarate - (A1*)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarate - (A1*)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
fumarate - (A1*)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

These - *
are - *
Abeta - (A1*
peptides - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

fumarate - (A1*)
are - *
generated generate (V*) *
from - *
fumarase - (A0*
Bby - *)
beta- - *
and - *
gamma-secretases - *
. - *

fumarate - (A1*)
were - *
generated generate (V*) *
from - *
fumarase - (A0*
Bby - *)
beta- - *
and - *
gamma-secretases - *
. - *

fumarate - (A1*)
have - *
been - *
generated generate (V*) *
from - *
fumarase - (A0*
Bby - *)
beta- - *
and - *
gamma-secretases - *
. - *

fumarate - (A1*)
will - *
be - *
generated generate (V*) *
from - *
fumarase - (A0*
Bby - *)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
fumarate - (A1*)
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
fumarate - (A1*)
. - *

These - *
are - *
specific - (A1*
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
degradation - (A0*)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
fumarate - (A1*)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
fumarate - (A1*)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
fumarate - (A1*)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
fumarate - (A1*)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
fumarate - (A1*)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
fumarase - (A0*
B - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
fumarate - (A1*)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

These - *
are - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
we - (A0*)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarase - (A0*
B - *)
generated generate (V*) *
fumarate - (A1*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarase - (A0*
B - *)
generate generate (V*) *
fumarate - (A1*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarase - (A0*
B - *)
that - *
generated generate (V*) *
fumarate - (A1*)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarase - (A0*
B - *)
that - *
generate generate (V*) *
fumarate - (A1*)
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarate - (A1*)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
fumarate - (A1*)
was - *
generated generate (V*) *
by - *
us - *
. - *

These - *
are - *
a - (A1*
functional - *
interaction - *
surface - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
sequential - (A1*
overlapping - *
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
TBC - *
method - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
superoxide - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
nNOS - (A0*)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
Abeta - (A1*
peptides - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
specific - (A1*
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
degradation - (A0*)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
we - (A0*)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
functional - *
interaction - *
surface - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
sequential - (A1*
overlapping - *
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
TBC - *
method - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
superoxide - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
nNOS - (A0*)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
Abeta - (A1*
peptides - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
specific - (A1*
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
degradation - (A0*)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
we - (A0*)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
functional - *
interaction - *
surface - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
sequential - (A1*
overlapping - *
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
TBC - *
method - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
superoxide - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
nNOS - (A0*)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
Abeta - (A1*
peptides - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
specific - (A1*
fragments - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
degradation - (A0*)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
we - (A0*)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
a - (A1*
functional - *
interaction - *
surface - *)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

sequential - (A1*
overlapping - *
fragments - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

superoxide - (A1*)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

Abeta - (A1*
peptides - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

specific - (A1*
fragments - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
we - (A0*)
. - *

a - (A1*
functional - *
interaction - *
surface - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

sequential - (A1*
overlapping - *
fragments - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

superoxide - (A1*)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

Abeta - (A1*
peptides - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

specific - (A1*
fragments - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - (A0*)
generated generate (V*) *
by - *
we - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

The - (A0*
TBC - *
method - *)
generating generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRwas - *)
optimized - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *)
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *)
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRwhich - *)
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRwhich - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
generating generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRcleaves - *)
microRNA - *
precursors - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
which - *
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *)
complex - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *)
complex - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

nNOS - (A0*)
generating generate (V*) *
superoxide - (A1*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
has - *
been - *
shown - *
to - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generates generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
generating generate (V*) *
Abeta - (A1*
peptides - *)
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
are - *
generated generate (V*) *
from - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRby - *)
beta- - *
and - *
gamma-secretases - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
were - *
generated generate (V*) *
from - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRby - *)
beta- - *
and - *
gamma-secretases - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
have - *
been - *
generated generate (V*) *
from - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRby - *)
beta- - *
and - *
gamma-secretases - *
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
will - *
be - *
generated generate (V*) *
from - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNRby - *)
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

degradation - (A0*)
generating generate (V*) *
specific - (A1*
fragments - *)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

we - (A0*)
generating generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
that - *
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
that - *
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

To - (A0*
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *)
tissues - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *)
tissues - *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generating generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

The - (A0*
TBC - *
method - *)
 - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

we - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

The - (A0*
TBC - *
method - *)
 - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

nNOS - (A0*)
generate generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradation - (A0*)
generate generate (V*) *
specific - (A1*
fragments - *)
. - *

we - (A0*)
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
are - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

superoxide - (A1*)
are - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

Abeta - (A1*
peptides - *)
are - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

specific - (A1*
fragments - *)
are - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
are - *
generated generate (V*) *
by - *
we - (A0*)
. - *

a - (A1*
functional - *
interaction - *
surface - *)
are - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
were - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

superoxide - (A1*)
were - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

Abeta - (A1*
peptides - *)
were - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
. - *

specific - (A1*
fragments - *)
were - *
generated generate (V*) *
by - *
degradation - (A0*)
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
were - (A0*)
generated generate (V*) *
by - *
we - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
were - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
was - *
optimized - *
to - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
TBC - *
method - *)
cleaves - *
microRNA - *
precursors - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
TBC - *
method - *)
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
TBC - *
method - *)
which - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
TBC - *
method - *)
which - *
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

The - (A0*
TBC - *
method - *)
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

nNOSwas - (A0*)
optimized - *
to - *
generate generate (V*) *
superoxide - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
TBC - *
method - *)
 - *
has - *
been - *
shown - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
TBC - *
method - *)
 - *
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
TBC - *
method - *)
 - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
sequential - (A1*
overlapping - *
fragments - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
 - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
was - *
optimized - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
from - *
The - (A0*
TBC - *
method - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
from - *
The - (A0*
TBC - *
method - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
have - *
been - *
generated generate (V*) *
from - *
The - (A0*
TBC - *
method - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

sequential - (A1*
overlapping - *
fragments - *)
will - *
be - *
generated generate (V*) *
from - *
The - (A0*
TBC - *
method - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

degradationwas - (A0*)
optimized - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
sequential - (A1*
overlapping - *
fragments - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
sequential - (A1*
overlapping - *
fragments - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
sequential - (A1*
overlapping - *
fragments - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
TBC - *
method - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
sequential - (A1*
overlapping - *
fragments - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

wewas - (A0*)
optimized - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
TBC - *
method - *)
 - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
TBC - *
method - *)
 - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
TBC - *
method - *)
 - *
that - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
TBC - *
method - *)
 - *
that - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
sequential - (A1*
overlapping - *
fragments - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*
analyse - *)
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
sequential - (A1*
overlapping - *
fragments - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
towas - *)
optimized - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

nNOS - (A0*)
generates generate (V*) *
superoxide - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
generates generate (V*) *
Abeta - (A1*
peptides - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

degradation - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

we - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
generated generate (V*) *
Abeta - (A1*
peptides - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

we - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*)
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
nNOS(approximately - (A0*)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - *)
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - *)
overlapping - *
fragments - *
were - *
generated generate (V*) *
by - *
degradation(approximately - (A0*)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
were - (A0*)
generated generate (V*) *
by - *
we(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*)
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
nNOS(approximately - (A0*)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - *)
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - *)
overlapping - *
fragments - *
are - *
generated generate (V*) *
by - *
degradation(approximately - (A0*)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
we(approximately - (A0*)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to(approximately - *)
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

nNOSwhich - (A0*)
generates generate (V*) *
superoxide - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generates generate (V*) *
Abeta - (A1*
peptides - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

degradationwhich - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

wewhich - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
towhich - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

nNOSwhich - (A0*)
generated generate (V*) *
superoxide - (A1*)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

degradationwhich - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

wewhich - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
towhich - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

nNOScleaves - (A0*)
microRNA - *
precursors - *
to - *
generate generate (V*) *
superoxide - (A1*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
has - *
been - *
shown - *
to - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
cleaves - *
microRNA - *
precursors - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
are - *
generated generate (V*) *
from - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
were - *
generated generate (V*) *
from - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
have - *
been - *
generated generate (V*) *
from - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
will - *
be - *
generated generate (V*) *
from - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *)
precursor - *
proteins - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *)
precursor - *
proteins - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

degradationcleaves - (A0*)
microRNA - *
precursors - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
does - *
not - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
or - *
occurs - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

wecleaves - (A0*)
microRNA - *
precursors - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
that - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
 - *
that - *
generate generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

To - *)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - *)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
tocleaves - *)
microRNA - *
precursors - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

we - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

nNOSwhich - (A0*)
generated generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradationwhich - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
. - *

wewhich - (A0*)
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
towhich - *)
generated generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

nNOSwhich - (A0*)
generates generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
which - *
generates generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradationwhich - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
. - *

wewhich - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
towhich - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

nNOS - (A0*)
generates generate (V*) *
superoxide - (A1*)
. - *

proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
generates generate (V*) *
Abeta - (A1*
peptides - *)
. - *

degradation - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
. - *

we - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
. - *

superoxide - (A1*)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

We - *
believe - *
this - (A0*
binding - *)
is - *
required - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
this - (A0*
binding - *)
is - *
found - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - *
believe - *
this - (A0*
binding - *)
is - *
shown - *
to - *
generate generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

this - (A0*
binding - *)
generates generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

this - (A0*
binding - *)
generated generate (V*) *
a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
is - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
within - *
the - *
recombinational - *
synapse - *
. - *

a - (A1*
higher - *
order - *
protein-DNA - *
complex - *)
was - *
generated generate (V*) *
by - *
this - (A0*
binding - *)
within - *
the - *
recombinational - *
synapse - *
. - *

We - (A0*
show - *
that - *
EKLF - *
requires - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *)
1 - *
(E-RC1) - *
to - *
generate generate (V*) *
a - (A1*
DNase - *
I - *
hypersensitive - *
transcriptionally - *
active - *
beta-globin - *
promoter - *
on - *
chromatin - *
templates - *
in - *
vitro - *)
. - *

a - (A1*
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
(E-RC1) - *
generated - *)
a - *
DNase - *)
I - *
hypersensitive - *
. - *

a - (A1*
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *
complex - *
1 - *
(E-RC1) - *
generates - *)
a - *
DNase - *)
I - *
hypersensitive - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
is - *
generated generate (V*) *
by - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *)
complex - *
1 - *
(E-RC1) - *
. - *

a - (A1*
DNase - *
I - *
hypersensitive - *
was - *
generated generate (V*) *
by - *
a - *
SWI/SNF-related - *
chromatin - *
remodeling - *
complex - *
EKLF - *
coactivator-remodeling - *)
complex - *
1 - *
(E-RC1) - *
. - *

These - *
are - *
fumarate - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
fumarase - (A0*
B - *)
which - *
generates generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
fumarate - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
fumarase - (A0*
B - *)
which - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
fumarate - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
fumarase - (A0*
B - *)
which - *
has - *
generated generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

These - *
are - *
fumarate - (A1*)
reductase - *
(encoded - *
by - *
the - *
frdABCD - *
operon - *
fumarase - (A0*
B - *)
which - *
will - *
generate generate (V*) *
fumarate - *
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
. - *

fumarate - (A1*)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
are - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

fumarate - (A1*)
from - *
malate - *
and - *
the - *
DcuB - *
permease - *
for - *
fumarate - *
malate - *
and - *
aspartate - *
were - *
generated generate (V*) *
by - *
fumarase - (A0*
B - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generating generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generated generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
generate generate (V*) *
spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
are - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

spectral - (A1*
changes - *
consistent - *
with - *
formation - *
of - *
a - *
dinitrosyl-iron-cysteine - *
complex - *)
were - *
generated generate (V*) *
by - *
NO - (A0*
reacts - *
anaerobically - *
with - *
the - *
Fe-S - *
cluster - *
of - *
purified - *
FNR - *)
. - *

The - (A0*
TBC - *
method - *)
was - *
optimized - *
to - *
generate generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
TBC - *
method - *)
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
TBC - *
method - *)
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
were - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

Sequential - (A1*
overlapping - *
fragments - *)
are - *
generated generate (V*) *
by - *
The - (A0*
TBC - *
method - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
TBC - *
method - *)
which - *
generates generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
TBC - *
method - *)
which - *
generated generate (V*) *
sequential - (A1*
overlapping - *
fragments - *)
(approximately - *
04-05 - *
kb) - *
for - *
each - *
of - *
the - *
gene - *
sequences - *
and - *
simultaneous - *
and - *
sequential - *
combinations - *
of - *
overlapping - *
fragments - *
were - *
tested - *
for - *
their - *
ability - *
to - *
be - *
assembled - *
under - *
an - *
array - *
of - *
PCR - *
conditions - *
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generated generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
which - *
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
generates generate (V*) *
the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
are - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
. - *

the - (A1*
21-23 - *
nt - *
long - *
mature - *
RNAs - *)
were - *
generated generate (V*) *
by - *
The - (A0*
bidentate - *
RNase - *
III - *
Dicer - *)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
nNOS - (A0*)
generates generate (V*) *
superoxide - (A1*)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
nNOS - (A0*)
generated generate (V*) *
superoxide - (A1*)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
superoxide - (A1*)
(O(2)-) - *
is - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
superoxide - (A1*)
(O(2)-) - *
was - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
superoxide - (A1*)
(O(2)-) - *
has - *
been - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
superoxide - (A1*)
(O(2)-) - *
will - *
be - *
generated generate (V*) *
by - *
nNOS - (A0*)
. - *

Abeta - (A1*
peptides - *)
were - *
generated generate (V*) *
from - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

Abeta - (A1*
peptides - *)
have - *
been - *
generated generate (V*) *
from - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

Abeta - (A1*
peptides - *)
will - *
be - *
generated generate (V*) *
from - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
by - *
beta- - *
and - *
gamma-secretases - *
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
. - *

proteolysis - *)
of - *
the - *
amyloid - *
precursor - *
proteins - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
degradation - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
degradation - *
did - *
not - *
generate generate (V*) *
specific - (A1*
fragments - *)
or - *
occured - *
rapidly - *
precludes - *
any - *
definitive - *
conclusions - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
degradation - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
specific - (A1*
fragments - *)
were - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
degradation - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
specific - (A1*
fragments - *)
are - *
not - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
degradation - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
specific - (A1*
fragments - *)
have - *
not - *
been - *
generated generate (V*) *
by - *
degradation - *
. - *

In - *
addition - *
there - *
was - *
an - *
apparent - *
absence - *
of - *
lower - *
molecular - *
weight - *
fragments - *
as - *
evidence - *
of - *
degradation - (A0*)
although - *
again - *
the - *
relatively - *
small - *
fraction - *
involved - *
and - *
the - *
possibility - *
that - *
specific - (A1*
fragments - *)
will - *
not - *
be - *
generated generate (V*) *
by - *
degradation - *
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
we - (A0*)
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
we - (A0*)
that - *
generated generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

To - *
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
we - (A0*)
that - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
is - *
generated generate (V*) *
by - *
us - *
. - *

To - (A0*)
analyse - *
specifically - *
protein - *
expression - *
of - *
FHL2 - *
in - *
human - *
tissues - *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
was - *
generated generate (V*) *
by - *
us - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
L723 - *
in - *
H3 - *
generates generate (V*) *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
L723 - *
in - *
H3 - *
generated generate (V*) *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
are - *
generated generate (V*) *
by - *
L723 - *
in - *
H3 - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
were - *
generated generate (V*) *
by - *
L723 - *
in - *
H3 - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
will - *
be - *
generated generate (V*) *
by - *
L723 - *
in - *
H3 - *
. - *

Although - (A1*
no - *
crystal - *
structure - *)
of - *
the - *
AR - *
is - *
available - *
to - *
date - *
one - *
might - *
speculate - *
that - *
the - *
correct - *
three-dimensional - *
interaction - *
surface - *
has - *
been - *
generated generate (V*) *
by - *
L723 - *
in - *
H3 - *
. - *

Abeta - (A1*
peptides - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

specific - (A1*
fragments - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
are - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

superoxide - (A1*)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

Abeta - (A1*
peptides - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *)
RNase - *
III - *
Dicer - *
. - *

specific - (A1*
fragments - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
were - (A0*)
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

a - (A1*
functional - *
interaction - *
surface - *)
were - *
generated generate (V*) *
by - *
The - *
bidentate - *
RNase - *
III - *
Dicer - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
has - *
been - *
shown - *
to - *
generate generate (V*) *
Abeta - (A1*
peptides - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
degradation - (A0*)
has - *
been - *
shown - *
to - *
generate generate (V*) *
specific - (A1*
fragments - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
we - (A0*)
has - *
been - *
shown - *
to - *
generate generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
has - *
been - *
shown - *
to - *
generate generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generates generate (V*) *
Abeta - (A1*
peptides - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
degradation - (A0*)
generates generate (V*) *
specific - (A1*
fragments - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
we - (A0*)
generates generate (V*) *
a - (A1*
monoclonal - *
antibody - *
against - *
FHL2 - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
the - (A0*
AR - *
N-terminus - *
is - *
required - *
to - *)
generates generate (V*) *
a - (A1*
functional - *
interaction - *
surface - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
proteolysis - (A0*
of - *
the - *
amyloid - *
precursor - *
proteins - *
(APP) - *)
 - *
generated generate (V*) *
Abeta - (A1*
peptides - *)
(O(2)-) - *
. - *

In - *
the - *
absence - *
of - *
L-arginine - *
degradation - (A0*)
generated generate (V*) *
specific - (A1*
fragments - *)
(O(2)-) - *
. - *

We - *
report - *
results - *
from - *
preliminary - *
transcription - *
microarray - *
experiments - *
that - *
revealed - *
two - *
previously - *
unknown - *
members - *
of - *
the - *
NarL - *
regulon: - *
the - *
aspA - *
gene - *
encoding - *
aspartate-ammonia - (A0*
lyase - *)
which - *
generates generate (V*) *
fumarate; - (A1*)
and - *
the - *
dcuSR - *
operon - *
encoding - *
the - *
dicarboxylate-responsive - *
regulatory - *
system - *
. - *

We - *
report - *
results - *
from - *
preliminary - *
transcription - *
microarray - *
experiments - *
that - *
revealed - *
two - *
previously - *
unknown - *
members - *
of - *
the - *
NarL - *
regulon: - *
the - *
aspA - *
gene - *
encoding - *
aspartate-ammonia - (A0*
lyase - *)
which - *
generated generate (V*) *
fumarate; - (A1*)
and - *
the - *
dcuSR - *
operon - *
encoding - *
the - *
dicarboxylate-responsive - *
regulatory - *
system - *
. - *

We - *
report - *
results - *
from - *
preliminary - *
transcription - *
microarray - *
experiments - *
that - *
revealed - *
two - *
previously - *
unknown - *
members - *
of - *
the - *
NarL - *
regulon: - *
the - *
aspA - *
gene - *
encoding - *
aspartate-ammonia - (A0*
lyase - *)
generating generate (V*) *
fumarate; - (A1*)
and - *
the - *
dcuSR - *
operon - *
encoding - *
the - *
dicarboxylate-responsive - *
regulatory - *
system - *
. - *

We - *
report - *
results - *
from - *
preliminary - *
transcription - *
microarray - *
experiments - *
that - *
revealed - *
two - *
previously - *
unknown - *
members - *
of - *
the - *
NarL - *
regulon: - *
the - *
aspA - *
gene - *
encoding - *
aspartate-ammonia - (A0*
lyase - *)
which - *
has - *
generated generate (V*) *
fumarate; - (A1*)
and - *
the - *
dcuSR - *
operon - *
encoding - *
the - *
dicarboxylate-responsive - *
regulatory - *
system - *
. - *

We - *
report - *
results - *
from - *
preliminary - *
transcription - *
microarray - *
experiments - *
that - *
revealed - *
two - *
previously - *
unknown - *
members - *
of - *
the - *
NarL - *
regulon: - *
the - *
aspA - *
gene - *
encoding - *
aspartate-ammonia - (A0*
lyase - *)
will - *
generate generate (V*) *
fumarate; - (A1*)
and - *
the - *
dcuSR - *
operon - *
encoding - *
the - *
dicarboxylate-responsive - *
regulatory - *
system - *
. - *

Prnd - (A0*)
generated generate (V*) *
major - (A1*
transcripts - *
of - *
17 - *
and - *
27 - *
kb - *
as - *)
well - *
as - *
some - *
unusual - *
chimeric - *
transcripts - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Major - (A1*
transcripts - *
of - *
17 - *
and - *
27 - *
are - *)
generated generate (V*) *
by - *
Prnd - *
as - *
some - *
unusual - *
chimeric - *
transcripts - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Major - (A1*
transcripts - *
of - *
17 - *
and - *
27 - *
were - *)
generated generate (V*) *
by - *
Prnd - *
as - *
some - *
unusual - *
chimeric - *
transcripts - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*)
which - *
generate generate (V*) *
major - (A1*
transcripts - *
of - *
17 - *
and - *
27 - *
kb - *
as - *)
well - *
as - *
some - *
unusual - *
chimeric - *
transcripts - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*)
which - *
generated generate (V*) *
major - (A1*
transcripts - *
of - *
17 - *
and - *
27 - *
kb - *
as - *)
well - *
as - *
some - *
unusual - *
chimeric - *
transcripts - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
intergenic - *
splicing - *
with - *
Prnp - *
which - *
generated - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
intergenic - *
splicing - *
with - *
Prnp - *
generate - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
are - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
were - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
have - *
been - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

Prnd - (A0*
generates generate (V*) *
major - *
transcripts - *)
of - *
17 - *
and - *
27 - *
kb - *
as - *
well - *
as - *
some - (A1*
unusual - *
chimeric - *
transcripts - *)
will - *
be - *
generated - *
by - *
intergenic - *
splicing - *
with - *
Prnp - *
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
to - *
generate generate (V*) *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
generates generate (V*) *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
generated generate (V*) *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
is - *
generated generate (V*) *
by - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
was - *
generated generate (V*) *
by - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
has - *
been - *
generated generate (V*) *
by - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
. - *

A - (A0*
transcription - *
start - *
site - *
is - *
located - *
approximately - *
4 - *
kilobases - *)
5 - *
to - *
the - *
translation - *
codon - *
and - *
mature - (A1*
HeLa - *
cell - *
mRNA - *)
will - *
be - *
generated generate (V*) *
by - *
an - *
RNA - *
splice - *
of - *
3863 - *
bases - *
occurs - *
in - *
the - *
5-untranslated - *
region - *
. - *

Human - (A1*
leukocyte - *
antigen - *
(HLA)-G - *
molecules - *)
were - *
generated generate (V*) *
by - *
an - (A0*
alternative - *
splicing - *
of - *
the - *
primary - *
transcript - *
of - *
the - *
gene - *)
and - *
display - *
specialized - *
function - *
in - *
regulating - *
the - *
immune - *
response - *
. - *

Human - (A1*
leukocyte - *
antigen - *
(HLA)-G - *
molecules - *)
have - *
been - *
generated generate (V*) *
by - *
an - (A0*
alternative - *
splicing - *
of - *
the - *
primary - *
transcript - *
of - *
the - *
gene - *)
and - *
display - *
specialized - *
function - *
in - *
regulating - *
the - *
immune - *
response - *
. - *

Human - (A1*
leukocyte - *
antigen - *
(HLA)-G - *
molecules - *)
will - *
be - *
generated generate (V*) *
by - *
an - (A0*
alternative - *
splicing - *
of - *
the - *
primary - *
transcript - *
of - *
the - *
gene - *)
and - *
display - *
specialized - *
function - *
in - *
regulating - *
the - *
immune - *
response - *
. - *

an - (A0*
alternative - *
splicing - *
of - *
the - *
primary - *
transcript - *
of - *
the - *
gene - *)
generated generate (V*) *
Human - (A1*
leukocyte - *
antigen - *
(HLA)-G - *
molecules - *)
. - *

an - (A0*
alternative - *
splicing - *
of - *
the - *
primary - *
transcript - *
of - *
the - *
gene - *)
generates generate (V*) *
Human - (A1*
leukocyte - *
antigen - *
(HLA)-G - *
molecules - *)
. - *

The - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
is - *
generated generate (V*) *
by - *
mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
FLAG - *
epitope - *
is - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

The - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
have - *
been - *
generated generate (V*) *
by - *
mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
FLAG - *
epitope - *
was - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

The - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
will - *
be - *
generated generate (V*) *
by - *
mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
FLAG - *
epitope - *
is - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
generated generate (V*) *
the - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
FLAG - *
epitope - *
was - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
generate generate (V*) *
the - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
FLAG - *
epitope - *
was - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
which - *
generated generate (V*) *
the - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
FLAG - *
epitope - *
was - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

mutating - (A0*
amino - *
acids - *
EE - *
(437 - *
and - *
438) - *
to - *
AA - *)
which - *
generate generate (V*) *
the - (A1*
DNA-binding - *
mutant - *
(Stat5aEE-AA) - *
of - *
Stat5a - *)
FLAG - *
epitope - *
was - *
added - *
to - *
the - *
C-terminus - *
of - *
Stat5aEE-AA - *
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
with - (A0*
10mM - *
EDTA - *)
will - *
inhibit inhibit (V*) *
Binding - (A2*)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
has - *
inhibited inhibit (V*) *
Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
. - *

GadX-dependent - (A2*
activation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
GadW - (A0*)
. - *

GadX-dependent - (A2*
activation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
GadW - (A0*)
. - *

GadX-dependent - (A2*
activation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
GadW - (A0*)
. - *

GadX-dependent - (A2*
activation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
GadW - (A0*)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
Nitric - (A0*
oxide - *)
has - *
inhibited inhibit (V*) *
platelet - (A2*
function - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
has - *
inhibited inhibit (V*) *
NK-cell-mediated - (A2*
cytotoxicity - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
has - *
inhibited inhibit (V*) *
the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
has - *
inhibited inhibit (V*) *
intermediate - (A2*
events - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
has - *
inhibited inhibit (V*) *
late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
with - (A0*
10mM - *
EDTA - *)
has - *
inhibited inhibit (V*) *
Binding - (A2*)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
that - *
inhibits inhibit (V*) *
Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
Nitric - (A0*
oxide - *)
that - *
inhibits inhibit (V*) *
platelet - (A2*
function - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
that - *
inhibits inhibit (V*) *
NK-cell-mediated - (A2*
cytotoxicity - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
that - *
inhibits inhibit (V*) *
the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
that - *
inhibits inhibit (V*) *
intermediate - (A2*
events - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
that - *
inhibits inhibit (V*) *
late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
with - (A0*
10mM - *
EDTA - *)
that - *
inhibits inhibit (V*) *
Binding - (A2*)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
that - *
will - *
inhibit inhibit (V*) *
Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
Nitric - (A0*
oxide - *)
that - *
will - *
inhibit inhibit (V*) *
platelet - (A2*
function - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
that - *
will - *
inhibit inhibit (V*) *
NK-cell-mediated - (A2*
cytotoxicity - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
that - *
will - *
inhibit inhibit (V*) *
the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
that - *
will - *
inhibit inhibit (V*) *
intermediate - (A2*
events - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
that - *
will - *
inhibit inhibit (V*) *
late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
with - (A0*
10mM - *
EDTA - *)
that - *
will - *
inhibit inhibit (V*) *
Binding - (A2*)
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
inhibits inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
inhibits inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
inhibited inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
inhibited inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
will - *
inhibit inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
will - *
inhibit inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
has - *
inhibited inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
has - *
inhibited inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
which - *
inhibits inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
which - *
inhibits inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

Here - (A2*
we - *
show - *
that - *)
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
phosphatase - *)
which - *
inhibited inhibit (V*) *
the - *
another - (A1*
protein - *)
 - *
activity - *
. - *

Here - (A2*
we - *)
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
chloramphenicol - (A0*)
which - *
inhibited inhibit (V*) *
the - *
them - (A1*)
activity - *
. - *

by - (A1*
rolipram - *)
inhibits inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *)
by - *
21-fold - *
. - *

protein - *)
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
inhibits inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

by - (A1*
rolipram - *)
inhibited inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *)
by - *
21-fold - *
. - *

protein - (A1*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
inhibited - *)
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

by - (A1*
rolipram - *)
will - *
inhibit inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *)
strongly - *
by - *
21-fold - *
. - *

protein - (A1*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
will - *
inhibit - *)
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

by - (A1*
rolipram - *)
has - *
inhibited inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *)
strongly - *
by - *
21-fold - *
. - *

protein - (A1*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
has - *
inhibited - *)
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
is - *)
inhibited inhibit (V*) *
by - *
by - (A0*
rolipram - *)
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
is - *
inhibited - *)
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
was - *)
inhibited inhibit (V*) *
by - *
by - (A0*
rolipram - *)
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
was - *
inhibited - *)
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
 - *
. - *

platelet - (A2*
function - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
Nitric - (A0*
oxide - *)
. - *

NK-cell-mediated - (A2*
cytotoxicity - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
. - *

the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
. - *

intermediate - (A2*
events - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
. - *

late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
. - *

Binding - (A2*)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
with - (A0*
10mM - *
EDTA - *)
. - *

platelet - (A2*
function - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
Nitric - (A0*
oxide - *)
. - *

NK-cell-mediated - (A2*
cytotoxicity - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
. - *

the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
. - *

intermediate - (A2*
events - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
. - *

late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
. - *

Binding - (A2*)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
with - (A0*
10mM - *
EDTA - *)
. - *

platelet - (A2*
function - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
Nitric - (A0*
oxide - *)
. - *

NK-cell-mediated - (A2*
cytotoxicity - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
. - *

the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
. - *

intermediate - (A2*
events - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
inhibits inhibit (V*) *
intermediate - (A2*
events - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
inhibits inhibit (V*) *
late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
with - (A0*
10mM - *
EDTA - *)
inhibits inhibit (V*) *
Binding - (A2*)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
will - *
inhibit inhibit (V*) *
Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
Nitric - (A0*
oxide - *)
will - *
inhibit inhibit (V*) *
platelet - (A2*
function - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
will - *
inhibit inhibit (V*) *
NK-cell-mediated - (A2*
cytotoxicity - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
will - *
inhibit inhibit (V*) *
the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
will - *
inhibit inhibit (V*) *
intermediate - (A2*
events - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
will - *
inhibit inhibit (V*) *
late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
is - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
was - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
will - *
be - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
which - *
is - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
which - *
was - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
is - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
was - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
has - *
been - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
will - *
be - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
which - *
is - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Transcription - (A1*
of - *
ptsG - *
encoding - *
glucose-specific - *
permease - *)
enzyme - *
IICB - *
(Glc) - *
in - (A3*
Escherichia - *
coli - *)
which - *
was - *
initiated - *
from - (A2*
two - *
promoters - *
P1 - *
and - *
P2 - *)
. - *

Moreover - *
Dam - (A0*
methylation - *)
inhibited inhibit (V*) *
binding - (A2*
of - *
Lrp/PapI - *)
near - *
the - *
GATC1028 - *
site - *
and - *
alters - *
binding - *
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *
. - *

Moreover - *
Dam - (A0*
methylation - *)
will - *
inhibit inhibit (V*) *
binding - (A2*
of - *
Lrp/PapI - *)
near - *
the - *
GATC1028 - *
site - *
and - *
alters - *
binding - *
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *
. - *

Moreover - *
Dam - (A0*
methylation - *)
has - *
inhibited inhibit (V*) *
binding - (A2*
of - *
Lrp/PapI - *)
near - *
the - *
GATC1028 - *
site - *
and - *
alters - *
binding - *
of - *
Lrp - *
at - *
the - *
GATC1130 - *
site - *
. - *

In - (A2*
addition - *
the - *)
AR - *
N-terminus - *
generates - *
a - *
functional - *
interaction - *
surface - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

In - (A2*
addition - *
the - *)
AR - *
N-terminus - *
generated - *
a - *
functional - *
interaction - *
surface - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

a - (A2*
functional - *
interaction - *)
surface - *
is - *
generated - *
by - *
the - *
AR - *
N-terminus - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

a - (A2*
functional - *
interaction - *)
surface - *
was - *
generated - *
by - *
the - *
AR - *
N-terminus - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

In - (A2*
addition - *
the - *)
AR - *
N-terminus - *
that - *
generates - *
a - *
functional - *
interaction - *
surface - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

In - (A2*
addition - *
the - *)
AR - *
N-terminus - *
that - *
generated - *
a - *
functional - *
interaction - *
surface - *
since - *
its - *
deletion - *
abolishes - *
FHL2 - *
binding - *
. - *

PDE4C - *)
is - *)
one - *
of - *
four - *
mammalian - *
genes - *
that - *
encode - *
multiple - *
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *
that - *
were - *
inhibited inhibit (V*) *
by - *
rolipram - *
. - *

Natural - (A1*
killer - *
(NK) - *
cells - *
express - *
cell-surface - *)
receptors - *
of - *)
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *
that - *
recognized - *
major - *
histocompatibility - *
complex - *
(MHC) - *
class - *
I - *
peptides - *
and - *
inhibited inhibit (V*) *
NK-cell-mediated - *
cytotoxicity - *
. - *

The - (A2*
N-terminal - *
SH3 - *
domain - *
(SH3A) - *
unlike - *)
other - *
SH3 - *
domains - *
from - *
intersectin - *
or - *
various - *
endocytic - *
proteins - *
specifically - *
inhibited inhibit (V*) *
intermediate - *)
events - *
leading - *
to - *
the - *
formation - *
of - *
clathrin-coated - *
pits - *
. - *

Intriguingly - *)
while - *
the - *
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
(de - *
Heuvel - *
et - *
al - *
1997; - *
Ringstad - *
et - *
al - *
1997) - *
amphiphysin - *
II - *
(Ramjaun - *
et - *
al - *
1997) - *
and - *
syndaphin - *
I - *
(Qualmann - *
et - *
al - *
1999) - *
selectively - *
inhibited inhibit (V*) *
late - *
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *
involving - *
membrane - *
fission - *
intersectin - *
SH3A - *
was - *
unique - *
in - *
its - *
ability - *
to - *
block - *
earlier - *
stages - *
(Simpson - *
et - *
al - *
1999) - *
. - *

Transcription - (A3*
of - *
the - *
divergently - *
transcribed - *
glpTQ - *)
and - *
glpACB - *
operons - *)
has - *
been - *
initiated - *
at - *
sites - *
separated - *
by - *
132 - *
base - *
pairs - *
(bp) - *
of - *
DNA - *
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
is - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

Polymerases - (A3*
that - *
initiate - *
transcription - (A1*)
with - *
RSF - *
can - *
only - *
extend - *)
their - *
transcripts - *
in - *
the - *
presence - *
of - *
FACT - *
(facilitates - *
chromatin - *
transcription) - *
. - *

Polymerases - (A3*
that - *
initiated - *
transcription - (A1*)
with - *
RSF - *
can - *
only - *
extend - *)
their - *
transcripts - *
in - *
the - *
presence - *
of - *
FACT - *
(facilitates - *
chromatin - *
transcription) - *
. - *

Polymerases - (A3*
that - *
will - *
initiate - *
transcription - (A1*)
with - *
RSF - *
can - *
only - *)
extend - *
their - *
transcripts - *
in - *
the - *
presence - *
of - *
FACT - *
(facilitates - *
chromatin - *
transcription) - *
. - *

Polymerases - (A3*
that - *
has - *
initiated - *
transcription - (A1*)
with - *
RSF - *
can - *
only - *)
extend - *
their - *
transcripts - *
in - *
the - *
presence - *
of - *
FACT - *
(facilitates - *
chromatin - *
transcription) - *
. - *

transcription - *)
was - *
initiated - *
by - *
Polymerases - (A0*)
in - *
the - *
presence - *
of - *
FACT - *
(facilitates - *
chromatin - *
transcription) - *
. - *

transcription - (A3*
is - *
initiated - *
by - *
Polymerases - (A0*)
in - *
the - *
presence - *
of - *
FACT - *)
(facilitates - *
chromatin - *
transcription) - *
. - *

The - (A1*
repression - *)
is - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

The - (A1*
repression - *)
was - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

The - (A1*
repression - *)
has - *
been - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

The - (A1*
repression - *)
will - *
be - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

The - (A1*
repression - *)
which - *
is - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

The - (A1*
repression - *)
which - *
was - *
initiated - *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

Transcription - (A2*
was - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

Transcription - (A2*
is - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

Transcription - (A2*
which - *
was - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

Transcription - (A2*
which - *
is - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

Transcription - (A2*
will - *
be - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

Transcription - (A2*
has - *
been - *
initiated - *)
from - *
a - *
sigma - *
(70) - *
-dependent - *
promoter - *
at - *
the - *
G - *
residue - *
of - *
the - *
upstream - *
GATC - *
sequence - *
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
GadW - (A0*)
inhibits inhibit (V*) *
GadX-dependent - (A2*
activation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
GadW - (A0*)
will - *
inhibit inhibit (V*) *
GadX-dependent - (A2*
activation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
GadW - (A0*)
has - *
inhibited inhibit (V*) *
GadX-dependent - (A2*
activation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
GadW - (A0*)
that - *
inhibits inhibit (V*) *
GadX-dependent - (A2*
activation - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
GadW - (A0*)
that - *
will - *
inhibit inhibit (V*) *
GadX-dependent - (A2*
activation - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
inhibits inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
inhibited inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
will - *
inhibit inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
has - *
inhibited inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
which - *
inhibits inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

Here - *
we - *
show - *
that - *
glnAp2 - *
expression - *
is - *
affected - *
by - *
different - *
carbon - *
sources - *
and - *
that - *
the - (A0*
CRP-cAMP - *
complex - *)
which - *
inhibited inhibit (V*) *
the - (A2*
glnAp2 - (A1*
promoter - *)
activity - *)
. - *

CRP-cAMP - *)
inhibits inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

CRP-cAMP - (A1*
inhibited inhibit (V*) *
sigma - *)
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

CRP-cAMP - (A1*
will - *
inhibit inhibit (V*) *
sigma - *)
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

CRP-cAMP - (A1*
has - *
inhibited inhibit (V*) *
sigma - *)
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *)
strongly - *
by - *
21-fold - *
is - *
inhibited inhibit (V*) *
by - *
CRP-cAMP - (A0*)
. - *

sigma - (A1*
(54) - *
-dependent - *
glnAp2 - *)
strongly - *
by - *
21-fold - *
was - *
inhibited inhibit (V*) *
by - *
CRP-cAMP - (A0*)
. - *

Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
was - *
also - *
inhibited inhibit (V*) *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
. - *

Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
is - *
also - *
inhibited inhibit (V*) *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
. - *

Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
. - *

Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
. - *

This - (A1*
synthetic - *
peptide - *
binds - *
to - *
P - *
and - *
inhibits inhibit (V*) *
its - *
binding - *)
to - *
C3b - *
. - *

This - (A1*
synthetic - *
peptide - *
bound - *
to - *
P - *
which - *
inhibited inhibit (V*) *
its - *)
binding - *
to - *
C3b - *
. - *

This - (A1*
synthetic - *
peptide - *
binds - *
to - *
P - *
which - *
inhibits inhibit (V*) *
its - *)
binding - *
to - *
C3b - *
. - *

rolipram - *)
inhibited inhibit (V*) *
multiple - *
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *
. - *

rolipram - *)
inhibits inhibit (V*) *
multiple - *
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *
. - *

rolipram - *)
which - *
inhibited inhibit (V*) *
multiple - *
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *
. - *

rolipram - *)
that - *
inhibits inhibit (V*) *
multiple - *
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *
. - *

Nitric - (A2*
oxide - *
(NO) - *)
activated - *
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *)
in - *
platelets - *
and - *
inhibited inhibit (V*) *
platelet - *
function - *
. - *

platelet - (A2*
function - *)
are - *
inhibited inhibit (V*) *
by - *
Nitric - *
oxide - *
(NO) - *
activates - *
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *
in - *
platelets - *
. - *

platelet - (A2*
function - *)
were - *
inhibited inhibit (V*) *
by - *
Nitric - *
oxide - *
(NO) - *
activates - *)
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *
in - *
platelets - *
. - *

platelet - (A2*
function - *)
has - *
been - *
inhibited inhibit (V*) *
by - *
Nitric - *
oxide - *
(NO) - *
activates - *)
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *
in - *
platelets - *
. - *

platelet - (A2*
function - *)
will - *
be - *
inhibited inhibit (V*) *
by - *
Nitric - *
oxide - *
(NO) - *
activates - *)
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *
in - *
platelets - *
. - *

Nitric - (A2*
oxide - *
(NO) - *)
activates - *
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *)
in - *
platelets - *
that - *
inhibits inhibit (V*) *
platelet - *
function - *
. - *

Nitric - (A2*
oxide - *
(NO) - *)
activated - *
the - *
soluble - *
isoform - *
of - *
guanylate - *
cyclase - *)
in - *
platelets - *
that - *
inhibited inhibit (V*) *
platelet - *
function - *
. - *

NK-cell-mediated - (A1*
cytotoxicity - *
was - *
inhibited - *)
by - *
cell-surface - *)
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *
. - *

NK-cell-mediated - (A1*
cytotoxicity - *
is - *
inhibited - *)
by - *
cell-surface - *)
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *
. - *

NK-cell-mediated - (A1*
cytotoxicity - *
has - *
been - *
inhibited - *)
by - *
cell-surface - *)
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *
. - *

NK-cell-mediated - (A1*
cytotoxicity - *
will - *
be - *
inhibited - *)
by - *
cell-surface - *)
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *
. - *

Transient - *)
overexpression - *
in - *
COS - *
cells - *)
verified - *
that - *
a - *
heat-stable - *
inhibitor - *
of - *
protein - *
kinase - *
is - *
produced - *
by - *
he - *
human - *
PKI - *
cDNA - *
and - *
protein - *
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *
inhibit inhibit (V*) *
both - *
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *
with - *
equal - *
efficacy - *
. - *

Transient - *)
overexpression - *
in - *
COS - *
cells - *)
verified - *
that - *
a - *
heat-stable - *
inhibitor - *
of - *
protein - *
kinase - *
is - *
produced - *
by - *
he - *
human - *
PKI - *
cDNA - *
both - *
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *
were - *
inhibited inhibit (V*) *
by - *
protein - *
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *
. - *

Transient - *)
overexpression - *
in - *
COS - *
cells - *)
verified - *
that - *
a - *
heat-stable - *
inhibitor - *
of - *
protein - *
kinase - *
is - *
produced - *
by - *
he - *
human - *
PKI - *
cDNA - *
both - *
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *
are - *
inhibited inhibit (V*) *
by - *
protein - *
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *
. - *

Transient - *)
overexpression - *
in - *
COS - *
cells - *)
verified - *
that - *
a - *
heat-stable - *
inhibitor - *
of - *
protein - *
kinase - *
is - *
produced - *
by - *
he - *
human - *
PKI - *
cDNA - *
both - *
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *
have - *
been - *
inhibited inhibit (V*) *
by - *
protein - *
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *
. - *

Transient - *)
overexpression - *
in - *
COS - *
cells - *)
verified - *
that - *
a - *
heat-stable - *
inhibitor - *
of - *
protein - *
kinase - *
is - *
produced - *
by - *
he - *
human - *
PKI - *
cDNA - *
both - *
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *
will - *
be - *
inhibited inhibit (V*) *
by - *
protein - *
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *
. - *

Here - (A2*
we - *)
have - *
found - *)
that - *
the - *
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *
was - *
inhibited inhibit (V*) *
by - *
the - *
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *
while - *
the - *
downreglation - *
of - *
phosphorylated - *
Stat1 - *
Stat2 - *
and - *
Stat3 - *
was - *
not - *
sensitive - *
to - *
these - *
inhibitors - *
. - *

the - (A2*
proteasome - *)
inhibitors - *)
MG132 - *
and - *
lactacystin - *
inhibited inhibit (V*) *
the - *
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *
. - *

the - (A2*
proteasome - *)
inhibitors - *)
MG132 - *
and - *
lactacystin - *
inhibits inhibit (V*) *
the - *
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *
. - *

the - (A2*
proteasome - *)
inhibitors - *)
MG132 - *
and - *
lactacystin - *
which - *
inhibited inhibit (V*) *
the - *
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *
. - *

the - (A2*
proteasome - *)
inhibitors - *)
MG132 - *
and - *
lactacystin - *
which - *
inhibits inhibit (V*) *
the - *
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *
. - *

For - *)
example - *
the - *
phosphatase - *)
may - *
associate - *
with - *
another - *
protein - *
and - *
thereby - *
be - *
inhibited inhibit (V*) *
in - *
its - *
function - *
or - *
localization - *
. - *

For - *)
example - *
the - *
phosphatase - *)
associates - *
with - *
another - *
protein - *
and - *
is - *
inhibited inhibit (V*) *
in - *
its - *
function - *
or - *
localization - *
. - *

For - *)
example - *
the - *
phosphatase - *)
associated - *
with - *
another - *
protein - *
and - *
was - *
inhibited inhibit (V*) *
in - *
its - *
function - *
or - *
localization - *
. - *

its - *)
function - *
or - *
localization - *)
inhibited inhibit (V*) *
the - *
phosphatase - *
associating - *
with - *
another - *
protein - *
. - *

its - *)
function - *
or - *
localization - *)
inhibits inhibit (V*) *
the - *
phosphatase - *
associating - *
with - *
another - *
protein - *
. - *

intermediate - (A2*
events - *
are - *
inhibited inhibit (V*) *
by - *
The - *)
N-terminal - *
SH3 - *
domain - *
(SH3A) - *
unlike - *
other - *
SH3 - *
domains - *
from - *
intersectin - *
or - *
various - *
endocytic - *
proteins - *)
. - *

intermediate - (A2*
events - *
were - *
inhibited inhibit (V*) *
by - *
The - *)
N-terminal - *
SH3 - *
domain - *
(SH3A) - *
unlike - *
other - *
SH3 - *
domains - *
from - *
intersectin - *
or - *
various - *
endocytic - *
proteins - *)
. - *

intermediate - *)
events - *
has - *
been - *
inhibited inhibit (V*) *
by - *
The - *
N-terminal - *
SH3 - *
domain - *
(SH3A) - *
unlike - *
other - *
SH3 - *
domains - *
from - *
intersectin - *
or - *
various - *
endocytic - *
proteins - *)
. - *

intermediate - (A2*
events - *
will - *
be - *
inhibited inhibit (V*) *
by - *)
The - *
N-terminal - *
SH3 - *
domain - *
(SH3A) - *
unlike - *
other - *
SH3 - *
domains - *
from - *
intersectin - *
or - *
various - *
endocytic - *
proteins - *)
. - *

late - (A2*
events - *)
of - *
clathrin-coated - *
vesicle - *
formation - *
were - *
inhibited inhibit (V*) *
by - *
the - *
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *
. - *

late - (A2*
events - *)
of - *
clathrin-coated - *
vesicle - *
formation - *
are - *
inhibited inhibit (V*) *
by - *
the - *
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *
. - *

late - (A2*
events - *)
of - *
clathrin-coated - *
vesicle - *
formation - *
has - *
been - *
inhibited inhibit (V*) *
by - *
the - *
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *
. - *

late - (A2*
events - *)
of - *
clathrin-coated - *
vesicle - *
formation - *
will - *
be - *
inhibited inhibit (V*) *
by - *
the - *
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *
. - *

The - (A2*)
half-life - *)
of - *
the - *
AGT - *
proteins - *
was - *
determined - *
by - *
growing - *
cells - *
at - *
37 - *
C - *
in - *
LB - *
broth - *
supplemented - *
with - *
50 - *
mg/ml - *
ampicillin - *
50 - *
mg/ml - *
kanamycin - *
and - *
02 - *
mM - *
IPTG - *
until - *
the - *
A600 - *
reached - *
03 - *
and - *
then - *
treating - *
them - *
with - *
50 - *
mg/ml - *
chloramphenicol - *
for - *
inhibiting inhibit (V*) *
protein - *
synthesis - *
. - *

The - (A2*)
half-life - *)
of - *
the - *
AGT - *
proteins - *
was - *
determined - *
by - *
growing - *
cells - *
at - *
37 - *
C - *
in - *
LB - *
broth - *
supplemented - *
with - *
50 - *
mg/ml - *
ampicillin - *
50 - *
mg/ml - *
kanamycin - *
and - *
02 - *
mM - *
IPTG - *
until - *
the - *
A600 - *
reached - *
03 - *
and - *
then - *
protein - *
synthesis - *
were - *
inhibited inhibit (V*) *
by - *
them - *
with - *
50 - *
mg/ml - *
chloramphenicol - *
. - *

The - (A2*)
half-life - *)
of - *
the - *
AGT - *
proteins - *
was - *
determined - *
by - *
growing - *
cells - *
at - *
37 - *
C - *
in - *
LB - *
broth - *
supplemented - *
with - *
50 - *
mg/ml - *
ampicillin - *
50 - *
mg/ml - *
kanamycin - *
and - *
02 - *
mM - *
IPTG - *
until - *
the - *
A600 - *
reached - *
03 - *
and - *
then - *
protein - *
synthesis - *
are - *
inhibited inhibit (V*) *
by - *
them - *
with - *
50 - *
mg/ml - *
chloramphenicol - *
. - *

The - (A2*)
half-life - *)
of - *
the - *
AGT - *
proteins - *
was - *
determined - *
by - *
growing - *
cells - *
at - *
37 - *
C - *
in - *
LB - *
broth - *
supplemented - *
with - *
50 - *
mg/ml - *
ampicillin - *
50 - *
mg/ml - *
kanamycin - *
and - *
02 - *
mM - *
IPTG - *
until - *
the - *
A600 - *
reached - *
03 - *
and - *
then - *
protein - *
synthesis - *
has - *
been - *
inhibited inhibit (V*) *
by - *
them - *
with - *
50 - *
mg/ml - *
chloramphenicol - *
. - *

The - (A2*)
half-life - *)
of - *
the - *
AGT - *
proteins - *
was - *
determined - *
by - *
growing - *
cells - *
at - *
37 - *
C - *
in - *
LB - *
broth - *
supplemented - *
with - *
50 - *
mg/ml - *
ampicillin - *
50 - *
mg/ml - *
kanamycin - *
and - *
02 - *
mM - *
IPTG - *
until - *
the - *
A600 - *
reached - *
03 - *
and - *
then - *
protein - *
synthesis - *
will - *
be - *
inhibited inhibit (V*) *
by - *
them - *
with - *
50 - *
mg/ml - *
chloramphenicol - *
. - *

late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
. - *

Binding - (A2*)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
has - *
also - *
been - *
inhibited inhibit (V*) *
with - (A0*
10mM - *
EDTA - *)
. - *

platelet - (A2*
function - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
Nitric - (A0*
oxide - *)
. - *

NK-cell-mediated - (A2*
cytotoxicity - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
. - *

the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
. - *

intermediate - (A2*
events - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
The - (A0*
N-terminal - *
SH3 - *
domain - *)
. - *

late - (A2*
events - *
of - *
clathrin-coated - *
vesicle - *
formation - *)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
the - (A0*
SH3C - *
and - *
SH3E - *
domains - *
of - *
intersectin - *
as - *
well - *
as - *
the - *
SH3 - *
domains - *
from - *
the - *
endocytic - *
proteins - *
endophilin - *
I - *
amphiphysin - *
II - *
and - *
syndaphin - *
I - *)
. - *

Binding - (A2*)
in - *
transiently - *
transfected - *
Jurkat - *
T-leukemia - *
cells - *
wil - *
be - *
also - *
inhibited inhibit (V*) *
with - (A0*
10mM - *
EDTA - *)
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
will - *
be - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

autophosphorylation - *)
of - *
the - *
sensor - *
protein - *
ArcB - *)
inhibited inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

autophosphorylation - *)
of - *
the - *
sensor - *
protein - *
ArcB - *)
inhibits inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
has - *
been - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
has - *
been - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

sigma - *)
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
was - *
inhibited inhibit (V*) *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
has - *
been - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

sigma - *)
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
is - *
inhibited inhibit (V*) *
by - *
autophosphorylation - (A0*
of - *
the - *
sensor - *
protein - *
ArcB - *)
. - *

autophosphorylation - *)
of - *
the - *
sensor - *
protein - *
ArcB - *)
has - *
inhibited inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

autophosphorylation - *)
of - *
the - *
sensor - *
protein - *
ArcB - *)
will - *
inhibit inhibit (V*) *
sigma - *
(54) - *
-dependent - *
glnAp2 - *
strongly - *
by - *
21-fold - *
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
was - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
was - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
was - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
is - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
is - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
which - *
is - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
coexpression - *
of - *
MAD-3 - *)
inhibits inhibit (V*) *
Functional - (A2*
activation - *
of - *
an - *
HIV - *
reporter - *
plasmid - *
by - *
p49/p65 - *)
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
which - *
was - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
which - *
was - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

sigma - (A1*
( - *
54 - *
) - *
-dependent - *
glnAp2 - *)
which - *
was - *
initiated - *
by - *
CRP-cAMP - (A0*)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
which - *
is - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
which - *
is - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
 - *
. - *

both - (A1*
the - *
C - *
alpha - *
and - *
C - *
beta - *
isoforms - *
of - *
the - *
PKA - *
catalytic - *
subunit - *)
will - *
be - *
initiated - *
by - *
protein - (A0*
extracts - *
from - *
the - *
transfected - *
COS - *
cells - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

multiple - (A1*
PDE4 - *
cyclic - *
AMP-specific - *
phosphodiesterase - *
isoforms - *)
will - *
be - *
initiated - *
by - *
by - (A0*
rolipram - *)
followed - *
by - *
phosphoryl - *
group - *
transfer - *
to - *
the - *
regulator - *
ArcA - *
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
Nitric - (A0*
oxide - *)
inhibits inhibit (V*) *
platelet - (A2*
function - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
cell-surface - (A0*
receptors - *
of - *
the - *
immunoglobulin - *
and - *
C-type - *
lectin - *
superfamilies - *)
inhibits inhibit (V*) *
NK-cell-mediated - (A2*
cytotoxicity - *)
. - *

GadX - *
activates - *
expression - *
of - *
gadA - *
and - *
gadBC - *
at - *
any - *
pH - *
while - *
by - (A0*
proteasome - *
inhibitors - *
MG132 - *
and - *
lactacystin - *)
inhibits inhibit (V*) *
the - (A2*
downregulation - *
of - *
phosphorylated - *
Stat4 - *
Stat5 - *
and - *
Stat6 - *)
. - *

It - (A2*
inhibited - *
Binding - *)
was - *
concentration - *
dependent - *
and - *
saturable - *
and - *
was - *
totally - *
inhibited - *
with - *
10mM - *
EDTA - *
. - *

It - (A2*
inhibites - *
Binding - *)
was - *
concentration - *
dependent - *
and - *
saturable - *
and - *
was - *
totally - *
inhibited - *
with - *
10mM - *
EDTA - *
. - *

Binding - (A2*
is - *
concentration - *)
dependent - *
and - *
saturable - *
and - *
is - *
totally - *
inhibited - *
with - *
10mM - *
EDTA - *
suggesting - *
that - *
divalent - *
cations - *
were - *
required - *
for - *
interaction - *
of - *
IN1B - *
with - *
Vero - *
cells - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
initiate initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
are - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
initiated initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
were - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
initiates initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
were - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
will - *
initiate initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
were - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
which - *
initiate initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
were - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

Apparently - (A2*
HeLa - *
cells - *)
either - *
which - *
initiated initiate (V*) *
transcription - *
at - *
multiple - *
sites - *
within - *
RPS14 - *
exon - *
1 - *
or - *
capped - *
5&apos; - *
oligonucleotides - *
were - *
removed - *
from - *
most - *
S14 - *
mRNAs - *
posttranscription - *
. - *

I - (A4*
kappa - *
B-epsilon - *)
translation - *
initiates initiate (V*) *
from - *
an - *)
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
exists - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

I - (A4*
kappa - *
B-epsilon - *)
translation - *
initiated initiate (V*) *
from - *
an - *)
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
existed - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

I - (A4*
kappa - *
B-epsilon - *)
translation - *
that - *
initiates initiate (V*) *
from - *)
an - *
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
exists - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

I - (A4*
kappa - *
B-epsilon - *)
translation - *
that - *
initiated initiate (V*) *
from - *)
an - *
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
existed - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

I - *)
kappa - *
B-epsilon - *)
translation - *
which - *
initiates initiate (V*) *
from - *
an - *
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
exists - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

I - *)
kappa - *
B-epsilon - *)
translation - *
which - *
initiated initiate (V*) *
from - *
an - *
internal - *
ATG - *
codon - *
to - *
give - *
rise - *
to - *
a - *
protein - *
of - *
45 - *
kDa - *
which - *
existed - *
as - *
multiple - *
phosphorylated - *
isoforms - *
in - *
resting - *
cells - *
 - *
. - *

Platelet - (A3*
agonists - *)
initiated initiate (V*) *
aggregation - (A1*
and - *
secretion - *)
by - *
activating - (A4*
receptors - *
coupled - *
to - *
the - *
G-protein - *
G(q) - *)
thereby - *
raising - *
cytosolic - *
Ca(2+) - *
[Ca(2+)](i) - *
. - *

Platelet - (A3*
agonists - *)
which - *
initiate initiate (V*) *
aggregation - (A1*
and - *
secretion - *)
by - *
activating - (A4*
receptors - *
coupled - *
to - *
the - *
G-protein - *
G(q) - *)
thereby - *
raising - *
cytosolic - *
Ca(2+) - *
[Ca(2+)](i) - *
. - *

Platelet - (A3*
agonists - *)
which - *
initiated initiate (V*) *
aggregation - (A1*
and - *
secretion - *)
by - *
activating - (A4*
receptors - *
coupled - *
to - *
the - *
G-protein - *
G(q) - *)
thereby - *
raising - *
cytosolic - *
Ca(2+) - *
[Ca(2+)](i) - *
. - *

Platelet - (A3*
agonists - *)
that - *
initiate initiate (V*) *
aggregation - (A1*
and - *
secretion - *)
by - *
activating - (A4*
receptors - *
coupled - *
to - *
the - *
G-protein - *
G(q) - *)
thereby - *
raising - *
cytosolic - *
Ca(2+) - *
[Ca(2+)](i) - *
. - *

Platelet - (A3*
agonists - *)
that - *
initiated initiate (V*) *
aggregation - (A1*
and - *
secretion - *)
by - *
activating - (A4*
receptors - *
coupled - *
to - *
the - *
G-protein - *
G(q) - *)
thereby - *
raising - *
cytosolic - *
Ca(2+) - *
[Ca(2+)](i) - *
. - *

Ligand - *)
binding - *
induced - *
cell - *
surface - *
receptor - *
complex - *
formation - *
and - *
activates - *
a - *
cascade - *
of - *
phosphorylation - *
events - *
of - *
intracellular - *
intermediaries - *
termed - *
Smads - *
which - *
initiated initiate (V*) *
transcriptional - *
regulation - *
. - *

Ligand - *)
binding - *
induces - *
cell - *
surface - *
receptor - *
complex - *
formation - *
and - *
activates - *
a - *
cascade - *
of - *
phosphorylation - *
events - *
of - *
intracellular - *
intermediaries - *
termed - *
Smads - *
initiate initiate (V*) *
transcriptional - *
regulation - *
. - *

Ligand - *)
binding - *
induced - *
cell - *
surface - *
receptor - *
complex - *
formation - *
and - *
activates - *
a - *
cascade - *
of - *
phosphorylation - *
events - *
of - *
intracellular - *
intermediaries - *
termed - *
Smads - *
initiated initiate (V*) *
transcriptional - *
regulation - *
. - *

Ligand - *)
binding - *
induces - *
cell - *
surface - *
receptor - *
complex - *
formation - *
and - *
activates - *
a - *
cascade - *
of - *
phosphorylation - *
events - *
of - *
intracellular - *
intermediaries - *
termed - *
Smads - *
that - *
initiate initiate (V*) *
transcriptional - *
regulation - *
. - *

Ligand - *)
binding - *
induced - *
cell - *
surface - *
receptor - *
complex - *
formation - *
and - *
activates - *
a - *
cascade - *
of - *
phosphorylation - *
events - *
of - *
intracellular - *
intermediaries - *
termed - *
Smads - *
that - *
initiated initiate (V*) *
transcriptional - *
regulation - *
. - *

Since - *)
RTKs - *
initiated initiate (V*) *
signaling - *
by - *
recruiting - *
downstream - *
components - *
to - *
the - *
activated - *
receptor - *
proteins - *
that - *
are - *
immediately - *
downstreamof - *
an - *
activated - *
RTK - *
can - *
be - *
identified - *
by - *
first - *
identifying - *
sequences - *
in - *
the - *
RTK - *
that - *
are - *
necessary - *
to - *
activate - *
downstream - *
signaling - *
(Schlessinger - *
and - *
Ullrich - *
1992; - *
Pawson - *
1995) - *
. - *

Since - (A3*
RTKs - *
which - *
initiate - *)
signaling - *
by - *
recruiting - *
downstream - *
components - *
to - *
the - *
activated - *
receptor - *
proteins - *
that - *
are - *
immediately - *
downstreamof - *
an - *
activated - *
RTK - *
can - *
be - *
identified - *
by - *
first - *
identifying - *
sequences - *
in - *
the - *
RTK - *
that - *
are - *
necessary - *
to - *
activate - *
downstream - *
signaling - *
(Schlessinger - *
and - *
Ullrich - *
1992; - *
Pawson - *
1995) - *
. - *

Since - (A3*
RTKs - *
that - *
initiated - *)
signaling - *
by - *
recruiting - *
downstream - *
components - *
to - *
the - *
activated - *
receptor - *
proteins - *
that - *
are - *
immediately - *
downstreamof - *
an - *
activated - *
RTK - *
can - *
be - *
identified - *
by - *
first - *
identifying - *
sequences - *
in - *
the - *
RTK - *
that - *
are - *
necessary - *
to - *
activate - *
downstream - *
signaling - *
(Schlessinger - *
and - *
Ullrich - *
1992; - *
Pawson - *
1995) - *
. - *

Since - (A3*
RTKs - *
that - *
initiate - *)
signaling - *
by - *
recruiting - *
downstream - *
components - *
to - *
the - *
activated - *
receptor - *
proteins - *
that - *
are - *
immediately - *
downstreamof - *
an - *
activated - *
RTK - *
can - *
be - *
identified - *
by - *
first - *
identifying - *
sequences - *
in - *
the - *
RTK - *
that - *
are - *
necessary - *
to - *
activate - *
downstream - *
signaling - *
(Schlessinger - *
and - *
Ullrich - *
1992; - *
Pawson - *
1995) - *
. - *

Since - (A3*
RTKs - *
which - *
initiated - *)
signaling - *
by - *
recruiting - *
downstream - *
components - *
to - *
the - *
activated - *
receptor - *
proteins - *
that - *
are - *
immediately - *
downstreamof - *
an - *
activated - *
RTK - *
can - *
be - *
identified - *
by - *
first - *
identifying - *
sequences - *
in - *
the - *
RTK - *
that - *
are - *
necessary - *
to - *
activate - *
downstream - *
signaling - *
(Schlessinger - *
and - *
Ullrich - *
1992; - *
Pawson - *
1995) - *
. - *

Sxl - (A4*
was - *)
a - *
key - *
regulator - *
of - *
sex - *)
determination - *
and - *
dosage - *
compensation - *
whose - *
transcription - *
was - *
initiated initiate (V*) *
only - *
in - *
female - *
blastoderm - *
embryos - *
. - *

Sxl - *)
is - *
a - *
key - *
regulator - *
of - *
sex - *
determination - *
and - *
dosage - *
compensation - *
whose - *
transcription - *
has - *
been - *
initiated initiate (V*) *
only - *
in - *
female - *
blastoderm - *
embryos - *
. - *

Sxl - (A4*
was - *)
a - *
key - *
regulator - *
of - *
sex - *)
determination - *
and - *
dosage - *
compensation - *
whose - *
transcription - *
will - *
be - *
initiated initiate (V*) *
only - *
in - *
female - *
blastoderm - *
embryos - *
. - *

Sxl - *)
is - *
a - *
key - *
regulator - *
of - *
sex - *
determination - *
and - *
dosage - *
compensation - *
whose - *
transcription - *
which - *
is - *
initiated initiate (V*) *
only - *
in - *
female - *
blastoderm - *
embryos - *
. - *

Sxl - (A4*
was - *)
a - *
key - *
regulator - *
of - *
sex - *)
determination - *
and - *
dosage - *
compensation - *
whose - *
transcription - *
which - *
was - *
initiated initiate (V*) *
only - *
in - *
female - *
blastoderm - *
embryos - *
. - *

SCF - (A2*
like - *)
the - *
other - *
dimeric - *
ligands - *
initated - *
signal - *)
transduction - *
by - *
direct - *
dimerization - *
of - *
its - *
receptor - *
Kitand - *
the - *
two - *
juxtaposed - *
receptors - *
undergo - *
tyrosine - *
autophosphorylation - *
(Heldin - *
1995; - *
Broudy - *
1997) - *
which - *
initiated initiate (V*) *
downstream - *
intracellular - *
signaling - *
. - *

SCF - (A2*
like - *)
the - *
other - *
dimeric - *
ligands - *
which - *
initates - *)
signal - *
transduction - *
by - *
direct - *
dimerization - *
of - *
its - *
receptor - *
Kitand - *
the - *
two - *
juxtaposed - *
receptors - *
undergo - *
tyrosine - *
autophosphorylation - *
(Heldin - *
1995; - *
Broudy - *
1997) - *
which - *
initiates initiate (V*) *
downstream - *
intracellular - *
signaling - *
. - *

SCF - (A2*
like - *)
the - *
other - *
dimeric - *
ligandswhich - *
initated - *)
signal - *
transduction - *
by - *
direct - *
dimerization - *
of - *
its - *
receptor - *
Kitand - *
the - *
two - *
juxtaposed - *
receptors - *
undergo - *
tyrosine - *
autophosphorylation - *
(Heldin - *
1995; - *
Broudy - *
1997) - *
which - *
initiated initiate (V*) *
downstream - *
intracellular - *
signaling - *
. - *

SCF - (A2*
like - *)
the - *
other - *
dimeric - *
ligands - *
that - *
initates - *)
signal - *
transduction - *
by - *
direct - *
dimerization - *
of - *
its - *
receptor - *
Kitand - *
the - *
two - *
juxtaposed - *
receptors - *
undergo - *
tyrosine - *
autophosphorylation - *
(Heldin - *
1995; - *
Broudy - *
1997) - *
which - *
initiates initiate (V*) *
downstream - *
intracellular - *
signaling - *
. - *

SCF - (A2*
like - *)
the - *
other - *
dimeric - *
ligands - *
that - *
initated - *)
signal - *
transduction - *
by - *
direct - *
dimerization - *
of - *
its - *
receptor - *
Kitand - *
the - *
two - *
juxtaposed - *
receptors - *
undergo - *
tyrosine - *
autophosphorylation - *
(Heldin - *
1995; - *
Broudy - *
1997) - *
which - *
initiated initiate (V*) *
downstream - *
intracellular - *
signaling - *
. - *

Tumours - *)
with - *
breakpoints - *
just - *
5&apos; - *)
to - *
exon - *
1 - *
or - *
distant - *
from - *
c-myc - *
had - *
normal - *
c-myc - *
mRNAs - *
of - *
225 - *
and - *
24 - *
kb - *
which - *
differ - *
at - *
their - *
5&apos; - *
ends - *
while - *
tumours - *
with - *
breakpoints - *
within - *
exon - *
1 - *
or - *
intron - *
1 - *
had - *
altered - *
c-myc - *
mRNAs - *
(21-27 - *
kb - *
in - *
Burkitt - *
lines) - *
initiated initiate (V*) *
within - *
intron - *
1 - *
. - *

Tumours - *)
with - *
breakpoints - *
just - *
5&apos; - *)
to - *
exon - *
1 - *
or - *
distant - *
from - *
c-myc - *
have - *
normal - *
c-myc - *
mRNAs - *
of - *
225 - *
and - *
24 - *
kb - *
which - *
differ - *
at - *
their - *
5&apos; - *
ends - *
while - *
tumours - *
with - *
breakpoints - *
within - *
exon - *
1 - *
or - *
intron - *
1 - *
alter - *
c-myc - *
mRNAs - *
(21-27 - *
kb - *
in - *
Burkitt - *
lines) - *
initiate initiate (V*) *
within - *
intron - *
1 - *
. - *

Tumours - *)
with - *
breakpoints - *
just - *
5&apos; - *)
to - *
exon - *
1 - *
or - *
distant - *
from - *
c-myc - *
have - *
normal - *
c-myc - *
mRNAs - *
of - *
225 - *
and - *
24 - *
kb - *
which - *
differ - *
at - *
their - *
5&apos; - *
ends - *
while - *
tumours - *
with - *
breakpoints - *
within - *
exon - *
1 - *
or - *
intron - *
1 - *
alter - *
c-myc - *
mRNAs - *
(21-27 - *
kb - *
in - *
Burkitt - *
lines) - *
initiating initiate (V*) *
within - *
intron - *
1 - *
. - *

Tumours - *)
with - *
breakpoints - *
just - *
5&apos; - *)
to - *
exon - *
1 - *
or - *
distant - *
from - *
c-myc - *
have - *
normal - *
c-myc - *
mRNAs - *
of - *
225 - *
and - *
24 - *
kb - *
which - *
differ - *
at - *
their - *
5&apos; - *
ends - *
while - *
tumours - *
with - *
breakpoints - *
within - *
exon - *
1 - *
or - *
intron - *
1 - *
alter - *
c-myc - *
mRNAs - *
(21-27 - *
kb - *
in - *
Burkitt - *
lines) - *
initiated initiate (V*) *
within - *
intron - *
1 - *
. - *

This - *)
has - *
led - *
to - *
the - *
prevailing - *
interpretation - *
that - *
genetic - *
changes - *
in - *
addition - *
to - *
those - *
present - *
in - *
the - *
most - *
advanced - *
clone - *
of - *
the - *
primary - *
tumor - *
are - *
required - *
for - *
initiating initiate (V*) *
invasion - *
dissemination - *
and - *
growth - *
at - *
anatomically - *
distant - *
sites - *
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
 - *
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
leads lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
has - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
 - *
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
will - *
lead lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
 - *
. - *

Further - (A0*
experiments - *)
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
leads lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
has - *
led lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
led lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
leads lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
which - *
has - *
led lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
which - *
led lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
will - *
lead lead (V*) *
us - *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

It - (A0*
has - *
been - *
shown - *
that - *
Crl - *
stimulates - *
the - *)
activity - *
of - *
sigma - *
(S) - *
leading lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - *)
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
lead lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - *)
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *)
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
was - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
. - *

an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *)
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
is - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
. - *

Our - (A2*
data - *
present - *
a - *
novel - *
apical - *
sorting - *)
pathway - *)
by - *
which - *
MV - *)
envelope - *
glycoproteins - *
are - *
chaperoned - *
by - *
the - *
M - *
protein - *
for - *
initiating - *
virus - *
release - *
at - *
that - *
surface - *
. - *

Our - (A2*
data - *
present - *
a - *
novel - *
apical - *
sorting - *)
pathway - *)
by - *
which - *
MV - *)
envelope - *
glycoproteins - *
are - *
chaperoned - *
by - *
the - *
M - *
protein - *
initiating - *
virus - *
release - *
at - *
that - *
surface - *
 - *
. - *

Our - (A2*
data - *
present - *
a - *
novel - *
apical - *
sorting - *)
pathway - *)
by - *
which - *
MV - *)
envelope - *
glycoproteins - *
are - *
chaperoned - *
by - *
the - *
M - *
protein - *
which - *
initiate - *
virus - *
release - *
at - *
that - *
surface - *
. - *

Our - (A2*
data - *
present - *
a - *
novel - *
apical - *
sorting - *)
pathway - *)
by - *
which - *
MV - *)
envelope - *
glycoproteins - *
are - *
chaperoned - *
by - *
the - *
M - *
protein - *
which - *
initiated - *
virus - *
release - *
at - *
that - *
surface - *
. - *

By - (A2*
direct - *
sequencing - *
of - *
aberrant - *
SSCA - *
conformers - *)
were - *
revealed - *
15 - *
different - *)
mutations - *
in - *
a - *
total - *
of - *
18 - *
unrelated - *
families - *
and - *
13 - *
single - *
patients - *
Of - *
these - *
10 - *
were - *
novel - *
(7 - *
missense - *
mutations - *
2 - *
mutations - *
which - *
lead lead (V*) *
to - *
frameshift - *
and - *
1 - *
mutation - *
predicted - *
to - *
affect - *
normal - *
splicing) - *
. - *

By - (A2*
direct - *
sequencing - *
of - *
aberrant - *
SSCA - *
conformers - *)
were - *
revealed - *
15 - *
different - *)
mutations - *
in - *
a - *
total - *
of - *
18 - *
unrelated - *
families - *
and - *
13 - *
single - *
patients - *
Of - *
these - *
10 - *
were - *
novel - *
(7 - *
missense - *
mutations - *
2 - *
mutations - *
which - *
led lead (V*) *
to - *
frameshift - *
and - *
1 - *
mutation - *
predicted - *
to - *
affect - *
normal - *
splicing) - *
. - *

By - (A2*
direct - *
sequencing - *
of - *
aberrant - *
SSCA - *
conformers - *)
were - *
revealed - *
15 - *
different - *)
mutations - *
in - *
a - *
total - *
of - *
18 - *
unrelated - *
families - *
and - *
13 - *
single - *
patients - *
Of - *
these - *
10 - *
were - *
novel - *
(7 - *
missense - *
mutations - *
2 - *
mutations - *
that - *
led lead (V*) *
to - *
frameshift - *
and - *
1 - *
mutation - *
predicted - *
to - *
affect - *
normal - *
splicing) - *
. - *

This - (A2*
was - *
caused - *)
by - *
a - *
point - *)
mutation - *
(GTC----ATC) - *)
at - *
codon - *
383 - *
which - *
led lead (V*) *
to - *
the - *
conservative - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
in - *
the - *
putative - *
fifth - *
extracellular - *
loop - *
of - *
the - *
transporter - *
. - *

This - (A2*
was - *
caused - *)
by - *
a - *
point - *)
mutation - *
(GTC----ATC) - *)
at - *
codon - *
383 - *
that - *
leads lead (V*) *
to - *
the - *
conservative - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
in - *
the - *
putative - *
fifth - *
extracellular - *
loop - *
of - *
the - *
transporter - *
. - *

This - (A2*
was - *
caused - *)
by - *
a - *
point - *)
mutation - *
(GTC----ATC) - *)
at - *
codon - *
383 - *
that - *
led lead (V*) *
to - *
the - *
conservative - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
in - *
the - *
putative - *
fifth - *
extracellular - *
loop - *
of - *
the - *
transporter - *
. - *

This - (A2*
was - *
caused - *)
by - *
a - *
point - *)
mutation - *
(GTC----ATC) - *)
at - *
codon - *
383 - *
leading lead (V*) *
to - *
the - *
conservative - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
in - *
the - *
putative - *
fifth - *
extracellular - *
loop - *
of - *
the - *
transporter - *
. - *

This - (A2*
was - *
caused - *)
by - *
a - *
point - *)
mutation - *
(GTC----ATC) - *)
at - *
codon - *
383 - *
has - *
led lead (V*) *
to - *
the - *
conservative - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
in - *
the - *
putative - *
fifth - *
extracellular - *
loop - *
of - *
the - *
transporter - *
. - *

Genetic - (A2*
deficiency - *
of - *
GM2 - *
activator - *
led lead (V*) *
to - *)
a - *
neurological - *
disorder - *)
an - *
atypical - *
form - *
of - *
Tay-Sachs - *
disease - *
(GM2 - *
gangliosidosis - *
variant - *
AB) - *
. - *

Genetic - (A2*
deficiency - *
of - *
GM2 - *
activator - *
which - *)
leads lead (V*) *
to - *
a - *
neurological - *)
disorder - *
an - *
atypical - *
form - *
of - *
Tay-Sachs - *
disease - *
(GM2 - *
gangliosidosis - *
variant - *
AB) - *
. - *

Genetic - (A2*
deficiency - *
of - *
GM2 - *
activator - *
leading - *)
to - *
a - *
neurological - *
disorder - *)
an - *
atypical - *
form - *
of - *
Tay-Sachs - *
disease - *
(GM2 - *
gangliosidosis - *
variant - *
AB) - *
. - *

Genetic - (A2*
deficiency - *
of - *
GM2 - *
activator - *
has - *
led - *)
to - *
a - *
neurological - *
disorder - *)
an - *
atypical - *
form - *
of - *
Tay-Sachs - *
disease - *
(GM2 - *
gangliosidosis - *
variant - *
AB) - *
. - *

This - *)
led lead (V*) *
to - *
a - *
substantial - *
diversity - *
of - *
nebulin - *)
and - *
nebulette - *
isoforms - *
. - *

This - *)
that - *
leads lead (V*) *
to - *
a - *
substantial - *)
diversity - *)
of - *
nebulin - *
and - *
nebulette - *
isoforms - *
. - *

This - *)
which - *
led lead (V*) *
to - *
a - *
substantial - *)
diversity - *)
of - *
nebulin - *
and - *
nebulette - *
isoforms - *
. - *

This - *)
leading lead (V*) *
to - *
a - *
substantial - *)
diversity - *
of - *)
nebulin - *
and - *
nebulette - *
isoforms - *
. - *

This - *)
has - *
led lead (V*) *
to - *
a - *
substantial - *)
diversity - *
of - *)
nebulin - *
and - *
nebulette - *
isoforms - *
. - *

Cotransfection - *)
of - *
GATA-4 - *
with - *
MEF2A - *
MEF2C - *)
or - *
MEF2D - *
led lead (V*) *
to - *
a - *
synergistic - *
40-to - *
50-fold - *
activation - *
of - *
the - *
ANF - *
promoter - *
(Figure - *
3A) - *
. - *

Cotransfection - (A2*
of - *
GATA-4 - *
with - *
MEF2A - *
MEF2C - *)
or - *
MEF2D - *
which - *)
leads lead (V*) *
to - *
a - *
synergistic - *
40-to - *
50-fold - *
activation - *
of - *
the - *
ANF - *
promoter - *
(Figure - *
3A) - *
. - *

Cotransfection - (A2*
of - *
GATA-4 - *
with - *
MEF2A - *
MEF2C - *)
or - *
MEF2D - *
which - *)
led lead (V*) *
to - *
a - *
synergistic - *
40-to - *
50-fold - *
activation - *
of - *
the - *
ANF - *
promoter - *
(Figure - *
3A) - *
. - *

Cotransfection - (A2*
of - *
GATA-4 - *
with - *
MEF2A - *
MEF2C - *)
or - *
MEF2D - *
leading - *)
to - *
a - *
synergistic - *
40-to - *
50-fold - *
activation - *
of - *
the - *
ANF - *
promoter - *
(Figure - *
3A) - *
. - *

Cotransfection - *)
of - *
GATA-4 - *
with - *
MEF2A - *
MEF2C - *)
or - *
MEF2D - *
has - *
led lead (V*) *
to - *
a - *
synergistic - *
40-to - *
50-fold - *
activation - *
of - *
the - *
ANF - *
promoter - *
(Figure - *
3A) - *
. - *

This - (A2*
in - *
turn - *
led lead (V*) *
to - *
synergistic - *)
activation - *)
of - *
the - *
ANF - *
and - *
other - *
MEF2 - *
target - *
promoters - *
independently - *
of - *
the - *
DNA-binding - *
activity - *
of - *
MEF2 - *
. - *

This - (A2*
in - *
turn - *
which - *
leads - *)
to - *
synergistic - *)
activation - *
of - *
the - *
ANF - *
and - *
other - *
MEF2 - *
target - *
promoters - *
independently - *
of - *
the - *
DNA-binding - *
activity - *
of - *
MEF2 - *
. - *

This - (A2*
in - *
turn - *
which - *
led - *)
to - *)
synergistic - *
activation - *)
of - *
the - *
ANF - *
and - *
other - *
MEF2 - *
target - *
promoters - *
independently - *
of - *
the - *
DNA-binding - *
activity - *
of - *
MEF2 - *
. - *

This - *)
in - *
turn - *
leading lead (V*) *
to - *
synergistic - *
activation - *)
of - *
the - *
ANF - *
and - *
other - *
MEF2 - *
target - *
promoters - *
independently - *
of - *
the - *
DNA-binding - *
activity - *
of - *
MEF2 - *
. - *

This - *)
in - *
turn - *
has - *
led lead (V*) *
to - *
synergistic - *
activation - *)
of - *
the - *
ANF - *
and - *
other - *
MEF2 - *
target - *
promoters - *
independently - *
of - *
the - *
DNA-binding - *
activity - *
of - *
MEF2 - *
. - *

This - (A2*
G:C - *
base - *
pair - *
is - *
also - *
the - *
strongest - *)
determinant - *
in - *
the - *)
sequence - *
selection - *
experiment - *
which - *
leads lead (V*) *
to - *
the - *
identification - *
of - *
the - *
BRE - *
(Lagrange - *
et - *
al - *
1998) - *
. - *

This - (A2*
G:C - *
base - *
pair - *
is - *
also - *
the - *
strongest - *)
determinant - *
in - *
the - *)
sequence - *
selection - *
experiment - *
has - *
led lead (V*) *
to - *
the - *
identification - *
of - *
the - *
BRE - *
(Lagrange - *
et - *
al - *
1998) - *
. - *

This - (A2*
G:C - *
base - *
pair - *
is - *
also - *
the - *
strongest - *)
determinant - *
in - *
the - *)
sequence - *
selection - *
experiment - *
leading lead (V*) *
to - *
the - *
identification - *
of - *
the - *
BRE - *
(Lagrange - *
et - *
al - *
1998) - *
. - *

This - (A2*
G:C - *
base - *
pair - *
is - *
also - *
the - *
strongest - *)
determinant - *
in - *
the - *)
sequence - *
selection - *
experiment - *
led lead (V*) *
to - *
the - *
identification - *
of - *
the - *
BRE - *
(Lagrange - *
et - *
al - *
1998) - *
. - *

This - (A2*
G:C - *
base - *
pair - *
is - *
also - *
the - *
strongest - *)
determinant - *
in - *
the - *)
sequence - *
selection - *
experiment - *
leads lead (V*) *
to - *
the - *
identification - *
of - *
the - *
BRE - *
(Lagrange - *
et - *
al - *
1998) - *
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
will - *
lead lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

It - (A0*
has - *
been - *
shown - *
that - *
Crl - *
stimulates - *
the - *
activity - *)
of - *
sigma - *
(S) - *
leading lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
lead - *)
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
led - *)
to - *
loss - (A1*
of - *
OmpF - *)
. - *

loss - (A1*
of - *
OmpF - *)
was - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *)
activity - *
of - *
sigma - *
(S) - *
. - *

loss - (A1*
of - *
OmpF - *)
is - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *)
activity - *
of - *
sigma - *
(S) - *
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
leads lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
 - *
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
leads lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
has - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
 - *
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
will - *
lead lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
 - *
. - *

Further - *)
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
leads lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
leads lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
has - *
led lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
led lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
leads lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
which - *
has - *
led lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
which - *
led lead (V*) *
us - *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
leads lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
has - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
has - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
has - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
will - *
lead lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
will - *
lead lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
will - *
lead lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
leads lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Closer - (A0*
examination - *
of - *
the - *
putative - *
signal - *
transduction - *
pathway - *
modulating - *
htrA - *
transcription - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
leads lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
leads lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
 - *
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
has - *
led lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
led lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
leads lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
which - *
has - *
led lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
which - *
led lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
will - *
lead lead (V*) *
us - *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
 - *
. - *

It - (A0*
has - *
been - *
shown - *
that - *)
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
leading lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *)
of - *
sigma - *
(S) - *
lead lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *)
of - *
sigma - *
(S) - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

C2+e-mediated - (A1*
transcriptional - *)
suppression - *)
was - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
. - *

C2+e-mediated - (A1*
transcriptional - *)
suppression - *)
is - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
leads lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
leads lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
has - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
 - *
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
has - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
 - *
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
will - *
lead lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
will - *
lead lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
 - *
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
led lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
 - *
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *
cDNA - *
expression - *
vector - *
introduced - *
into - *)
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
leads lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Further - (A0*
experiments - *
with - *
an - *
antisense-ref - *)
cDNA - *
expression - *
vector - *
introduced - *
into - *
cultured - *
cells - *
suggested - *
that - *
DNA - *
(nCaRE) - *
-ref1 - *
interaction - *
which - *
leads lead (V*) *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
has - *
led lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

It - (A0*
has - *
been - *
shown - *
that - *
Crl - *
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
leading lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - *)
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
lead lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
(S) - *
led lead (V*) *
to - *
the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
. - *

the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
was - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *)
sigma - *
(S) - *
. - *

the - (A1*
identification - *
of - *
two - *
new - *
genes - *)
is - *
led lead (V*) *
to - *
by - *
Crl - *
stimulates - *
the - *
activity - *
of - *)
sigma - *
(S) - *
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
led lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
leads lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

By - (A2*
direct - *
sequencing - *
of - *
aberrant - *
SSCA - *
conformers - *)
were - *
revealed - *
15 - *
different - *)
mutations - *
in - *
a - *
total - *
of - *
18 - *
unrelated - *
families - *
and - *
13 - *
single - *
patients - *
Of - *
these - *
10 - *
were - *
novel - *
(7 - *
missense - *
mutations - *
2 - *
mutations - *
that - *
lead lead (V*) *
to - *
frameshift - *
and - *
1 - *
mutation - *
predicted - *
to - *
affect - *
normal - *
splicing) - *
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
which - *
has - *
led lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
which - *
led lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

Crl - (A0*
stimulates - *
the - *
activity - *
of - *
sigma - *
( - *
S - *
) - *)
will - *
lead lead (V*) *
us - *
to - *
an - (A1*
increased - *
transcription - *
rate - *
of - *
a - *
subset - *
of - *
genes - *
of - *
the - *
rpoS - *
regulon - *
in - *
stationary - *
phase - *)
. - *

DNA - (A0*
( - *
nCaRE - *
) - *
-ref1 - *
interaction - *)
but - *
not - *
a - *
wild-type - *
strain - *
led lead (V*) *
to - *
C2+e-mediated - (A1*
transcriptional - *
suppression - *)
. - *

This - (A1*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
might - *
led lead (V*) *
to - *
abnormal - (A2*
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *)
and - *
brought - *
about - *
unstable - *
and - *
abnormal - *
ALD - *
protein; - *
the - *
lignoceryl - *
CoA - *
ligase - *
could - *
not - *
transport - *
very - *
long - *
chain - *
fatty - *
acids - *
(VLCFA) - *
into - *
peroxisome - *
and - *
could - *
not - *
function - *
normally; - *
consequently - *
defective - *
beta-oxidation - *
of - *
VLCFA - *
in - *
peroxisome - *
could - *
result - *
in - *
an - *
accumulation - *
of - *
VLCFAS - *
in - *
the - *
central - *
nervous - *
system - *
adrenal - *
gland - *
and - *
blood - *
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
leads lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
has - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
will - *
lead lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
led lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Transduction - (A0*
of - *
the - *
marA - *
region - *
from - *
a - *
Mar - *
strain - *)
but - *
not - *
a - *
wild-type - *
strain - *
which - *
leads lead (V*) *
to - *
loss - (A1*
of - *
OmpF - *)
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
led lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
leads lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
has - *
led lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
will - *
lead lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
which - *
led lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

Growth - (A1*
of - *
Escherichia - *)
coli - *
in - *
the - *
presence - *
of - *
nitrate - *
or - *
nitrite - *)
which - *
leads lead (V*) *
to - *
a - *
45 - *
* - *
10 - *
/ - *
100 - *
decrease - *
in - *
expression - *
when - *
cells - *
were - *
cultivated - *
in - *
rich - *
medium - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
led lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
leads lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
has - *
led lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
will - *
lead lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
which - *
led lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

The - (A0*
loss - *
of - *
TreR - *
function - *)
which - *
leads lead (V*) *
to - *
derepression - (A1*
of - *
treB - *)
encoding - *
an - *
enzymeIITre - *
of - *
the - *
PTS - *
for - *
trehalose - *
and - *
of - *
treC - *
encoding - *
TreC - *
the - *
cytoplasmic - *
trehalose-6-phosphate - *
hydrolase - *
. - *

In - (A2*
this - *
homologous - *
part - *)
of - *
the - *
genes - *
GPB - *)
lacks - *
one - *
exon - *)
due - *
to - *
a - *
point - *
mutation - *
at - *
the - *
5&apos; - *
splicing - *
site - *
of - *
the - *
third - *
intron - *
which - *
inactivated - *
the - *
5&apos; - *
cleavage - *
event - *
of - *
splicing - *
and - *
led lead (V*) *
to - *
ligation - *
of - *
the - *
second - *
to - *
the - *
fourth - *
exon - *
. - *

In - (A2*
this - *
homologous - *
part - *)
of - *
the - *
genes - *
GPB - *)
lacks - *
one - *
exon - *)
due - *
to - *
a - *
point - *
mutation - *
at - *
the - *
5&apos; - *
splicing - *
site - *
of - *
the - *
third - *
intron - *
which - *
inactivated - *
the - *
5&apos; - *
cleavage - *
event - *
of - *
splicing - *
and - *
has - *
led lead (V*) *
to - *
ligation - *
of - *
the - *
second - *
to - *
the - *
fourth - *
exon - *
. - *

In - (A2*
this - *
homologous - *
part - *)
of - *
the - *
genes - *
GPB - *)
lacks - *
one - *
exon - *)
due - *
to - *
a - *
point - *
mutation - *
at - *
the - *
5&apos; - *
splicing - *
site - *
of - *
the - *
third - *
intron - *
which - *
inactivated - *
the - *
5&apos; - *
cleavage - *
event - *
of - *
splicing - *
and - *
will - *
lead lead (V*) *
to - *
ligation - *
of - *
the - *
second - *
to - *
the - *
fourth - *
exon - *
. - *

In - (A2*
this - *
homologous - *
part - *)
of - *
the - *
genes - *
GPB - *)
lacks - *
one - *
exon - *)
due - *
to - *
a - *
point - *
mutation - *
at - *
the - *
5&apos; - *
splicing - *
site - *
of - *
the - *
third - *
intron - *
which - *
inactivates - *
the - *
5&apos; - *
cleavage - *
event - *
of - *
splicing - *
and - *
that - *
leads lead (V*) *
to - *
ligation - *
of - *
the - *
second - *
to - *
the - *
fourth - *
exon - *
. - *

In - (A2*
this - *
homologous - *
part - *)
of - *
the - *
genes - *
GPB - *)
lacks - *
one - *
exon - *)
due - *
to - *
a - *
point - *
mutation - *
at - *
the - *
5&apos; - *
splicing - *
site - *
of - *
the - *
third - *
intron - *
which - *
inactivated - *
the - *
5&apos; - *
cleavage - *
event - *
of - *
splicing - *
and - *
which - *
led lead (V*) *
to - *
ligation - *
of - *
the - *
second - *
to - *
the - *
fourth - *
exon - *
. - *

We - (A2*
also - *
studied - *
in - *
detail - *
a - *
complex - *
splice - *)
site - *
mutation - *
3332dupl8bp - *
which - *
was - *
found - *)
to - *
lead - *)
to - *
an - *
abnormal - *
JAG1 - *
mRNA - *
resulting - *
in - *
a - *
premature - *
stop - *
codon - *
. - *

We - (A2*
also - *
studied - *
in - *
detail - *
a - *
complex - *
splice - *)
site - *
mutation - *
3332dupl8bp - *
which - *
led lead (V*) *
to - *
an - *)
abnormal - *)
JAG1 - *
mRNA - *
resulting - *
in - *
a - *
premature - *
stop - *
codon - *
. - *

We - (A2*
also - *
study - *
in - *
detail - *
a - *
complex - *
splice - *
site - *
mutation - *
3332dupl8bp - *
which - *
lead lead (V*) *
to - *
an - *)
abnormal - *)
JAG1 - *
mRNA - *
resulting - *
in - *
a - *
premature - *
stop - *
codon - *
. - *

We - (A2*
also - *
studied - *
in - *
detail - *
a - *
complex - *
splice - *)
site - *
mutation - *
3332dupl8bp - *
led lead (V*) *
to - *
an - *
abnormal - *)
JAG1 - *)
mRNA - *
resulting - *
in - *
a - *
premature - *
stop - *
codon - *
. - *

We - (A2*
also - *
study - *
in - *
detail - *
a - *
complex - *
splice - *
site - *
mutation - *
3332dupl8bp - *
lead lead (V*) *
to - *
an - *
abnormal - *)
JAG1 - *)
mRNA - *
resulting - *
in - *
a - *
premature - *
stop - *
codon - *
. - *

This - *)
patient&apos;s - *
DNA - *
contains - *
a - *
C----A - *)
transversion - *
in - *
the - *
splice - *
acceptor - *
sequence - *)
of - *
the - *
last - *
intron - *
of - *
the - *
only - *
ERCC-3 - *
allele - *
leads lead (V*) *
to - *
a - *
4 - *
bp - *
insertion - *
in - *
the - *
mRNA - *
and - *
an - *
inactivates - *
frameshift - *
in - *
the - *
C-terminus - *
of - *
the - *
protein - *
. - *

This - *)
patient&apos;s - *
DNA - *
contains - *
a - *
C----A - *)
transversion - *
in - *
the - *
splice - *
acceptor - *
sequence - *)
of - *
the - *
last - *
intron - *
of - *
the - *
only - *
ERCC-3 - *
allele - *
led lead (V*) *
to - *
a - *
4 - *
bp - *
insertion - *
in - *
the - *
mRNA - *
and - *
an - *
inactivated - *
frameshift - *
in - *
the - *
C-terminus - *
of - *
the - *
protein - *
. - *

This - *)
patient&apos;s - *
DNA - *
contains - *
a - *
C----A - *)
transversion - *
in - *
the - *
splice - *
acceptor - *
sequence - *)
of - *
the - *
last - *
intron - *
of - *
the - *
only - *
ERCC-3 - *
allele - *
which - *
leads lead (V*) *
to - *
a - *
4 - *
bp - *
insertion - *
in - *
the - *
mRNA - *
and - *
an - *
inactivates - *
frameshift - *
in - *
the - *
C-terminus - *
of - *
the - *
protein - *
. - *

This - *)
patient&apos;s - *
DNA - *
contains - *
a - *
C----A - *)
transversion - *
in - *
the - *
splice - *
acceptor - *
sequence - *)
of - *
the - *
last - *
intron - *
of - *
the - *
only - *
ERCC-3 - *
allele - *
which - *
led lead (V*) *
to - *
a - *
4 - *
bp - *
insertion - *
in - *
the - *
mRNA - *
and - *
an - *
inactivated - *
frameshift - *
in - *
the - *
C-terminus - *
of - *
the - *
protein - *
. - *

G979A - (A2*)
affects - *
a - *
splice - *
consensus - *)
site - *
at - *
the - *
end - *
of - *
exon - *
8 - *
and - *
G1488T - *
in - *
exon - *
14 - *
led lead (V*) *
to - *
a - *
replacement - *
of - *
a - *
positive - *
charge - *
in - *
a - *
highly - *
conserved - *
putative - *
transmembrane - *
domain - *
(R496S) - *
. - *

G979A - (A2*)
affects - *
a - *
splice - *
consensus - *)
site - *
at - *
the - *
end - *
of - *
exon - *
8 - *
and - *
G1488T - *
in - *
exon - *
14 - *
which - *
leads lead (V*) *
to - *
a - *
replacement - *
of - *
a - *
positive - *
charge - *
in - *
a - *
highly - *
conserved - *
putative - *
transmembrane - *
domain - *
(R496S) - *
. - *

G979A - (A2*)
affects - *
a - *
splice - *
consensus - *)
site - *
at - *
the - *
end - *
of - *
exon - *
8 - *
and - *
G1488T - *
in - *
exon - *
14 - *
which - *
led lead (V*) *
to - *
a - *
replacement - *
of - *
a - *
positive - *
charge - *
in - *
a - *
highly - *
conserved - *
putative - *
transmembrane - *
domain - *
(R496S) - *
. - *

G979A - (A2*)
affects - *
a - *
splice - *
consensus - *)
site - *
at - *
the - *
end - *
of - *
exon - *
8 - *
and - *
G1488T - *
in - *
exon - *
14 - *
that - *
leads lead (V*) *
to - *
a - *
replacement - *
of - *
a - *
positive - *
charge - *
in - *
a - *
highly - *
conserved - *
putative - *
transmembrane - *
domain - *
(R496S) - *
. - *

G979A - (A2*)
affects - *
a - *
splice - *
consensus - *)
site - *
at - *
the - *
end - *
of - *
exon - *
8 - *
and - *
G1488T - *
in - *
exon - *
14 - *
has - *
led lead (V*) *
to - *
a - *
replacement - *
of - *
a - *
positive - *
charge - *
in - *
a - *
highly - *
conserved - *
putative - *
transmembrane - *
domain - *
(R496S) - *
. - *

Disruption - (A2*
of - *
the - *
SNU246 - *
gene - *
in - *
yeast - *)
was - *)
lethal - *
and - *
led lead (V*) *
to - *
a - *
splicing - *
defect - *
in - *
vivo - *
indicating - *)
that - *
the - *
protein - *
is - *
essential - *
for - *
splicing - *
. - *

Disruption - (A2*
of - *
the - *
SNU246 - *
gene - *
in - *
yeast - *)
is - *)
lethal - *
and - *
which - *
leads lead (V*) *
to - *
a - *
splicing - *
defect - *
in - *
vivo - *)
indicating - *
that - *
the - *
protein - *
is - *
essential - *
for - *
splicing - *
. - *

Disruption - (A2*
of - *
the - *
SNU246 - *
gene - *
in - *
yeast - *)
was - *)
lethal - *
and - *
which - *
led lead (V*) *
to - *
a - *
splicing - *
defect - *
in - *
vivo - *)
indicating - *
that - *
the - *
protein - *
is - *
essential - *
for - *
splicing - *
. - *

Disruption - (A2*
of - *
the - *
SNU246 - *
gene - *
in - *
yeast - *)
was - *)
lethal - *
and - *
leading lead (V*) *
to - *
a - *
splicing - *
defect - *
in - *
vivo - *)
indicating - *
that - *
the - *
protein - *
is - *
essential - *
for - *
splicing - *
. - *

The - (A2*
mutations - *
identified - *
include: - *
two - *
frameshifts - *)
and - *
a - *
splice - *
site - *
mutation - *
leading lead (V*) *
to - *
truncated - *
OA1 - *
proteins; - *)
a - *
deletion - *
of - *
a - *
threonine - *
codon - *
at - *
position - *
290; - *
and - *
four - *
missense - *
mutations - *
two - *
of - *
which - *
involve - *
amino - *
acids - *
located - *
within - *
putative - *
transmembrane - *
domains - *
. - *

The - (A2*
mutations - *
identified - *
include: - *
two - *
frameshifts - *)
and - *
a - *
splice - *
site - *
mutation - *
which - *
lead lead (V*) *
to - *
truncated - *
OA1 - *)
proteins; - *
a - *
deletion - *
of - *
a - *
threonine - *
codon - *
at - *
position - *
290; - *
and - *
four - *
missense - *
mutations - *
two - *
of - *
which - *
involve - *
amino - *
acids - *
located - *
within - *
putative - *
transmembrane - *
domains - *
. - *

The - (A2*
mutations - *
identified - *
include: - *
two - *
frameshifts - *)
and - *
a - *
splice - *
site - *
mutation - *
which - *
led lead (V*) *
to - *
truncated - *
OA1 - *)
proteins; - *
a - *
deletion - *
of - *
a - *
threonine - *
codon - *
at - *
position - *
290; - *
and - *
four - *
missense - *
mutations - *
two - *
of - *
which - *
involve - *
amino - *
acids - *
located - *
within - *
putative - *
transmembrane - *
domains - *
. - *

The - (A2*
mutations - *
identified - *
include: - *
two - *
frameshifts - *)
and - *
a - *
splice - *
site - *
mutation - *
that - *
lead lead (V*) *
to - *
truncated - *
OA1 - *)
proteins; - *
a - *
deletion - *
of - *
a - *
threonine - *
codon - *
at - *
position - *
290; - *
and - *
four - *
missense - *
mutations - *
two - *
of - *
which - *
involve - *
amino - *
acids - *
located - *
within - *
putative - *
transmembrane - *
domains - *
. - *

The - *)
mutations - *
identified - *
include: - *
two - *
frameshifts - *)
and - *
a - *
splice - *
site - *
mutation - *
have - *
led lead (V*) *
to - *
truncated - *
OA1 - *
proteins; - *
a - *
deletion - *
of - *
a - *
threonine - *
codon - *
at - *
position - *
290; - *
and - *
four - *
missense - *
mutations - *
two - *
of - *
which - *
involve - *
amino - *
acids - *
located - *
within - *
putative - *
transmembrane - *
domains - *
. - *

These - (A2*
results - *
suggest - *
that - *
the - *
distinct - *)
amino - *)
termini - *
led lead (V*) *
to - *
the - *
targeting - *
of - *
individual - *
VDAC - *
isoforms - *
to - *
different - *
cellular - *
compartments - *
. - *

These - (A2*
results - *
suggest - *
that - *
the - *
distinct - *)
amino - *)
termini - *
leading lead (V*) *
to - *
the - *
targeting - *
of - *
individual - *
VDAC - *
isoforms - *
to - *
different - *
cellular - *
compartments - *
. - *

These - (A2*
results - *
suggest - *
that - *
the - *
distinct - *)
amino - *)
termini - *
 - *
has - *
led lead (V*) *
to - *
the - *
targeting - *
of - *
individual - *
VDAC - *
isoforms - *
to - *
different - *
cellular - *
compartments - *
. - *

These - (A2*
results - *
suggest - *
that - *
the - *
distinct - *)
amino - *)
termini - *
 - *
which - *
led lead (V*) *
to - *
the - *
targeting - *
of - *
individual - *
VDAC - *
isoforms - *
to - *
different - *
cellular - *
compartments - *
. - *

This - (A1*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
might - *
lead lead (V*) *
to - *
abnormal - (A2*
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *)
and - *
bring - *
about - *
unstable - *
and - *
abnormal - *
ALD - *
protein; - *
the - *
lignoceryl - *
CoA - *
ligase - *
could - *
not - *
transport - *
very - *
long - *
chain - *
fatty - *
acids - *
(VLCFA) - *
into - *
peroxisome - *
and - *
could - *
not - *
function - *
normally; - *
consequently - *
defective - *
beta-oxidation - *
of - *
VLCFA - *
in - *
peroxisome - *
could - *
result - *
in - *
an - *
accumulation - *
of - *
VLCFAS - *
in - *
the - *
central - *
nervous - *
system - *
adrenal - *
gland - *
and - *
blood - *
. - *

This - (A1*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
might - *
leading lead (V*) *
to - *
abnormal - (A2*
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *)
and - *
bring - *
about - *
unstable - *
and - *
abnormal - *
ALD - *
protein; - *
the - *
lignoceryl - *
CoA - *
ligase - *
could - *
not - *
transport - *
very - *
long - *
chain - *
fatty - *
acids - *
(VLCFA) - *
into - *
peroxisome - *
and - *
could - *
not - *
function - *
normally; - *
consequently - *
defective - *
beta-oxidation - *
of - *
VLCFA - *
in - *
peroxisome - *
could - *
result - *
in - *
an - *
accumulation - *
of - *
VLCFAS - *
in - *
the - *
central - *
nervous - *
system - *
adrenal - *
gland - *
and - *
blood - *
. - *

This - (A1*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
might - *
has - *
led lead (V*) *
to - *
abnormal - (A2*
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *)
and - *
brought - *
about - *
unstable - *
and - *
abnormal - *
ALD - *
protein; - *
the - *
lignoceryl - *
CoA - *
ligase - *
could - *
not - *
transport - *
very - *
long - *
chain - *
fatty - *
acids - *
(VLCFA) - *
into - *
peroxisome - *
and - *
could - *
not - *
function - *
normally; - *
consequently - *
defective - *
beta-oxidation - *
of - *
VLCFA - *
in - *
peroxisome - *
could - *
result - *
in - *
an - *
accumulation - *
of - *
VLCFAS - *
in - *
the - *
central - *
nervous - *
system - *
adrenal - *
gland - *
and - *
blood - *
. - *

The - (A2*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
leading - *)
to - *
abnormal - *
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *
appears - *
to - *
be - *
one - *
of - *
the - *
causes - *
of - *
X-linked - *
recessive - *
adrenoleukodystrophy - *
. - *

The - (A2*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
leads - *)
to - *
abnormal - *
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *
appears - *
to - *
be - *
one - *
of - *
the - *
causes - *
of - *
X-linked - *
recessive - *
adrenoleukodystrophy - *
. - *

The - (A2*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
led lead (V*) *
to - *)
abnormal - *
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *
appears - *
to - *
be - *
one - *
of - *
the - *
causes - *
of - *
X-linked - *
recessive - *
adrenoleukodystrophy - *
. - *

The - (A2*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
which - *)
leads lead (V*) *
to - *
abnormal - *
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *
appears - *
to - *
be - *
one - *
of - *
the - *
causes - *
of - *
X-linked - *
recessive - *
adrenoleukodystrophy - *
. - *

The - (A2*
splice - *
mutation - *
in - *
5 - *
end - *
of - *
intron - *)
5 - *
has - *
led - *)
to - *
abnormal - *
splice - *
in - *
exon - *
5 - *
and - *
exon - *
6 - *
appears - *
to - *
be - *
one - *
of - *
the - *
causes - *
of - *
X-linked - *
recessive - *
adrenoleukodystrophy - *
. - *

In - *)
mice - *
inactivation - *
of - *
the - *
MEF2C - *
gene - *
which - *)
is - *
the - *
first - *
MEF2 - *
isoform - *
expressed - *
during - *
embryonic - *
development - *
led lead (V*) *
to - *
cardiac - *
morphogenetic - *
defects - *
vascular - *
abnormalities - *
and - *
lethality - *
by - *
embryonic - *
day - *
95 - *
(Lin - *
et - *
al - *
1997 - *
1998; - *
Bi - *
et - *
al - *
1999) - *
. - *

In - *)
mice - *
inactivation - *
of - *
the - *
MEF2C - *
gene - *
which - *)
is - *
the - *
first - *
MEF2 - *
isoform - *
expressed - *
during - *
embryonic - *
development - *
leading lead (V*) *
to - *
cardiac - *
morphogenetic - *
defects - *
vascular - *
abnormalities - *
and - *
lethality - *
by - *
embryonic - *
day - *
95 - *
(Lin - *
et - *
al - *
1997 - *
1998; - *
Bi - *
et - *
al - *
1999) - *
. - *

In - *)
mice - *
inactivation - *
of - *
the - *
MEF2C - *
gene - *
which - *)
is - *
the - *
first - *
MEF2 - *
isoform - *
expressed - *
during - *
embryonic - *
development - *
has - *
led lead (V*) *
to - *
cardiac - *
morphogenetic - *
defects - *
vascular - *
abnormalities - *
and - *
lethality - *
by - *
embryonic - *
day - *
95 - *
(Lin - *
et - *
al - *
1997 - *
1998; - *
Bi - *
et - *
al - *
1999) - *
. - *

In - *)
mice - *
inactivation - *
of - *
the - *
MEF2C - *
gene - *
which - *)
is - *
the - *
first - *
MEF2 - *
isoform - *
expressed - *
during - *
embryonic - *
development - *
which - *
leads lead (V*) *
to - *
cardiac - *
morphogenetic - *
defects - *
vascular - *
abnormalities - *
and - *
lethality - *
by - *
embryonic - *
day - *
95 - *
(Lin - *
et - *
al - *
1997 - *
1998; - *
Bi - *
et - *
al - *
1999) - *
. - *

In - *)
mice - *
inactivation - *
of - *
the - *
MEF2C - *
gene - *
which - *)
is - *
the - *
first - *
MEF2 - *
isoform - *
expressed - *
during - *
embryonic - *
development - *
which - *
led lead (V*) *
to - *
cardiac - *
morphogenetic - *
defects - *
vascular - *
abnormalities - *
and - *
lethality - *
by - *
embryonic - *
day - *
95 - *
(Lin - *
et - *
al - *
1997 - *
1998; - *
Bi - *
et - *
al - *
1999) - *
. - *

It - (A1*
was - *
reported - *)
that - *
GPI - *
anchoring - *)
ability - *
has - *
been - *
lost lose (V*) *
when - *
the - *
microsomal - *
membranes - *
of - *
Trypanosoma - *
brucei - *
were - *
washed - *
at - *
high - *
pH - *
(Sharma - *
et - *
al - *
2000) - *
whereas - *
similar - *
treatment - *
of - *
the - *
mammalian - *
microsomal - *
membranes - *
had - *
no - *
effect - *
(Vidugiriene - *
and - *
Menon - *
1995) - *
. - *

all - (A1*
Paurkinje - *
cells - *)
postnatally - *
are - *
lost lose (V*) *
by - *
aggregation - *
chimeras - *
between - *
Lc/+ - *
mice - *
. - *

To - (A1*
this - *
end - *
we - *
made - *)
aggregation - *
chimeras - *
between - *
Lc/+ - *
mice - *
has - *
lost lose (V*) *
all - *
Purkinje - *
cells - *
postnatally - *
and - *
+/+ - *
control - *
mice - *
. - *

To - (A1*
this - *
end - *
we - *
made - *)
aggregation - *
chimeras - *
between - *
Lc/+ - *
mice - *
losing lose (V*) *
all - *
Purkinje - *
cells - *
postnatally - *
and - *
+/+ - *
control - *
mice - *
. - *

To - (A1*
this - *
end - *
we - *
made - *)
aggregation - *
chimeras - *
between - *
Lc/+ - *
mice - *
which - *
lost lose (V*) *
all - *
Purkinje - *
cells - *
postnatally - *
and - *
+/+ - *
control - *
mice - *
. - *

The - *)
mice - *
that - *
do - *
not - *
lose lose (V*) *
weight - *
during - *)
the - *
treatment - *
. - *

The - *)
mice - *
that - *
did - *
not - *
lose lose (V*) *
weight - *
during - *
the - *
treatment - *
. - *

It - (A1*
was - *
reported - *)
that - *
GPI - *
anchoring - *)
ability - *
would - *
be - *
lost lose (V*) *
when - *
the - *
microsomal - *
membranes - *
of - *
Trypanosoma - *
brucei - *
were - *
washed - *
at - *
high - *
pH - *
(Sharma - *
et - *
al - *
2000) - *
whereas - *
similar - *
treatment - *
of - *
the - *
mammalian - *
microsomal - *
membranes - *
have - *
no - *
effect - *
(Vidugiriene - *
and - *
Menon - *
1995) - *
. - *

It - (A1*
was - *
reported - *)
that - *
GPI - *
anchoring - *)
ability - *
will - *
be - *
lost lose (V*) *
when - *
the - *
microsomal - *
membranes - *
of - *
Trypanosoma - *
brucei - *
were - *
washed - *
at - *
high - *
pH - *
(Sharma - *
et - *
al - *
2000) - *
whereas - *
similar - *
treatment - *
of - *
the - *
mammalian - *
microsomal - *
membranes - *
had - *
no - *
effect - *
(Vidugiriene - *
and - *
Menon - *
1995) - *
. - *

It - (A1*
was - *
reported - *)
that - *
GPI - *
anchoring - *)
ability - *
is - *
lost lose (V*) *
when - *
the - *
microsomal - *
membranes - *
of - *
Trypanosoma - *
brucei - *
were - *
washed - *
at - *
high - *
pH - *
(Sharma - *
et - *
al - *
2000) - *
whereas - *
similar - *
treatment - *
of - *
the - *
mammalian - *
microsomal - *
membranes - *
have - *
no - *
effect - *
(Vidugiriene - *
and - *
Menon - *
1995) - *
. - *

These - (A2*
interactions - *)
were - *
lost lose (V*) *
with - *
a - *
separation - *
of - *
DNA-binding - *
sites - *
of - *
}3 - *)
bp - *
as - *
can - *
occur - *
for - *
natural - *
SRE - *
sequences - *
while - *
a - *
smaller - *
spacing - *
inhibited - *
the - *
simultaneous - *
binding - *
of - *
both - *
proteins - *
. - *

These - (A1*
data - *
suggest - *
that - *)
phosphorylation - *)
of - *
the - *
MuSK - *
NPXY - *
site - *
which - *
leads - *
to - *
recruitment - *
of - *
a - *
phosphotyrosine-binding - *
domain-containing - *
protein - *
that - *
functions - *
to - *
stimulate - *
phosphorylation - *
and - *
clustering - *
of - *
AchRs - *
. - *

Stat3 - (A2*
is - *
activated - *
in - *
v-Src - *
?r - *
v-abl-transformed - *)
cells - *
and - *
along - *
other - *
Stats - *
in - *
acute - *
T-cell - *
leukemia - *
cells - *
losing lose (V*) *
IL-2 - *
dependency - *
(Migone - *
et - *
al - *
1995; - *
Yu - *
et - *
al - *
1995) - *
. - *

Stat3 - (A2*
is - *
activated - *
in - *
v-Src - *
?r - *
v-abl-transformed - *)
cells - *
and - *
along - *
other - *
Stats - *
in - *
acute - *
T-cell - *
leukemia - *
cells - *
that - *
will - *
lose lose (V*) *
IL-2 - *
dependency - *
(Migone - *
et - *
al - *
1995; - *
Yu - *
et - *
al - *
1995) - *
. - *

Stat3 - (A2*
is - *
activated - *
in - *
v-Src - *
?r - *
v-abl-transformed - *)
cells - *
and - *
along - *
other - *
Stats - *
in - *
acute - *
T-cell - *
leukemia - *
cells - *
that - *
lose lose (V*) *
IL-2 - *
dependency - *
(Migone - *
et - *
al - *
1995; - *
Yu - *
et - *
al - *
1995) - *
. - *

Stat3 - (A2*
is - *
activated - *
in - *
v-Src - *
?r - *
v-abl-transformed - *)
cells - *
and - *
along - *
other - *
Stats - *
in - *
acute - *
T-cell - *
leukemia - *
cells - *
that - *
lost lose (V*) *
IL-2 - *
dependency - *
(Migone - *
et - *
al - *
1995; - *
Yu - *
et - *
al - *
1995) - *
. - *

Stat3 - (A2*
is - *
activated - *
in - *
v-Src - *
?r - *
v-abl-transformed - *)
cells - *
and - *
along - *
other - *
Stats - *
in - *
acute - *
T-cell - *
leukemia - *
cells - *
that - *
have - *
lost lose (V*) *
IL-2 - *
dependency - *
(Migone - *
et - *
al - *
1995; - *
Yu - *
et - *
al - *
1995) - *
. - *

all - (A1*
Purkinje - *
cells - *)
postnatally - *
were - *
lost lose (V*) *
by - *
aggregation - *
chimeras - *
between - *
Lc/+ - *
mice - *
. - *

These - (A2*
interactions - *)
which - *
are - *
lost lose (V*) *
with - *
a - *
separation - *
of - *
DNA-binding - *
sites - *)
of - *
}3 - *
bp - *
as - *
can - *
occur - *
for - *
natural - *
SRE - *
sequences - *
while - *
a - *
smaller - *
spacing - *
inhibited - *
the - *
simultaneous - *
binding - *
of - *
both - *
proteins - *
. - *

These - *)
interactions - *)
have - *
ben - *
lost lose (V*) *
with - *
a - *
separation - *
of - *
DNA-binding - *
sites - *
of - *
}3 - *
bp - *
as - *
can - *
occur - *
for - *
natural - *
SRE - *
sequences - *
while - *
a - *
smaller - *
spacing - *
would - *
inhibit - *
the - *
simultaneous - *
binding - *
of - *
both - *
proteins - *
. - *

These - (A2*
interactions - *)
are - *
lost lose (V*) *
with - *
a - *
separation - *
of - *
DNA-binding - *
sites - *
of - *
}3 - *)
bp - *
as - *
can - *
occur - *
for - *
natural - *
SRE - *
sequences - *
while - *
a - *
smaller - *
spacing - *
inhibits - *
the - *
simultaneous - *
binding - *
of - *
both - *
proteins - *
. - *

Previous - *)
studies - *
have - *
emphasized - *
the - *
high - *)
sensitivity - *
of - *
the - *
N-terminal - *
region - *
to - *
proteolytic - *
cleavage - *
leading - *
to - *
truncated - *
species - *
losing lose (V*) *
the - *
first - *
20&amp;#8211; - *
70 - *
residues - *
but - *
that - *
retain - *
enzymatic - *
activity - *
and - *
dimeric - *
structure - *
. - *

No - (A1*
severe - *)
complications - *
have - *
been - *
reported - *)
and - *
after - *
the - *
BIB - *
removal - *
subjects - *
are - *
maintaining - *
the - *
obtained - *
results - *
with - *
some - *
of - *
them - *
has - *
lost lose (V*) *
weight - *
. - *

No - (A1*
severe - *)
complications - *
have - *
been - *
reported - *)
and - *
after - *
the - *
BIB - *
removal - *
subjects - *
are - *
maintaining - *
the - *
obtained - *
results - *
with - *
some - *
of - *
them - *
will - *
lose lose (V*) *
weight - *
. - *

No - (A1*
severe - *)
complications - *
have - *
been - *
reported - *)
and - *
after - *
the - *
BIB - *
removal - *
subjects - *
are - *
maintaining - *
the - *
obtained - *
results - *
with - *
some - *
of - *
them - *
lost lose (V*) *
weight - *
. - *

No - (A1*
severe - *)
complications - *
have - *
been - *
reported - *)
and - *
after - *
the - *
BIB - *
removal - *
subjects - *
are - *
maintaining - *
the - *
obtained - *
results - *
with - *
some - *
of - *
them - *
lose lose (V*) *
weight - *
. - *

No - (A1*
severe - *)
complications - *
have - *
been - *
reported - *)
and - *
after - *
the - *
BIB - *
removal - *
subjects - *
are - *
maintaining - *
the - *
obtained - *
results - *
with - *
some - *
of - *
them - *
continuing - *
losing lose (V*) *
weight - *
. - *

This - (A0*
study - *)
investigated - *
whether - *
informing - *
obese - *
individuals - *
that - *
they - *
has - *
lose lose (V*) *
only - *
modest - *
amounts - *
of - *
weight - (A1*)
would - *
lead - *
them - *
to - *
adopt - *
more - *
realistic - *
weight - *
loss - *
expectations - *
. - *

This - (A0*
study - *)
investigated - *
whether - *
informing - *
obese - *
individuals - *
that - *
they - *
lose lose (V*) *
only - *
modest - *
amounts - *
of - *
weight - (A1*)
would - *
lead - *
them - *
to - *
adopt - *
more - *
realistic - *
weight - *
loss - *
expectations - *
. - *

This - (A0*
study - *)
investigated - *
whether - *
informing - *
obese - *
individuals - *
that - *
they - *
lost lose (V*) *
only - *
modest - *
amounts - *
of - *
weight - (A1*)
would - *
lead - *
them - *
to - *
adopt - *
more - *
realistic - *
weight - *
loss - *
expectations - *
. - *

This - (A0*
study - *)
investigated - *
whether - *
informing - *
obese - *
individuals - *
that - *
they - *
will - *
lose lose (V*) *
only - *
modest - *
amounts - *
of - *
weight - (A1*)
would - *
lead - *
them - *
to - *
adopt - *
more - *
realistic - *
weight - *
loss - *
expectations - *
. - *

its - (A1*
prokaryote-type - *)
organelle - *)
genome - *
is - *
lost lose (V*) *
completely - *
by - *
no - *
known - *
plastid - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

Previous - *)
studies - *
have - *
emphasized - *
the - *
high - *)
sensitivity - *
of - *
the - *
N-terminal - *
region - *
to - *
proteolytic - *
cleavage - *
leading - *
to - *
truncated - *
species - *
that - *
will - *
lost lose (V*) *
the - *
first - *
20&amp;#8211; - *
70 - *
residues - *
but - *
that - *
retain - *
enzymatic - *
activity - *
and - *
dimeric - *
structure - *
. - *

Previous - *)
studies - *
have - *
emphasized - *
the - *
high - *)
sensitivity - *
of - *
the - *
N-terminal - *
region - *
to - *
proteolytic - *
cleavage - *
leading - *
to - *
truncated - *
species - *
that - *
lose lose (V*) *
the - *
first - *
20&amp;#8211; - *
70 - *
residues - *
but - *
that - *
retain - *
enzymatic - *
activity - *
and - *
dimeric - *
structure - *
. - *

No - (A1*
known - *
plastid - *)
completely - *)
lost lose (V*) *
its - *
prokaryote-type - *
organelle - *
genome - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

These - (A1*
data - *
suggest - *
that - *)
phosphorylation - *)
of - *
the - *
MuSK - *
NPXY - *
site - *
led - *
to - *
recruitment - *
of - *
a - *
phosphotyrosine-binding - *
domain-containing - *
protein - *
that - *
functions - *
to - *
stimulate - *
phosphorylation - *
and - *
clustering - *
of - *
AchRs - *
. - *

The - *)
mice - *
which - *
do - *
not - *
lose lose (V*) *
weight - *
during - *
the - *
treatment - *
. - *

Sph - (A2*
I - *
cleavage - *)
site - *
within - *
exon - *
3 - *
has - *
been - *
characterized - *
is - *
lost lose (V*) *
by - *
A - *
new - *
transthyretin - *
variant - *
. - *

The - *)
mice - *
do - *
not - *
lose lose (V*) *
weight - *
during - *)
the - *
treatment - *
. - *

A - (A2*
new - *)
transthyretin - *)
variant - *
losing lose (V*) *
an - *
Sph - *
I - *
cleavage - *
site - *
within - *
exon - *
3 - *
has - *
been - *
characterized - *
. - *

A - (A2*
new - *)
transthyretin - *)
variant - *
has - *
lost lose (V*) *
an - *
Sph - *
I - *
cleavage - *
site - *
within - *
exon - *
3 - *
has - *
been - *
characterized - *
. - *

Sph - (A2*
I - *
cleavage - *)
site - *
within - *
exon - *
3 - *
has - *
been - *
characterized - *
was - *
lost lose (V*) *
by - *
A - *
new - *
transthyretin - *
variant - *
. - *

A - (A2*
new - *)
transthyretin - *)
variant - *
which - *
loses lose (V*) *
an - *
Sph - *
I - *
cleavage - *
site - *
within - *
exon - *
3 - *
has - *
been - *
characterized - *
. - *

These - (A1*
data - *
suggest - *
that - *)
phosphorylation - *)
of - *
the - *
MuSK - *
NPXY - *
site - *
has - *
led - *
to - *
recruitment - *
of - *
a - *
phosphotyrosine-binding - *
domain-containing - *
protein - *
that - *
functions - *
to - *
stimulate - *
phosphorylation - *
and - *
clustering - *
of - *
AchRs - *
. - *

its - (A1*
prokaryote-type - *)
organelle - *)
genome - *
was - *
lost lose (V*) *
completely - *
by - *
no - *
known - *
plastid - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

Previous - *)
studies - *
have - *
emphasized - *
the - *
high - *)
sensitivity - *
of - *
the - *
N-terminal - *
region - *
to - *
proteolytic - *
cleavage - *
leading - *
to - *
truncated - *
species - *
that - *
lost lose (V*) *
the - *
first - *
20&amp;#8211; - *
70 - *
residues - *
but - *
that - *
retain - *
enzymatic - *
activity - *
and - *
dimeric - *
structure - *
. - *

No - (A1*
known - *
plastid - *)
completely - *)
which - *
loses lose (V*) *
its - *
prokaryote-type - *
organelle - *
genome - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

These - (A1*
data - *
suggest - *
that - *)
phosphorylation - *)
of - *
the - *
MuSK - *
NPXY - *
site - *
leading - *
to - *
recruitment - *
of - *
a - *
phosphotyrosine-binding - *
domain-containing - *
protein - *
that - *
functions - *
to - *
stimulate - *
phosphorylation - *
and - *
clustering - *
of - *
AchRs - *
. - *

No - (A1*
known - *
plastid - *)
completely - *)
which - *
lost lose (V*) *
its - *
prokaryote-type - *
organelle - *
genome - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

These - (A1*
data - *
suggest - *
that - *)
phosphorylation - *)
of - *
the - *
MuSK - *
NPXY - *
site - *
which - *
led - *
to - *
recruitment - *
of - *
a - *
phosphotyrosine-binding - *
domain-containing - *
protein - *
that - *
functions - *
to - *
stimulate - *
phosphorylation - *
and - *
clustering - *
of - *
AchRs - *
. - *

No - (A1*
known - *
plastid - *)
completely - *)
loses lose (V*) *
its - *
prokaryote-type - *
organelle - *
genome - *
but - *
all - *
show - *
considerablegenome - *
reduction - *
and - *
dependency - *
on - *
the - *
nucleus - *
to - *
fulfill - *
plastid - *
functions - *
(Martin - *
and - *
Hrrmann - *
1998) - *
. - *

The - *)
mice - *
which - *
did - *
not - *
lose lose (V*) *
weight - *)
during - *
the - *
treatment - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
HVDAC - (A1*
genes - *)
are - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
HVDAC - (A1*
genes - *)
were - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
HVDAC - (A1*
genes - *)
has - *
been - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

the - (A1*
ability - *)
to - *
interact - *
with - *
the - *
X - *
protein - *
and - *
to - *
bring - *
it - *
into - *
the - *
initiation - *
complex - *
are - *
lost - *
by - *
the - *
C-terminal-deletion - *
mutant - *
of - *
hnRNP - *
A1 - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
some - (A1*
of - *
which - *)
will - *
be - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
some - (A1*
of - *
which - *)
has - *
been - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
some - (A1*
of - *
which - *)
were - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
some - (A1*
of - *
which - *)
are - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

An - *
immunopurification - *
approach - *
has - *
been - *
used - *
to - *
demonstrate - *
that - *
human - *
RNA - *
Pol - *
III - *
is - *
composed - *
of - *
16 - *
subunits - *
HVDAC - (A1*
genes - *)
will - *
be - *
apparently - *
modified modify (V*) *
in - *
HeLa - *
cells - *
. - *

the - (A1*
ability - *)
to - *
interact - *
with - *
the - *
X - *
protein - *
and - *
to - *
bring - *
it - *
into - *
the - *
initiation - *
complex - *
were - *
lost - *
by - *
the - *
C-terminal-deletion - *
mutant - *
of - *
hnRNP - *
A1 - *
. - *

These - *
results - *
lead - *
us - *
to - *
conclude - *
that - *
EnvZ - (A0*)
and - *
OmpR - (A1*)
act - *
in - *
sequential - *
fashion - *
to - *
activate - *
porin - *
gene - *
expression; - *
ie - *
EnvZ - *
modifies modify (V*) *
or - *
in - *
some - *
way - *
directs - *
OmpR - *
which - *
in - *
turn - *
acts - (A3*
at - *
the - *
appropriate - *
porin - *
gene - *
promoter - *)
. - *

These - *
results - *
lead - *
us - *
to - *
conclude - *
that - *
EnvZ - (A0*)
and - *
OmpR - (A1*)
act - *
in - *
sequential - *
fashion - *
to - *
activate - *
porin - *
gene - *
expression; - *
ie - *
EnvZ - *
modified modify (V*) *
or - *
in - *
some - *
way - *
directs - *
OmpR - *
which - *
in - *
turn - *
acts - (A3*
at - *
the - *
appropriate - *
porin - *
gene - *
promoter - *)
. - *

These - *
results - *
lead - *
us - *
to - *
conclude - *
that - *
EnvZ - (A0*)
and - *
OmpR - (A1*)
act - *
in - *
sequential - *
fashion - *
to - *
activate - *
porin - *
gene - *
expression; - *
ie - *
EnvZ - *
has - *
modified modify (V*) *
or - *
in - *
some - *
way - *
directs - *
OmpR - *
which - *
in - *
turn - *
acts - (A3*
at - *
the - *
appropriate - *
porin - *
gene - *
promoter - *)
. - *

These - *
results - *
lead - *
us - *
to - *
conclude - *
that - *
EnvZ - (A0*)
and - *
OmpR - (A1*)
act - *
in - *
sequential - *
fashion - *
to - *
activate - *
porin - *
gene - *
expression; - *
ie - *
EnvZ - *
which - *
modifies modify (V*) *
or - *
in - *
some - *
way - *
directs - *
OmpR - *
which - *
in - *
turn - *
acts - (A3*
at - *
the - *
appropriate - *
porin - *
gene - *
promoter - *)
. - *

Analysis - *
of - *
one - *
cDNA - *
revealed - *
an - *
unusual - *
splicing - *
event - *
involving - *
EZH1 - *
and - *
a - *
tandemly - *
linked - *
gene - *
GPR2 - *
and - *
suggests - *
a - (A0*
potential - *
mechanism - *)
for - *
modifying modify (V*) *
the - *
EZH1 - (A1*
protein - *
in - *
the - *
conserved - *
C-terminal - *
domain - *)
. - *

Analysis - *
of - *
one - *
cDNA - *
revealed - *
an - *
unusual - *
splicing - *
event - *
involving - *
EZH1 - *
and - *
a - *
tandemly - *
linked - *
gene - *
GPR2 - *
and - *
suggests - *
a - (A0*
potential - *
mechanism - *)
to - *
modify modify (V*) *
the - *
EZH1 - (A1*
protein - *
in - *
the - *
conserved - *
C-terminal - *
domain - *)
. - *

Analysis - *
of - *
one - *
cDNA - *
revealed - *
an - *
unusual - *
splicing - *
event - *
involving - *
EZH1 - *
and - *
a - *
tandemly - *
linked - *
gene - *
GPR2 - *
and - *
suggests - *
a - (A0*
potential - *
mechanism - *)
that - *
modify modify (V*) *
the - *
EZH1 - (A1*
protein - *
in - *
the - *
conserved - *
C-terminal - *
domain - *)
. - *

Analysis - *
of - *
one - *
cDNA - *
revealed - *
an - *
unusual - *
splicing - *
event - *
involving - *
EZH1 - *
and - *
a - *
tandemly - *
linked - *
gene - *
GPR2 - *
and - *
suggests - *
a - (A0*
potential - *
mechanism - *)
which - *
modified modify (V*) *
the - *
EZH1 - (A1*
protein - *
in - *
the - *
conserved - *
C-terminal - *
domain - *)
. - *

The - (A1*
C-terminal-deletion - *)
mutant - *
of - *
hnRNP - *
A1 - *
lost - *
the - *
ability - *
to - *
interact - *
with - *
the - *
X - *
protein - *
and - *
to - *
bring - *
it - *
into - *
the - *
initiation - *
complex - *
resulting - *
in - *
and - *
inhibition - *
of - *
MHV - *
RNA - *
transcription - *
and - *
replication - *
. - *

The - (A1*
C-terminal-deletion - *)
mutant - *
of - *
hnRNP - *
A1 - *
which - *
loses - *
the - *
ability - *
to - *
interact - *
with - *
the - *
X - *
protein - *
and - *
to - *
bring - *
it - *
into - *
the - *
initiation - *
complex - *
resulting - *
in - *
and - *
inhibition - *
of - *
MHV - *
RNA - *
transcription - *
and - *
replication - *
. - *

The - (A1*
C-terminal-deletion - *)
mutant - *
of - *
hnRNP - *
A1 - *
which - *
lost - *
the - *
ability - *
to - *
interact - *
with - *
the - *
X - *
protein - *
and - *
to - *
bring - *
it - *
into - *
the - *
initiation - *
complex - *
resulting - *
in - *
and - *
inhibition - *
of - *
MHV - *
RNA - *
transcription - *
and - *
replication - *
. - *

To - (A3*
define - *
the - *
subcellular - *)
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
are - *
modified modify (V*) *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
recognized - *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
. - *

To - (A3*
define - *
the - *
subcellular - *)
location - *
of - *
HVDAC - *
isoforms - *
it - *
modified modify (V*) *
HVDAC - *
genes - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
recognized - *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
. - *

To - (A3*
define - *
the - *
subcellular - *)
location - *
of - *
HVDAC - *
isoforms - *
it - *
modifies modify (V*) *
HVDAC - *
genes - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
recognized - *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
. - *

To - (A3*
define - *
the - *
subcellular - *)
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
will - *
be - *
modified modify (V*) *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
recognized - *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
. - *

We - (A3*
modified - *)
Pfalciparum - *
genetically - *)
by - *
transfection - *
(Crabb - *
and - *
Cowman - *
1996; - *
Crabb - *
et - *
al - *
1997a) - *
to - *
disrupt - *
the - *
RAP1 - *
gene - *
. - *

We - (A3*
modify - *)
Pfalciparum - *)
genetically - *)
by - *
transfection - *
(Crabb - *
and - *
Cowman - *
1996; - *
Crabb - *
et - *
al - *
1997a) - *
to - *
disrupt - *
the - *
RAP1 - *
gene - *
. - *

We - (A3*
have - *)
modified - *)
Pfalciparum - *)
genetically - *
by - *
transfection - *
(Crabb - *
and - *
Cowman - *
1996; - *
Crabb - *
et - *
al - *
1997a) - *
to - *
disrupt - *
the - *
RAP1 - *
gene - *
. - *

We - (A3*
will - *)
modify - *)
Pfalciparum - *
genetically - *
by - *
transfection - *
(Crabb - *
and - *
Cowman - *
1996; - *
Crabb - *
et - *
al - *
1997a) - *
to - *
disrupt - *
the - *
RAP1 - *
gene - *
. - *

The - (A3*
template - *
fragments - *
that - *
are - *
mutated mutate (V*) *
by - *)
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *
using - *)
the - *
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

The - (A3*
template - *
fragments - *
which - *
were - *
mutated mutate (V*) *
by - *
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *
using - *)
the - *
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

The - (A3*
template - *
fragments - *
will - *
be - *
mutated mutate (V*) *
by - *
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *
using - *)
the - *
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

The - (A3*
template - *
fragments - *
have - *
been - *
mutated mutate (V*) *
by - *)
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *
using - *)
the - *
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

The - (A3*
template - *
fragments - *
are - *
mutated mutate (V*) *
by - *
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *
using - *
the - *)
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

In - (A1*
COS-7 - *
cells - *
cotransfected - *)
with - *
PKA-Calpha - *
and - *
SOX9 - *
expression - *
plasmids - *
PKA - *
enhanced - *
the - *
phosphorylation - *
of - *
wild-type - *
SOX9 - *
but - *
did - *
not - *
affect - *
phosphorylation - *
of - *
a - *
SOX9 - (A0*
protein - *)
in - *
which - *
the - *
two - *
PKA - *
phosphorylation - *
sites - *
(S - *
(64) - *
and - *
S - *
(211)) - *
will - *
be - *
mutated mutate (V*) *
. - *

This - (A3*
epitope - *)
which - *
is - *
HLA-A2 - *
restricted - *
includes - *
two - *
amino - *
acids - *
commonly - *
mutated mutate (V*) *
(V82A - *
and - *
I84V) - *
in - *
the - *
face - *
of - *
protease - *
inhibitor - *
therapy - *
. - *

This - (A3*
epitope - *)
which - *
is - *
HLA-A2 - *
restricted - *
includes - *
two - *
amino - *
acids - *
commonly - *
mutate mutate (V*) *
(V82A - *
and - *
I84V) - *
in - *
the - *
face - *
of - *
protease - *
inhibitor - *
therapy - *
. - *

We - (A1*
have - *
identified - *)
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
are - *
mutated mutate (V*) *
to - *
the - (A2*
eh2/GEH - *
sequence - *)
to - (A3*
glutamic - *
acid - *)
. - *

This - (A3*
epitope - *)
which - *
is - *
HLA-A2 - *
restricted - *
includes - *
two - *
amino - *
acids - *
commonly - *
mutating mutate (V*) *
(V82A - *
and - *
I84V) - *
in - *
the - *
face - *
of - *
protease - *
inhibitor - *
therapy - *
. - *

This - (A3*
epitope - *)
which - *
is - *
HLA-A2 - *
restricted - *
includes - *
two - *
amino - *
acids - *
that - *
commonly - *
mutated mutate (V*) *
(V82A - *
and - *
I84V) - *
in - *
the - *
face - *
of - *
protease - *
inhibitor - *
therapy - *
. - *

To - *)
determine - *
how - *
activators - *
interact - *
with - *
the - *
complex - *
and - *
to - *
examine - *
the - *
importance - *
of - *
these - *
interactions - *
relative - *
to - *
other - *
potential - *
targeting - *
mechanisms - *
for - *
SWI/SNF - *
function - *
we - *
will - *
identify - *
and - *
mutate mutate (V*) *
the - *
activator-interaction - *
domains - *
in - *
the - *
complex - *
. - *

To - *)
determine - *
how - *
activators - *
interact - *
with - *
the - *
complex - *
and - *
to - *
examine - *
the - *
importance - *
of - *
these - *
interactions - *
relative - *
to - *
other - *
potential - *
targeting - *
mechanisms - *
for - *
SWI/SNF - *
function - *
we - *
have - *
identified - *
and - *
mutated mutate (V*) *
the - *
activator-interaction - *
domains - *
in - *
the - *
complex - *
. - *

To - *)
determine - *
how - *
activators - *
interact - *
with - *
the - *
complex - *
and - *
to - *
examine - *
the - *
importance - *
of - *
these - *
interactions - *
relative - *
to - *
other - *
potential - *
targeting - *
mechanisms - *
for - *
SWI/SNF - *
function - *
we - *
found - *
to - *
identify - *
and - *
mutate mutate (V*) *
the - *
activator-interaction - *
domains - *
in - *
the - *
complex - *
. - *

To - *)
determine - *
how - *
activators - *
interact - *
with - *
the - *
complex - *
and - *
to - *
examine - *
the - *
importance - *
of - *
these - *
interactions - *
relative - *
to - *
other - *
potential - *
targeting - *
mechanisms - *
for - *
SWI/SNF - *
function - *
we - *
identify - *
and - *
mutate mutate (V*) *
the - *
activator-interaction - *
domains - *
in - *
the - *
complex - *
. - *

This - (A3*
epitope - *)
which - *
is - *
HLA-A2 - *
restricted - *
includes - *
two - *
amino - *
acids - *
that - *
commonly - *
has - *
mutated mutate (V*) *
(V82A - *
and - *
I84V) - *
in - *
the - *
face - *
of - *
protease - *
inhibitor - *
therapy - *
. - *

To - *)
determine - *
how - *
activators - *
interact - *
with - *
the - *
complex - *
and - *
to - *
examine - *
the - *
importance - *
of - *
these - *
interactions - *
relative - *
to - *
other - *
potential - *
targeting - *
mechanisms - *
for - *
SWI/SNF - *
function - *
we - *
identified - *
and - *
mutated mutate (V*) *
the - *
activator-interaction - *
domains - *
in - *
the - *
complex - *
. - *

In - (A1*
COS-7 - *
cells - *
cotransfected - *)
with - *
PKA-Calpha - *
and - *
SOX9 - *
expression - *
plasmids - *
PKA - *
enhanced - *
the - *
phosphorylation - *
of - *
wild-type - *
SOX9 - *
but - *
did - *
not - *
affect - *
phosphorylation - *
of - *
a - *
SOX9 - (A0*
protein - *)
in - *
which - *
the - *
two - *
PKA - *
phosphorylation - *
sites - *
(S - *
(64) - *
and - *
S - *
(211)) - *
are - *
mutated mutate (V*) *
. - *

In - (A1*
COS-7 - *
cells - *
cotransfected - *)
with - *
PKA-Calpha - *
and - *
SOX9 - *
expression - *
plasmids - *
PKA - *
enhanced - *
the - *
phosphorylation - *
of - *
wild-type - *
SOX9 - *
but - *
did - *
not - *
affect - *
phosphorylation - *
of - *
a - *
SOX9 - (A0*
protein - *)
in - *
which - *
the - *
two - *
PKA - *
phosphorylation - *
sites - *
(S - *
(64) - *
and - *
S - *
(211)) - *
were - *
mutated mutate (V*) *
. - *

We - *
have - *
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
ALK4 - (A0*
extracellular - *
domain - *)
(Leu40 - (A1*
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *)
that - *
when - *
will - *
be - *
mutated mutate (V*) *
to - *
alanine - (A2*)
have - (A3*
substantial - *
effects - *
on - *
ALK4-trunc - *
dominant - *
negative - *
activity - *)
. - *

We - *
have - *
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
ALK4 - (A0*
extracellular - *
domain - *)
(Leu40 - (A1*
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *)
that - *
when - *
has - *
been - *
mutated mutate (V*) *
to - *
alanine - (A2*)
have - (A3*
substantial - *
effects - *
on - *
ALK4-trunc - *
dominant - *
negative - *
activity - *)
. - *

We - *
have - *
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
ALK4 - (A0*
extracellular - *
domain - *)
(Leu40 - (A1*
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *)
that - *
when - *
are - *
mutated mutate (V*) *
to - *
alanine - (A2*)
have - (A3*
substantial - *
effects - *
on - *
ALK4-trunc - *
dominant - *
negative - *
activity - *)
. - *

We - *
have - *
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
ALK4 - (A0*
extracellular - *
domain - *)
(Leu40 - (A1*
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *)
that - *
when - *
were - *
mutated mutate (V*) *
to - *
alanine - (A2*)
have - (A3*
substantial - *
effects - *
on - *
ALK4-trunc - *
dominant - *
negative - *
activity - *)
. - *

We - *
have - *
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
ALK4 - (A0*
extracellular - *
domain - *)
(Leu40 - (A1*
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *)
that - *
when - *
mutated mutate (V*) *
to - *
alanine - (A2*)
have - (A3*
substantial - *
effects - *
on - *
ALK4-trunc - *
dominant - *
negative - *
activity - *)
. - *

Taken - (A3*
together - *
these - *
data - *
suggest - *)
tha - *
the - *
SH3 - *
acts - *
to - *
position - *
the - *
U5 - *
region - *
through - *
its - *
own - *
association - *
with - *
the - *
GUK - *
domain - *
and - *
that - *
the - *
binding - *
of - *
either - *
U5 - *
or - *
SH3 - *
can - *
be - *
modified - *
by - *
that - *
factors - *
to - *
the - *
GUK - *
domain - *
. - *

Taken - (A3*
together - *
these - *
data - *
suggest - *)
tha - *
the - *
SH3 - *
acts - *
to - *
position - *
the - *
U5 - *
region - *
through - *
its - *
own - *
association - *
with - *
the - *
GUK - *
domain - *
and - *
that - *
factors - *
which - *
can - *
modifiy - *
the - *
binding - *
of - *
either - *
U5 - *
or - *
SH3 - *
to - *
the - *
GUK - *
domain - *
may - *
regulate - *
GKAP - *
binding - *
to - *
the - *
GUK - *
domain - *
. - *

Analyses - *
of - *
transcription - *
in - *
vivo - *
of - *
agn"-lacZ - *
that - *
has - *
been - *
mutated mutate (V*) *
Dam - (A0*
target - *
sequences - *)
support - *
this - *
conclusion - *
. - *

Analyses - *
of - *
transcription - *
in - *
vivo - *
of - *
agn"-lacZ - *
that - *
will - *
be - *
mutated mutate (V*) *
Dam - (A0*
target - *
sequences - *)
support - *
this - *
conclusion - *
. - *

Analyses - *
of - *
transcription - *
in - *
vivo - *
of - *
agn"-lacZ - *
that - *
were - *
mutated mutate (V*) *
Dam - (A0*
target - *
sequences - *)
support - *
this - *
conclusion - *
. - *

Analyses - *
of - *
transcription - *
in - *
vivo - *
of - *
agn"-lacZ - *
that - *
are - *
mutated mutate (V*) *
Dam - (A0*
target - *
sequences - *)
support - *
this - *
conclusion - *
. - *

Analyses - *
of - *
transcription - *
in - *
vivo - *
of - *
agn"-lacZ - *
with - *
mutated mutate (V*) *
Dam - (A0*
target - *
sequences - *)
support - *
this - *
conclusion - *
. - *

We - (A1*
have - *
identified - *)
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
were - *
mutated mutate (V*) *
to - *
the - (A2*
eh2/GEH - *
sequence - *)
to - (A3*
glutamic - *
acid - *)
. - *

We - (A1*
have - *
identified - *)
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
will - *
be - *
mutated mutate (V*) *
to - *
the - (A2*
eh2/GEH - *
sequence - *)
to - (A3*
glutamic - *
acid - *)
. - *

In - (A1*
COS-7 - *
cells - *
cotransfected - *)
with - *
PKA-Calpha - *
and - *
SOX9 - *
expression - *
plasmids - *
PKA - *
enhanced - *
the - *
phosphorylation - *
of - *
wild-type - *
SOX9 - *
but - *
did - *
not - *
affect - *
phosphorylation - *
of - *
a - *
SOX9 - (A0*
protein - *)
in - *
which - *
the - *
two - *
PKA - *
phosphorylation - *
sites - *
(S - *
(64) - *
and - *
S - *
(211)) - *
has - *
been - *
mutated mutate (V*) *
. - *

We - (A1*
have - *)
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
mutated mutate (V*) *
to - *
allele - (A2*)
with - (A3*
the - *
premature - *
translation - *
termination - *)
. - *

We - (A1*
have - *
identified - *)
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
mutated mutate (V*) *
to - *
the - (A2*
eh2/GEH - *
sequence - *)
to - (A3*
glutamic - *
acid - *)
. - *

We - (A1*
have - *)
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
were - *
mutated mutate (V*) *
to - *
allele - (A2*)
with - (A3*
the - *
premature - *
translation - *
termination - *)
. - *

We - (A1*
have - *)
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
are - *
mutated mutate (V*) *
to - *
allele - (A2*)
with - (A3*
the - *
premature - *
translation - *
termination - *)
. - *

We - (A1*
have - *)
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
has - *
been - *
mutated mutate (V*) *
to - *
allele - (A2*)
with - (A3*
the - *
premature - *
translation - *
termination - *)
. - *

We - (A1*
have - *
identified - *)
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
has - *
been - *
mutated mutate (V*) *
to - *
the - (A2*
eh2/GEH - *
sequence - *)
to - (A3*
glutamic - *
acid - *)
. - *

We - (A1*
have - *)
identified - *
five - *
hydrophobic - *
amino - *
acid - *
residues - *
on - *
the - *
p53 - (A0*)
(Leu40 - *
Ile70 - *
Val73 - *
Leu75 - *
and - *
Pro77) - *
that - *
when - *
will - *
be - *
mutated mutate (V*) *
to - *
allele - (A2*)
with - (A3*
the - *
premature - *
translation - *
termination - *)
. - *

To - (A2*
mutatate - *
amino - *)
acids - *)
EE(437 - *
and - *
438) - *
to - *
AA - *
generated - *
the - *
DNA-binding - *
mutant(Stat5aEE-AA) - *
of - *
Stat5a - *
. - *

The - (A3*
template - *
fragments - *
which - *
have - *
been - *
mutated - *)
by - *
the - *
sequence - *
of - *
SAP97 - *
RAT - *
accession - *
No - *
Q62696) - *)
using - *
the - *
program - *
Swiss - *
PDB - *
Viewer - *
(Guex - *
and - *
Peitsch - *
1997) - *
. - *

Induction - *
of - *
a - *
mutation - *
in - *
the - *
lacI - (A0*)
gene - *
will - *
result - *
in - *
the - (A3*
loss - *
of - *
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *
in - *
mutated mutate (V*) *
cells - *)
. - *

Induction - (A3*
of - *
a - *
mutation - *
in - *
the - *
lacI - (A0*)
gene - *
will - *
result - *
in - *
the - *
loss - *
of - *)
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *
that - *
is - *
mutated mutate (V*) *
cells - *
. - *

Induction - (A3*
of - *
a - *
mutation - *
in - *
the - *
lacI - (A0*)
gene - *
will - *
result - *
in - *
the - *
loss - *
of - *)
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *
that - *
was - *
mutated mutate (V*) *
cells - *
. - *

Cotransfections - *
with - *
plasmids - *
expressing - *
WT-1 - *
WTAR - *
(a - *
mutated mutate (V*) *
form - *
of - *
WT-1) - *
p53 - (A0*)
and - *
a - *
mutated - *
form - *
of - *
p53 - *
revealed - *
a - *
complex - *
pattern - *
of - *
regulation - *
with - *
a - *
3-fold - *
induction - *
with - *
WT-1 - *
a - (A3*
7-fold - *
induction - *)
with - *
mutated - *
p53 - *
and - *
a - *
4-fold - *
repression - *
with - *
wild-type - *
p53 - *
. - *

Cotransfections - *
with - *
plasmids - *
expressing - *
WT-1 - *
WTAR - *
(a - *
mutated mutate (V*) *
form - *
of - *
WT-1) - *
p53 - (A0*)
and - *
a - *
mutated - *
form - *
of - *
p53 - *
revealed - *
a - *
complex - *
pattern - *
of - *
regulation - *
with - *
a - *
3-fold - *
induction - *
with - *
WT-1 - *
a - (A3*
7-fold - *
induction - *)
that - *
is - *
mutated - *
p53 - *
and - *
a - *
4-fold - *
repression - *
with - *
wild-type - *
p53 - *
. - *

Cotransfections - *
with - *
plasmids - *
expressing - *
WT-1 - *
WTAR - *
(a - *
mutated mutate (V*) *
form - *
of - *
WT-1) - *
p53 - (A0*)
and - *
a - *
mutated - *
form - *
of - *
p53 - *
revealed - *
a - *
complex - *
pattern - *
of - *
regulation - *
with - *
a - *
3-fold - *
induction - *
with - *
WT-1 - *
a - (A3*
7-fold - *
induction - *)
that - *
was - *
mutated - *
p53 - *
and - *
a - *
4-fold - *
repression - *
with - *
wild-type - *
p53 - *
. - *

Cotransfections - *
with - *
plasmids - *
expressing - *
WT-1 - *
WTAR - *
(a - *
mutated mutate (V*) *
form - *
of - *
WT-1) - *
p53 - (A0*)
and - *
a - *
mutated - *
form - *
of - *
p53 - *
revealed - *
a - *
complex - *
pattern - *
of - *
regulation - *
with - *
a - *
3-fold - *
induction - *
with - *
WT-1 - *
a - (A3*
7-fold - *
induction - *)
that - *
were - *
mutated - *
p53 - *
and - *
a - *
4-fold - *
repression - *
with - *
wild-type - *
p53 - *
. - *

The - (A3*
exon - *
5 - *
mutates mutate (V*) *
allele - *
with - *
the - *
premature - *
translation - *
termination - *
resulted - *
in - *
severe - *)
deficiency - *
of - *
Hex - *
A - *
. - *

The - (A3*
exon - *
5 - *
which - *
mutated mutate (V*) *
allele - *
with - *
the - *
premature - *
translation - *
termination - *
resulted - *)
in - *
severe - *
deficiency - *
of - *
Hex - *
A - *
. - *

The - (A3*
exon - *
5 - *
which - *
mutates mutate (V*) *
allele - *
with - *
the - *
premature - *
translation - *
termination - *
resulted - *)
in - *
severe - *
deficiency - *
of - *
Hex - *
A - *
. - *

The - (A3*
exon - *
5 - *
has - *
mutated mutate (V*) *
allele - *
with - *
the - *
premature - *
translation - *
termination - *
resulted - *
in - *)
severe - *
deficiency - *
of - *
Hex - *
A - *
. - *

The - (A3*
exon - *
5 - *
mutating mutate (V*) *
allele - *
with - *
the - *
premature - *
translation - *
termination - *
resulted - *
in - *
severe - *)
deficiency - *
of - *
Hex - *
A - *
. - *

The - *)
gene - *)
which - *
is - *
mutated mutate (V*) *
in - *
variant - *
late-infantile - *
neuronal - *
ceroid - *
lipofuscinosis - *
(CLN6) - *
and - *
in - *
nclf - *
mutant - *
mice - *
encodes - *
a - *
novel - *
predicted - *
transmembrane - *
protein - *
. - *

The - (A2*
gene - *)
which - *
was - *
mutated - *)
in - *
variant - *
late-infantile - *
neuronal - *
ceroid - *
lipofuscinosis - *
(CLN6) - *
and - *
in - *
nclf - *
mutant - *
mice - *
encodes - *
a - *
novel - *
predicted - *
transmembrane - *
protein - *
. - *

The - (A2*
gene - *)
which - *
has - *
been - *
mutated - *)
in - *
variant - *
late-infantile - *
neuronal - *
ceroid - *
lipofuscinosis - *
(CLN6) - *
and - *
in - *
nclf - *
mutant - *
mice - *
encodes - *
a - *
novel - *
predicted - *
transmembrane - *
protein - *
. - *

The - (A2*
gene - *)
that - *
will - *
be - *
mutated - *)
in - *
variant - *
late-infantile - *
neuronal - *
ceroid - *
lipofuscinosis - *
(CLN6) - *
and - *
in - *
nclf - *
mutant - *
mice - *
encodes - *
a - *
novel - *
predicted - *
transmembrane - *
protein - *
. - *

Transient - (A2*
expression - *
of - *
the - *
exon - *
8 - *
mutates - *)
alpha-chain - *
cDNA - *
in - *
COS-1 - *
cells - *
resulted - *
in - *
deficiency - *
of - *
enzymatic - *
activity - *
. - *

Alpha-chain - (A2*
cDNA - *
in - *
COS-1 - *
cells - *
are - *
mutated - *)
by - *
transient - *
expression - *
of - *
the - *
exon - *
8 - *
resulted - *
in - *
deficiency - *
of - *
enzymatic - *
activity - *
. - *

Alpha-chain - (A2*
cDNA - *
in - *
COS-1 - *
cells - *
were - *
mutated - *)
by - *
transient - *
expression - *
of - *
the - *
exon - *
8 - *
resulted - *
in - *
deficiency - *
of - *
enzymatic - *
activity - *
. - *

Transient - *)
expression - *
of - *
the - *
exon - *
8 - *
which - *
mutated mutate (V*) *
alpha-chain - *
cDNA - *
in - *
COS-1 - *
cells - *
resulted - *
in - *
deficiency - *
of - *
enzymatic - *
activity - *
. - *

Transient - (A2*
expression - *
of - *
the - *
exon - *
8 - *
that - *
mutates - *)
alpha-chain - *
cDNA - *
in - *
COS-1 - *
cells - *
resulted - *
in - *
deficiency - *
of - *
enzymatic - *
activity - *
. - *

RCA - (A2*
is - *
comprised - *)
of - *
two - *
major - *
steps: - *
(i) - *
identifying - *
pairs - *
of - *
residue - *
positions - *
that - *
mutated mutate (V*) *
in - *
a - *
coordinated - *
manner - *
and - *
(ii) - *
using - *
these - *
results - *
to - *
identify - *
protein - *
regions - *
that - *
interact - *
with - *
an - *
uncommonly - *
high - *
number - *
of - *
other - *
residues - *
. - *

RCA - (A2*
is - *
comprised - *)
of - *
two - *
major - *
steps: - *
(i) - *
identifying - *
pairs - *
of - *
residue - *
positions - *
which - *
mutate mutate (V*) *
in - *
a - *
coordinated - *
manner - *
and - *
(ii) - *
using - *
these - *
results - *
to - *
identify - *
protein - *
regions - *
that - *
interact - *
with - *
an - *
uncommonly - *
high - *
number - *
of - *
other - *
residues - *
. - *

RCA - (A2*
is - *
comprised - *)
of - *
two - *
major - *
steps: - *
(i) - *
identifying - *
pairs - *
of - *
residue - *
positions - *
has - *
mutated mutate (V*) *
in - *
a - *
coordinated - *
manner - *
and - *
(ii) - *
using - *
these - *
results - *
to - *
identify - *
protein - *
regions - *
that - *
interact - *
with - *
an - *
uncommonly - *
high - *
number - *
of - *
other - *
residues - *
. - *

RCA - (A2*
is - *
comprised - *)
of - *
two - *
major - *
steps: - *
(i) - *
identifying - *
pairs - *
of - *
residue - *
positions - *
mutating mutate (V*) *
in - *
a - *
coordinated - *
manner - *
and - *
(ii) - *
using - *
these - *
results - *
to - *
identify - *
protein - *
regions - *
that - *
interact - *
with - *
an - *
uncommonly - *
high - *
number - *
of - *
other - *
residues - *
. - *

To - (A3*
mutate mutate (V*) *
a - *
conserved - *)
phenylalanine - *
of - *
the - *
eh1/GEH - *
sequence - *
to - *
glutamic - *
acid - *
abolished - *
groucho - *
binding - *
(Jimnez - *
et - *
al - *
1999) - *
. - *

Phosphorylation - *)
of - *
PDK1 - *)
was - *
not - *
altered - *
by - *
treating - *
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *
and - *
four - *
of - *
the - *
sites - *
are - *
mutated mutate (V*) *
without - *
loss - *
of - *
activity - *
. - *

Phosphorylation - *)
of - *
PDK1 - *)
was - *
not - *
altered - *
by - *
treating - *
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *
and - *
four - *
of - *
the - *
sites - *
were - *
mutated mutate (V*) *
without - *
loss - *
of - *
activity - *
. - *

Phosphorylation - *)
of - *
PDK1 - *)
was - *
not - *
altered - *
by - *
treating - *
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *
and - *
four - *
of - *
the - *
sites - *
will - *
be - *
mutated mutate (V*) *
without - *
loss - *
of - *
activity - *
. - *

Phosphorylation - *)
of - *
PDK1 - *)
was - *
not - *
altered - *
by - *
treating - *
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *
and - *
four - *
of - *
the - *
sites - *
have - *
been - *
mutated mutate (V*) *
without - *
loss - *
of - *
activity - *
. - *

Phosphorylation - *)
of - *
PDK1 - *)
was - *
not - *
altered - *
by - *
treating - *
the - *
cells - *
with - *
insulin-like - *
growth - *
factor-I - *
and - *
four - *
of - *
the - *
sites - *
which - *
were - *
mutated mutate (V*) *
without - *
loss - *
of - *
activity - *
. - *

The - (A2*
DNA-binding - *)
mutant(Stat5aEE-AA) - *)
of - *
Stat5a - *
was - *
generated - *
by - *
mutating mutate (V*) *
amino - *
acids - *
EE(437 - *
and - *
438) - *
to - *
AA - *
. - *

Mutating - (A2*
amino - *)
acids - *
EE(437 - *)
and - *
438) - *
to - *
AA - *
generated - *
the - *
DNA-binding - *
mutant(Stat5aEE-AA) - *
of - *
Stat5a - *
. - *

For - (A2*
mutating mutate (V*) *
amino - *
acids - *)
EE(437 - *
and - *
438) - *
to - *
AA - *
generated - *
the - *
DNA-binding - *
mutant(Stat5aEE-AA) - *
of - *
Stat5a - *
. - *

Further - (A2*
HIV-specific - *)
CD4+ - *
T - *
cells - *
of - *
viremic - *
patients - *
could - *
be - *
found - *
to - *
proliferate proliferate (V*) *
in - *
response - *
to - *
HIV - *
antigens - *
when - *
costimulation - *
was - *
provided - *
by - *
anti-CD28 - *
antibody - *
in - *
vitro - *
. - *

Further - (A2*
HIV-specific - *)
CD4+ - *
T - *
cells - *
of - *
viremic - *
patients - *
could - *
be - *
shown - *
to - *
proliferate proliferate (V*) *
in - *
response - *
to - *
HIV - *
antigens - *
when - *
costimulation - *
was - *
provided - *
by - *
anti-CD28 - *
antibody - *
in - *
vitro - *
. - *

Cancer - (A1*
cells - *
are - *
characterized - *
by - *
either - *
an - *)
increased - *
ability - *
for - *
proliferating proliferate (V*) *
or - *
a - *
diminished - *
capacity - *
to - *
undergo - *
programmed - *
cell - *
death - *
. - *

Cancer - (A1*
cells - *
was - *
characterized - *
by - *
either - *
an - *)
increased - *
ability - *
to - *
proliferate proliferate (V*) *
or - *
a - *
diminished - *
capacity - *
to - *
undergo - *
programmed - *
cell - *
death - *
. - *

Cancer - (A1*
cells - *
wil - *
be - *
characterized - *
by - *
either - *)
an - *
increased - *
ability - *
for - *
proliferating proliferate (V*) *
or - *
a - *
diminished - *
capacity - *
to - *
undergo - *
programmed - *
cell - *
death - *
. - *

Cancer - (A1*
cells - *
has - *
been - *
characterized - *
by - *
either - *)
an - *
increased - *
ability - *
to - *
proliferate proliferate (V*) *
or - *
a - *
diminished - *
capacity - *
to - *
undergo - *
programmed - *
cell - *
death - *
. - *

Our - (A1*
observations - *
illustrate - *
that - *
the - *
human - *)
placenta - *
is - *
endowed - *
with - *
the - *
biochemical - *
machinery - *
proliferating proliferate (V*) *
indefinitely - *
throughout - *
gestation - *
yet - *
there - *
are - *
intrinsic - *
mechanisms - *
that - *
effectively - *
circumscribe - *
the - *
extent - *
and - *
duration - *
of - *
trophoblast - *
proliferation - *
. - *

Further - (A2*
HIV-specific - *)
CD4+ - *
T - *
cells - *
of - *
viremic - *
patients - *
could - *
be - *
proven - *
to - *
proliferate proliferate (V*) *
in - *
response - *
to - *
HIV - *
antigens - *
when - *
costimulation - *
was - *
provided - *
by - *
anti-CD28 - *
antibody - *
in - *
vitro - *
. - *

After - *)
androgen - *
withdrawal - *)
and - *
antiandrogen - *
treatment - *
the - *
androgen - *
responsive - *
prostated - *
cancer - *
cells - *
cease - *
to - *
proliferate proliferate (V*) *
and - *
undergo - *
apoptosis - *
causing - *
tumor - *
regression - *
. - *

After - *)
androgen - *
withdrawal - *)
and - *
antiandrogen - *
treatment - *
the - *
androgen - *
responsive - *
prostate - *
cancer - *
cells - *
cease - *
proliferating proliferate (V*) *
and - *
undergo - *
apoptosis - *
causing - *
tumor - *
regression - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
that - *
proliferated proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

Our - (A1*
observations - *
illustrate - *
that - *
the - *
human - *)
placenta - *
has - *
been - *
endowed - *
with - *
the - *
biochemical - *
machinery - *
to - *
proliferate proliferate (V*) *
indefinitely - *
throughout - *
gestation - *
yet - *
there - *
are - *
intrinsic - *
mechanisms - *
that - *
effectively - *
circumscribe - *
the - *
extent - *
and - *
duration - *
of - *
trophoblast - *
proliferation - *
. - *

Our - (A1*
observations - *
illustrate - *
that - *
the - *
human - *)
placenta - *
was - *
endowed - *
with - *
the - *
biochemical - *
machinery - *
for - *
proliferating proliferate (V*) *
indefinitely - *
throughout - *
gestation - *
yet - *
there - *
are - *
intrinsic - *
mechanisms - *
that - *
effectively - *
circumscribe - *
the - *
extent - *
and - *
duration - *
of - *
trophoblast - *
proliferation - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
has - *
proliferated proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
that - *
proliferate proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
will - *
proliferate proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
proliferated proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

Stat5ab-/-peripheral - (A2*
T - *
cells - *
has - *)
been - *
regained - *
the - *
ability - *
to - *
proliferate proliferate (V*) *
upon - *
introduction - *
of - *
full-length - *
wild-type - *
Stat5a - *
(Figure - *
6B) - *
. - *

Stat5ab-/-peripheral - (A2*
T - *
cells - *
will - *)
regain - *
the - *
ability - *
to - *
proliferate proliferate (V*) *
upon - *
introduction - *
of - *
full-length - *
wild-type - *
Stat5a - *
(Figure - *
6B) - *
. - *

Stat5ab-/-peripheral - (A2*
T - *
cells - *
were - *)
regained - *
the - *
ability - *
to - *
proliferate proliferate (V*) *
upon - *
introduction - *
of - *
full-length - *
wild-type - *
Stat5a - *
(Figure - *
6B) - *
. - *

Stat5ab-/-peripheral - (A2*
T - *
cells - *
regained - *)
the - *
ability - *
to - *
proliferate proliferate (V*) *
upon - *
introduction - *
of - *
full-length - *
wild-type - *
Stat5a - *
(Figure - *
6B) - *
. - *

Adult - (A3*
naive - *
T - *
cells - *
which - *)
are - *
at - *
rest - *
in - *
normal - *
conditions - *
that - *
will - *
proliferate proliferate (V*) *
strongly - *
when - *
transferred - *
to - *
lymphopenic - *
hosts - *
 - *
. - *

HSC - *)
was - *
continued - *
to - *
proliferate proliferate (V*) *
in - *
the - *
bone - *
marrow - *
and - *
spleen - *
through - *
8 - *
days - *
of - *
G-CSF - *
treatment - *
but - *
HSC - *
released - *
into - *
the - *
blood - *
tended - *
to - *
be - *
in - *
G0/G1 - *
phase - *
. - *

HSC - *)
has - *
been - *
continued - *
to - *
proliferate proliferate (V*) *
in - *
the - *
bone - *
marrow - *
and - *
spleen - *
through - *
8 - *
days - *
of - *
G-CSF - *
treatment - *
but - *
HSC - *
released - *
into - *
the - *
blood - *
tended - *
to - *
be - *
in - *
G0/G1 - *
phase - *
. - *

HSC - *)
will - *
continue - *
to - *
proliferate proliferate (V*) *
in - *
the - *
bone - *
marrow - *
and - *
spleen - *
through - *
8 - *
days - *
of - *
G-CSF - *
treatment - *
but - *
HSC - *
released - *
into - *
the - *
blood - *
tended - *
to - *
be - *
in - *
G0/G1 - *
phase - *
. - *

The - *)
ability - *
of - *
EBD - *
cells - *
that - *
have - *
to - *)
proliferate - *)
in - *
vivo - *
was - *
examined - *
by - *
injection - *
of - *
3 - *
? - *
106 - *
LVEC - *
cells - *
into - *
the - *
calf - *
muscle - *
of - *
3 - *
immunocompromised - *
mice - *
. - *

The - *)
ability - *
of - *
EBD - *
cells - *
that - *
make - *
to - *)
proliferate - *)
in - *
vivo - *
was - *
examined - *
by - *
injection - *
of - *
3 - *
? - *
106 - *
LVEC - *
cells - *
into - *
the - *
calf - *
muscle - *
of - *
3 - *
immunocompromised - *
mice - *
. - *

The - *)
ability - *
of - *
EBD - *
cells - *
that - *
is - *
able - *)
to - *
proliferate - *)
in - *
vivo - *
was - *
examined - *
by - *
injection - *
of - *
3 - *
? - *
106 - *
LVEC - *
cells - *
into - *
the - *
calf - *
muscle - *
of - *
3 - *
immunocompromised - *
mice - *
. - *

In - (A1*
contrast - *)
for - *
mutating - *
the - *
C-terminal - *
MAP - *
kinase - *
sites - *
(T235 - *
and - *
T239) - *
essentially - *
abolished - *
the - *
EGF-stimulated - *
increase - *
in - *
phosphorylation - *
and - *
prevented - *
the - *
EGF-induced - *
mobility - *
shift - *
(Figure - *
5C - *
lanes - *
7 - *
and - *
8) - *
. - *

For - (A1*
example - *)
for - *
mutating - *
the - *
C-terminal - *
MAP - *
kinase - *
sites - *
(T235 - *
and - *
T239) - *
essentially - *
abolished - *
the - *
EGF-stimulated - *
increase - *
in - *
phosphorylation - *
and - *
prevented - *
the - *
EGF-induced - *
mobility - *
shift - *
(Figure - *
5C - *
lanes - *
7 - *
and - *
8) - *
. - *

Our - (A1*
reseach - *)
shown - *
that - *
mutating - *
the - *
C-terminal - *
MAP - *
kinase - *
sites - *
(T235 - *
and - *
T239) - *
essentially - *
abolished - *
the - *
EGF-stimulated - *
increase - *
in - *
phosphorylation - *
and - *
prevented - *
the - *
EGF-induced - *
mobility - *
shift - *
(Figure - *
5C - *
lanes - *
7 - *
and - *
8) - *
. - *

These - (A2*
results - *)
show - *
that - *
intrasplenically - *
transplanted - *
fetal - *
liver - *
cells - *
proliferated proliferate (V*) *
and - *
differentiated - *
into - *
mature - *
cells - *
displaying - *
a - *
GST - *
expression - *
pattern - *
with - *
respective - *
enzyme - *
activities - *
similar - *
to - *
adult - *
liver - *
. - *

These - (A2*
results - *)
show - *
that - *
intrasplenically - *
transplanted - *
fetal - *
liver - *
cells - *
will - *
proliferate proliferate (V*) *
and - *
differentiate - *
into - *
mature - *
cells - *
displaying - *
a - *
GST - *
expression - *
pattern - *
with - *
respective - *
enzyme - *
activities - *
similar - *
to - *
adult - *
liver - *
. - *

These - (A2*
results - *)
show - *
that - *
intrasplenically - *
transplanted - *
fetal - *
liver - *
cells - *
have - *
proliferated proliferate (V*) *
and - *
differentiated - *
into - *
mature - *
cells - *
displaying - *
a - *
GST - *
expression - *
pattern - *
with - *
respective - *
enzyme - *
activities - *
similar - *
to - *
adult - *
liver - *
. - *

short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
are - *
recognized recognize (V*) *
by - *
the - (A0*
proteins - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
were - *
recognized recognize (V*) *
by - *
the - (A0*
proteins - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
NarL - *
protein - *)
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

the - (A0*
proteins - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

the - (A0*
proteins - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

the - (A0*
proteins - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

the - (A0*
proteins - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
autologous - *
serum - *)
recognized recognize (V*) *
the - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
A - (A0*
monoclonal - *
antibody - *)
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
will - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

the - (A0*
proteins - *)
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
proteins - *)
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
proteins - *)
will - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
proteins - *)
has - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
proteins - *)
which - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
proteins - *)
which - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
in - *
the - *
regulated - *
promoters - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
will - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
will - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

We - *
show - *
that - *
the - (A0*
proteins - *)
recognizes recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
proteins - *)
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
proteins - *)
will - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
proteins - *)
has - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
NarL - *
protein - *)
will - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
autologous - *
serum - *)
will - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
will - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
A - (A0*
monoclonal - *
antibody - *)
will - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
will - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
will - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
will - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
has - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
has - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
has - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
NarL - *
protein - *)
has - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
autologous - *
serum - *)
has - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
has - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
A - (A0*
monoclonal - *
antibody - *)
has - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
has - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
has - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
has - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

We - *
show - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognizes recognize (V*) *
multiple - (A1*
binding - *
sites - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
will - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
has - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

multiple - (A1*
binding - *
sites - *)
are - *
recognized recognize (V*) *
by - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
. - *

multiple - (A1*
binding - *
sites - *)
were - *
recognized recognize (V*) *
by - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
. - *

The - (A0*
NarL - *
protein - *)
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

the - (A0*
autologous - *
serum - *)
recognize recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
multiple - (A1*
binding - *
sites - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
multiple - (A1*
binding - *
sites - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
multiple - (A1*
binding - *
sites - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
NarL - *
protein - *)
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
autologous - *
serum - *)
recognized recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
will - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
will - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
NarL - *
protein - *)
will - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
autologous - *
serum - *)
will - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
will - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
will - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
will - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
will - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
will - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
has - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
has - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
NarL - *
protein - *)
has - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
autologous - *
serum - *)
has - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
has - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
has - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
has - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
has - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
has - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
which - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
which - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
NarL - *
protein - *)
which - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
autologous - *
serum - *)
which - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
which - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
which - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
which - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
which - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
which - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
which - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
which - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
NarL - *
protein - *)
which - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
in - *
the - *
regulated - *
promoters - *
. - *

the - (A0*
autologous - *
serum - *)
which - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
which - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
in - *
the - *
regulated - *
promoters - *
. - *

A - (A0*
monoclonal - *
antibody - *)
which - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
in - *
the - *
regulated - *
promoters - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
which - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
which - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
in - *
the - *
regulated - *
promoters - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
which - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
in - *
the - *
regulated - *
promoters - *
. - *

We - *
show - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognizes recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
will - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
has - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
are - *
recognized recognize (V*) *
by - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
. - *

The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
were - *
recognized recognize (V*) *
by - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *)
expression - *
by - *
immunofluorescence - *
with - *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

We - *
show - *
that - *
The - (A0*
NarL - *
protein - *)
recognizes recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

the - (A0*
cAMP-CRP - *
activator - *
complex - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

We - *
show - *
that - *
the - (A0*
autologous - *
serum - *)
recognizes recognize (V*) *
the - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognizes recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
A - (A0*
monoclonal - *
antibody - *)
recognizes recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
two - (A1*
sites - *
in - *
tsx-p2 - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
two - (A1*
sites - *
in - *
tsx-p2 - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

We - *
show - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognizes recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognizes recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognizes recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
NarL - *
protein - *)
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
autologous - *
serum - *)
recognized recognize (V*) *
the - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
A - (A0*
monoclonal - *
antibody - *)
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
NarL - *
protein - *)
will - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
autologous - *
serum - *)
will - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
will - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
A - (A0*
monoclonal - *
antibody - *)
will - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
will - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
will - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
will - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
NarL - *
protein - *)
has - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
autologous - *
serum - *)
has - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
has - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
A - (A0*
monoclonal - *
antibody - *)
has - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
has - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
has - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
has - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
proteins - *)
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
proteins - *)
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
proteins - *)
will - *
recognize recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
proteins - *)
has - *
recognized recognize (V*) *
short - (A1*
motifs - *
within - *
the - *
protected - *
region - *)
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
will - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
has - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
which - *
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
which - *
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
in - *
the - *
regulated - *
promoters - *
. - *

The - *)
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
recognizes recognize (V*) *
the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
activates - *
transcription - *
mediated - *
by - *
RNA - *
polymerase - *
I - *
through - *
cooperative - *
interactions - *
with - *
the - *
species-specific - *
factor - *
SL1 - *
. - *

The - *)
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
recognized recognize (V*) *
the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
activates - *
transcription - *
mediated - *
by - *
RNA - *
polymerase - *
I - *
through - *
cooperative - *
interactions - *
with - *
the - *
species-specific - *
factor - *
SL1 - *
. - *

The - *)
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
will - *
recognize recognize (V*) *
the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
activates - *
transcription - *
mediated - *
by - *
RNA - *
polymerase - *
I - *
through - *
cooperative - *
interactions - *
with - *
the - *
species-specific - *
factor - *
SL1 - *
. - *

The - *)
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
has - *
recognized recognize (V*) *
the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
and - *
activates - *
transcription - *
mediated - *
by - *
RNA - *
polymerase - *
I - *
through - *
cooperative - *
interactions - *
with - *
the - *
species-specific - *
factor - *
SL1 - *
. - *

the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
is - *
recognized - *)
by - *
The - *
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
. - *

the - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
was - *
recognized - *)
by - *
The - *
eukaryotic - *
upstream - *
binding - *
factor - *
(UBF) - *
. - *

We - *
show - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognizes recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
will - *
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

We - *
show - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
has - *
recognized recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
that - *
are - *
separated - *
by - *
33 - *
bp - *
: - *
a - *
high-affinity - *
site - *
(CRP-1) - *
overlaps - *
the - *
-35 - *
region - *
and - *
a - *
low-affinity - *
site - *
(CRP-2) - *
is - *
centered - *
around - *
position - *
-74 - *
bp - *
. - *

two - (A1*
sites - *
in - *
tsx-p2 - *)
are - *
recognized recognize (V*) *
by - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
. - *

two - (A1*
sites - *
in - *
tsx-p2 - *)
were - *
recognized recognize (V*) *
by - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
. - *

The - (A0*
NarL - *
protein - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

The - (A0*
NarL - *
protein - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

The - (A0*
NarL - *
protein - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

The - (A0*
NarL - *
protein - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

Treatment - *)
of - *
endothelial - *)
cells - *
of - *
different - *
origin - *
with - *
the - *
ganglioside - *
biosynthesis - *
inhibitors - *
fumonisin - *
B1 - *
D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol - *
or - *
D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl - *
impaired - *
their - *
capacity - *
to - *
proliferate - *
when - *
exposed - *
to - *
FGF2 - *
. - *

Treatment - *)
of - *
endothelial - *)
cells - *
of - *
different - *
origin - *
with - *
the - *
ganglioside - *
biosynthesis - *
inhibitors - *
fumonisin - *
B1 - *
D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol - *
or - *
D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl - *
will - *
impaird - *
their - *
capacity - *
to - *
proliferate - *
when - *
exposed - *
to - *
FGF2 - *
. - *

Anti-64kD - (A0*
human - *
autoantigen - *)
D1 - *
antibodies - *
recognized recognize (V*) *
specifically - *
a - *
approximately - *
70kD - *
polypeptide - *
in - *
western - *
blots - *
of - *
extraocular - *
muscle - *
sternothyroid - *
muscle - *
and - *
smooth - *
muscle - *
. - *

A - (A0*
approximately - *
70kD - *
polypeptide - *)
in - *
western - *
blots - *
of - *
extraocular - *
muscle - *
sternothyroid - *
muscle - *
and - *
smooth - *
muscle - *
is - *
recognized recognize (V*) *
by - *
Anti-64kD - *
human - *
autoantigen - *
D1 - *
. - *

A - (A0*
approximately - *
70kD - *
polypeptide - *)
in - *
western - *
blots - *
of - *
extraocular - *
muscle - *
sternothyroid - *
muscle - *
and - *
smooth - *
muscle - *
was - *
recognized recognize (V*) *
by - *
Anti-64kD - *
human - *
autoantigen - *
D1 - *
. - *

A - (A0*
approximately - *
70kD - *
polypeptide - *)
in - *
western - *
blots - *
of - *
extraocular - *
muscle - *
sternothyroid - *
muscle - *
and - *
smooth - *
muscle - *
has - *
been - *
recognized recognize (V*) *
by - *
Anti-64kD - *
human - *
autoantigen - *
D1 - *
. - *

A - (A0*
approximately - *
70kD - *
polypeptide - *)
in - *
western - *
blots - *
of - *
extraocular - *
muscle - *
sternothyroid - *
muscle - *
and - *
smooth - *
muscle - *
will - *
be - *
recognized recognize (V*) *
by - *
Anti-64kD - *
human - *
autoantigen - *
D1 - *
. - *

These - (A1*
bands - *
can - *)
be - *
detected - *
with - *
four - *
different - *
specific - *
antibodies - *
recognizing recognize (V*) *
the - *
different - *
nonmuscle - *
myosin - *
heavy - *
chain - *
isoforms - *
(A - *
and - *
B) - *
. - *

These - (A1*
bands - *
can - *)
be - *
detected - *
with - *
four - *
different - *
specific - *
antibodies - *
which - *
recognize recognize (V*) *
the - *
different - *
nonmuscle - *
myosin - *
heavy - *
chain - *
isoforms - *
(A - *
and - *
B) - *
. - *

These - (A1*
bands - *
can - *)
be - *
detected - *
with - *
four - *
different - *
specific - *
antibodies - *
which - *
recognized recognize (V*) *
the - *
different - *
nonmuscle - *
myosin - *
heavy - *
chain - *
isoforms - *
(A - *
and - *
B) - *
. - *

These - (A1*
bands - *
can - *)
be - *
detected - *
with - *
four - *
different - *
specific - *
antibodies - *
that - *
recognize recognize (V*) *
the - *
different - *
nonmuscle - *
myosin - *
heavy - *
chain - *
isoforms - *
(A - *
and - *
B) - *
. - *

These - (A1*
bands - *
can - *)
be - *
detected - *
with - *
four - *
different - *
specific - *
antibodies - *
that - *
recognized recognize (V*) *
the - *
different - *
nonmuscle - *
myosin - *
heavy - *
chain - *
isoforms - *
(A - *
and - *
B) - *
. - *

Individual - *
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - (A0*
monoclonal - *
antibody - *)
which - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - (A0*
monoclonal - *
antibody - *)
which - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
the - (A1*
STAT1 - *
N-terminus - *)
are - *
recognized recognize (V*) *
by - *
a - (A0*
monoclonal - *
antibody - *)
. - *

Individual - *
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
the - (A1*
STAT1 - *
N-terminus - *)
were - *
recognized recognize (V*) *
by - *
a - (A0*
monoclonal - *
antibody - *)
. - *

A - (A1*
monoclonal - *
antibody - *)
which - *
recognizes - *)
the - *
STAT1 - *
N-terminus - *
was - *
purchased - *
from - *
Transduction - *
Laboratories - *
(Lexington - *
KY) - *
. - *

A - (A1*
monoclonal - *
antibody - *)
which - *
recognized - *)
the - *
STAT1 - *
N-terminus - *
was - *
purchased - *
from - *
Transduction - *
Laboratories - *
(Lexington - *
KY) - *
. - *

The - *)
STAT1 - *
N-terminus - *)
are - *
recognized recognize (V*) *
by - *
A - *
monoclonal - *
antibody - *
purchasing - *
from - *
Transduction - *
Laboratories - *
(Lexington - *
KY) - *
. - *

The - (A1*
STAT1 - *
N-terminus - *)
were - *
recognized - *)
by - *
A - *
monoclonal - *
antibody - *
purchasing - *
from - *
Transduction - *
Laboratories - *
(Lexington - *
KY) - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
which - *
are - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
which - *
were - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
that - *
are - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
that - *
were - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
that - *
have - *
been - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
two - *
forms - *)
of - *
Stat3 - *
(Stat3fm - *)
and - *
Stat3sm) - *
that - *
will - *
be - *
recognized recognize (V*) *
by - *
this - *
antibody - *
in - *
PKR+/+MEFs - *
are - *
indicated - *
. - *

The - (A1*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *
was - *
not - *
recognized - *)
in - *
the - *
immunoprecipitaiton - *
with - *
anti-Stat3 - *
pAb - *
as - *
it - *
is - *
raised - *
against - *
a - *
C-terminal - *
region - *
of - *
Stat3 - *
that - *
is - *
missing - *
in - *
Stat3Beta - *
. - *

The - (A1*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *
that - *)
is - *
not - *)
recognized recognize (V*) *
in - *
the - *
immunoprecipitaiton - *
with - *
anti-Stat3 - *
pAb - *
as - *
it - *
is - *
raised - *
against - *
a - *
C-terminal - *
region - *
of - *
Stat3 - *
that - *
is - *
missing - *
in - *
Stat3Beta - *
. - *

The - (A1*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *
that - *)
was - *
not - *)
recognized recognize (V*) *
in - *
the - *
immunoprecipitaiton - *
with - *
anti-Stat3 - *
pAb - *
as - *
it - *
is - *
raised - *
against - *
a - *
C-terminal - *
region - *
of - *
Stat3 - *
that - *
is - *
missing - *
in - *
Stat3Beta - *
. - *

The - (A1*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *
has - *
not - *
been - *)
recognized recognize (V*) *
in - *
the - *
immunoprecipitaiton - *
with - *
anti-Stat3 - *
pAb - *
as - *
it - *
is - *
raised - *
against - *
a - *
C-terminal - *
region - *
of - *
Stat3 - *
that - *
is - *
missing - *
in - *
Stat3Beta - *
. - *

The - (A1*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *
will - *)
not - *
be - *)
recognized recognize (V*) *
in - *
the - *
immunoprecipitaiton - *
with - *
anti-Stat3 - *
pAb - *
as - *
it - *
is - *
raised - *
against - *
a - *
C-terminal - *
region - *
of - *
Stat3 - *
that - *
is - *
missing - *
in - *
Stat3Beta - *
. - *

heptamers - (A1*
in - *
other - *
arrangements - *)
are - *
recognized recognize (V*) *
by - *
The - (A0*
NarL - *
protein - *)
. - *

the - (A1*
epitopes - *)
are - *
recognized recognize (V*) *
by - *
the - (A0*
autologous - *
serum - *)
. - *

COOH-terminal - (A1*
epitopes - *)
are - *
recognized recognize (V*) *
by - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
. - *

the - (A1*
STAT1 - *
N-terminus - *)
are - *
recognized recognize (V*) *
by - *
A - (A0*
monoclonal - *
antibody - *)
. - *

The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
are - *
recognized recognize (V*) *
by - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
. - *

anti-Stat3 - (A1*
pAb - *)
 - *
are - *
recognized recognize (V*) *
by - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
. - *

epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
are - *
recognized recognize (V*) *
by - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
. - *

heptamers - (A1*
in - *
other - *
arrangements - *)
were - *
recognized recognize (V*) *
by - *
The - (A0*
NarL - *
protein - *)
. - *

the - (A1*
epitopes - *)
were - *
recognized recognize (V*) *
by - *
the - (A0*
autologous - *
serum - *)
. - *

COOH-terminal - (A1*
epitopes - *)
were - *
recognized recognize (V*) *
by - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
. - *

the - (A1*
STAT1 - *
N-terminus - *)
were - *
recognized recognize (V*) *
by - *
A - (A0*
monoclonal - *
antibody - *)
. - *

The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
were - *
recognized recognize (V*) *
by - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
. - *

anti-Stat3 - (A1*
pAb - *)
 - *
were - *
recognized recognize (V*) *
by - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
. - *

epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
were - *
recognized recognize (V*) *
by - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
. - *

the - (A0*
autologous - *
serum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
the - (A1*
epitopes - *)
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

A - (A0*
monoclonal - *
antibody - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
heptamers - (A1*
in - *
other - *
arrangements - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
heptamers - (A1*
in - *
other - *
arrangements - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognizes recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

the - (A0*
autologous - *
serum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

A - (A0*
monoclonal - *
antibody - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

the - (A0*
autologous - *
serum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

A - (A0*
monoclonal - *
antibody - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
will - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

the - (A0*
autologous - *
serum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
. - *

by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

A - (A0*
monoclonal - *
antibody - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
also - *
binds - *
to - *
these - *
7-2-7 - *
sites - *
but - *
unlike - *
NarP - *
also - *
has - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

Individual - (A0*
cell - *)
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
the - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *)
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
the - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *)
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
the - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *)
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
the - (A1*
epitopes - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *)
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
the - (A1*
epitopes - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
COOH-terminal - (A1*
epitopes - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - *)
cell - *
clones - *
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
COOH-terminal - (A1*
epitopes - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *)
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *)
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *)
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
recognizing recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *)
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *)
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *)
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *)
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *)
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *)
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
a - *
monoclonal - *
antibody - *
which - *
recognized recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
and - *
by - *
western - *
blotting - *
. - *

Individual - (A0*
cell - *
clones - *)
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *)
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
anti-Stat3 - (A1*
pAb - *)
 - *
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *)
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
are - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *)
were - *
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *)
analyzed - *
for - *
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
anti-Stat3 - (A1*
pAb - *)
 - *
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Individual - (A0*
cell - *
clones - *
were - *
analyzed - *
for - *)
STAT1 - *
expression - *
by - *
immunofluorescence - *
with - *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
were - *
recognized recognize (V*) *
by - *
a - *
monoclonal - *
antibody - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognize recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognize recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
cAMP-CRP - *
activator - *
complex - *)
recognize recognize (V*) *
two - (A1*
sites - *
in - *
tsx-p2 - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
NarL - *
protein - *)
recognize recognize (V*) *
heptamers - (A1*
in - *
other - *
arrangements - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
the - (A0*
autologous - *
serum - *)
recognize recognize (V*) *
the - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
by - (A0*
either - *
of - *
two - *
monoclonal - *
antibodies - *)
recognize recognize (V*) *
COOH-terminal - (A1*
epitopes - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
A - (A0*
monoclonal - *
antibody - *)
recognize recognize (V*) *
the - (A1*
STAT1 - *
N-terminus - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
this - (A0*
antibody - *
in - *
PKR+/+MEFs - *)
recognize recognize (V*) *
The - (A1*
two - *
forms - *
of - *
Stat3 - *
(Stat3fm - *
and - *
Stat3sm) - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
lower - *
form - *
of - *
Stat3 - *
Stat3Beta - *)
recognize recognize (V*) *
anti-Stat3 - (A1*
pAb - *)
 - *
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
affinity-purified - (A0*
polyclonal - *
anti-LMP-1 - *
antiserum - *)
recognize recognize (V*) *
epitopes - (A1*
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
Most - (A0*
regulators - *
belonging - *
to - *
the - *
AraC/XylS - *
family - *)
recognized recognize (V*) *
multiple - (A1*
binding - *
sites - *)
. - *

Footprinting - *
assays - *
have - *
suggested - *
that - *
these - *
regulators - *
protect - *
a - *
stretch - *
of - *
up - *
to - *
20 - *
bp - *
in - *
the - *
target - *
promoters - *
and - *
multiple - *
alignments - *
of - *
binding - *
sites - *
for - *
a - *
number - *
of - *
regulators - *
have - *
shown - *
that - *
The - (A0*
eukaryotic - *
upstream - *
binding - *
factor - *
( - *
UBF - *
) - *)
recognized recognize (V*) *
The - (A1*
ribosomal - *
RNA - *
gene - *
promoter - *)
 - *
. - *

As - (A1*
a - *
result - *
of - *
alternate - *)
splicing - *
and - *
subsequent - *
frameshift - *
the - *
reported - *
g16 - *
protein - *
is - *
603 - *
amino - *
acids - *
shorter - *
than - *
the - *
NY-LU-12 - *
product - *
(1123 - *
residues) - *
at - *
its - *
COOH - *
terminus - *
and - *
would - *
therefore - *
lack - *
the - *
epitopes - *
which - *
are - *
recognized recognize (V*) *
by - *
the - *
autologous - *
serum - *
. - *

As - (A1*
a - *
result - *
of - *
alternate - *)
splicing - *
and - *
subsequent - *
frameshift - *
the - *
reported - *
g16 - *
protein - *
is - *
603 - *
amino - *
acids - *
shorter - *
than - *
the - *
NY-LU-12 - *
product - *
(1123 - *
residues) - *
at - *
its - *
COOH - *
terminus - *
and - *
would - *
therefore - *
lack - *
the - *
epitopes - *
which - *
were - *
recognized recognize (V*) *
by - *
the - *
autologous - *
serum - *
. - *

As - (A1*
a - *
result - *
of - *
alternate - *)
splicing - *
and - *
subsequent - *
frameshift - *
the - *
reported - *
g16 - *
protein - *
is - *
603 - *
amino - *
acids - *
shorter - *
than - *
the - *
NY-LU-12 - *
product - *
(1123 - *
residues) - *
at - *
its - *
COOH - *
terminus - *
and - *
would - *
therefore - *
the - *
autologous - *
serum - *
recognized recognize (V*) *
the - *
epitopes - *
. - *

As - (A1*
a - *
result - *
of - *
alternate - *)
splicing - *
and - *
subsequent - *
frameshift - *
the - *
reported - *
g16 - *
protein - *
is - *
603 - *
amino - *
acids - *
shorter - *
than - *
the - *
NY-LU-12 - *
product - *
(1123 - *
residues) - *
at - *
its - *
COOH - *
terminus - *
and - *
would - *
therefore - *
the - *
autologous - *
serum - *
recognizes recognize (V*) *
the - *
epitopes - *
. - *

These - (A1*
mutations - *)
identified - *
by - *
standard - *)
methods - *
of - *
reverse - *
transcription - *
PCRdideoxy-chain - *
termination - *
and - *
cycle - *
sequencing - *
alter - *
highly - *
conserved - *
sequences - *
at - *
intron/exon - *
boundaries - *
and - *
prevent - *
the - *
RNA-splicing - *
apparatus - *
from - *
properly - *
which - *
recognized recognize (V*) *
the - *
normal - *
splice - *
junction - *
. - *

These - (A1*
mutations - *)
identified - *
by - *
standard - *)
methods - *
of - *
reverse - *
transcription - *
PCRdideoxy-chain - *
termination - *
and - *
cycle - *
sequencing - *
alter - *
highly - *
conserved - *
sequences - *
at - *
intron/exon - *
boundaries - *
and - *
prevent - *
the - *
RNA-splicing - *
apparatus - *
from - *
properly - *
which - *
recognize recognize (V*) *
the - *
normal - *
splice - *
junction - *
. - *

These - (A1*
mutations - *)
identified - *
by - *
standard - *)
methods - *
of - *
reverse - *
transcription - *
PCRdideoxy-chain - *
termination - *
and - *
cycle - *
sequencing - *
alter - *
highly - *
conserved - *
sequences - *
at - *
intron/exon - *
boundaries - *
and - *
the - *
normal - *
splice - *
junction - *
is - *
recognized recognize (V*) *
by - *
the - *
RNA-splicing - *
apparatus - *
. - *

These - (A1*
mutations - *)
identified - *
by - *
standard - *)
methods - *
of - *
reverse - *
transcription - *
PCRdideoxy-chain - *
termination - *
and - *
cycle - *
sequencing - *
alter - *
highly - *
conserved - *
sequences - *
at - *
intron/exon - *
boundaries - *
and - *
the - *
normal - *
splice - *
junction - *
was - *
recognized recognize (V*) *
by - *
the - *
RNA-splicing - *
apparatus - *
. - *

A - (A1*
number - *)
of - *
Ags - *
which - *
is - *
recognized recognize (V*) *
by - *
class - *
I-restricted - *
melanoma-specific - *
T - *
cells - *
have - *
recently - *
been - *
isolated - *
raising - *
the - *
hope - *
that - *
this - *
will - *
lead - *
to - *
the - *
development - *
of - *
improved - *
therapies - *
. - *

A - (A1*
number - *)
of - *
Ags - *
which - *
was - *
recognized recognize (V*) *
by - *
class - *
I-restricted - *
melanoma-specific - *
T - *
cells - *
have - *
recently - *
been - *
isolated - *
raising - *
the - *
hope - *
that - *
this - *
will - *
lead - *
to - *
the - *
development - *
of - *
improved - *
therapies - *
. - *

Class - (A1*
I-restricted - *)
melanoma-specific - *
T - *
cells - *
recognized recognize (V*) *
A - *
number - *
of - *
Ags - *
isolating - *
raising - *
the - *
hope - *
that - *
this - *
will - *
lead - *
to - *
the - *
development - *
of - *
improved - *
therapies - *
. - *

Class - (A1*
I-restricted - *)
melanoma-specific - *
T - *
cells - *
recognize recognize (V*) *
A - *
number - *
of - *
Ags - *
isolating - *
raising - *
the - *
hope - *
that - *
this - *
will - *
lead - *
to - *
the - *
development - *
of - *
improved - *
therapies - *
. - *

Exactly - (A1*
how - *
specific - *
splice - *
sites - *)
were - *
recognized recognize (V*) *
during - *
the - *
processing - *
of - *
complex - *
precursor - *
messenger - *
RNAs - *)
is - *
not - *
clear - *
. - *

Exactly - (A1*
how - *
specific - *
splice - *
sites - *)
have - *
been - *
recognized recognize (V*) *
during - *
the - *
processing - *
of - *
complex - *
precursor - *
messenger - *)
RNAs - *
is - *
not - *
clear - *
. - *

Exactly - *)
how - *
specific - *
splice - *
sites - *)
will - *
be - *
recognized recognize (V*) *
during - *
the - *
processing - *
of - *
complex - *
precursor - *
messenger - *
RNAs - *
is - *
not - *
clear - *
. - *

To - *)
define - *
the - *)
subcellular - *
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
were - *
modified - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
which - *
are - *
recognized recognize (V*) *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
 - *
. - *

To - *)
define - *
the - *)
subcellular - *
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
were - *
modified - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
which - *
were - *
recognized recognize (V*) *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
 - *
. - *

To - *)
define - *
the - *)
subcellular - *
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
were - *
modified - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
which - *
have - *
been - *
recognized recognize (V*) *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
 - *
. - *

To - *)
define - *
the - *)
subcellular - *
location - *
of - *
HVDAC - *
isoforms - *
HVDAC - *
genes - *
were - *
modified - *
so - *
that - *
the - *
encoded - *
proteins - *
contain - *
COOH-terminal - *
epitopes - *
which - *
will - *
be - *
recognized recognize (V*) *
by - *
either - *
of - *
two - *
monoclonal - *
antibodies - *
 - *
. - *

We - *
speculated - *
that - *
that - (A1*
repression - *)
may - *
be - *
the - *
result result (V*) *
of - (A0*
co-operative - *
binding - *
of - *
the - *
repressor - *)
in - *
mast - *
cells - *
. - *

These - *
observations - *
show - *
this - (A1*)
is - *
the - *
result result (V*) *
of - (A0*
the - *
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
to - *
its - *
two - *
sites - *
resulting - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

the - (A0*
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
in - *
mast - *
cells - *
resulted result (V*) *
to - *
that - (A1*
repression - *)
. - *

the - (A0*
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
in - *
mast - *
cells - *
results result (V*) *
to - *
that - (A1*
repression - *)
. - *

A - (A2*
role - *
for - *
SOS-1 - *
in - *
FGFR-mediated - *)
signaling - *
during - *
development - *)
Hyperactive - *
EGL-15 - *
FGF - *
receptor - *
signaling - *
conferred - *
by - *
either - *
an - *
activated - *
egl-15 - *
or - *
a - *
lf - *
clr-1 - *
mutation - *
has - *
resulted result (V*) *
in - *
a - *
Clr - *
phenotype - *
. - *

A - (A2*
role - *
for - *
SOS-1 - *
in - *
FGFR-mediated - *)
signaling - *
during - *
development - *)
Hyperactive - *
EGL-15 - *
FGF - *
receptor - *
signaling - *
conferred - *
by - *
either - *
an - *
activated - *
egl-15 - *
or - *
a - *
lf - *
clr-1 - *
mutation - *
will - *
result result (V*) *
in - *
a - *
Clr - *
phenotype - *
. - *

A - (A2*
role - *
for - *
SOS-1 - *
in - *
FGFR-mediated - *)
signaling - *
during - *
development - *)
Hyperactive - *
EGL-15 - *
FGF - *
receptor - *
signaling - *
conferred - *
by - *
either - *
an - *
activated - *
egl-15 - *
or - *
a - *
lf - *
clr-1 - *
mutation - *
which - *
resulted result (V*) *
in - *
a - *
Clr - *
phenotype - *
. - *

A - (A2*
role - *
for - *
SOS-1 - *
in - *
FGFR-mediated - *)
signaling - *
during - *
development - *)
Hyperactive - *
EGL-15 - *
FGF - *
receptor - *
signaling - *
conferred - *
by - *
either - *
an - *
activated - *
egl-15 - *
or - *
a - *
lf - *
clr-1 - *
mutation - *
which - *
results result (V*) *
in - *
a - *
Clr - *
phenotype - *
. - *

A - (A2*
role - *
for - *
SOS-1 - *
in - *
FGFR-mediated - *)
signaling - *
during - *
development - *)
Hyperactive - *
EGL-15 - *
FGF - *
receptor - *
signaling - *
conferred - *
by - *
either - *
an - *
activated - *
egl-15 - *
or - *
a - *
lf - *
clr-1 - *
mutation - *
resulted result (V*) *
in - *
a - *
Clr - *
phenotype - *
. - *

Fluctuation - *)
in - *
the - *
ras-dependent - *
signaling - *
that - *
has - *
resulted - *)
in - *
a - *
dramatic - *
change - *
in - *
vulval - *
induction - *)
under - *
the - *
condition - *
where - *
a - *
low - *
level - *
activity - *
of - *
LET-23/SEM-5/SOS-1 - *
is - *
present - *
. - *

Fluctuation - *)
in - *
the - *
ras-dependent - *
signaling - *
that - *
will - *
result - *)
in - *
a - *
dramatic - *
change - *
in - *
vulval - *
induction - *)
under - *
the - *
condition - *
where - *
a - *
low - *
level - *
activity - *
of - *
LET-23/SEM-5/SOS-1 - *
is - *
present - *
. - *

Fluctuation - *)
in - *
the - *
ras-dependent - *
signaling - *
resulted result (V*) *
in - *
a - *
dramatic - *)
change - *
in - *
vulval - *
induction - *
under - *)
the - *
condition - *
where - *
a - *
low - *
level - *
activity - *
of - *
LET-23/SEM-5/SOS-1 - *
is - *
present - *
. - *

Fluctuation - *)
in - *
the - *
ras-dependent - *
signaling - *
results result (V*) *
in - *
a - *
dramatic - *)
change - *
in - *
vulval - *
induction - *
under - *)
the - *
condition - *
where - *
a - *
low - *
level - *
activity - *
of - *
LET-23/SEM-5/SOS-1 - *
is - *
present - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
that - *
resulted result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
which - *
has - *
resulted result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
which - *
will - *
result result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
which - *
resulted result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
which - *
results result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

Complete - (A2*
sequencing - *)
of - *
the - *)
prion - *
protein - *
open - *
reading - *
frame - *)
of - *
a - *
68-year-old - *
woman - *
affected - *
by - *
a - *
familial - *
form - *
of - *
Creutzfeldt-Jakob - *
disease - *
(CJD) - *
revealed - *
a - *
new - *
mutation - *
at - *
codon - *
210 - *
resulting result (V*) *
in - *
the - *
substitution - *
of - *
isoleucine - *
for - *
valine - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
that - *
has - *
resulted result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
that - *
will - *
result result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
which - *
has - *
resulted result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
which - *
will - *
result result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
which - *
resulted result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
which - *
results result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
. - *

The - (A2*
change - *
may - *
cause - *
the - *)
heat - *
instability - *)
and - *
affect - *
the - *
net - *)
charge - *
of - *
the - *
variant - *
subunit - *
resulting result (V*) *
in - *
an - *
electrophoretic - *
LDH-B - *
subunit - *
variant - *
of - *
the - *
fast - *
type - *
 - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
that - *
result result (V*) *
in - *
a - *
marked - *
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
that - *
resulted result (V*) *
in - *)
a - *
marked - *
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
will - *
result result (V*) *
in - *
a - *
marked - *
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
has - *
resulted result (V*) *
in - *)
a - *
marked - *
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
result result (V*) *
in - *
a - *
marked - *)
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Expression - *)
of - *
isoform - *)
II - *
cDNA - *
in - *
COS7 - *
cells - *
resulted result (V*) *
in - *
a - *
marked - *)
increase - *
in - *
PAF - *
acetylhydrolase - *
activity - *
. - *

Affinity-purified - *)
polyclonal - *
anti-LMP-1 - *
antiserum - *
recognized - *)
epitopes - *
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *
with - *
a - *
RAT - *
monoclonal - *
anti-HA - *
antibody - *
(Boehringer-Ingelheim) - *
that - *
recognizes - *
the - *
sequence(YPYDVPDYA) - *
at - *
a - *
1:500 - *
dilution - *
with - *
rabbit - *
polyclonal - *
anti-CD40 - *
antiserum - *
that - *
recognizes - *
the - *
C-terminus - *
of - *
CD40 - *
at - *
a - *
1:500 - *
dilution - *
or - *
with - *
rabbit - *
polyclonal - *
anti-GFP - *
or - *
anti-RFP - *
(Clontech) - *
antiserum - *
at - *
a - *
1:250 - *
dilution - *
. - *

Affinity-purified - *)
polyclonal - *
anti-LMP-1 - *
antiserum - *
recognizes - *)
epitopes - *
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *
with - *
a - *
RAT - *
monoclonal - *
anti-HA - *
antibody - *
(Boehringer-Ingelheim) - *
that - *
recognizes - *
the - *
sequence(YPYDVPDYA) - *
at - *
a - *
1:500 - *
dilution - *
with - *
rabbit - *
polyclonal - *
anti-CD40 - *
antiserum - *
that - *
recognizes - *
the - *
C-terminus - *
of - *
CD40 - *
at - *
a - *
1:500 - *
dilution - *
or - *
with - *
rabbit - *
polyclonal - *
anti-GFP - *
or - *
anti-RFP - *
(Clontech) - *
antiserum - *
at - *
a - *
1:250 - *
dilution - *
. - *

Blots - (A2*
were - *
probed - *
with - *
affinity-purified - *)
polyclonal - *
anti-LMP-1 - *)
antiserum - *
recognizing - *
epitopes - *
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *
with - *
a - *
RAT - *
monoclonal - *
anti-HA - *
antibody - *
(Boehringer-Ingelheim) - *
that - *
recognizes - *
the - *
sequence(YPYDVPDYA) - *
at - *
a - *
1:500 - *
dilution - *
with - *
rabbit - *
polyclonal - *
anti-CD40 - *
antiserum - *
that - *
recognizes - *
the - *
C-terminus - *
of - *
CD40 - *
at - *
a - *
1:500 - *
dilution - *
or - *
with - *
rabbit - *
polyclonal - *
anti-GFP - *
or - *
anti-RFP - *
(Clontech) - *
antiserum - *
at - *
a - *
1:250 - *
dilution - *
. - *

Blots - (A2*
were - *
probed - *
with - *
affinity-purified - *)
polyclonal - *
anti-LMP-1 - *)
antiserum - *
that - *
recognized - *
epitopes - *
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *
with - *
a - *
RAT - *
monoclonal - *
anti-HA - *
antibody - *
(Boehringer-Ingelheim) - *
that - *
recognizes - *
the - *
sequence(YPYDVPDYA) - *
at - *
a - *
1:500 - *
dilution - *
with - *
rabbit - *
polyclonal - *
anti-CD40 - *
antiserum - *
that - *
recognizes - *
the - *
C-terminus - *
of - *
CD40 - *
at - *
a - *
1:500 - *
dilution - *
or - *
with - *
rabbit - *
polyclonal - *
anti-GFP - *
or - *
anti-RFP - *
(Clontech) - *
antiserum - *
at - *
a - *
1:250 - *
dilution - *
. - *

Blots - (A2*
were - *
probed - *
with - *
affinity-purified - *)
polyclonal - *
anti-LMP-1 - *)
antiserum - *
that - *
recognizes - *
epitopes - *
in - *
the - *
C-terminus - *
of - *
LMP-1 - *
at - *
a - *
1:200 - *
dilution - *
with - *
a - *
RAT - *
monoclonal - *
anti-HA - *
antibody - *
(Boehringer-Ingelheim) - *
that - *
recognizes - *
the - *
sequence(YPYDVPDYA) - *
at - *
a - *
1:500 - *
dilution - *
with - *
rabbit - *
polyclonal - *
anti-CD40 - *
antiserum - *
that - *
recognizes - *
the - *
C-terminus - *
of - *
CD40 - *
at - *
a - *
1:500 - *
dilution - *
or - *
with - *
rabbit - *
polyclonal - *
anti-GFP - *
or - *
anti-RFP - *
(Clontech) - *
antiserum - *
at - *
a - *
1:250 - *
dilution - *
. - *

it - (A1*
was - *)
resulted result (V*) *
by - *
co-operative - *)
binding - *
of - *
the - *
repressor - *
to - *
its - *
two - *
sites - *
to - *
repression - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

it - (A1*
is - *)
resulted result (V*) *
by - *
co-operative - *
binding - *
of - *
the - *
repressor - *
to - *
its - *
two - *
sites - *
to - *
repression - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

co-operative - *)
binding - *
of - *
the - *
repressor - *)
to - *
its - *
two - *
sites - *
resulted result (V*) *
to - *
repression - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

co-operative - *)
binding - *
of - *
the - *
repressor - *)
to - *
its - *
two - *
sites - *
results result (V*) *
to - *
repression - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

These - *
observations - *
show - *
that - (A1*
repression - *)
is - *
the - *
result result (V*) *
of - (A0*
co-operative - *
binding - *
of - *
the - *
repressor - *)
to - *
its - *
two - *
sites - *
resulting - *
in - *
the - *
formation - *
of - *
a - *
loop - *
of - *
DNA - *
. - *

the - (A0*
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
in - *
mast - *
cells - *
resulted result (V*) *
to - *
this - (A1*)
. - *

the - (A0*
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
in - *
mast - *
cells - *
results result (V*) *
to - *
this - (A1*)
. - *

Exon - *)
13 - *
skipping - *
in - *
s1031 - *
animals - *)
will - *
result result (V*) *
in - *
a - *
543 - *
bp - *
product - *)
. - *

Exon - *)
13 - *
skipping - *
in - *
s1031 - *
animals - *)
resulted result (V*) *
in - *
a - *
543 - *
bp - *
product - *)
. - *

Human - (A2*
mucin - *
gene - *
MUC5B - *
the - *
107-kb - *)
large - *
central - *
exon - *
encodes - *)
various - *
alternate - *
subdomains - *
which - *
has - *
resulted result (V*) *
in - *
a - *
super-repeat - *
. - *

Human - (A2*
mucin - *
gene - *
MUC5B - *
the - *
107-kb - *)
large - *
central - *
exon - *
encodes - *)
various - *
alternate - *
subdomains - *
which - *
will - *
result result (V*) *
in - *
a - *
super-repeat - *
. - *

Human - (A2*
mucin - *
gene - *
MUC5B - *
the - *
107-kb - *)
large - *
central - *
exon - *
encodes - *)
various - *
alternate - *
subdomains - *
which - *
resulted result (V*) *
in - *
a - *
super-repeat - *
. - *

Exon - *)
13 - *
skipping - *
in - *
s1031 - *
animals - *)
which - *
results result (V*) *
in - *
a - *
543 - *
bp - *)
product - *
. - *

Human - (A2*
mucin - *
gene - *
MUC5B - *
the - *
107-kb - *)
large - *
central - *
exon - *
encodes - *)
various - *
alternate - *
subdomains - *
which - *
result result (V*) *
in - *
a - *
super-repeat - *
. - *

Human - (A2*
mucin - *
gene - *
MUC5B - *
the - *
107-kb - *)
large - *
central - *
exon - *
encodes - *)
various - *
alternate - *
subdomains - *
resulting result (V*) *
in - *
a - *
super-repeat - *
. - *

We - *
speculated - *
that - *
this - (A1*)
may - *
be - *
the - *
result result (V*) *
of - (A0*
the - *
expression - *
of - *
isoforms - *
of - *
Nrf1 - *)
in - *
mast - *
cells - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
which - *
resulted result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
has - *
resulted result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
that - *
result result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
that - *
resulted result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
will - *
result result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Two - *)
are - *
missense - *
mutations - *
in - *
exon - *
2 - *
(G339D - *)
and - *
R340C) - *
and - *)
the - *
other - *
three - *
alterations - *
(a - *
nonsense - *
mutation - *
a - *
frameshift - *
and - *
a - *
splicing - *
mutation) - *
are - *
likely - *
to - *
result result (V*) *
in - *
truncated - *
nonfunctional - *
proteins - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
that - *
resulted result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
that - *
result result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
has - *
resulted result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
will - *
result result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
which - *
resulted result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
which - *
result result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
resulted result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Alternative - (A2*
splicing - *)
of - *
exon - *)
2 - *
(139 - *
nt) - *
and - *
alternative - *
transcriptional - *)
initiation - *
result result (V*) *
in - *
mRNA - *
species - *
with - *
distinct - *
5&apos;UTRs - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
which - *
resulted result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
which - *
results result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
have - *
resulted result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
will - *
result result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
resulted result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Sequence - (A2*
analysis - *
of - *
the - *
IDHbeta - *)
gene - *
indicates - *
that - *
the - *
difference - *)
in - *
the - *)
C-terminal - *
28 - *
amino - *
acids - *
between - *
beta(1) - *
and - *
beta(2) - *
proteins - *
results result (V*) *
from - *
alternative - *
splicing - *
of - *
a - *
single - *
transcript - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
that - *
resulted result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
that - *
result result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
has - *
resulted result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
will - *
result result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
resulted result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

Both - (A2*
the - *
5&apos; - *
and - *
3&apos; - *
splice - *
site - *)
mutations - *
(1060 - *
+ - *
2t--&gt;c - *
and - *
678-7g--&gt;a - *)
respectively) - *
result result (V*) *
in - *
high - *
proportions - *
of - *
mature - *
mRNAs - *
containing - *
introns - *
which - *
has - *
not - *
been - *
observed - *
for - *
other - *
splicing - *
mutations - *
. - *

We - (A2*
also - *
reported - *
the - *
existence - *
of - *
isoforms - *
of - *
NF-YA - *)
that - *
has - *)
resulted result (V*) *
from - *
differential - *
splicing - *
. - *

We - (A2*
also - *
report - *
the - *
existence - *
of - *)
isoforms - *
of - *
NF-YA - *)
that - *
will - *)
result result (V*) *
from - *
differential - *
splicing - *
. - *

The - *)
research - *
show - *
the - *
existence - *)
of - *
isoforms - *
of - *
NF-YA - *
which - *
resulted result (V*) *
from - *
differential - *
splicing - *
. - *

The - *)
research - *
show - *
the - *
existence - *)
of - *
isoforms - *
of - *
NF-YA - *
which - *
result result (V*) *
from - *
differential - *
splicing - *
. - *

We - (A2*
also - *
reported - *
the - *
existence - *
of - *
isoforms - *
of - *
NF-YA - *)
which - *
resulted - *)
from - *
differential - *
splicing - *
. - *

We - (A2*
also - *
report - *
the - *
existence - *
of - *)
isoforms - *
of - *
NF-YA - *)
which - *
result - *)
from - *
differential - *
splicing - *
. - *

it - *
is - *
resulted result (V*) *
by - *
the - (A1*
negative - *
effect - *
of - *
the - *
cpxA - *
mutation - *)
from - (A0*
a - *
decreased - *
transcription - *
of - *
the - *
curlin - *
encoding - *
csgA - *
gene - *)
. - *

it - *
was - *
resulted result (V*) *
by - *
the - (A1*
negative - *
effect - *
of - *
the - *
cpxA - *
mutation - *)
from - (A0*
a - *
decreased - *
transcription - *
of - *
the - *
curlin - *
encoding - *
csgA - *
gene - *)
. - *

We - *
show - *
that - *
the - (A1*
negative - *
effect - *
of - *
the - *
cpxA - *
mutation - *)
on - *
biofilm - *
formation - *
resulted result (V*) *
from - (A0*
a - *
decreased - *
transcription - *
of - *
the - *
curlin - *
encoding - *
csgA - *
gene - *)
. - *

We - *
show - *
that - *
the - (A1*
negative - *
effect - *
of - *
the - *
cpxA - *
mutation - *)
on - *
biofilm - *
formation - *
results result (V*) *
from - (A0*
a - *
decreased - *
transcription - *
of - *
the - *
curlin - *
encoding - *
csgA - *
gene - *)
. - *

Induction - (A0*
of - *
a - *
mutation - *
in - *
the - *
lacI - *
gene - *)
has - *
resulted result (V*) *
in - (A1*
the - *
loss - *
of - *
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *)
in - *
mutated - *
cells - *
. - *

Induction - (A0*
of - *
a - *
mutation - *
in - *
the - *
lacI - *
gene - *)
resulted result (V*) *
in - (A1*
the - *
loss - *
of - *
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *)
in - *
mutated - *
cells - *
. - *

Induction - (A0*
of - *
a - *
mutation - *
in - *
the - *
lacI - *
gene - *)
results result (V*) *
in - (A1*
the - *
loss - *
of - *
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *)
in - *
mutated - *
cells - *
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
alter - *
the - *
phasing - *
of - *
the - *
binding - *
sites - *
has - *
 - *
resulted result (V*) *
in - (A1*
simultaneous - *
derepression - *
of - *
both - *
genes - *)
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
alter - *
the - *
phasing - *
of - *
the - *
binding - *
sites - *
will - *
result result (V*) *
in - (A1*
simultaneous - *
derepression - *
of - *
both - *
genes - *)
. - *

Mutations - (A0*)
which - *
prevent - *
repressor - *
binding - *
to - *
either - *
site - *
or - *
alter - *
the - *
phasing - *
of - *
the - *
binding - *
sites - *
resulted result (V*) *
in - (A1*
simultaneous - *
derepression - *
of - *
both - *
genes - *)
. - *

Induction - (A0*
of - *
a - *
mutation - *
in - *
the - *
lacI - *
gene - *)
which - *
results result (V*) *
in - (A1*
the - *
loss - *
of - *
transcriptional - *
repression - *
of - *
the - *
lacZ - *
gene - *)
in - *
mutated - *
cells - *
. - *

Exon - *)
13 - *
skipping - *
in - *
s1031 - *
animals - *)
has - *
resulted result (V*) *
in - *
a - *
543 - *
bp - *
product - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
has - *
resulted result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
will - *
result result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
that - *
resulted result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
that - *
results result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
which - *
resulted result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
which - *
results result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Decreased - (A2*
EGL-15 - *
signaling - *
conferred - *
by - *
a - *
partial - *
lf - *
egl-15 - *)
mutation - *
resulted result (V*) *
in - *
a - *
scrawny - *
body - *
morphology - *
phenotype(Kokel - *
et - *
al - *
1998) - *
. - *

Exon - *)
13 - *
skipping - *
in - *
s1031 - *
animals - *)
which - *
resulted result (V*) *
in - *
a - *
543 - *
bp - *)
product - *
. - *

Translation - *)
of - *
this - *
RNA - *
is - *
initiated - *
by - *
a - *
ribosome - *
shunt - *
mechanism - *
in - *
which - *
ribosomes - *
translate - *
the - *
most - *
5"-proximal - *
short - *
ORF - *
(sORF - *
A) - *
that - *
skipped skip (V*) *
a - (A1*
large - *
region - *
of - *
the - *
leader - *
containing - *
a - *
putative - *
RNA - *
encapsidation - *
signal - *)
and - *
reinitiate - *
translation - *
at - *
the - *
first - *
long - *
viral - *
ORF - *
. - *

The - (A1*
centromere - *)
has - *
been - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
. - *

The - (A1*
centromere - *)
which - *
was - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
 - *
. - *

The - (A1*
centromere - *)
which - *
is - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
. - *

The - (A1*
centromere - *)
that - *
will - *
be - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
 - *
. - *

Megakaryocytes - (A1*
undergo - *)
an - *
endomitotic - *)
cell - *
cycle - *
which - *
consists - *
of - *
an - *
S - *
phase - *
interrupted - *
by - *
a - *
gap - *
during - *
which - *
the - *
cells - *
skip skip (V*) *
anaphase - *
B - *
and - *
cytokinesis - *
. - *

Translation - *)
of - *
this - *
RNA - *
is - *
initiated - *
by - *
a - *
ribosome - *
shunt - *
mechanism - *
in - *
which - *
ribosomes - *
translate - *
the - *
most - *
5"-proximal - *
short - *
ORF - *
(sORF - *
A) - *
which - *
skipped skip (V*) *
a - (A1*
large - *
region - *
of - *
the - *
leader - *
containing - *
a - *
putative - *
RNA - *
encapsidation - *
signal - *)
and - *
reinitiate - *
translation - *
at - *
the - *
first - *
long - *
viral - *
ORF - *
. - *

Translation - *)
of - *
this - *
RNA - *
is - *
initiated - *
by - *
a - *
ribosome - *
shunt - *
mechanism - *
in - *
which - *
ribosomes - *
translate - *
the - *
most - *
5"-proximal - *
short - *
ORF - *
(sORF - *
A) - *
that - *
skip skip (V*) *
a - (A1*
large - *
region - *
of - *
the - *
leader - *
containing - *
a - *
putative - *
RNA - *
encapsidation - *
signal - *)
and - *
reinitiate - *
translation - *
at - *
the - *
first - *
long - *
viral - *
ORF - *
. - *

Translation - *)
of - *
this - *
RNA - *
is - *
initiated - *
by - *
a - *
ribosome - *
shunt - *
mechanism - *
in - *
which - *
ribosomes - *
translate - *
the - *
most - *
5"-proximal - *
short - *
ORF - *
(sORF - *
A) - *
which - *
skip skip (V*) *
a - (A1*
large - *
region - *
of - *
the - *
leader - *
containing - *
a - *
putative - *
RNA - *
encapsidation - *
signal - *)
and - *
reinitiate - *
translation - *
at - *
the - *
first - *
long - *
viral - *
ORF - *
. - *

Translation - *)
of - *
this - *
RNA - *
is - *
initiated - *
by - *
a - *
ribosome - *
shunt - *
mechanism - *
in - *
which - *
ribosomes - *
translate - *
the - *
most - *
5"-proximal - *
short - *
ORF - *
(sORF - *
A) - *
then - *
skip skip (V*) *
a - (A1*
large - *
region - *
of - *
the - *
leader - *
containing - *
a - *
putative - *
RNA - *
encapsidation - *
signal - *)
and - *
reinitiate - *
translation - *
at - *
the - *
first - *
long - *
viral - *
ORF - *
. - *

In - (A1*
the - *
case - *
of - *
the - *
12-membered - *
ring - *
macrolide - *
an - *
acyl-enzyme - *
intermediate - *)
on - *
PikAIII - *
will - *
skip skip (V*) *
efficiently - *
the - *
last - *
extension - *
step - *
and - *
is - *
cyclized - *
by - *
the - *
TE - *
domain - *
of - *
PikAIV - *
presumably - *
as - *
a - *
result - *
of - *
a - *
PikAIII-PikAIV - *
interaction - *
. - *

In - (A1*
the - *
case - *
of - *
the - *
12-membered - *
ring - *
macrolide - *
an - *
acyl-enzyme - *
intermediate - *)
on - *
PikAIII - *
has - *
skipped skip (V*) *
efficiently - *
the - *
last - *
extension - *
step - *
and - *
is - *
cyclized - *
by - *
the - *
TE - *
domain - *
of - *
PikAIV - *
presumably - *
as - *
a - *
result - *
of - *
a - *
PikAIII-PikAIV - *
interaction - *
. - *

In - (A1*
the - *
case - *
of - *
the - *
12-membered - *
ring - *
macrolide - *
an - *
acyl-enzyme - *
intermediate - *)
on - *
PikAIII - *
skips skip (V*) *
efficiently - *
the - *
last - *
extension - *
step - *
and - *
is - *
cyclized - *
by - *
the - *
TE - *
domain - *
of - *
PikAIV - *
presumably - *
as - *
a - *
result - *
of - *
a - *
PikAIII-PikAIV - *
interaction - *
. - *

In - (A1*
the - *
case - *
of - *
the - *
12-membered - *
ring - *
macrolide - *
an - *
acyl-enzyme - *
intermediate - *)
on - *
PikAIII - *
skipped skip (V*) *
efficiently - *
the - *
last - *
extension - *
step - *
and - *
is - *
cyclized - *
by - *
the - *
TE - *
domain - *
of - *
PikAIV - *
presumably - *
as - *
a - *
result - *
of - *
a - *
PikAIII-PikAIV - *
interaction - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
could - *
be - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
generates - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
has - *
been - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
generated - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
will - *
be - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
can - *
generate - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
 - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
is - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
generates - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
was - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
generated - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
. - *

The - (A1*
centromere - *)
will - *
be - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
 - *
. - *

Direct - (A1*
sequencing - *)
of - *
the - *
PAF-2 - *
gene - *)
revealed - *
a - *
homozygous - *
1-bp - *
insertion - *
at - *
nucleotide - *
511 - *
(511 - *
insT) - *
in - *
one - *
patient - *
with - *
group - *
C - *
Zellweger - *
syndrome - *
(ZS) - *
which - *
introduces - *
a - *
premature - *
termination - *
codon - *
in - *
the - *
PAF-2 - *
gene - *
and - *
in - *
the - *
second - *
patient - *
revealed - *
a - *
splice-site - *
mutation - *
in - *
intron - *
3 - *
(IVS3+1G--&gt;A) - *
which - *
will - *
skip skip (V*) *
exon - *
3 - *
an - *
event - *
that - *
leads - *
to - *
peroxisome - *
deficiency - *
. - *

Direct - (A1*
sequencing - *)
of - *
the - *
PAF-2 - *
gene - *)
revealed - *
a - *
homozygous - *
1-bp - *
insertion - *
at - *
nucleotide - *
511 - *
(511 - *
insT) - *
in - *
one - *
patient - *
with - *
group - *
C - *
Zellweger - *
syndrome - *
(ZS) - *
which - *
introduces - *
a - *
premature - *
termination - *
codon - *
in - *
the - *
PAF-2 - *
gene - *
and - *
in - *
the - *
second - *
patient - *
revealed - *
a - *
splice-site - *
mutation - *
in - *
intron - *
3 - *
(IVS3+1G--&gt;A) - *
which - *
has - *
skipped skip (V*) *
exon - *
3 - *
an - *
event - *
that - *
leads - *
to - *
peroxisome - *
deficiency - *
 - *
. - *

Direct - (A1*
sequencing - *)
of - *
the - *
PAF-2 - *
gene - *)
revealed - *
a - *
homozygous - *
1-bp - *
insertion - *
at - *
nucleotide - *
511 - *
(511 - *
insT) - *
in - *
one - *
patient - *
with - *
group - *
C - *
Zellweger - *
syndrome - *
(ZS) - *
which - *
introduces - *
a - *
premature - *
termination - *
codon - *
in - *
the - *
PAF-2 - *
gene - *
and - *
in - *
the - *
second - *
patient - *
revealed - *
a - *
splice-site - *
mutation - *
in - *
intron - *
3 - *
(IVS3+1G--&gt;A) - *
which - *
skips skip (V*) *
exon - *
3 - *
an - *
event - *
that - *
leads - *
to - *
peroxisome - *
deficiency - *
. - *

Direct - (A1*
sequencing - *)
of - *
the - *
PAF-2 - *
gene - *)
revealed - *
a - *
homozygous - *
1-bp - *
insertion - *
at - *
nucleotide - *
511 - *
(511 - *
insT) - *
in - *
one - *
patient - *
with - *
group - *
C - *
Zellweger - *
syndrome - *
(ZS) - *
which - *
introduces - *
a - *
premature - *
termination - *
codon - *
in - *
the - *
PAF-2 - *
gene - *
and - *
in - *
the - *
second - *
patient - *
revealed - *
a - *
splice-site - *
mutation - *
in - *
intron - *
3 - *
(IVS3+1G--&gt;A) - *
which - *
skipped skip (V*) *
exon - *
3 - *
an - *
event - *
that - *
leads - *
to - *
peroxisome - *
deficiency - *
 - *
. - *

One - (A1*
variant - *)
has - *
found - *
to - *
result - *
from - *)
failure - *
to - *
use - *
the - *
normal - *
splice - *
donor - *
site - *
of - *
intron - *
12 - *
. - *

One - (A1*
variant - *)
has - *
shown - *
to - *
result - *
from - *)
failure - *
to - *
use - *
the - *
normal - *
splice - *
donor - *
site - *
of - *
intron - *
12 - *
. - *

One - (A1*
variant - *)
which - *
resulted - *
from - *
failure - *)
to - *
use - *
the - *
normal - *
splice - *
donor - *
site - *
of - *
intron - *
12 - *
. - *

One - (A1*
variant - *)
which - *
results - *
from - *
failure - *)
to - *
use - *
the - *
normal - *
splice - *
donor - *
site - *
of - *
intron - *
12 - *
. - *

One - (A1*
variant - *)
resulted - *
from - *
failure - *
to - *)
use - *
the - *
normal - *
splice - *
donor - *
site - *
of - *
intron - *
12 - *
. - *

Megakaryocytes - (A1*
undergo - *)
an - *
endomitotic - *)
cell - *
cycle - *
which - *
consists - *
of - *
an - *
S - *
phase - *
interrupted - *
by - *
a - *
gap - *
during - *
which - *
the - *
cells - *
skipped skip (V*) *
anaphase - *
B - *
and - *
cytokinesis - *
. - *

Megakaryocytes - (A1*
undergo - *)
an - *
endomitotic - *)
cell - *
cycle - *
which - *
consists - *
of - *
an - *
S - *
phase - *
interrupted - *
by - *
a - *
gap - *
during - *
which - *
the - *
cells - *
has - *
skipped skip (V*) *
anaphase - *
B - *
and - *
cytokinesis - *
. - *

Megakaryocytes - (A1*
undergo - *)
an - *
endomitotic - *)
cell - *
cycle - *
which - *
consists - *
of - *
an - *
S - *
phase - *
interrupted - *
by - *
a - *
gap - *
during - *
which - *
the - *
cells - *
will - *
skip skip (V*) *
anaphase - *
B - *
and - *
cytokinesis - *
. - *

Xist - *)
RNA - *
coats - *
the - *
autosome - *
but - *
skips skip (V*) *
the - *
Xic - *
Tg - *
raising - *
the - *
possibility - *
that - *
X - *
chromosome - *
domains - *
escape - *
inactivation - *
by - *
excluding - *
Xist - *
RNA - *
binding - *
. - *

Xist - *)
RNA - *
coated - *
the - *
autosome - *
but - *
has - *
skipped skip (V*) *
the - *
Xic - *
Tg - *
raising - *
the - *
possibility - *
that - *
X - *
chromosome - *
domains - *
escape - *
inactivation - *
by - *
excluding - *
Xist - *
RNA - *
binding - *
. - *

Xist - *)
RNA - *
coats - *
the - *
autosome - *
but - *
will - *
skip skip (V*) *
the - *
Xic - *
Tg - *
raising - *
the - *
possibility - *
that - *
X - *
chromosome - *
domains - *
escape - *
inactivation - *
by - *
excluding - *
Xist - *
RNA - *
binding - *
. - *

The - (A1*
centromere - *)
is - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
. - *

The - (A1*
centromere - *)
that - *
has - *
been - *
skipped skip (V*) *
on - *
all - *
Tg - *
autosomes - *
as - *
on - *
the - *
female - *
Xi - *
. - *

Finally - (A1*
a - *
stop - *)
codon-containing - *
exon - *
(exon - *
4) - *
can - *
be - *
skipped skip (V*) *
by - *
alternative - *
splicing - *
and - *
can - *
generate - *
a - *
transcript - *
that - *
is - *
predicted - *
to - *
encode - *
a - *
fusion - *
protein - *
 - *
. - *

CD1c - (A4*
having - *)
a - *
duplicated - *)
form - *
of - *
this - *
exon - *
has - *
been - *
spliced splice (V*) *
out - *
 - *
. - *

CD1c - (A4*
having - *)
a - *
duplicated - *)
form - *
of - *
this - *
exon - *
was - *
spliced splice (V*) *
out - *
 - *
. - *

CD1c - (A4*
having - *)
a - *
duplicated - *)
form - *
of - *
this - *
exon - *
is - *
spliced splice (V*) *
out - *
 - *
. - *

The - (A1*)
mouse - *)
polymeric - *
immunoglobulin - *
receptor - *
gene - *
has - *
a - *
654 - *
nt - *
exon - (A2*)
that - *
will - *
be - *
efficiently - *
spliced splice (V*) *
into - *
the - *
mRNA - *
. - *

The - (A1*)
mouse - *)
polymeric - *
immunoglobulin - *
receptor - *
gene - *
has - *
a - *
654 - *
nt - *
exon - (A2*)
that - *
has - *
been - *
efficiently - *
spliced splice (V*) *
into - *
the - *
mRNA - *
. - *

The - (A1*)
mouse - *)
polymeric - *
immunoglobulin - *
receptor - *
gene - *
has - *
a - *
654 - *
nt - *
exon - (A2*)
that - *
was - *
efficiently - *
spliced splice (V*) *
into - *
the - *
mRNA - *
. - *

Exons - (A3*
outside - *)
this - *
size - *
range - *
were - *
spliced splice (V*) *
into - *
the - *
mature - *
mRNA - *
. - *

Exons - (A3*
outside - *)
this - *
size - *
range - *
are - *
spliced splice (V*) *
into - *
the - *
mature - *
mRNA - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
which - *
has - *
been - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
which - *
was - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
which - *
is - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
will - *
be - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
has - *
been - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
was - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
is - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
that - *
have - *
been - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
that - *
will - *
be - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
that - *
were - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
have - *
been - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
will - *
be - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

The - (A2*
pre-mRNAs - *)
from - *
all - *)
of - *
these - *
genes - *)
were - *
spliced splice (V*) *
with - *
little - *
or - *
no - *
exon-skipping - *
(ref - *
16; - *
also - *
Fig - *
1 - *
C - *
and - *
data - *
not - *
shown) - *
suggesting - *
that - *
correct - *
exon - *
inclusion - *
can - *
be - *
managed - *
by - *
the - *
yeast - *
gene - *
expression - *
machinery - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
which - *
has - *
been - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
which - *
is - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
which - *
was - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
will - *
be - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
has - *
been - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

When - *)
incubated - *)
in - *
nuclear - *
extracts - *
or - *
transfected - *
in - *
HeLa - *
cells - *
the - *
C2Gloi2 - *
substrate - *
is - *
spliced splice (V*) *
predominantly - *
following - *
the - *
exon-skipping - *
pathway - *
to - *
a - *
level - *
similar - *
to - *
that - *
obtained - *
with - *
the - *
C2 - *
substrate - *
(data - *
not - *
shown - *
and - *
Fig - *
2 - *
E - *
compare - *
lane - *
3 - *
to - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
that - *)
will - *
be - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
that - *)
has - *
been - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
that - *)
is - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
that - *)
was - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
will - *)
be - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - (A2*
casp-2 - *)
minigene - *)
(C2) - *
has - *)
been - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

The - *)
casp-2 - *)
minigene - *)
(C2) - *
is - *
spliced splice (V*) *
efficiently - *
in - *
vitro - *
and - *
the - *
ratio - *
of - *
casp-2S - *
to - *
casp-2L - *
mRNAs - *
produced - *
was - *
similar - *
to - *
the - *
one - *
observed - *
in - *
vivo - *
(Fig - *
1 - *
C - *
lane - *
1) - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
which - *
was - *
made - *
that - *
was - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
which - *
has - *
been - *
made - *
that - *
can - *
be - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
could - *
made - *
that - *
is - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
would - *
be - *
made - *
that - *
was - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
will - *
be - *
made - *
that - *
can - *
be - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
is - *
made - *
that - *
is - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
was - *
made - *
that - *
was - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

The - *)
Supt4h - *)
gene - *
is - *
spliced - *)
normally - *
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
was - *
spliced - *)
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
that - *
is - *
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
that - *
was - *
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
which - *)
is - *
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
which - *)
was - *
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
will - *
be - *
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

The - (A4*
Supt4h - *)
gene - *
has - *
been - *)
spliced splice (V*) *
normally - *)
from - *
five - *
exons - *
encoded - *
by - *
chromosome - *
11 - *
. - *

An - (A2*
additional - *)
observation - *)
with - *
the - *)
tandem - *
repeat-containing - *
3? - *
substrates - *
was - *
that - *
the - *
efficiency - *
of - *
bimolecular - *
exon - *
ligation - *
decreased - *
stepwise - *
with - *
each - *
mutation - *
that - *
moved - *
the - *
5?-most - *
AG - *
6 - *
nt - *
further - *
downstream - *
such - *
that - *
RNA - *
3I - *
splices splice (V*) *
only - *
20% - *
as - *
efficiently - *
as - *
RNA - *
3F - *
(Fig - *
1 - *
C - *
Left) - *
. - *

An - (A2*
additional - *)
observation - *)
with - *
the - *)
tandem - *
repeat-containing - *
3? - *
substrates - *
was - *
that - *
the - *
efficiency - *
of - *
bimolecular - *
exon - *
ligation - *
decreased - *
stepwise - *
with - *
each - *
mutation - *
that - *
moved - *
the - *
5?-most - *
AG - *
6 - *
nt - *
further - *
downstream - *
such - *
that - *
RNA - *
3I - *
has - *
spliced splice (V*) *
only - *
20% - *
as - *
efficiently - *
as - *
RNA - *
3F - *
(Fig - *
1 - *
C - *
Left) - *
. - *

An - (A2*
additional - *)
observation - *)
with - *
the - *)
tandem - *
repeat-containing - *
3? - *
substrates - *
was - *
that - *
the - *
efficiency - *
of - *
bimolecular - *
exon - *
ligation - *
decreased - *
stepwise - *
with - *
each - *
mutation - *
that - *
moved - *
the - *
5?-most - *
AG - *
6 - *
nt - *
further - *
downstream - *
such - *
that - *
RNA - *
3I - *
will - *
splice splice (V*) *
only - *
20% - *
as - *
efficiently - *
as - *
RNA - *
3F - *
(Fig - *
1 - *
C - *
Left) - *
. - *

Thre - (A3*
of - *
the - *)
revertants - *
obtained - *)
from - *
the - *
null - *
allele - *
unc-68(e540) - *
which - *
displayed - *
normal - *
motility - *
had - *
intragenic - *
mutations - *
that - *
resulted - *
in - *
failure - *
splicing splice (V*) *
out - *
intron - *
21 - *
. - *

It - *)
does - *
not - *)
splice splice (V*) *
out - *
this - *
intron - *
this - *
resulted - *
in - *
a - *
substitution - *
of - *
the - *
final - *
13 - *
amino - *
acids - *
of - *
the - *
deduced - *
amino - *
acid - *
sequence - *
. - *

It - (A4*
did - *
not - *)
splice splice (V*) *
out - *
this - *
intron - *
this - *
resulted - *
in - *
a - *
substitution - *
of - *)
the - *
final - *
13 - *
amino - *
acids - *
of - *
the - *
deduced - *
amino - *
acid - *
sequence - *
. - *

this - *)
intron - *)
was - *
not - *
spliced splice (V*) *
out - *
resulting - *
in - *
a - *
substitution - *
of - *
the - *
final - *
13 - *
amino - *
acids - *
of - *
the - *
deduced - *
amino - *
acid - *
sequence - *
. - *

this - (A4*
intron - *)
is - *
not - *
spliced splice (V*) *
out - *
resulting - *
in - *
a - *
substitution - *
of - *
the - *
final - *)
13 - *
amino - *
acids - *
of - *
the - *
deduced - *
amino - *
acid - *
sequence - *
. - *

Non-coding - *)
introns - *
were - *
spliced splice (V*) *
out - *
in - *
order - *
to - *
generate - *
a - *
mature - *
messenger - *
RNA - *
molecule - *
used - *
to - *
encode - *
proteins - *
. - *

Non-coding - *)
introns - *
are - *
spliced splice (V*) *
out - *
in - *
order - *
to - *
generate - *
a - *
mature - *
messenger - *
RNA - *
molecule - *
used - *
to - *
encode - *
proteins - *
. - *

It - (A2*
spliced - *)
in - *
order - *
to - *
generate - *
a - *
mature - *
messenger - *
RNA - *
molecule - *
used - *
to - *
encode - *
proteins - *
. - *

It - (A2*
splices - *)
in - *
order - *
to - *
generate - *
a - *
mature - *
messenger - *
RNA - *
molecule - *
used - *
to - *
encode - *
proteins - *
. - *

We - (A3*
have - *)
shown - *)
that - *
in - *
the - *
human - *
as - *
in - *
the - *
chicken - *
one - *
exon - *
will - *
be - *
spliced splice (V*) *
out - *
of - *
the - *
MLC3nm - *
transcript - *
in - *
smooth - *
muscle - *
to - *
give - *
an - *
alternative - *
product - *
. - *

Moreover - (A2*
exon - *)
16 - *
will - *)
be - *
spliced splice (V*) *
out - *
from - *
the - *
mature - *
transcripts - *
that - *
contain - *
exons - *
15 - *
to - *
24 - *
. - *

We - (A2*
also - *
identified - *)
four - *
transcriptional - *
units - *
that - *
has - *
been - *
spliced splice (V*) *
but - *
contain - *
no - *
obvious - *
open - *
reading - *
frame - *
. - *

We - (A2*
also - *
identified - *)
four - *
transcriptional - *
units - *
that - *
will - *
be - *
spliced splice (V*) *
but - *
contain - *
no - *
obvious - *
open - *
reading - *
frame - *
. - *

We - (A2*
also - *
identified - *)
four - *
transcriptional - *
units - *
that - *
were - *
spliced splice (V*) *
but - *
contain - *
no - *
obvious - *
open - *
reading - *
frame - *
. - *

We - (A2*
also - *
identified - *)
four - *
transcriptional - *
units - *
that - *
are - *
spliced splice (V*) *
but - *
contain - *
no - *
obvious - *
open - *
reading - *
frame - *
. - *

The - (A1*
structure - *)
of - *
different - *)
cDNA - *
clones - *
indicates - *
that - *
USF - *
RNA - *
has - *
been - *
differentially - *
spliced splice (V*) *
and - *
alternative - *
exon - *
usage - *
may - *
regulate - *
the - *
levels - *
of - *
functional - *
USF - *
protein - *
. - *

The - (A1*
structure - *)
of - *
different - *)
cDNA - *
clones - *
indicates - *
that - *
USF - *
RNA - *
will - *
be - *
differentially - *
spliced splice (V*) *
and - *
alternative - *
exon - *
usage - *
may - *
regulate - *
the - *
levels - *
of - *
functional - *
USF - *
protein - *
. - *

However - (A3*
a - *
pre-mRNA - *)
containing - *)
mutations - *
in - *
SE2 - *
which - *
will - *
be - *
spliced splice (V*) *
predominantly - *
using - *
the - *
nt - *
3605 - *
3" - *
splice - *
site - *
. - *

The - (A1*
structure - *)
of - *
different - *)
cDNA - *
clones - *
indicates - *
that - *
USF - *
RNA - *
was - *
differentially - *
spliced splice (V*) *
and - *
alternative - *
exon - *
usage - *
may - *
regulate - *
the - *
levels - *
of - *
functional - *
USF - *
protein - *
. - *

Consequently - *)
exon - *
30 - *
which - *
was - *
spliced splice (V*) *
together - *
with - *
the - *
intron - *
 - *
 - *
. - *

Consequently - *)
exon - *
30 - *
which - *
is - *
spliced splice (V*) *
together - *
with - *
the - *
intron - *
 - *
 - *
. - *

Consequently - *)
exon - *
30 - *
will - *
be - *
spliced splice (V*) *
together - *
with - *
the - *
intron - *
 - *
 - *
. - *

Consequently - *)
exon - *
30 - *
has - *
been - *
spliced splice (V*) *
together - *
with - *
the - *
intron - *
 - *
 - *
. - *

Consequently - *)
exon - *
30 - *
was - *
spliced splice (V*) *
together - *
with - *
the - *
intron - *
 - *
 - *
. - *

The - (A2*
observation - *
that - *)
Tg - (A0*
Xist - *
RNA - *)
has - *
skipped - *
the - *
ectopic - *
Xic - *
raises - *
the - *
possibility - *
that - *
the - *
Xic - *
lacks - *
Xist-binding - *
sites - *
and - *
therefore - *
escapes - *
inactivation - *
on - *
the - *
Xi - *
. - *

The - (A2*
observation - *
that - *)
Tg - (A0*
Xist - *
RNA - *)
will - *
skip - *
the - *
ectopic - *
Xic - *
raises - *
the - *
possibility - *
that - *
the - *
Xic - *
lacks - *
Xist-binding - *
sites - *
and - *
therefore - *
escapes - *
inactivation - *
on - *
the - *
Xi - *
. - *

The - (A2*
observation - *
that - *)
Tg - (A0*
Xist - *
RNA - *)
skipped - *
the - *
ectopic - *
Xic - *
raises - *
the - *
possibility - *
that - *
the - *
Xic - *
lacks - *
Xist-binding - *
sites - *
and - *
therefore - *
escapes - *
inactivation - *
on - *
the - *
Xi - *
. - *

Moreover - (A2*
exon - *)
16 - *
which - *)
is - *
spliced splice (V*) *
out - *
from - *
the - *
mature - *
transcripts - *
that - *
contain - *
exons - *
15 - *
to - *
24 - *
. - *

Moreover - (A2*
exon - *)
16 - *
has - *)
ben - *
spliced splice (V*) *
out - *
from - *
the - *
mature - *
transcripts - *
that - *
contain - *
exons - *
15 - *
to - *
24 - *
. - *

A - (A4*
caspase-2 - *)
minigene - *)
construct - *
which - *
is - *
made - *
that - *
is - *
alternatively - *
spliced splice (V*) *
in - *
transfected - *
cells - *
and - *
in - *
nuclear - *
extracts - *
. - *

Moreover - (A2*
exon - *)
16 - *
is - *)
spliced splice (V*) *
out - *
from - *
the - *
mature - *
transcripts - *
that - *
contain - *
exons - *
15 - *
to - *
24 - *
. - *

Moreover - (A2*
exon - *)
16 - *
was - *)
spliced splice (V*) *
out - *
from - *
the - *
mature - *
transcripts - *
that - *
contain - *
exons - *
15 - *
to - *
24 - *
. - *

an - (A2*
intron - *)
is - *
spliced splice (V*) *
out - *
during - *
mRNA - *
processing - *
. - *

an - (A2*
intron - *)
was - *
spliced splice (V*) *
out - *
during - *
mRNA - *
processing - *
. - *

It - (A2*
splices - *)
out - *
an - *
intron - *
during - *
mRNA - *
processing - *
. - *

It - (A2*
spliced - *)
out - *
an - *
intron - *
during - *
mRNA - *
processing - *
. - *

It - *)
will - *)
splice splice (V*) *
out - *
putative - *
intron - *
sequences - *
in - *
transcripts - *
which - *
spanned - *
exon-intron - *
boundaries - *
is - *
expected - *
in - *
antisense - *
transcripts - *
as - *
candidate - *
donor - *
and - *
acceptor - *
sites - *
were - *
only - *
present - *
in - *
the - *
gene - *
when - *
. - *

It - *)
spliced - *)
out - *
putative - *
intron - *
sequences - *
in - *
transcripts - *
which - *
spanned - *
exon-intron - *
boundaries - *
is - *
expected - *
in - *
antisense - *
transcripts - *
as - *
candidate - *
donor - *
and - *
acceptor - *
sites - *
were - *
only - *
present - *
in - *
the - *
gene - *
when - *
. - *

It - *)
splices - *)
out - *
putative - *
intron - *
sequences - *
in - *
transcripts - *
which - *
spanned - *
exon-intron - *
boundaries - *
is - *
expected - *
in - *
antisense - *
transcripts - *
as - *
candidate - *
donor - *
and - *
acceptor - *
sites - *
were - *
only - *
present - *
in - *
the - *
gene - *
when - *
. - *

A - (A2*
retained - *)
intron - *)
in - *
the - *
5&apos; - *
UTR - *
of - *
HYAL1 - *
mRNA - *
was - *
spliced splice (V*) *
out - *
by - *
the - *
cell - *
lines - *
. - *

A - (A2*
retained - *)
intron - *)
in - *
the - *
5&apos; - *
UTR - *
of - *
HYAL1 - *
mRNA - *
is - *
spliced splice (V*) *
out - *
by - *
the - *
cell - *
lines - *
. - *

The - (A2*
cell - *)
lines - *
splices - *)
out - *
a - *
retained - *
intron - *
in - *
the - *
5&apos; - *
UTR - *
of - *
HYAL1 - *
mRNA - *
. - *

The - (A2*
cell - *)
lines - *
spliced - *)
out - *
a - *
retained - *
intron - *
in - *
the - *
5&apos; - *
UTR - *
of - *
HYAL1 - *
mRNA - *
. - *

Thre - (A3*
of - *
the - *)
revertants - *
obtained - *)
from - *
the - *
null - *
allele - *
unc-68(e540) - *
intragenic - *
mutations - *
will - *
be - *
spliced splice (V*) *
out - *
intron - *
21 - *
. - *

Thre - (A3*
of - *
the - *)
revertants - *
obtained - *)
from - *
the - *
null - *
allele - *
unc-68(e540) - *
intragenic - *
mutations - *
have - *
been - *
spliced splice (V*) *
out - *
intron - *
21 - *
. - *

Thre - (A3*
of - *
the - *)
revertants - *
obtained - *)
from - *
the - *
null - *
allele - *
unc-68(e540) - *
intragenic - *
mutations - *
were - *
spliced splice (V*) *
out - *
intron - *
21 - *
. - *

Thre - (A3*
of - *
the - *)
revertants - *
obtained - *)
from - *
the - *
null - *
allele - *
unc-68(e540) - *
intragenic - *
mutations - *
are - *
spliced splice (V*) *
out - *
intron - *
21 - *
. - *

We - (A3*
have - *)
shown - *)
that - *
in - *
the - *
human - *
as - *
in - *
the - *
chicken - *
one - *
exon - *
has - *
been - *
spliced splice (V*) *
out - *
of - *
the - *
MLC3nm - *
transcript - *
in - *
smooth - *
muscle - *
to - *
give - *
an - *
alternative - *
product - *
. - *

We - (A3*
have - *)
shown - *)
that - *
in - *
the - *
human - *
as - *
in - *
the - *
chicken - *
one - *
exon - *
was - *
spliced splice (V*) *
out - *
of - *
the - *
MLC3nm - *
transcript - *
in - *
smooth - *
muscle - *
to - *
give - *
an - *
alternative - *
product - *
. - *

CD1c - (A4*
having - *)
a - *
duplicated - *)
form - *
of - *
this - *
exon - *
will - *
be - *
spliced splice (V*) *
out - *
 - *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
which - *
are - *
divergently - *
transcribed transcribe (V*) *
. - *

NEP-2 - (A3*)
specifically - *
has - *)
transcribed transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

NEP-2 - (A3*)
specifically - *
will - *)
transcribe transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

NEP-2 - (A3*)
specifically - *
that - *)
transcribes transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

NEP-2 - (A3*)
specifically - *
that - *)
transcribed transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
is - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
was - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
has - *
been - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
will - *
be - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
which - *
is - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

This - (A1*
operon - *)
activated - *
by - *
growth - *
on - *
glycolate - (A0*)
which - *
was - *
transcribed transcribe (V*) *
as - *
a - (A3*
single - *
message - *)
and - *
is - *
under - *
the - *
positive - *
control - *
of - *
GlcC - *
encoded - *
by - *
a - *
divergent - *
gene - *
. - *

In - (A4*
the - *)
remaining - *
allelic - *
p53 - *
gene - *)
there - *
is - *
a - *
single-base - *
substitution - *
of - *
G - *
to - *
T - *
at - *
position - *
1 - *
within - *
the - *
splice - *
donor - *
site - *
of - *
intron - *
7 - *
and - *
the - *
mutated - *
intron - *
is - *
not - *
spliced - *
out - *
during - *
the - *
mRNA - *
maturation - *
process - *
. - *

In - (A4*
the - *)
remaining - *
allelic - *
p53 - *
gene - *)
there - *
was - *
a - *
single-base - *
substitution - *
of - *
G - *
to - *
T - *
at - *
position - *
1 - *
within - *
the - *
splice - *
donor - *
site - *
of - *
intron - *
7 - *
and - *
the - *
mutated - *
intron - *
has - *
not - *
been - *
spliced - *
out - *
during - *
the - *
mRNA - *
maturation - *
process - *
. - *

In - (A4*
the - *)
remaining - *
allelic - *
p53 - *
gene - *)
there - *
is - *
a - *
single-base - *
substitution - *
of - *
G - *
to - *
T - *
at - *
position - *
1 - *
within - *
the - *
splice - *
donor - *
site - *
of - *
intron - *
7 - *
and - *
the - *
mutated - *
intron - *
will - *
not - *
be - *
spliced - *
out - *
during - *
the - *
mRNA - *
maturation - *
process - *
. - *

The - *)
gene - *
is - *
transcribed - *)
in - *
a - *
large - *
variety - *
of - *
organs - *
and - *
tissues - *
and - *
shows - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A4*
gene - *
was - *
transcribed - *)
in - *
a - *
large - *
variety - *
of - *)
organs - *
and - *
tissues - *
and - *
showed - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A4*
gene - *
has - *
been - *)
transcribed transcribe (V*) *
in - *
a - *
large - *
variety - *)
of - *
organs - *
and - *
tissues - *
and - *
shows - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A4*
gene - *
will - *
be - *)
transcribed transcribe (V*) *
in - *
a - *
large - *
variety - *)
of - *
organs - *
and - *
tissues - *
and - *
showed - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A4*
gene - *
which - *
 - *
is - *
transcribed transcribe (V*) *
in - *
a - *
large - *
variety - *)
of - *
organs - *
and - *
tissues - *
and - *
shows - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A4*
gene - *
which - *
was - *)
transcribed transcribe (V*) *
in - *
a - *
large - *
variety - *)
of - *
organs - *
and - *
tissues - *
and - *
showed - *
differential - *
splicing - *
of - *
two - *
exons - *
giving - *
rise - *
to - *
at - *
least - *
three - *
different - *
transcripts - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
are - *
transcribed transcribe (V*) *
probably - *
due - *
to - *
alternative - *)
splicing - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
have - *
been - *
transcribed transcribe (V*) *
probably - *
due - *
to - *
alternative - *
splicing - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
will - *
be - *
transcribed transcribe (V*) *
probably - *
due - *
to - *
alternative - *)
splicing - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
which - *
were - *
transcribed transcribe (V*) *
probably - *
due - *
to - *)
alternative - *
splicing - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
which - *
are - *
transcribed transcribe (V*) *
probably - *
due - *
to - *
alternative - *
splicing - *
. - *

The - (A3*
75- - *
and - *)
35-kb - *
FZD5 - *
mRNAs - *
which - *
have - *
been - *
transcribed transcribe (V*) *
probably - *
due - *)
to - *
alternative - *
splicing - *
. - *

glpD - (A4*
and - *
glpR - *)
of - *
Escherichia - *
coli - *
K-12 - *
were - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
has - *
been - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
will - *
be - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
has - *
been - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
were - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
are - *
divergently - *
transcribed transcribe (V*) *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
which - *
were - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
which - *
are - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
will - *
be - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
which - *
were - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
which - *
are - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
will - *
be - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
were - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
E - (A4*
 - *
coli - *
chromosome - *)
demonstrated - *
that - *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
are - *
divergently - *
transcribed transcribe (V*) *
. - *

The - (A3*
fNF-E2 - *
isoform - *
was - *)
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

The - (A3*
fNF-E2 - *
isoform - *
has - *)
been - *
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

The - (A3*
fNF-E2 - *
isoform - *
will - *)
be - *
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

The - (A3*
fNF-E2 - *
isoform - *
that - *)
is - *
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

The - (A3*
fNF-E2 - *
isoform - *
that - *)
was - *
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

The - (A3*
fNF-E2 - *
isoform - *
that - *)
has - *
been - *
transcribed transcribe (V*) *
from - *
an - *
alternative - *
promoter - *
located - *
in - *
the - *
3&apos; - *
end - *
of - *
the - *
first - *
intron - *
and - *
joined - *
by - *
alternative - *
splicing - *
to - *
the - *
second - *
and - *
third - *
exons - *
which - *
are - *
shared - *
by - *
both - *
RNA - *
isoforms - *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
was - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *
features - *)
eg - *
polyadenylation - *
and - *
splicing - *
. - *

NEP-2 - (A3*)
specifically - *
that - *)
has - *
transcribed transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
has - *
been - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *
features - *)
eg - *
polyadenylation - *
and - *
splicing - *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
will - *
be - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *
features - *)
eg - *
polyadenylation - *
and - *
splicing - *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
which - *
was - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *
features - *)
eg - *
polyadenylation - *
and - *
splicing - *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
which - *
has - *
been - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *)
features - *
eg - *
polyadenylation - *
and - *
splicing - *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
which - *
transcribed transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

NEP-2 - (A3*)
specifically - *
that - *)
will - *
transcribe transcribe (V*) *
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

Subsequently - *)
the - *
negative-strand - *
RNAs - *
are - *
transcribed transcribe (V*) *
mRNAs - *
which - *
include - *
a - *
genomic-sized - *
RNA - *
and - *
a - *
nested - *
set - *
of - *
subgenomic - *
mRNA - *
transcripts - *
all - *
with - *
an - *
identical - *
5_ - *
non-translated - *
leader - *
sequence - *
of - *
72&amp;#8211; - *
77 - *
nucleotides - *
and - *
3_ - *
co-terminal - *
polyadenylated - *
ends - *
. - *

Subsequently - *)
the - *
negative-strand - *
RNAs - *
were - *
transcribed transcribe (V*) *
mRNAs - *
which - *
include - *
a - *
genomic-sized - *
RNA - *
and - *
a - *
nested - *
set - *
of - *
subgenomic - *
mRNA - *
transcripts - *
all - *
with - *
an - *
identical - *
5_ - *
non-translated - *
leader - *
sequence - *
of - *
72&amp;#8211; - *
77 - *
nucleotides - *
and - *
3_ - *
co-terminal - *
polyadenylated - *
ends - *
. - *

Subsequently - *)
the - *
negative-strand - *
RNAs - *
are - *
used - *
has - *
been - *
transcribed transcribe (V*) *
mRNAs - *
which - *
include - *
a - *
genomic-sized - *
RNA - *
and - *
a - *
nested - *
set - *
of - *
subgenomic - *
mRNA - *
transcripts - *
all - *
with - *
an - *
identical - *
5_ - *
non-translated - *
leader - *
sequence - *
of - *
72&amp;#8211; - *
77 - *
nucleotides - *
and - *
3_ - *
co-terminal - *
polyadenylated - *
ends - *
. - *

The - *
ula - (A3*
regulon - *)
responsible - *
for - *
the - *
utilization - *
of - *
L-ascorbate - *
in - *
Escherichia - (A4*
coli - *)
is - *
formed - *
by - *
two - *
divergently - *
transcribed transcribe (V*) *
operons - *
ulaG - (A1*
and - *
ulaABCDEF - *)
. - *

The - *
ula - (A3*
regulon - *)
responsible - *
for - *
the - *
utilization - *
of - *
L-ascorbate - *
in - *
Escherichia - (A4*
coli - *)
is - *
formed - *
by - *
two - *
divergently - *
transcribes transcribe (V*) *
operons - *
ulaG - (A1*
and - *
ulaABCDEF - *)
. - *

operons - (A4*
ulaG - *)
and - *
ulaABCDEF - *)
are - *
transcribed transcribe (V*) *
by - *
The - *
ula - (A3*
regulon - *)
. - *

operons - (A4*
ulaG - *)
and - *
ulaABCDEF - *)
were - *
transcribed transcribe (V*) *
by - *
The - *
ula - (A3*
regulon - *)
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribed transcribe (V*) *
glpTQ-glpACB - (A1*
operons - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribes transcribe (V*) *
glpTQ-glpACB - (A1*
operons - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

glpTQ-glpACB - (A4*
operons - *)
of - *
Escherichia - *
coli - *
K-12 - *
are - *
transcribed transcribe (V*) *
. - *

glpTQ-glpACB - (A4*
operons - *)
of - *
Escherichia - *
coli - *
K-12 - *
were - *
transcribed transcribe (V*) *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
are - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
were - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribed transcribe (V*) *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribed transcribe (V*) *
glpD - (A1*
and - *
glpR - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
are - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
were - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
has - *
been - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
will - *
be - *
divergently - *
transcribed transcribe (V*) *
. - *

This - (A1*
antisense-BCMA - *)
RNA - *
which - *
will - *
be - *
transcribed transcribe (V*) *
from - *
the - *
same - *
locus - *
as - *
BCMA - *
and - *
exhibits - *
mRNA - *
characteristic - *)
features - *
eg - *
polyadenylation - *
and - *
splicing - *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
which - *
are - *
divergently - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
Escherichia - (A4*
coli - *
K-12s - *)
demonstrated - *
that - *
glpTQ-glpACB - (A1*
operons - *)
which - *
were - *
divergently - *
transcribed transcribe (V*) *
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribes transcribe (V*) *
the - (A1*
two - *
genes - *
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

The - *)
fhlA - *
gene - *
resides - *
next - *
to - *
the - *)
hydB - *
gene - *
at - *
59 - *
min - *
in - *
the - *
E - *
coli - *
chromosome - *
and - *
the - *
two - *
genes - *
has - *
been - *
transcribed transcribe (V*) *
in - *
opposite - *
directions - *
. - *

Interaction - *)
at - *
a - *
distance - *
between - *
multiple - *
operators - *
controls - *
the - *
adjacent - *
divergently - *
transcribes transcribe (V*) *
glpD - (A1*
and - *
glpR - *)
of - *
Escherichia - *
coli - *
K-12 - *
. - *

the - (A4*
two - *
genes - *)
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
of - *
Escherichia - *
coli - *
K-12 - *
are - *
transcribed transcribe (V*) *
. - *

glpD - (A4*
and - *
glpR - *)
of - *
Escherichia - *
coli - *
K-12 - *
are - *
transcribed transcribe (V*) *
. - *

the - (A4*
two - *
genes - *)
/ - *
fhlA - *
gene - *
/ - *
hydB - *
gene - *)
of - *
Escherichia - *
coli - *
K-12 - *
were - *
transcribed transcribe (V*) *
. - *

Restriction - *
endonuclease - *
cleavage - *
analysis - *
of - *
these - (A4*
two - *
plasmids - *)
demonstrated - *
that - *
glpD - (A1*
and - *
glpR - *)
which - *
were - *
divergently - *
transcribed transcribe (V*) *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
transcribes transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
transcribed transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
have - *
transcribes transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
which - *
transcribes transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

KLK14 - *)
is - *
approximately - *)
54 - *
kb - *
in - *
length - *
spanning - *
seven - *
exons - *
and - *
by - *
Northern - *
blot - *
analysis - *
that - *
transcribed transcribe (V*) *
two - *
alternative - *
transcripts - *
present - *
only - *
in - *
prostate - *
(15 - *
kb) - *
and - *
skeletal - *
muscle - *
(19 - *
kb) - *
. - *

The - (A1*
plastid - *)
genome - *
is - *
transcribed transcribe (V*) *
by - *
a - *
plastid-encoded - *
prokaryotic-type - *
RNA - *
polymerase - *
(PEP) - *
and - *
by - *
a - *
nucleus-encoded - *
phage-type - *
RNA - *
polymerase - *
(NEP) - *
. - *

The - (A1*
plastid - *)
genome - *
was - *
transcribed transcribe (V*) *
by - *
a - *
plastid-encoded - *
prokaryotic-type - *
RNA - *
polymerase - *
(PEP) - *
and - *
by - *
a - *
nucleus-encoded - *
phage-type - *
RNA - *
polymerase - *
(NEP) - *
. - *

The - (A1*
plastid - *)
genome - *
is - *
found - *
to - *
be - *
transcribed transcribe (V*) *
by - *
a - *
plastid-encoded - *
prokaryotic-type - *
RNA - *
polymerase - *
(PEP) - *
and - *
by - *
a - *
nucleus-encoded - *
phage-type - *
RNA - *
polymerase - *
(NEP) - *
. - *

The - (A1*
plastid - *)
genome - *
has - *
been - *
transcribed transcribe (V*) *
by - *
a - *
plastid-encoded - *
prokaryotic-type - *
RNA - *
polymerase - *
(PEP) - *
and - *
by - *
a - *
nucleus-encoded - *
phage-type - *
RNA - *
polymerase - *
(NEP) - *
. - *

The - (A1*
plastid - *)
genome - *
will - *
be - *
transcribed transcribe (V*) *
by - *
a - *
plastid-encoded - *
prokaryotic-type - *
RNA - *
polymerase - *
(PEP) - *
and - *
by - *
a - *
nucleus-encoded - *
phage-type - *
RNA - *
polymerase - *
(NEP) - *
. - *

NEP-2 - (A3*)
specifically - *
transcribed - *)
the - *
rrn - *
operon - *
in - *
the - *
presence - *
of - *
the - *
transcription - *
factor - *
CDF2 - *
. - *

This - (A1*
construct - *)
will - *
be - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

This - (A1*
construct - *)
has - *
been - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

This - (A1*
construct - *)
is - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

We - (A2*
and - *)
others - *
have - *
shown - *
that - *)
FGF8b - (A0*)
will - *
transform transform (V*) *
the - *
midbrain - *
into - *
a - *
cerebellum - *
fate - *
whereas - *
FGF8a - *
can - *
promote - *
midbrain - *
development - *
. - *

We - (A2*
and - *)
others - *
have - *
shown - *
that - *)
FGF8b - (A0*)
can - *
transform transform (V*) *
the - *
midbrain - *
into - *
a - *
cerebellum - *
fate - *
whereas - *
FGF8a - *
can - *
promote - *
midbrain - *
development - *
. - *

FGF8b - (A2*
transforms transform (V*) *
the - *
midbrain - *)
into - *
a - *
cerebellum - *
fate - *
whereas - *
FGF8a - *
can - *
promote - *
midbrain - *
development - *
. - *

FGF8b - (A2*
transformed transform (V*) *
the - *
midbrain - *)
into - *
a - *
cerebellum - *
fate - *
whereas - *
FGF8a - *
can - *
promote - *
midbrain - *
development - *
. - *

They - (A2*
also - *
indicate - *)
that - *
spinach - *
harvested - *
in - *
March - *
should - *
contain - *
preferentially - *
NEP - *
ie - *
the - *
enzyme - *
that - *
has - *
transcribed - *
the - *
rrn - *
operon - *
at - *
PC - *
. - *

They - (A2*
also - *
indicate - *)
that - *
spinach - *
harvested - *
in - *
March - *
should - *
contain - *
preferentially - *
NEP - *
ie - *
the - *
enzyme - *
that - *
will - *
transcribe - *
the - *
rrn - *
operon - *
at - *
PC - *
. - *

They - (A2*
also - *
indicate - *)
that - *
spinach - *
harvested - *
in - *
March - *
should - *
contain - *
preferentially - *
NEP - *
ie - *
the - *
enzyme - *
that - *
transcribed - *
the - *
rrn - *
operon - *
at - *
PC - *
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
that - *
will - *
be - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
that - *
are - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
that - *
were - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
has - *
been - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
will - *
be - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
are - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

Expression - (A1*
of - *
recombinat - *
proteins - *
Full-lenght - *
and - *
C-terminal - *
SBP2 - *
constructs - *
in - *
pASK-IB7 - *)
were - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
BL21 - *
(Promega) - *)
. - *

To - (A0*)
generate - *
GST - *
fusion - *
proteins - *
the - (A1*
relevant - *
DNA - *
fragments - *)
were - *
cloned - *
into - *
pGex2T(Pharmacia) - *
and - *
can - *
transforme - *
into - (A2*
the - *
bacterial - *
strains - *
BL21 - *
or - *
TOPP - *
(Stratagene) - *)
. - *

To - (A0*)
generate - *
GST - *
fusion - *
proteins - *
the - (A1*
relevant - *
DNA - *
fragments - *)
were - *
cloned - *
into - *
pGex2T(Pharmacia) - *
and - *
will - *
transforme - *
into - (A2*
the - *
bacterial - *
strains - *
BL21 - *
or - *
TOPP - *
(Stratagene) - *)
. - *

To - (A0*)
generate - *
GST - *
fusion - *
proteins - *
the - (A1*
relevant - *
DNA - *
fragments - *)
were - *
cloned - *
into - *
pGex2T(Pharmacia) - *
and - *
transforme - *
into - (A2*
the - *
bacterial - *
strains - *
BL21 - *
or - *
TOPP - *
(Stratagene) - *)
. - *

Expression - (A1*
plasmids - *
of - *
the - *
combinations - *
indicated - *
(central - *
panel) - *)
has - *
been - *
transformed transform (V*) *
into - (A2*
yeast - *)
and - *
selected - *
for - *
by - *
growth - *
on - *
plates - *
lacking - *
leucine - *
and - *
tryptophan - *
(left - *
panel) - *
. - *

Expression - (A1*
plasmids - *
of - *
the - *
combinations - *
indicated - *
(central - *
panel) - *)
will - *
be - *
transformed transform (V*) *
into - (A2*
yeast - *)
and - *
selected - *
for - *
by - *
growth - *
on - *
plates - *
lacking - *
leucine - *
and - *
tryptophan - *
(left - *
panel) - *
. - *

This - (A1*
construct - *)
thatwas - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

We - (A2*
and - *)
others - *
have - *
shown - *
that - *)
FGF8b - (A0*)
could - *
transform transform (V*) *
the - *
midbrain - *
into - *
a - *
cerebellum - *
fate - *
whereas - *
FGF8a - *
can - *
promote - *
midbrain - *
development - *
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
will - *
be - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
which - *
was - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
which - *
is - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
that - *
has - *
been - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
that - *
will - *
be - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

The - (A1*
DNA - *
of - *
budded - *
viruses - *)
(BVs) - *
transformed transform (V*) *
E - (A2*
coli - *)
. - *

E - (A2*
coli - *)
was - *
transformed transform (V*) *
by - *
The - (A1*
DNA - *
of - *
budded - *
viruses - *)
(BVs) - *
. - *

E - (A2*
coli - *)
is - *
transformed transform (V*) *
by - *
The - (A1*
DNA - *
of - *
budded - *
viruses - *)
(BVs) - *
. - *

Expression - (A1*
plasmids - *
of - *
the - *
combinations - *
indicated - *
(central - *
panel) - *)
are - *
transformed transform (V*) *
into - (A2*
yeast - *)
and - *
selected - *
for - *
by - *
growth - *
on - *
plates - *
lacking - *
leucine - *
and - *
tryptophan - *
(left - *
panel) - *
. - *

The - (A1*
DNA - *
of - *
budded - *
viruses - *)
(BVs) - *
transforms transform (V*) *
E - (A2*
coli - *)
. - *

This - (A1*
construct - *)
that - *
has - *
been - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

This - (A1*
construct - *)
which - *
will - *
be - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
is - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

For - (A0*)
expression - *
of - *
the - *
recombinant - *
protein - *
pET28a-5 - (A1*)
has - *
been - *
transformed transform (V*) *
into - (A2*
Escherichia - *
coli - *
strain - *
BL21(DE3) - *)
. - *

This - (A1*
construct - *)
which - *
is - *
transformed transform (V*) *
into - (A2*
the - *
yeast - *
strain - *
HF7c - *
(Clontech) - *)
. - *

Interestingly - *)
in - (A2*
vitro - *)
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
will - *
translate translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injury - *)
from - *
improved - (A1*
survival - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Interestingly - *)
in - (A2*
vitro - *)
translated translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
will - *
translate translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assay - *)
from - *
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
extracellular - (A2*
signals - *)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

Acj6 - (A0*
and - *
Drifter - *)
use - *
signalling - *
networks - *
to - *
translate translate (V*) *
with - *
high - *
fidelity - *
PN - (A2*
lineage - *
information - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Acj6 - (A0*
and - *
Drifter - *)
translated translate (V*) *
with - *
high - *
fidelity - *
PN - (A2*
lineage - *
information - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Acj6 - (A0*
and - *
Drifter - *)
translate translate (V*) *
with - *
high - *
fidelity - *
PN - (A2*
lineage - *
information - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
are - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
were - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
the - (A2*
functionscomplex - *)
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
PN - (A2*
lineage - *
information - *)
 - *
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
PN - (A2*
lineage - *
information - *)
 - *
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
translated translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
PN - (A2*
lineage - *
information - *)
 - *
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
will - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
PN - (A2*
lineage - *
information - *)
 - *
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
has - *
translated translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
This - (A2*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

PN - (A2*
lineage - *)
information - *)
 - *
may - *
translate - *)
into - *
faster - *
activation - *
of - *
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

PN - (A2*
lineage - *)
information - *)
 - *
translated - *)
into - *
faster - *
activation - *
of - *
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

PN - (A2*
lineage - *)
information - *)
 - *
translates - *)
into - *
faster - *
activation - *
of - *
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

PN - (A2*
lineage - *)
information - *)
 - *
has - *
translated - *)
into - *
faster - *
activation - *
of - *
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

PN - (A2*
lineage - *)
information - *)
 - *
will - *
translate - *)
into - *
faster - *
activation - *
of - *
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
group - (A1*
behaviors - *)
 - *
. - *

The - (A0*
simple - *)
rules - *
governing - *
how - *
PN - (A2*
lineage - *
information - *)
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificityare - *)
found - *
across - *
social - *
groups - *
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injuryimproved - *)
survival - *)
. - *

Interestingly - *)
PN - (A2*
lineage - *
information - *)
 - *
failed - *
to - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Interestingly - *)
PN - (A2*
lineage - *
information - *)
 - *
felt - *
to - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Interestingly - *)
PN - (A2*
lineage - *
information - *)
 - *
decline - *
to - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Interestingly - *)
PN - (A2*
lineage - *
information - *)
 - *
translate translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Interestingly - *)
PN - (A2*
lineage - *
information - *)
 - *
translated translate (V*) *
into - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Thus - *
Cells - (A0*)
translate translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assayhuge - *)
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
extracellular - (A2*
signals - *)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
the - (A2*
functionscomplex - *)
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
This - (A2*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
group - (A1*
behaviors - *)
 - *
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injuryimproved - *)
survival - *)
. - *

Thus - *
Cells - (A0*)
translated translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assayhuge - *)
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

extracellular - (A2*
signals - *)
is - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

the - (A2*
functionsis - *)
translated translate (V*) *
by - *
Cells - (A0*)
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

Thisis - (A2*)
translated translate (V*) *
by - *
Cells - (A0*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

local - (A2*
interactions - *
among - *
individuals - *)
is - *
translated translate (V*) *
by - *
Cells - (A0*)
group - (A1*
behaviors - *)
 - *
. - *

this - (A2*
reduction - *
in - *
liver - *
injuryis - *)
translated translate (V*) *
by - *
Cells - (A0*)
improved - (A1*
survival - *)
. - *

differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assayis - *)
translated translate (V*) *
by - *
Cells - (A0*)
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

extracellular - (A2*
signals - *)
was - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

the - (A2*
functionswas - *)
translated translate (V*) *
by - *
Cells - (A0*)
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

Thiswas - (A2*)
translated translate (V*) *
by - *
Cells - (A0*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

local - (A2*
interactions - *
among - *
individuals - *)
was - *
translated translate (V*) *
by - *
Cells - (A0*)
group - (A1*
behaviors - *)
 - *
. - *

this - (A2*
reduction - *
in - *
liver - *
injurywas - *)
translated translate (V*) *
by - *
Cells - (A0*)
improved - (A1*
survival - *)
. - *

differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assaywas - *)
translated translate (V*) *
by - *
Cells - (A0*)
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

extracellular - (A2*
signals - *)
has - *
been - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

the - (A2*
functionshas - *)
been - *
translated translate (V*) *
by - *
Cells - (A0*)
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

Thishas - (A2*)
been - *
translated translate (V*) *
by - *
Cells - (A0*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

local - (A2*
interactions - *
among - *
individuals - *)
has - *
been - *
translated translate (V*) *
by - *
Cells - (A0*)
group - (A1*
behaviors - *)
 - *
. - *

this - (A2*
reduction - *
in - *
liver - *
injuryhas - *)
been - *
translated translate (V*) *
by - *
Cells - (A0*)
improved - (A1*
survival - *)
. - *

Acj6 - (A0*
and - *
Drifter - *)
translates translate (V*) *
PN - (A2*
lineage - *
information - *)
 - *
from - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Thus - *
ISGF3 - (A0*
gamma - *)
translated translate (V*) *
in - (A2*
vitrorecombinant - *)
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

in - (A2*
vitrois - *)
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

in - (A2*
vitrowas - *)
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

in - (A2*
vitrohas - *)
been - *
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

in - (A2*
vitrowill - *)
be - *
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
translates translate (V*) *
extracellular - (A2*
signals - *)
 - *
from - *
into - (A1*
specific - *
cellular - *
functions - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

ISGF3 - (A0*
gamma - *)
use - *
signalling - *
networks - *
to - *
translate translate (V*) *
with - *
high - *
fidelity - *
in - (A2*
vitrorecombinant - *)
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

ISGF3 - (A0*
gamma - *)
translated translate (V*) *
with - *
high - *
fidelity - *
in - (A2*
vitrorecombinant - *)
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

ISGF3 - (A0*
gamma - *)
translate translate (V*) *
with - *
high - *
fidelity - *
in - (A2*
vitrorecombinant - *)
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

in - (A2*
vitroare - *)
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

The - (A0*
ArC/XylS - *
family - *
of - *
prokaryotic - *
positive - *)
transcriptional - *
regulators - *
includes - *
more - *
than - *
100 - *
proteins - *
and - *
polypeptides - *
derived - *
from - *
open - *
reading - *
frames - *
translated translate (V*) *
from - (A1*
DNA - *
sequences - *)
. - *

The - (A0*
ArC/XylS - *
family - *
was - *
translated translate (V*) *
from - (A1*
DNA - *
sequences - *)
. - *

The - *)
ArC/XylS - *
family - *
is - *
translated translate (V*) *
from - (A1*
DNA - *
sequences - *)
. - *

The - (A0*
ArC/XylS - *
family - *
of - *
prokaryotic - *
positive - *)
transcriptional - *
regulators - *
includes - *
more - *
than - *
100 - *
proteins - *
and - *
polypeptides - *
derived - *
from - *
open - *
reading - *
frames - *
will - *
be - *
translated translate (V*) *
from - (A1*
DNA - *
sequences - *)
. - *

ISGF3 - (A0*
gamma - *)
translated translate (V*) *
in - (A2*
vitro - *)
from - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

ISGF3 - (A0*
gamma - *)
translates translate (V*) *
in - (A2*
vitro - *)
from - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

ISGF3 - (A0*
gamma - *)
has - *
translated translate (V*) *
in - (A2*
vitro - *)
from - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

ISGF3 - (A0*
gamma - *)
will - *
translate translate (V*) *
in - (A2*
vitro - *)
from - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
are - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
 - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
has - *
been - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
will - *
be - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
 - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
which - *
were - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
that - *
are - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
 - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
that - *
has - *
been - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
. - *

Stat1 - (A1*
Stat1 - *
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
that - *
will - *
be - *
translated translate (V*) *
in - (A3*
vitro - *)
and - *
partially - *
purified - *
on - *
heparin-agarose - *
 - *
. - *

Stat1 - (A1*
Y701F - *)
which - *
is - *
translated translate (V*) *
in - (A3*
vitro - *)
can - *
also - *
dimerize - *
on - *
the - *
LMP2 - *
GAS - *
. - *

Stat1 - (A1*
Y701F - *)
which - *
was - *
translated translate (V*) *
in - (A3*
vitro - *)
can - *
also - *
dimerize - *
on - *
the - *
LMP2 - *
GAS - *
. - *

Stat1 - (A1*
Y701F - *)
which - *
has - *
been - *
translated translate (V*) *
in - (A3*
vitro - *)
can - *
also - *
dimerize - *
on - *
the - *
LMP2 - *
GAS - *
. - *

Stat1 - (A1*
Y701F - *)
which - *
will - *
be - *
translated translate (V*) *
in - (A3*
vitro - *)
can - *
also - *
dimerize - *
on - *
the - *
LMP2 - *
GAS - *
. - *

In - (A3*
vitro - *)
translation - *
and - *
partial - *
purification - *
o - *
fStat1 - *
Stat1 - (A1*
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
are - *
translated translate (V*) *
in - *
vitro - *
using - *
the - *
T7-based - *
coupled - *
transcription-translation - *
kit - *
(Promega) - *
as - *
per - *
the - *
manufacturer - *
fs - *
instructions - *
. - *

In - (A3*
vitro - *)
translation - *
and - *
partial - *
purification - *
o - *
fStat1 - *
Stat1 - (A1*
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
will - *
be - *
translated translate (V*) *
in - *
vitro - *
using - *
the - *
T7-based - *
coupled - *
transcription-translation - *
kit - *
(Promega) - *
as - *
per - *
the - *
manufacturer - *
fs - *
instructions - *
. - *

In - (A3*
vitro - *)
translation - *
and - *
partial - *
purification - *
o - *
fStat1 - *
Stat1 - (A1*
Y701F - *
Stat1 - *
N135 - *
Stat1 - *
N200 - *
and - *
Stat5/1 - *)
has - *
been - *
translated translate (V*) *
in - *
vitro - *
using - *
the - *
T7-based - *
coupled - *
transcription-translation - *
kit - *
(Promega) - *
as - *
per - *
the - *
manufacturer - *
fs - *
instructions - *
. - *

We - (A0*
also - *)
report - *
the - *
first - *
definitive - *
incorporation - *
of - *
Sec - *
into - *
a - (A1*
selenoprotein - *)
which - *
is - *
translated translate (V*) *
in - (A3*
reticulocyte - *
lysates - *)
. - *

We - (A0*
also - *)
report - *
the - *
first - *
definitive - *
incorporation - *
of - *
Sec - *
into - *
a - (A1*
selenoprotein - *)
which - *
was - *
translated translate (V*) *
in - (A3*
reticulocyte - *
lysates - *)
. - *

We - (A0*
also - *)
report - *
the - *
first - *
definitive - *
incorporation - *
of - *
Sec - *
into - *
a - (A1*
selenoprotein - *)
which - *
will - *
be - *
translated translate (V*) *
in - (A3*
reticulocyte - *
lysates - *)
. - *

We - (A0*
also - *)
report - *
the - *
first - *
definitive - *
incorporation - *
of - *
Sec - *
into - *
a - (A1*
selenoprotein - *)
which - *
has - *
been - *
translated translate (V*) *
in - (A3*
reticulocyte - *
lysates - *)
. - *

Malaria - *
is - *
an - *
attractive - *
model - *
for - *
the - *
development - *
and - *
validation - *
of - *
approaches - *
translating translate (V*) *
genomic - (A2*
information - *)
to - (A1*
vaccine - *
development - *)
because - *
of - *
the - *
critical - *
need - *
for - *
effective - *
anti-malarial - *
interventions - *
and - *
because - *
the - *
Plasmodium - *
parasite - *
is - *
a - *
complex - *
multistage - *
pathogen - *
targeted - *
by - *
multiple - *
immune - *
responses - *
. - *

Thus - *
Acj6 - (A0*
and - *
Drifter - *)
translated translate (V*) *
PN - (A2*
lineage - *
information - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
is - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
was - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
has - *
been - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

PN - (A2*
lineage - *
information - *)
will - *
be - *
translated translate (V*) *
by - *
Acj6 - (A0*
and - *
Drifter - *)
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
. - *

Cells - (A0*)
translated translate (V*) *
with - *
high - *
fidelity - *
extracellular - (A2*
signals - *)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

Cells - (A0*)
translate translate (V*) *
with - *
high - *
fidelity - *
extracellular - (A2*
signals - *)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

extracellular - (A2*
signals - *)
are - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

extracellular - (A2*
signals - *)
were - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

In - (A0*)
addition - *
our - *
data - *
show - *
that - *
the - (A2*
functions - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
translated translate (V*) *
into - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

In - (A0*)
addition - *
our - *
data - *
show - *
that - *
the - (A2*
functions - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
will - *
translate translate (V*) *
into - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

In - (A0*)
addition - *
our - *
data - *
show - *
that - *
the - (A2*
functions - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
has - *
translated translate (V*) *
into - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

This - (A2*)
translated translate (V*) *
into - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

This - (A2*)
translates translate (V*) *
into - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

This - (A2*)
has - *
translated translate (V*) *
into - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

This - (A2*)
will - *
translate translate (V*) *
into - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

Local - (A2*
interactions - *
among - *
individuals - *)
translated translate (V*) *
into - *
group - (A1*
behaviors - *)
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Local - (A2*
interactions - *
among - *
individuals - *)
translate translate (V*) *
into - *
group - (A1*
behaviors - *)
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Group - (A1*
behaviors - *)
are - *
translated translate (V*) *
by - *
local - (A2*
interactions - *
among - *
individuals - *)
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Group - (A1*
behaviors - *)
were - *
translated translate (V*) *
by - *
local - (A2*
interactions - *
among - *
individuals - *)
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Interestingly - (A0*)
this - (A2*
reduction - *
in - *
liver - *
injury - *)
felt - *
to - *
translate translate (V*) *
into - *
improved - (A1*
survival - *)
. - *

Interestingly - (A0*)
this - (A2*
reduction - *
in - *
liver - *
injury - *)
decline - *
to - *
translate translate (V*) *
into - *
improved - (A1*
survival - *)
. - *

Interestingly - (A0*)
this - (A2*
reduction - *
in - *
liver - *
injury - *)
translate translate (V*) *
into - *
improved - (A1*
survival - *)
. - *

Interestingly - (A0*)
this - (A2*
reduction - *
in - *
liver - *
injury - *)
translated translate (V*) *
into - *
improved - (A1*
survival - *)
. - *

Remarkably - (A2*
differences - *
between - *
ligands - *
that - *)
seem - *
small - *
in - *
the - *
[35S]GTPgammaS - *)
binding - *
assay - *
translated translate (V*) *
into - *
huge - *
differences - *
in - *
the - *
magnitude - *
of - *
Ca2+ - *
responses - *
. - *

Remarkably - (A2*
differences - *
between - *
ligands - *
that - *)
seem - *
small - *
in - *
the - *
[35S]GTPgammaS - *)
binding - *
assay - *
will - *
translate translate (V*) *
into - *
huge - *
differences - *
in - *
the - *
magnitude - *
of - *
Ca2+ - *
responses - *
. - *

Remarkably - (A2*
differences - *
between - *
ligands - *
that - *)
seem - *
small - *
in - *
the - *
[35S]GTPgammaS - *)
binding - *
assay - *
has - *
translated translate (V*) *
into - *
huge - *
differences - *
in - *
the - *
magnitude - *
of - *
Ca2+ - *
responses - *
. - *

differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assayhas - *)
been - *
translated translate (V*) *
by - *
Cells - (A0*)
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

extracellular - (A2*
signals - *)
will - *
be - *
translated translate (V*) *
by - *
Cells - (A0*)
into - (A1*
specific - *
cellular - *
functions - *)
. - *

the - (A2*
functionswill - *)
be - *
translated translate (V*) *
by - *
Cells - (A0*)
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
. - *

Thiswill - (A2*)
be - *
translated translate (V*) *
by - *
Cells - (A0*)
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
. - *

local - (A2*
interactions - *
among - *
individuals - *)
will - *
be - *
translated translate (V*) *
by - *
Cells - (A0*)
group - (A1*
behaviors - *)
 - *
. - *

this - (A2*
reduction - *
in - *
liver - *
injurywill - *)
be - *
translated translate (V*) *
by - *
Cells - (A0*)
improved - (A1*
survival - *)
. - *

differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assaywill - *)
be - *
translated translate (V*) *
by - *
Cells - (A0*)
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
. - *

Acj6 - (A0*
and - *
Drifter - *)
translated translate (V*) *
PN - (A2*
lineage - *
information - *)
 - *
from - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Thus - *
ISGF3 - (A0*
gamma - *)
translate translate (V*) *
in - (A2*
vitrorecombinant - *)
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
translated translate (V*) *
extracellular - (A2*
signals - *)
 - *
from - *
into - (A1*
specific - *
cellular - *
functions - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

in - (A2*
vitrowere - *)
translated translate (V*) *
by - *
ISGF3 - (A0*
gamma - *)
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
translated translate (V*) *
the - (A2*
functions - *)
from - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
in - (A2*
vitro - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
in - (A2*
vitro - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
translated translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
in - (A2*
vitro - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
will - *
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

In - (A0*
addition - *)
our - *
data - *
show - *
that - *
in - (A2*
vitro - *)
performed - *
by - *
these - *
molecules/pathways - *
in - *
promoting - *
cell - *
survival - *
or - *
apoptosis/anoikis - *
has - *
translated translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
translated translate (V*) *
This - (A2*)
from - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

in - (A2*
vitro - *)
may - *
translate translate (V*) *
into - *
faster - *
activation - *
of - *)
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

in - (A2*
vitro - *)
translated translate (V*) *
into - *
faster - *
activation - *
of - *
the - *)
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

in - (A2*
vitro - *)
translates translate (V*) *
into - *
faster - *
activation - *
of - *
the - *)
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

in - (A2*
vitro - *)
has - *
translated translate (V*) *
into - *
faster - *
activation - *
of - *)
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

in - (A2*
vitro - *)
will - *
translate translate (V*) *
into - *
faster - *
activation - *
of - *)
the - *
muscle - *
fibres - *
thus - *
partly - *
explaining - *
the - *
increase - *
in - *
power - *
output - *
. - *

Cells - (A0*)
translated translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
 - *
from - *
group - (A1*
behaviors - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

The - (A0*
simple - *)
rules - *
governing - *
how - *
in - (A2*
vitro - *)
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishableare - *)
found - *
across - *
social - *
groups - *
giving - *
social - *
insects - *
the - *
potential - *
to - *
have - *
a - *
profound - *
impact - *
on - *
our - *
understanding - *
of - *
the - *
interplay - *
between - *
network - *
dynamics - *
and - *
social - *
evolution - *
. - *

Cells - (A0*)
translated translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injury - *)
from - *
improved - (A1*
survival - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Interestingly - *)
in - (A2*
vitro - *)
failed - *
to - *
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Interestingly - *)
in - (A2*
vitro - *)
felt - *
to - *
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Interestingly - *)
in - (A2*
vitro - *)
decline - *
to - *
translate translate (V*) *
into - *
recombinant - (A1*
clones - *
bound - *
DNA - *
with - *
a - *
specificity - *
indistinguishable - *)
. - *

Cells - (A0*)
translated translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assay - *)
from - *
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
translates translate (V*) *
the - (A2*
functions - *)
from - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
translates translate (V*) *
This - (A2*)
from - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
translates translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
 - *
from - *
group - (A1*
behaviors - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
translates translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injury - *)
from - *
improved - (A1*
survival - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
translates translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assay - *)
from - *
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Acj6 - (A0*
and - *
Drifter - *)
has - *
translated translate (V*) *
PN - (A2*
lineage - *
information - *)
 - *
from - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
extracellular - (A2*
signals - *)
 - *
from - *
into - (A1*
specific - *
cellular - *
functions - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
the - (A2*
functions - *)
from - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
This - (A2*)
from - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
 - *
from - *
group - (A1*
behaviors - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
this - (A2*
reduction - *
in - *
liver - *
injury - *)
from - *
improved - (A1*
survival - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
has - *
translated translate (V*) *
differences - (A2*
between - *
ligands - *
that - *
seem - *
small - *
in - *
the - *
35SGTPgammaS - *
binding - *
assay - *)
from - *
huge - (A1*
differences - *
in - *
the - *
magnitude - *
of - *
C2+ - *
responses - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Acj6 - (A0*
and - *
Drifter - *)
will - *
translate translate (V*) *
PN - (A2*
lineage - *
information - *)
 - *
from - *
into - (A1*
distinct - *
dendritic - *
targeting - *
specificity - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
will - *
translate translate (V*) *
extracellular - (A2*
signals - *)
 - *
from - *
into - (A1*
specific - *
cellular - *
functions - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
will - *
translate translate (V*) *
the - (A2*
functions - *)
from - *
complex - (A1*
differential - *
modulations - *
of - *
individual - *
Bcl-2 - *
homologs - *)
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
will - *
translate translate (V*) *
This - (A2*)
from - *
faster - (A1*
activation - *
of - *
the - *
muscle - *
fibres - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Cells - (A0*)
will - *
translate translate (V*) *
local - (A2*
interactions - *
among - *
individuals - *)
 - *
from - *
group - (A1*
behaviors - *)
 - *
from - *
that - *
of - *
ISGF3 - *
gamma - *
purified - *
from - *
HeLa - *
cells - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
which - *
will - *
be - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
which - *
was - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
which - *
is - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
would - *
be - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
will - *
be - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

Alternative - *)
splicing - *
of - *
exon - *
4 - *
results - *
in - *
a - (A2*
transcript - *)
was - *
translated translate (V*) *
into - (A1*
a - *
C-terminal - *
truncated - *
protein - *
containing - *
the - *
first - *
second - *
and - *
third - *
transmembrane - *
domains - *)
while - *
the - *
splicing - *
out - *
of - *
exons - *
3 - *
and - *
4 - *
would - *
produce - *
a - *
protein - *
with - *
five - *
membrane-spanning - *
domains - *
but - *
lacking - *
the - *
third - *
and - *
fourth - *
domains - *
present - *
in - *
the - *
ET-AR - *
protein - *
 - *
. - *

This - (A1*
mutant - *)
was - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
is - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
will - *
be - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
has - *
been - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
 - *
which - *
was - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
whihc - *
is - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
which - *
will - *
be - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - (A1*
mutant - *)
which - *
has - *
been - *
translated translate (V*) *
in - *
the - *
presence - *
of - *
C-terminal - *
SBP2 - *
and - *
as - *
shown - *
in - *
Figure - *
6C - *
no - *
readthrough - *
is - *
detectable - *
when - *
the - *
AUGA - *
element - *
is - *
deleted - *
indicating - *
that - *
the - *
stimulatory - *
effect - *
is - *
entirely - *
3 - *
UTR - *
dependent - *
. - *

This - *
review - *
examines - *
the - (A0*
use - *
of - *
new - *
and - *
emerging - *
DNA - *
tissue - *
and - *
live-cell - *
transfection - *
microarray - *
technologies - *)
that - *
can - *
be - *
used - *
to - *
discover - *
validate - *
and - *
translated translate (V*) *
information - (A1*
resulting - *
from - *
the - *
completion - *
of - *
the - *
Human - *
Genome - *
Project - *)
. - *

This - *
review - *
examines - *
the - (A0*
use - *
of - *
new - *
and - *
emerging - *
DNA - *
tissue - *
and - *
live-cell - *
transfection - *
microarray - *
technologies - *)
that - *
can - *
be - *
used - *
to - *
translate translate (V*) *
information - (A1*
resulting - *
from - *
the - *
completion - *
of - *
the - *
Human - *
Genome - *
Project - *)
. - *

This - *
review - *
examines - *
the - (A0*
use - *
of - *
new - *
and - *
emerging - *
DNA - *
tissue - *
and - *
live-cell - *
transfection - *
microarray - *
technologies - *)
that - *
was - *
translated translate (V*) *
information - (A1*
resulting - *
from - *
the - *
completion - *
of - *
the - *
Human - *
Genome - *
Project - *)
. - *

This - *
review - *
examines - *
the - (A0*
use - *
of - *
new - *
and - *
emerging - *
DNA - *
tissue - *
and - *
live-cell - *
transfection - *
microarray - *
technologies - *)
that - *
is - *
translated translate (V*) *
information - (A1*
resulting - *
from - *
the - *
completion - *
of - *
the - *
Human - *
Genome - *
Project - *)
. - *

Persistent - (A0*)
diuretic - *
use - *
results - *
in - *
dynamic - (A2*
changes - *
in - *
ECW - *
and - *
other - *
body - *
fluid - *
compartments - *)
that - *
translated translate (V*) *
into - *
chronic - (A1*
blood - *
pressure - *
reduction - *)
. - *

Persistent - (A0*)
diuretic - *
use - *
results - *
in - *
dynamic - (A2*
changes - *
in - *
ECW - *
and - *
other - *
body - *
fluid - *
compartments - *)
that - *
will - *
translate translate (V*) *
into - *
chronic - (A1*
blood - *
pressure - *
reduction - *)
. - *

Persistent - (A0*)
diuretic - *
use - *
results - *
in - *
dynamic - (A2*
changes - *
in - *
ECW - *
and - *
other - *
body - *
fluid - *
compartments - *)
that - *
has - *
translated translate (V*) *
into - *
chronic - (A1*
blood - *
pressure - *
reduction - *)
. - *

Persistent - (A0*)
diuretic - *
use - *
results - *
in - *
dynamic - (A2*
changes - *
in - *
ECW - *
and - *
other - *
body - *
fluid - *
compartments - *)
which - *
translate translate (V*) *
into - *
chronic - (A1*
blood - *
pressure - *
reduction - *)
. - *

Persistent - (A0*)
diuretic - *
use - *
results - *
in - *
dynamic - (A2*
changes - *
in - *
ECW - *
and - *
other - *
body - *
fluid - *
compartments - *)
translated translate (V*) *
into - *
chronic - (A1*
blood - *
pressure - *
reduction - *)
. - *

These - (A2*
changes - *)
further - *
translated translate (V*) *
into - *
altered - (A1*
expression - *
levels - *
and - *
time - *
kinetics - *
of - *
a - *
number - *
of - *
early - *
genes - *)
(peak - *
expression - *
at - *
2 - *
h - *
after - *
stimulation) - *
. - *

altered - (A1*
expression - *
levels - *
and - *
time - *
kinetics - *
of - *
a - *
number - *
of - *
early - *
genes - *)
are - *
translated translate (V*) *
by - *
These - (A2*
changes - *)
. - *

altered - (A1*
expression - *
levels - *
and - *
time - *
kinetics - *
of - *
a - *
number - *
of - *
early - *
genes - *)
were - *
translated translate (V*) *
by - *
These - (A2*
changes - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
which - *
was - *
also - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
which - *
has - *
been - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
which - *
is - *
also - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
will - *
also - *
be - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
which - *
will - *
be - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
has - *
also - *
been - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
is - *
also - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
the - (A1*
receptor - *)
was - *
also - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
which - *
is - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
which - *
was - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
has - *
been - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
will - *
be - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
is - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
PVR - (A1*)
was - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
is - *
also - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

PVR - (A1*)
that - *
were - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
was - *
also - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
will - *
also - *
be - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
has - *
also - *
been - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
is - *
also - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
was - *
also - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
has - *
been - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

the - (A1*
receptor - *)
that - *
were - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
will - *
be - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
is - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
which - *
was - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
has - *
been - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
will - *
be - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
is - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
was - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

PVR - (A1*)
that - *
are - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

the - (A1*
receptor - *)
that - *
are - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

PVR - (A1*)
has - *
been - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

the - (A1*
receptor - *)
has - *
been - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

PVR - (A1*)
will - *
be - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

the - (A1*
receptor - *)
will - *
be - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

PVR - (A1*)
were - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
truncated - *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

the - (A1*
receptor - *)
were - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

PVR - (A1*)
are - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

the - (A1*
receptor - *)
are - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
will - *
truncate truncate (V*) *
the - *
protein - *
product - *
. - *

Previous - *)
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
truncating truncate (V*) *
or - *
substitute - *
the - (A1*
protein - *
product - *)
have - *
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
have - *
truncated - *
the - *
protein - *
product - *
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
are - *
found - *
to - *
truncate truncate (V*) *
the - *
protein - *
product - *
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
truncate truncate (V*) *
the - *
protein - *
product - *
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
truncated - *
the - *
protein - *
product - *
. - *

Virtually - (A1*
all - *)
wild-type - (A0*
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *)
are - *
predicted - *
to - *
truncate truncate (V*) *
the - *
protein - *
product - *
. - *

Previous - *)
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
to - *
truncate truncate (V*) *
or - *
substitute - *
the - (A1*
protein - *
product - *)
have - *
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
will - *
truncate truncate (V*) *
the - (A1*
protein - *)
product - *
. - *

The - (A0*
majority - *)
of - *
changes - *
truncated - *
the - (A1*
protein - *
product - *)
 - *
through - *
nonsense - *
mutations - *
(32%) - *
insertions - *
or - *
deletions - *
(296%) - *
or - *
splicing - *
changes - *
(62%) - *
although - *
the - *
figures - *
were - *
biased - *
by - *
the - *
methods - *
employed - *
and - *
in - *
sequenced - *
areas - *
approximately - *
50% - *
of - *
all - *
mutations - *
were - *
missense - *
or - *
in-frame - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
have - *
truncated - *
the - (A1*
protein - *)
product - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
are - *
found - *
to - *
truncate truncate (V*) *
the - (A1*
protein - *)
product - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
truncate truncate (V*) *
the - (A1*
protein - *)
product - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
truncated - *
the - (A1*
protein - *)
product - *
. - *

Virtually - *
all - *
through - (A0*
nonsense - *
mutations - *
(32 - *
* - *
10 - *
/ - *
100) - *
insertions - *
or - *
deletions - *
(296 - *
* - *
10 - *
/ - *
100) - *
or - *
splicing - *
changes - *
(62 - *
* - *
10 - *
/ - *
100) - *)
 - *
are - *
predicted - *
to - *
truncate truncate (V*) *
the - (A1*
protein - *)
product - *
. - *

Previous - *)
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
truncating truncate (V*) *
or - *
substitute - *
the - (A1*
proteinhave - *)
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

The - *)
majority - *
of - *
changes - *
truncated - *
the - (A1*
poly(C) - *
tracts - *)
 - *
through - *
nonsense - *
mutations - *
(32%) - *
insertions - *
or - *
deletions - *
(296%) - *
or - *
splicing - *
changes - *
(62%) - *
although - *
the - *
figures - *
were - *
biased - *
by - *
the - *
methods - *
employed - *
and - *
in - *
sequenced - *
areas - *
approximately - *
50% - *
of - *
all - *
mutations - *
were - *
missense - *
or - *
in-frame - *
. - *

Previous - *)
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
to - *
truncate truncate (V*) *
or - *
substitute - *
the - (A1*
proteinhave - *)
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

To - *
address - *
the - *
mechanisms - *
of - *
activation - *
by - *
CRP - *
and - *
the - *
RNA - *
polymerase - *
alpha-subunit - *
C-terminal - *
domain - *
( - *
alpha-CTD - *
) - *
at - *
rhaSR - *
we - *
tested - *
the - *
effects - *
of - *
alanine - *
substitutions - *
in - *
CRP - *
activating - *
regions - *
1 - *
and - *
2 - *
overexpression - *
of - *
a - *
truncated - *
version - *
of - *
alpha - *
( - *
ALK4 - (A1*)
) - *
and - *
alanine - *
substitutions - *
throughout - *
alpha-CTD - *
 - *
. - *

Using - *
the - *
complex - *
structure - *
of - *
bone - *
morphogenetic - *
protein-2 - *
bound - *
to - *
its - *
type - *
I - *
receptor - *
( - *
ALK3 - *
) - *
as - *
a - *
guide - *
we - *
introduced - *
extracellular - *
domain - *
mutations - *
in - *
the - *
context - *
of - *
the - *
truncated - *
alpha-Delt235 - (A1*)
( - *
ALK4-trunc - *
) - *
construct - *
and - *
assessed - *
the - *
ability - *
of - *
the - *
mutants - *
to - *
inhibit - *
activin - *
function - *
 - *
 - *
. - *

To - *
address - *
the - *
mechanisms - *
of - *
activation - *
by - *
CRP - *
and - *
the - *
RNA - *
polymerase - *
alpha-subunit - *
C-terminal - *
domain - *
( - *
alpha-CTD - *
) - *
at - *
rhaSR - *
we - *
tested - *
the - *
effects - *
of - *
alanine - *
substitutions - *
in - *
CRP - *
activating - *
regions - *
1 - *
and - *
2 - *
overexpression - *
of - *
a - *
truncated - *
version - *
of - *
alpha - *
( - *
protein - (A1*)
) - *
and - *
alanine - *
substitutions - *
throughout - *
alpha-CTD - *
 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
alpha-Delt235 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
has - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Using - *
the - *
complex - *
structure - *
of - *
bone - *
morphogenetic - *
protein-2 - (A1*)
bound - *
to - *
its - *
type - *
I - *
receptor - *
( - *
ALK3 - *
) - *
as - *
a - *
guide - *
we - *
introduced - *
extracellular - *
domain - *
mutations - *
in - *
the - *
context - *
of - *
the - *
truncated - *
protein - *
( - *
ALK4-trunc - *
) - *
construct - *
and - *
assessed - *
the - *
ability - *
of - *
the - *
mutants - *
to - *
inhibit - *
activin - *
function - *
 - *
 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
ALK4 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
has - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
alpha-Delt235 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncates - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
ALK4 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncates - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
alpha-Delt235 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
ALK4 - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
PVR - (A1*)
which - *
is - *
also - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
PVR - (A1*)
which - *
was - *
also - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
PVR - (A1*)
will - *
also - *
be - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
PVR - (A1*)
has - *
also - *
been - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

Therefor - *
to - *
generate - *
a - *
comparable - *
soluble - *
fragment - *
to - *
IC1-2D/190 - *
PVR - (A1*)
is - *
also - *
truncated - *
prior - (A3*
to - *
the - *
PP-motif - *)
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
which - *
has - *
been - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
which - *
will - *
be - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
which - *
is - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
which - *
was - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
has - *
been - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
will - *
be - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

To - *
generate - *
this - *
protein - *
the - (A1*
receptor - *)
is - *
truncated - *
prior - (A3*
to - *
two - *
consecutive - *
proline - *
residues - *)
(`PP-motif_) - *
present - *
in - *
the - *
junction - *
between - *
domains - *
2 - *
and - *
3 - *
(Figure - *
1) - *
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
that - *
were - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
that - *
are - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
has - *
been - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
will - *
be - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
were - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

C-terminally - (A1*
truncated - *
Stat5a - *
proteins - *)
are - *
truncated - *
at - (A3*
amino - *
acids - *
762 - *
or - *
773 - *)
. - *

Specifically - *
the - (A1*
Stat5a - *
molecule - *)
in - *
which - *
the - *
C-terminus - (A2*)
has - *
been - *
truncated - *
at - (A3*
amino - *
acids - *
740 - *
or - *
751 - *)
effectively - *
blocked - *
the - *
induction - *
of - *
both - *
CIS - *
and - *
OSM - *
whereas - *
the - *
C-terminal - *
truncations - *
at - *
amino - *
acids - *
762 - *
or - *
773 - *
had - *
no - *
effect - *
on - *
the - *
induction - *
of - *
either - *
gene - *
. - *

Specifically - *
the - (A1*
Stat5a - *
molecule - *)
in - *
which - *
the - *
C-terminus - (A2*)
will - *
be - *
truncated - *
at - (A3*
amino - *
acids - *
740 - *
or - *
751 - *)
effectively - *
blocked - *
the - *
induction - *
of - *
both - *
CIS - *
and - *
OSM - *
whereas - *
the - *
C-terminal - *
truncations - *
at - *
amino - *
acids - *
762 - *
or - *
773 - *
had - *
no - *
effect - *
on - *
the - *
induction - *
of - *
either - *
gene - *
. - *

Specifically - *
the - (A1*
Stat5a - *
molecule - *)
in - *
which - *
the - *
C-terminus - (A2*)
is - *
truncated - *
at - (A3*
amino - *
acids - *
740 - *
or - *
751 - *)
effectively - *
blocked - *
the - *
induction - *
of - *
both - *
CIS - *
and - *
OSM - *
whereas - *
the - *
C-terminal - *
truncations - *
at - *
amino - *
acids - *
762 - *
or - *
773 - *
had - *
no - *
effect - *
on - *
the - *
induction - *
of - *
either - *
gene - *
. - *

To - *
evaluate - *
the - *
role - *
of - *
the - *
N-terminus - *
of - *
MMspI - (A1*)
2-hydroxy-5-nitrobenzyl - (A0*
bromide - *
(HNBB) - *)
will - *
truncate truncate (V*) *
MMspI - *
between - *
residues - (A3*
34 - *
and - *
35 - *)
. - *

To - *
evaluate - *
the - *
role - *
of - *
the - *
N-terminus - *
of - *
MMspI - (A1*)
2-hydroxy-5-nitrobenzyl - (A0*
bromide - *
(HNBB) - *)
has - *
truncated - *
MMspI - *
between - *
residues - (A3*
34 - *
and - *
35 - *)
. - *

To - *
evaluate - *
the - *
role - *
of - *
the - *
N-terminus - *
of - *
MMspI - (A1*)
2-hydroxy-5-nitrobenzyl - (A0*
bromide - *
(HNBB) - *)
was - *
found - *
to - *
truncate truncate (V*) *
MMspI - *
between - *
residues - (A3*
34 - *
and - *
35 - *)
. - *

To - *
evaluate - *
the - *
role - *
of - *
the - *
N-terminus - *
of - *
MMspI - (A1*)
2-hydroxy-5-nitrobenzyl - (A0*
bromide - *
(HNBB) - *)
truncates - *
MMspI - *
between - *
residues - (A3*
34 - *
and - *
35 - *)
. - *

To - *
evaluate - *
the - *
role - *
of - *
the - *
N-terminus - *
of - *
MMspI - (A1*)
2-hydroxy-5-nitrobenzyl - (A0*
bromide - *
(HNBB) - *)
truncated - *
MMspI - *
between - *
residues - (A3*
34 - *
and - *
35 - *)
. - *

Virtually - *
all - *
TSC1 - (A0*
mutations - *)
will - *
truncate truncate (V*) *
the - (A1*
protein - *
product - *)
. - *

Virtually - *
all - *
TSC1 - (A0*
mutations - *)
have - *
truncated - *
the - (A1*
protein - *
product - *)
. - *

Virtually - *
all - *
TSC1 - (A0*
mutations - *)
are - *
found - *
to - *
truncate truncate (V*) *
the - (A1*
protein - *
product - *)
. - *

Virtually - *
all - *
TSC1 - (A0*
mutations - *)
truncate truncate (V*) *
the - (A1*
protein - *
product - *)
. - *

Virtually - *
all - *
TSC1 - (A0*
mutations - *)
truncated - *
the - (A1*
protein - *
product - *)
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
which - *
have - *
truncated - *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
which - *
will - *
truncate truncate (V*) *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
which - *
truncated - *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
which - *
truncate truncate (V*) *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
have - *
truncated - *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Frameshift - (A0*
SOX9 - *
mutations - *)
will - *
truncate truncate (V*) *
its - (A2*
two - *
activation - *
domains - *)
while - *
all - *
missense - *
mutations - *
reported - *
to - *
date - *
lie - *
in - *
the - *
high - *
mobility - *
group - *
(HMG) - *
DNA-binding - *
domain - *
. - *

Previous - (A0*
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *)
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
truncating truncate (V*) *
or - *
substitute - *
the - (A1*
poly(C) - *
tracts - *)
have - *
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

Previous - (A0*
studies - *
using - *
wild-type - *
Encephalomyocarditis - *
virus - *
(EMCV) - *
and - *
Mengo - *
virus - *
which - *
have - *
long - *
poly(C) - *)
tracts - *
(61 - *
to - *
146 - *
C&apos;s) - *
at - *
the - *
5&apos; - *
non - *
translated - *
region - *
of - *
the - *
genome - *
and - *
variants - *
of - *
these - *
viruses - *
genetically - *
engineered - *
to - *
truncate truncate (V*) *
or - *
substitute - *
the - (A1*
poly(C) - *
tracts - *)
have - *
produced - *
conflicting - *
data - *
on - *
the - *
role - *
of - *
the - *
poly(C) - *
tract - *
in - *
the - *
virulence - *
of - *
these - *
viruses - *
. - *

The - (A0*
majority - *
of - *
changes - *
truncated - *
the - (A1*
protein - *)
through - *
nonsense - *
mutations - *
(32%) - *
insertions - *
or - *
deletions - *
(296%) - *
or - *
splicing - *)
changes - *
(62%) - *
although - *
the - *
figures - *
were - *
biased - *
by - *
the - *
methods - *
employed - *
and - *
in - *
sequenced - *
areas - *
approximately - *
50% - *
of - *
all - *
mutations - *
were - *
missense - *
or - *
in-frame - *
. - *

To - *
address - *
the - *
mechanisms - *
of - *
activation - *
by - *
CRP - *
and - *
the - *
RNA - *
polymerase - *
alpha-subunit - *
C-terminal - *
domain - *
( - *
alpha-CTD - *
) - *
at - *
rhaSR - *
we - *
tested - *
the - *
effects - *
of - *
alanine - *
substitutions - *
in - *
CRP - *
activating - *
regions - *
1 - *
and - *
2 - *
overexpression - *
of - *
a - *
truncated - *
version - *
of - *
alpha - *
( - *
alpha-Delt235 - (A1*)
) - *
and - *
alanine - *
substitutions - *
throughout - *
alpha-CTD - *
 - *
. - *

Using - *
the - *
complex - *
structure - *
of - *
bone - *
morphogenetic - *
protein-2 - *
bound - *
to - *
its - *
type - *
I - *
receptor - *
( - *
ALK3 - *
) - *
as - *
a - *
guide - *
we - *
introduced - *
extracellular - *
domain - *
mutations - *
in - *
the - *
context - *
of - *
the - *
truncated - *
ALK4 - (A1*)
( - *
ALK4-trunc - *
) - *
construct - *
and - *
assessed - *
the - *
ability - *
of - *
the - *
mutants - *
to - *
inhibit - *
activin - *
function - *
 - *
 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
protein - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
has - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
protein - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncates - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
protein - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
truncated - *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

Electrophoretic - *
mobility - *
shift - *
assays - *
showed - *
that - *
the - *
full-length - *
BCL6 - *
protein - (A1*)
extracted - *
from - *
transfected - *
COS - *
cells - *
and - *
a - *
bacterially - *
expressed - *
will - *
truncate truncate (V*) *
protein - *
containing - *
the - *
BCL6 - *
zinc - *
fingers - *
can - *
bind - *
specifically - *
to - *
DNA - *
from - *
the - *
U3 - *
promoter/enhancer - *
region - *
of - *
HIV-1 - *
. - *

The - (A0*
majority - *
of - *
changes - *
have - *
found - *
to - *
truncate truncate (V*) *
the - (A1*
protein - *)
through - *
nonsense - *
mutations - *
(32%) - *
insertions - *
or - *
deletions - *
(296%) - *)
or - *
splicing - *
changes - *
(62%) - *
although - *
the - *
figures - *
were - *
biased - *
by - *
the - *
methods - *
employed - *
and - *
in - *
sequenced - *
areas - *
approximately - *
50% - *
of - *
all - *
mutations - *
were - *
missense - *
or - *
in-frame - *
. - *

The - (A0*
majority - *
of - *
changes - *
have - *
shown - *
to - *
truncate truncate (V*) *
the - (A1*
protein - *)
through - *
nonsense - *
mutations - *
(32%) - *
insertions - *
or - *
deletions - *
(296%) - *)
or - *
splicing - *
changes - *
(62%) - *
although - *
the - *
figures - *
were - *
biased - *
by - *
the - *
methods - *
employed - *
and - *
in - *
sequenced - *
areas - *
approximately - *
50% - *
of - *
all - *
mutations - *
were - *
missense - *
or - *
in-frame - *
. - *

The - *)
putative - *
resulting - *
protein - *
retained - *
the - *
region - *
encoding - *
the - *
structural - *
and - *
functional - *
elements - *
of - *
the - *
amine - *
oxidase - *
but - *
the - (A2*
second - *
and - *
fourth - *
SRCR - *
domains - *)
were - *
truncated - *
and - *
the - *
potential - *
BMP-1 - *
cleavage - *
site - *
was - *
not - *
present - *
. - *

The - *)
putative - *
resulting - *
protein - *
retained - *
the - *
region - *
encoding - *
the - *
structural - *
and - *
functional - *
elements - *
of - *
the - *
amine - *
oxidase - *
but - *
the - (A2*
second - *
and - *
fourth - *
SRCR - *
domains - *)
is - *
truncated - *
and - *
the - *
potential - *
BMP-1 - *
cleavage - *
site - *
was - *
not - *
present - *
. - *

The - *)
putative - *
resulting - *
protein - *
retained - *
the - *
region - *
encoding - *
the - *
structural - *
and - *
functional - *
elements - *
of - *
the - *
amine - *
oxidase - *
but - *
the - (A2*
second - *
and - *
fourth - *
SRCR - *
domains - *)
will - *
be - *
truncated - *
and - *
the - *
potential - *
BMP-1 - *
cleavage - *
site - *
was - *
not - *
present - *
. - *

The - *)
putative - *
resulting - *
protein - *
retained - *
the - *
region - *
encoding - *
the - *
structural - *
and - *
functional - *
elements - *
of - *
the - *
amine - *
oxidase - *
but - *
the - (A2*
second - *
and - *
fourth - *
SRCR - *
domains - *)
has - *
been - *
truncated - *
and - *
the - *
potential - *
BMP-1 - *
cleavage - *
site - *
was - *
not - *
present - *
. - *

Two - *
of - *
these - *
variants - *
result - *
in - *
altered - (A0*
postsynaptic - *
density - *
95 - *
(PSD95) - *
isoforms - *)
that - *
dramatically - *
truncate truncate (V*) *
the - (A1*
protein									 - *)
. - *

Two - *
of - *
these - *
variants - *
result - *
in - *
altered - (A0*
postsynaptic - *
density - *
95 - *
(PSD95) - *
isoforms - *)
that - *
dramatically - *
truncated - *
the - (A1*
protein - *)
. - *

Two - *
of - *
these - *
variants - *
result - *
in - *
altered - (A0*
postsynaptic - *
density - *
95 - *
(PSD95) - *
isoforms - *)
that - *
dramatically - *
will - *
truncate truncate (V*) *
the - (A1*
protein - *)
. - *

Two - *
of - *
these - *
variants - *
result - *
in - *
altered - (A0*
postsynaptic - *
density - *
95 - *
(PSD95) - *
isoforms - *)
that - *
dramatically - *
has - *
truncated - *
the - (A1*
protein - *)
. - *

Two - *
of - *
these - *
variants - *
result - *
in - *
altered - (A0*
postsynaptic - *
density - *
95 - *
(PSD95) - *
isoforms - *)
that - *
dramatically - *
could - *
truncate truncate (V*) *
the - (A1*
protein - *)
. - *

We - *
used - *
a - (A0*
gene-targeting - *
approach - *)
to - *
truncate truncate (V*) *
the - (A1*
titin - *
gene - *)
so - *
that - *
the - *
kinase - *
domain - *
and - *
other - *
domains - *
downstream - *
of - *
the - *
kinase - *
were - *
not - *
expressed - *
. - *

We - *
found - *
a - (A0*
gene-targeting - *
approach - *)
to - *
truncate truncate (V*) *
the - (A1*
titin - *
gene - *)
so - *
that - *
the - *
kinase - *
domain - *
and - *
other - *
domains - *
downstream - *
of - *
the - *
kinase - *
were - *
not - *
expressed - *
. - *

